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The fi ve viruses that cause infections of the liver are responsible 
for a widely prevalent and growing disease burden. No country, 
rich or poor, is spared. These viruses are important as they 
cause infectious diseases in their own right. Hepatitis A and E 
viruses are major foodborne and waterborne infections, which 
cause millions of cases of acute illness every year, with several 
months sometimes needed for full recovery. But viral hepatitis 
also makes a substantial contribution to the burden of chronic 
diseases and the premature mortality they cause. Worldwide, 
infections with hepatitis B and C viruses cause an estimated 
57% of cases of liver cirrhosis and 78% of cases of primary 
liver cancer. The availability of a vaccine that confers lifelong 
protection against infection with the hepatitis B virus gives 
public health a rare opportunity to prevent a leading cause of 
cancer, especially in low- and middle-income countries.
The signifi cance of these challenges and opportunities was 
formally acknowledged in 2010, when the World Health 
Assembly adopted its fi rst resolution on viral hepatitis. That 
resolution, which called for a comprehensive approach to 
prevention and control, opened a new era of awareness about 
the magnitude of disease caused by viral hepatitis and the need 
for urgent action on several fronts.
As attention to viral hepatitis continues to build, so has 
recognition of the many strategies available for prevention 
and control in all resource settings. Control measures for viral 
hepatitis fi t well with the current drive to strengthen health 
systems, especially as many measures touch on the fundamental 
capacities of a well-functioning health system. These include 
reaching every child with immunization programmes that 
include hepatitis B vaccine, protecting against mother-to-child 
transmission of the virus, and ensuring the safety of blood, 
transfusion services, organ donation, and injection practices. 
The broad social and environmental determinants of viral 
hepatitis further call for improvements in housing, sanitation, 
and food and water safety. The fact that many infections are 
silent, causing no symptoms until there is irreversible damage 
to the liver, points to the urgent need for universal access to 
immunization, screening, diagnosis, and antiviral therapy.
As hepatitis viruses show great diversity in their prevalence and 
modes of transmission in diff erent parts of the world, policies 
and strategies for prevention and control need to be tailored to 
the specifi c national or sub-national context. The 2010 World 
Health Assembly resolution urged Member States to generate 
reliable information as a foundation for building prevention and 
control measures that match the local epidemiological profi le 
and health system capacities.
This report is a contribution to that objective. It sets out the 
results of a survey conducted in mid-2012 by the World Health 
Organization and the World Hepatitis Alliance. The survey aimed 
to gather country-specifi c baseline data on hepatitis policies in 
WHO Member States in all six regions. Survey data also off er 
insight into conditions in specifi c countries that may have 
hindered past eff orts to achieve hepatitis policy objectives. Gaps 
that need to be fi lled are identifi ed, as are specifi c areas of policy 
development where WHO assistance is needed. Such baseline 
data will serve as a solid benchmark as countries, supported by 
WHO and its partners, seek to make the “silent” epidemic of viral 
hepatitis more visible – and more manageable.
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Viral hepatitis is a group of infectious diseases that aff ects hun-
dreds of millions of people worldwide, causing serious illness 
and death from acute hepatitis infection, liver cancer and liver 
cirrhosis. Although there are eff ective tools and strategies for 
the prevention and treatment of hepatitis, low awareness of 
hepatitis has limited their impact. Given the variation in how the 
fi ve main types of hepatitis (A, B, C, D and E) manifest across and 
within countries, global prevention and control eff orts need to 
be transformed into national and sub-national prevention and 
control strategies.
In 2010, the World Health Assembly adopted resolution WHA 
63.18 in recognition of viral hepatitis as a global public health 
problem. The World Health Organization (WHO) followed up on 
the resolution by crafting a strategy that addresses four axes: 
awareness-raising, partnerships and resource mobilization; evi-
dence-based policy and data for action; prevention of transmis-
sion; and screening, care and treatment.
The periodic evaluation of implementation of the WHO strategy 
requires an initial baseline survey of all Member States. In mid-
2012, WHO, in collaboration with the World Hepatitis Alliance, 
conducted such a survey, asking Member States to provide in-
formation relating to the aforementioned four axes of the WHO 
strategy. In particular, Member States were asked whether key 
prevention and control activities are being conducted. This re-
port presents the results. The fi rst chapter provides an introduc-
tion to viral hepatitis and to the global response to this group of 
diseases. The second chapter provides a global overview of the 
survey fi ndings. Chapters three through eight present fi ndings 
from the six WHO regions, including summaries of data from all 
responding countries. Additional survey data, study methodol-
ogy information and the survey instrument can be found in An-
nexes A–E.
One hundred and twenty-six Member States submitted the 
survey for a response rate of 64.9%. The regional response 
rate varied from 26.1% for the African Region to 100% for the 
South-East Asia Region. Across income groups, the response 
rate ranged from 47.4% for low-income countries to 80.0% for 
high-income countries.
Implementing a national response to comprehensively address 
viral hepatitis is a challenge for many governments. Because 
of the high burden of hepatitis-related diseases and the dif-
ferent routes of transmission and health outcomes, they need 
to simultaneously implement a variety of prevention and care 
interventions. Additionally, government offi  cials should focus 
on monitoring hepatitis outbreaks and disease trends while col-
laborating with civil society to raise awareness about hepatitis. 
The results of the survey indicate that some Member States are 
addressing some aspects of this response but that much more 
needs to be done. 
An important step that can help Member States to identify pri-
orities and marshal resources is to develop a written national 
strategy or plan that focuses exclusively or primarily on viral 
hepatitis. This plan could either stand alone or function as part 
of a broader health-planning document. Only 37.3% of respond-
ing Member States reported the existence of such a plan. Even 
fewer (28.6%) had a governmental unit dedicated to addressing 
hepatitis prevention and control. Furthermore, the number of 
government staff  working full-time on hepatitis-related activi-
ties is small; more than half of the countries reported having no 
more than two employees. 
Almost three fourths of responding Member States reported 
that they had a viral hepatitis prevention and control pro-
gramme that included activities targeting specifi c populations. 
The populations most commonly targeted were health-care 
workers, including health-care waste handlers (86.0% of re-
sponding Member States within this subset), and people who 
inject drugs (54.8% of responding Member States within this 
subset). 
National governments can play an important role in making 
their citizens aware of the importance of viral hepatitis, how 
to avoid getting infected and how to seek care. World Hepati-
tis Day (28 July), which was established in 2010 as part of the 
World Health Assembly resolution 63.18, is an important means 
of raising awareness about hepatitis. Two years after the pas-
sage of the resolution, almost 40% of responding Member 
States reported that they had engaged in activities to mark 
World Hepatitis Day. However, it is important for the remaining 
Member States, particularly where the burden of viral hepatitis 
is high, to organize World Hepatitis Day activities. Civil society 
organizations can play a signifi cant role in further publicizing 
health messages for World Hepatitis Day and throughout the 
year. However, less than half of responding Member States re-
ported that they collaborated with civil society groups within 
their countries to develop and implement the governmental 
viral hepatitis prevention and control programme.
Obtaining reliable data is important for planning and moni-
toring the implementation of hepatitis control activities. Most 
Member States (82.5%) reported having a national surveillance 
programme that regularly collected data and reported results re-
garding hepatitis incidence. In only approximately half of these 
Member States did the surveillance system include a method 
for monitoring chronic hepatitis B and C, which are responsible 
for most hepatitis-related morbidity and deaths. To properly as-
sess the scope of chronic hepatitis requires conducting regular 
prevalence serosurveys in both the general and most-at-risk 
populations; however, only about two thirds of Member States 
reported conducting such surveys. 
There have been signifi cant advances in the prevention of viral 
hepatitis. The most important is the wide-scale implementation 
of universal childhood vaccination for hepatitis B. As of 2011, 
180 countries included hepatitis B vaccination in their routine 
vaccine schedules and the coverage is approaching 80%. The 
survey results provide additional data concerning national 
hepatitis B vaccination policies. Slightly more than three fourths 
of Member States reported having a specifi c policy for the pre-
vention of mother-to-child transmission which includes vacci-
nation. This is important as infection transmitted from mothers 
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to their children is the principal route of transmission in many 
countries, particularly in Asia. Health-care workers are another 
group requiring special attention for vaccination in view of their 
high risk of infection through needle-stick injuries. Almost two 
thirds of Member States reported having a vaccination policy 
for health-care workers. 
In many countries, transmission of hepatitis to patients through 
unsafe injection practices in health-care settings is still a prob-
lem. The majority of the responding Member States reported 
addressing this through a national policy on injection safety and 
recommending the use of single-use syringes. 
With the development of reliable tests to identify hepatitis infec-
tions, transmission of hepatitis through transfusions is prevent-
able; 94.4% and 91.3% of Member States reported screening 
all donated blood units for hepatitis B and C, respectively. The 
survey was not able to assess other recommended practices, 
such as the promotion of blood donations from voluntary non-
remunerated blood donors or the utilization of quality control 
measures for laboratory testing. 
Hepatitis treatment is undergoing a revolution. New medica-
tions are being developed and introduced, which will improve 
control and provide higher cure rates for hepatitis B and C. It is 
important for countries to be prepared for the anticipated scale 
up of treatment by training health-care providers, establishing 
national treatment guidelines, and including hepatitis medica-
tions in their essential medicines lists. The survey results indi-
cate that much progress must be made in these key areas. Only 
half of reporting Member States indicated that they have clini-
cal guidelines for the treatment of hepatitis, and less than half 
reported including key medications for the treatment of hepa-
titis B such as tenofovir or entecavir in their essential medicines 
list. Only 54.8% reported including pegylated interferon, which 
is the current mainstay of hepatitis C treatment. Encouragingly, 
approximately 60% of Member States reported having publicly 
funded treatment programmes. The survey was not able to as-
sess the geographical coverage of these treatment services or 
their success in reaching most-at-risk populations. 
One of WHO’s core functions is to help Member States in their 
eff orts to improve the health of their populations. In the sur-
vey, Member States were asked to indicate areas in which they 
might want assistance from WHO for the prevention and control 
of viral hepatitis. Respondents most commonly selected the fol-
lowing: developing a national plan for viral hepatitis prevention 
and control (58.1%), estimating the national burden of viral hep-
atitis (54.8%) and developing education/training programmes 
for health professionals (54.0%). In order to provide this assist-
ance, it will be important to identify adequate resources and co-
ordinate activities at WHO Headquarters and the regional levels.
The survey has limitations that constrain the ability to inter-
pret the results, including a low response rate from the African 
Region. In addition, it was not possible to collect information 
concerning the quality of the programmes or their geographi-
cal scope. Nevertheless, the survey does document notable 
achievements, particularly in the area of prevention of hepatitis 
transmission. National governments still need to do much more 
to comprehensively address this global killer. Furthermore, in 
view of limited resources, it will be vital for all relevant organi-
zations at the international, national and local levels to work 
together to maximize the impact of hepatitis control activities.  
vii

1GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Chapter 1:
Introduction
Viral hepatitis is a group of infectious diseases that aff ects 
hundreds of millions of people worldwide. Five distinct hepatitis 
viruses have been identifi ed: A, B, C, D and E. Hepatitis B and C, 
which can lead to chronic hepatitis, are particularly prevalent; 
240 million people are thought to be chronically infected 
with hepatitis B and 184 million people have antibodies to 
hepatitis C. 1,2
The fi ve hepatitis viruses have diff erent epidemiological 
profi les and also vary in terms of their impact and duration. The 
transmission route depends on the type of virus. Transmission 
routes that contribute greatly to the spread of hepatitis are 
exposure to infected blood via blood transfusion or unsafe 
injection practices, consumption of contaminated food and 
drinking water, and transmission from mother to child during 
pregnancy and delivery. Unsafe injection practices, including 
the use of unsterile needles and syringes, serve as a major 
pathway for the spread of hepatitis B and C, and reducing 
transmission of both diseases means changing these practices.
Due to its largely asymptomatic nature, viral hepatitis is a silent 
epidemic; most people are unaware of their infection. Untreated 
chronic hepatitis B and C infection can result in liver cirrhosis 
and liver cancer. According to the Global Burden of Disease 
estimates, hepatitis B and hepatitis C together caused 1.4 million 
deaths in 2010, including deaths from acute infection, liver 
cancer and cirrhosis.3 To put these fi gures in the context of other 
major infectious diseases, it is estimated that malaria caused 
660 000 deaths in 2010,4 and tuberculosis and HIV 1.4 and 1.7 
million deaths, respectively, in 2011.5,6 Prevention and control of 
hepatitis can therefore make a signifi cant contribution to saving 
lives by preventing cancer and thereby reducing the burden of 
noncommunicable diseases.
The global public health response to viral hepatitis recognizes 
that surveillance and control are vital to ensure that testing, 
care and treatment are available to all people who need these 
services in every country of the world. As there is an eff ective 
vaccine for hepatitis B, immunization has been a central strategy 
for most countries to reduce the burden of hepatitis B. There is 
no vaccine available to prevent the spread of hepatitis C, but the 
screening of blood products and the use of sterile needles and 
syringes have contributed to lowering hepatitis C transmission 
in many countries.
However, as with other major public health challenges, the 
mere existence of eff ective tools and strategies for prevention 
and treatment is not enough to halt viral hepatitis. A major 
stumbling block has been the low awareness of viral hepatitis, 
both in the general population and among key populations. 
Since knowledge about the various risks and transmission 
routes is central to preventing the spread of hepatitis, increasing 
awareness is an important component of the global public 
health response.
Increasing awareness is also key to making hepatitis a larger 
part of the local, national and regional health agenda. Gaps 
can be seen between policy and practice, as even in countries 
with evidence-informed hepatitis policies, there is inadequate 
implementation of protocols for prevention, treatment and 
control. This situation indicates a need for improvement in the 
response to viral hepatitis at all levels.
A global problem with a global response
Viral hepatitis is a global health problem from which no country, 
rich or poor, is spared. This problem takes a multitude of 
diff erent forms, with factors such as the type of hepatitis, the 
most common transmission pathways, and the most eff ective 
strategies for diagnosis and treatment all varying across and 
within countries. Thus, global eff orts to make hepatitis a public 
health priority need to be transformed into prevention and 
control strategies that are tailored to specifi c conditions at the 
national and sub-national levels.
1  Prevention and control of viral hepatitis infection: framework for global action. 
Geneva, WHO, 2012.
2  Mohd Hanafi ah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology 
of hepatitis C virus infection: new estimates of age-specifi c antibody to HCV 
seroprevalence. Hepatology, 2013, 57(4):1333–1342.
3  Lozano R et al. Global and regional mortality from 235 causes of death for 20 age 
groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease 
Study 2010. Lancet, 2012, 380(9859):2095–2128. 
4  World malaria report 2012. Geneva, WHO, 2012. Available at: http://www.who.
int/malaria/publications/world_malaria_report_2012/wmr2012_no_profi les.pdf 
(accessed on 03 May 2013).
5  Global tuberculosis report 2012. Geneva, WHO, 2012. Available at: http://www.
who.int/tb/publications/global_report/gtbr12_main.pdf (accessed on 03 May 
2013).
6  UNAIDS Report on the global AIDS epidemic 2012. Geneva, 2012. Available at: 
http://www.unaids.org/en/resources/publications/2012/name,76121,en.asp 
(accessed on 03 May 2013).
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In 2010, the World Health Assembly adopted resolution WHA 
63.18 in recognition of viral hepatitis as a global public health 
problem.7 The resolution emphasized the need for governments 
and populations to take action to prevent, diagnose and treat 
viral hepatitis, and called upon the World Health Organization 
(WHO) to develop and implement a comprehensive global 
strategy to support these eff orts. WHO has crafted guidance 
for the World Health Assembly’s 194 Member States within a 
health systems approach, as described in Prevention and control 
of viral hepatitis infection: framework for global action.1 The WHO 
strategy addresses the following axes:
1. Awareness-raising, Partnerships and Resource Mobilization
2. Evidence-based Policy and Data for Action
3. Prevention of Transmission
4. Screening, Care and Treatment.
The 2010 resolution adopted by the World Health Assembly 
furthermore designated 28 July as World Hepatitis Day, 
envisioning this as an opportunity for Member States to 
promote awareness about viral hepatitis.7 The fi rst offi  cial World 
Hepatitis Day was in 2011. WHO encourages governments, 
international organizations and civil society groups around 
the world to observe World Hepatitis Day with activities that 
call attention to the disease burden imposed by viral hepatitis, 
and to the prevention and control measures that need to be 
implemented.
Monitoring the response: the 2012 survey
The periodic evaluation of implementation of the WHO strategy 
requires an initial baseline survey of how all Member States are 
responding to viral hepatitis. In mid-2012, WHO and the World 
Hepatitis Alliance conducted such a survey, asking Member 
States to provide information relating to the four axes of the 
WHO strategy.
This report presents the survey results. It describes the major 
dimensions of prevention and control policies and programmes 
for viral hepatitis in WHO Member States. Furthermore, survey 
data provide insight into how conditions in specifi c countries 
may have hindered previous eff orts to achieve hepatitis policy 
objectives. Findings also highlight gaps that must be addressed 
in order to improve hepatitis policies and programmes at the 
national and global levels. 
The second chapter of this report provides an overview of the 
global fi ndings. Chapters three through eight present fi ndings 
from the six WHO regions, including summaries of data from 
all responding countries. Additional data for selected survey 
questions appear in Annexes A–C. Annex D describes the study 
methodology, and Annex E the survey instrument.
It is anticipated that follow-up surveys, some utilizing the same 
questionnaire and others addressing specifi c issues in greater 
detail, will be carried out every one to two years to monitor 
overall progress in implementation of the WHO hepatitis 
prevention and control strategy.
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7  World Health Organization. Sixty-third World Health Assembly. Viral hepatitis: 
WHA 63.18. Geneva, Switzerland, 21 May 2010.
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Chapter 2:
Global fi ndings
One hundred and twenty-six Member States submitted the 
World Health Organization/World Hepatitis Alliance survey 
(“WHO/Alliance survey”) (Figure 1), a response rate of 64.9%. 
Respondents and non-respondents are listed by WHO region in 
Box 1. 
Response levels by region are presented in Table 1, along with 
response levels by income group according to the World Bank 
classifi cation. The regional response rate varied from 26.1% 
for the African Region to 100% for the South-East Asia Region. 
Across income groups, the response rate ranged from 80.0% for 
high-income countries to 47.4% for low-income countries.
Box 1. Responses to the 2012 Global Hepatitis Survey from each WHO region
Table 1. Responses received by WHO region and income groupa
WHO African Region 
Member States that submitted surveys:
WHO South-East Asia Region 
Member States that submitted surveys:
WHO Western Pacifi c Region 
Member States that submitted surveys:
WHO Region of the Americas 
Member States that submitted surveys:
WHO European Region 
Member States that submitted surveys:
WHO Eastern Mediterranean Region 
Member States that submitted surveys:
Member States that did not submit surveys: 
Member States that did not submit surveys: 
Member States that did not submit surveys: 
Member States that did not submit surveys: 
Member States that did not submit surveys: 
Member States that did not submit surveys: 
Cameroon, Chad, Comoros, Côte d’Ivoire, Mali, Mauritania, Nigeria, 
Rwanda, Sierra Leone, South Africa, United Republic of Tanzania and 
Zimbabwe
Bangladesh, Bhutan, Democratic People’s Republic of Korea, In-
dia, Indonesia, Maldives, Myanmar, Nepal, Sri Lanka, Thailand and 
Timor-Leste
Australia, Brunei Darussalam, Cambodia, China, Japan, Kiribati, Lao 
People’s Democratic Republic, Malaysia, Mongolia, New Zealand, 
Papua New Guinea, Singapore, Solomon Islands, Tonga and 
Viet Nam
Antigua and Barbuda, Argentina, Bahamas, Barbados, Brazil, 
Canada, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, 
El Salvador, Grenada, Guatemala, Guyana, Honduras, Jamaica, 
Mexico, Nicaragua, Panama, Paraguay, Peru, Saint Kitts and Nevis, 
Saint Lucia, Suriname, United States of America and Uruguay
Albania, Andorra, Armenia, Austria, Azerbaijan, Belarus, Belgium, 
Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, 
France, Georgia, Germany, Hungary, Ireland, Israel, Italy, Kyrgyzstan, 
Latvia, Lithuania, Luxembourg, Malta, Montenegro, Netherlands, 
Poland, Republic of Moldova, Russian Federation, San Marino, Ser-
bia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Tajikistan, The 
former Yugoslav Republic of Macedonia, Turkey, Ukraine, United 
Kingdom of Great Britain and Northern Ireland, and Uzbekistan
Africa (N=46)
Americas (N=35)
Eastern Mediterranean (N=22)
Europe (N=53)
South-East Asia (N=11)
Western Pacifi c (N=27)
Total: Income group
High income
(N=50)
0 (0%)
5 (83.3%)
4 (66.7%)
26 (83.9%)
n/a
5 (83.3%)
40 (80.0%)
Upper–middle income
(N=53)
1 (12.5%)
16 (80.0%)
3 (60.0%)
10 (71.4%)
2 (100%)
2 (50.0%)
34 (64.2%)
Lower–middle income
(N=50)
3 (27.3%)
6 (85.7%)
8 (88.9%)
5 (100%)
5 (100%)
7 (53.8%)
34 (68.0%)
Low income
(N=38)
8 (26.9%)
0 (0%)
2 (100%)
3 (100%)
4 (100%)
1 (25.0%)
18 (47.4%)
Other
(N=3)b
n/a
n/a
n/a
n/a
n/a
0 (0%)
0 (0%)
Afghanistan, Bahrain, Djibouti, Egypt, Iran (Islamic Republic of), Iraq, 
Jordan, Kuwait, Lebanon, Oman, Pakistan, Qatar, Somalia, South 
Sudan, Sudan, Syrian Arab Republic and Yemen
Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cape 
Verde, Central African Republic, Congo, Democratic Republic of 
the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, 
Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, 
Malawi, Mauritius, Mozambique, Namibia, Niger, Sao Tome and 
Principe, Senegal, Seychelles, Swaziland, Togo, Uganda and Zambia
no country
Cook Islands, Fiji, Marshall Islands, Micronesia (Federated States of), 
Nauru, Niue, Palau, Philippines, Republic of Korea, Samoa, Tuvalu 
and Vanuatu
a Source for income group classifi cations: World Bank 2012 data (http://data.worldbank.org/about/country-classifi cations/country-and-lending-groups.)
b Income group classifi cations were not available for three Western Pacifi c countries that did not submit surveys: Cook Islands, Nauru and Niue.
   n/a = not available
Belize, Bolivia (Plurinational State of), Chile, Dominica, Haiti, Saint 
Vincent and the Grenadines, Trinidad and Tobago, and Venezuela 
(Bolivarian Republic of)
Bosnia and Herzegovina, Greece, Iceland, Kazakhstan, Monaco, 
Norway, Portugal, Romania and Turkmenistan
Libya, Morocco, Saudi Arabia, Tunisia and United Arab Emirates
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Figure 1. Map of global responses
Figure 2. Responses to the question, “Is there a written national strategy or plan that focuses exclusively or primarily on the 
prevention and control of viral hepatitis?”
Yes
No
No data
Yes
No
No response
No data
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National coordination
Forty-seven responding Member States (37.3%) reported the 
existence of a written national strategy or plan that focuses 
exclusively or primarily on the prevention and control of viral 
hepatitis (Figure 2).
Eighteen of the 47 Member States with a strategy or plan 
reported that it focuses exclusively on viral hepatitis, and 20 
reported that it addresses other diseases as well. Five countries 
reported that the strategy or plan addresses only hepatitis B and 
one reported that it addresses only hepatitis C. Three countries 
reported that the strategy or plan addresses both hepatitis B 
and hepatitis C.
The 47 Member States that reported the existence of a strategy 
or plan were asked about its specifi c components. Forty-six 
reported the inclusion of a component for vaccination. Forty-
three reported the inclusion of a component for prevention 
of transmission in health-care settings, and the same number 
for general prevention and surveillance. Thirty-seven reported 
the inclusion of a component for treatment and care. Thirty-six 
reported the inclusion of a component for raising awareness. 
Thirty-fi ve reported the inclusion of a component for the 
prevention of transmission via injecting drug use.
Thirty-six responding Member States (28.6%) reported that they 
had a governmental unit or department responsible solely for 
viral hepatitis-related activities. Member States that did so were 
asked to indicate the number of staff  members in the unit or 
department. Responses (N=30) ranged from 0.1 (New Zealand) 
to 250 (Brazil) (median, 5).
Member States were asked to report the number of people 
working full-time on hepatitis-related activities in all 
government agencies or bodies. Among the 47 Member States 
that provided data for this question, the number ranged from 0 
to 213 (median, 2), with Armenia reporting the highest number.
Ninety-three responding Member States (73.8%) reported that 
they had a viral hepatitis prevention and control programme 
that included activities targeting specifi c populations. The 
populations most commonly targeted were health-care workers, 
including health-care waste handlers (86.0% of responding 
Member States within this subset) and people who inject drugs 
(54.8% of responding Member States within this subset). Forty-
four responding Member States (47.3%) reported the inclusion 
of activities targeting people living with HIV and 36 responding 
Member States (38.7%) reported the inclusion of activities 
targeting prisoners. Groups identifi ed less frequently included 
migrants, indigenous populations, low-income populations, 
those who are uninsured and those who are homeless.
Awareness-raising and partnerships
Forty-eight responding Member States (38.1%) reported that 
they had held events for World Hepatitis Day 2012 (28 July).
Since January 2011, 36 responding Member States (28.6%) had 
funded some type of viral hepatitis public awareness campaign 
other than World Hepatitis Day (Annex A).
Sixty responding Member States (47.6%) reported that they 
collaborated with civil society groups within their countries 
to develop and implement the governmental viral hepatitis 
prevention and control programme.
Evidence-based policy and data for action
One hundred and four responding Member States (82.5%) 
reported that they have routine surveillance for viral hepatitis; 
details are given in Table 2.
Table 2. Types of surveillance in Member States reporting the 
existence of routine surveillance for viral hepatitis (N=104)
There is a national 
surveillance system for acute 
hepatitis infection for the 
following forms of hepatitis:
hepatitis A
hepatitis B
hepatitis C
hepatitis D
hepatitis E
There is a national 
surveillance system for 
chronic hepatitis infection 
for the following forms of 
hepatitis:
hepatitis B
hepatitis C
hepatitis D
Yes (%)
86.5
96.2
85.6
38.5
45.2
52.9
49.0
23.1
No (%)
5.8
2.9
9.6
41.3
35.6
43.3
46.2
64.4
Do not 
know 
(%)
0
0
0
1.0
1.0
0
0
0
No 
response 
(%)
7.7
1.0
4.8
19.2
18.3
3.8
4.8
12.5
a  These fi gures represent data from 55 of the 57 Member States. Data from the 
Russian Federation and Mali are not included here because those Member States 
reported the information in a diff erent way. See the Russian Federation and Mali 
country fi ndings elsewhere in the report for information about undiff erentiated/
unclassifi ed hepatitis in those Member States.
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One hundred and seven responding Member States (84.9%) 
indicated that their countries have standard case defi nitions 
for hepatitis infection and 100 (79.4%) indicated that their 
countries have a central registry for the reporting of deaths, 
including hepatitis deaths.
Fifty-seven Member States reported on the proportion of 
hepatitis cases and deaths registered as “undiff erentiated” or 
“unclassifi ed” hepatitis. The reported proportion ranged from 
0% to 100% (median, 1.0%).a Additional survey fi ndings on 
surveillance are presented in Table 3.
Member States were asked how often hepatitis disease reports 
were published. Of the responding Member States, 40.5% 
reported that they publish hepatitis disease reports annually; 
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Figure 3. Responses to the question, “Has your government 
established the goal of eliminating hepatitis B?” (N=12)a
No 
(67.5%)
Yes 
(23.8%)
Do not 
know 
(4.8%)
No response 
4.0%
a  Four Member States that answered ”yes” to this question (Australia, Latvia, 
Republic of Moldova and Sweden) added comments indicating that their goals 
relate to reducing rather than eliminating hepatitis B.
21.4%, monthly; and 12.7%, weekly. No hepatitis disease report 
is published by 23.8% of responding Member States.
Thirty-two responding Member States (25.4%) reported the 
existence of a national public health research agenda for viral 
hepatitis.
Forty-one responding Member States (32.5%) reported that 
viral hepatitis serosurveys are conducted regularly. Among this 
subset, 17.1% indicated that serosurveys take place at least 
once per year and, of the same subset, 43.9% reported that the 
most recent viral hepatitis serosurvey was carried out in either 
2011 or 2012.
Prevention of transmission
Fifty-one responding Member States (40.5%) reported that they 
have a national hepatitis A vaccination policy.
Thirty responding Member States (23.8%) reported that 
they have established the goal of eliminating or reducing 
hepatitis B (Figure 3).
Member States were asked to report, for a given recent year, 
the percentage of newborn infants who had received the fi rst 
dose of hepatitis B vaccine within 24 hours of birth. Among the 
86 Member States that provided this information, responses 
ranged from 0% to 100% (median, 58.0%). Member States were 
also asked to report, for a given recent year, the percentage of 
one-year-olds (ages 12–23 months) who had received three 
doses of hepatitis B vaccine. Among the 101 Member States that 
provided this information, responses ranged from 0% to 100% 
(median, 92.0%).
Ninety-six responding Member States (76.2%) reported the 
existence of a national policy that specifi cally targets mother-to-
child transmission of hepatitis B; details are presented in Annex 
B. Of the Member States with such a policy, 65.6% indicated that 
one component of the policy calls for screening of all pregnant 
women for hepatitis B.
Eighty-eight responding Member States (69.8%) reported 
the existence of a specifi c national strategy and/or policy/
guidelines for preventing hepatitis B and hepatitis C infection 
in health-care settings.
Eighty responding Member States (63.5%) reported that health-
care workers are vaccinated against hepatitis B prior to starting 
work that might put them at risk of exposure to blood.
One hundred and nine responding Member States (86.5%) 
reported the existence of a national policy on injection safety 
in health-care settings. These Member States were asked which 
types of syringes the policy recommends for therapeutic 
injections. Single-use syringes are recommended in 77.1% of 
policies, and auto-disable syringes in 30.3% (Figure 4).
One hundred and ten responding Member States (87.3%) 
reported that single-use or auto-disable syringes, needles and 
cannulas are always available in all health-care facilities.
Member States were asked for offi  cial estimates of the number 
and percentage of unnecessary injections administered 
annually in health-care settings (e.g. injections that are given 
when an equivalent oral medication is available). One hundred 
and thirteen Member States reported that the fi gures are not 
known and six did not reply. Among the seven responding 
Member States providing this information, responses ranged 
from 0% to 68.0% (median, 14.0%), with Denmark and Tonga 
reporting 0% and Mongolia reporting 68.0%.
Additional fi ndings relating to the prevention of hepatitis 
transmission are presented in Table 4.
Screening, care and treatment
Member States were asked how health professionals in their 
countries obtain the skills and competencies required to 
eff ectively care for people with viral hepatitis. Responding 
Member States most frequently indicated that these are acquired 
in schools for health professionals (pre-service education, 
Table 3. Data registration and surveillance (N=126)
Liver cancer cases are registered 
nationally
Cases with HIV/hepatitis 
coinfection are registered 
nationally
Hepatitis outbreaks are reported
If YES – Hepatitis outbreaks are 
further investigated (N=115)
Yes (%)
69.8
47.6
91.3
94.8
No (%)
22.2
45.2
5.6
4.3
Do not 
know 
(%)
5.6
5.6
3.2
0.9
No 
response 
(%)
2.4
1.6
0
0
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Table 4. Hepatitis prevention: policies, practices and 
guidelines (N=126)
There is a national infection 
control policy for blood banks
All donated blood units 
(including family donations) and 
blood products nationwide are 
screened for hepatitis B
All donated blood units 
(including family donations) and 
blood products nationwide are 
screened for hepatitis C
There is a national policy relating 
to the prevention of viral 
hepatitis among people who 
inject drugs
The government has guidelines 
that address how hepatitis A 
and hepatitis E can be prevented 
through food and water safety
Yes (%)
88.9
94.4
91.3
34.1
50.0
No (%)
5.6
3.2
3.2
51.6
39.7
Do not 
know 
(%)
4.0
0
4.0
11.1
7.9
No 
response 
(%)
1.6
2.4
1.6
3.2
2.4
Figure 5. Responses to the question, “Are there national 
clinical guidelines for the management of viral hepatitis?” 
(N=126)
No 
(38.1%)
Yes 
(50.8%)
No response 
(4.0%) Do
not 
know 
7.1%
77.0%). Additionally, on-the-job training was identifi ed in 73.0% 
of responses and postgraduate training in 61.6%.
Sixty-four responding Member States (50.8%) reported the 
existence of national clinical guidelines for the management of 
viral hepatitis (Figure 5). Thirty-fi ve of these 64 Member States 
indicated that the guidelines include recommendations for 
cases with HIV coinfection. Forty-four of 74 responding Member 
States indicated that there are national clinical guidelines for 
the management of HIV, which include recommendations for 
coinfection with viral hepatitis.
Fifty-nine responding Member States (46.8%) indicated that 
they have a national policy relating to screening and referral to 
care for hepatitis B. Forty-eight (38.1%) reported that they have 
such a policy for hepatitis C.
Regarding hepatitis B testing, 116 responding Member States 
(92.1%) indicated that people register by name for testing. One 
hundred and one members of that subset (87.1%) indicated that 
the names are kept confi dential. Fifty-two responding Member 
States (41.3%) reported that the hepatitis B test is free of charge 
for all individuals. Among the 70 other Member States that 
answered the question, 43 (61.4%) reported that the hepatitis 
B test is free of charge for members of specifi c groups. Groups 
identifi ed included blood donors, health-care workers, pregnant 
women, people living with HIV, patients on haemodialysis, 
prisoners and people who inject drugs. Sixty-one responding 
Member States (48.4%) reported that the hepatitis B test is 
compulsory for members of specifi c groups. Groups identifi ed 
included blood donors, health-care workers, pregnant women, 
people living with HIV, patients on haemodialysis and prisoners.
Regarding hepatitis C testing, 109 responding Member States 
(86.5%) indicated that people register by name for testing. 
Ninety-fi ve members of that subset (87.2%) indicated that the 
names are kept confi dential. Forty-eight responding Member 
States (38.1%) reported that the hepatitis C test is free of charge 
for all individuals. Among the 69 other Member States that 
answered the question, 39 (56.5%) reported that the hepatitis C 
test is free of charge for members of specifi c groups. Groups 
identifi ed included blood donors, health-care workers, pregnant 
women, people living with HIV, patients on haemodialysis, 
prisoners and people who inject drugs. Fifty-seven responding 
Figure 4. Proportion of responding Member States with 
national policies on injection safety in health-care settings 
which recommend single-use syringes and auto-disable 
syringes for therapeutic injections (N=109)
a  Respondents could select both “single-use syringes” and “auto-disable syringes”.
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Single-use
syringesa
Auto-disable 
syringesa
Do not know
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Lamivudine 
Interferon alpha 
Pegylated interferon
Tenofovir
Entecavir
Adefovir dipivoxil
Telbivudine
Ribavirin
Pegylated interferon
Interferon alpha
Telaprevir
Boceprevir
66.7
54.0
50.8
48.4
34.9
34.1
23.8
57.9
54.8
45.2
19.8
18.3
% of Member States reporting its 
inclusion (N=126)
% of Member States reporting its 
inclusion (N=126)
Drugs for treating 
hepatitis B
Drugs for treating 
hepatitis C
Table 5. Drugs for treating hepatitis B and C on national 
essential medicines lists or subsidized by governments
Awareness-raising, partnerships and resource mobilization (fi rst WHO strategic axis)
Developing the national plan for viral hepatitis prevention and control
Integrating viral hepatitis programmes into other health services
Awareness-raising
Evidence-based policy and data for action (second WHO strategic axis)
Viral hepatitis surveillance
Estimating the national burden of viral hepatitis
Developing tools to assess the eff ectiveness of interventions
Assessing the economic impact of viral hepatitis
Prevention of transmission (third WHO strategic axis)
Increasing coverage of the birth dose of the hepatitis B vaccine
Screening, care and treatment (fourth WHO strategic axis)
Increasing access to treatment
Increasing access to diagnostics
Improving laboratory quality
Developing education/training programmes for health professionals
58.7%
48.4%
50.8%
52.4%
54.8%
43.7%
49.2%
31.7% 
46.0%
49.2%
44.6%a
54.0%
Table 6. Viral hepatitis control and prevention: areas in which Member States indicated interest in receiving WHO assistance 
(N=126)
a N = 113 (This response option was not included in the survey completed by Belarus, Colombia and countries in the South-East Asia Region.)
Member States (45.2%) reported that the hepatitis C test is 
compulsory for members of specifi c groups. Groups identifi ed 
included blood donors, health-care workers, pregnant women, 
people living with HIV, patients on haemodialysis and prisoners.
Seventy-nine responding Member States (62.7%) reported 
that publicly funded treatment is available for hepatitis B. 
Seventy-fi ve responding Member States (59.5%) reported that 
publicly funded treatment is available for hepatitis C. Fourteen 
responding Member States reported the amount spent on 
publicly funded treatment for hepatitis B and hepatitis C. 
Details can be found in the summaries of country fi ndings later 
in this report (see Argentina, Armenia, Bahrain, Croatia, Egypt, 
Lithuania, Myanmar, New Zealand, Pakistan, Poland, San Marino, 
Spain, Syrian Arab Republic and Turkey).
One hundred and three responding Member States (81.7%) 
reported that at least one available drug for treating for hepatitis 
B is on the national essential medicines list or is subsidized by 
the government (Table 5). The drugs most commonly reported 
were lamivudine, interferon alpha and pegylated interferon.
Eighty-three responding Member States (65.9%) reported 
that at least one available drug for treating for hepatitis C is 
on the national essential medicines list or is subsidized by 
the government. The drugs most commonly reported were 
ribavirin, pegylated interferon and interferon alpha.
World Health Organization assistance
Member States were asked to indicate areas in which they might 
want assistance from WHO for the prevention and control of viral 
hepatitis. Respondents most commonly selected the following: 
developing the national plan for viral hepatitis prevention and 
control (58.1%), estimating the national burden of viral hepatitis 
(54.8%) and developing education/training programmes for 
health professionals (54.0%) (Tables 6 and 7). Responses from 
individual Member States appear in Annex C.
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Table 7. Viral hepatitis control and prevention: areas in which Member States indicated interest in receiving WHO assistance 
by income group (N=126)
a N = 30 (This response option was not included in the survey completed by Belarus, Colombia, Maldives and Thailand.)
b N = 29 (This response option was not included in the survey completed by Bhutan, India, Indonesia, Sri Lanka and Timor-Leste.)
c N = 14 (This response option was not included in the survey completed by Bangladesh, Democratic People’s Republic of Korea, Myanmar and Nepal.)
Awareness-raising, partnerships and resource mobilization
(fi rst WHO strategic axis)
Developing the national plan for viral hepatitis prevention and control
Integrating viral hepatitis programmes into other health services
Awareness-raising
Evidence-based policy and data for action (second WHO strategic axis)
Viral hepatitis surveillance
Estimating the national burden of viral hepatitis
Developing tools to assess the eff ectiveness of interventions
Assessing the economic impact of viral hepatitis
Prevention of transmission (third WHO strategic axis)
Increasing coverage of the birth dose of the hepatitis B vaccine
Screening, care and treatment (fourth WHO strategic axis)
Increasing access to treatment
Increasing access to diagnostics
Improving laboratory quality
Developing education/training programmes for health professionals
High
income
(N=50)
27.5%
20.0%
17.5%
12.5%
25.0%
20.0%
25.0%
10.0%
10.0%
5.0%
22.5%
5.0%
Upper–
middle 
income
(N=53)
58.8%
58.8%
50.0%
55.9%
61.8%
52.9%
55.9%
41.2%
44.1%
43.3%a
55.9%
29.4%
Lower–
middle
income
(N=50)
73.5%
64.7%
73.5%
79.4%
67.6%
58.8%
70.6%
76.5%
76.5%
75.9%b
76.5%
47.1%
Low
income
(N=38)
100%
61.1%
83.3%
83.3%
83.3%
50.0%
50.0%
77.8%
94.4%
92.9%c
83.3%
66.7%
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Chapter 3:
WHO African Region
Forty-six Member States make up the World Health Organization 
(WHO) African Region, which has a total population of 857 
million.1 The African Region ranks behind the other fi ve WHO 
regions on key measures of overall population health. It has 
the lowest life expectancy at birth (54 years in 2009) and the 
highest infant and under-fi ve mortality rates.2 It has the highest 
level of unmet need for family planning and one of the lowest 
immunization coverage levels among one-year-olds.2 The 
African Region furthermore has severe shortages in its health 
workforce.3
Like the rest of the world, the African Region has seen 
noncommunicable diseases become a greater public health 
challenge in recent years. Deaths from noncommunicable 
diseases are expected to increase by more than 20% in the 
Region by 2020.4 Currently, however, it is the only region 
where mortality from communicable, maternal, perinatal 
and nutritional conditions still exceeds mortality from 
noncommunicable diseases.5
All of the African Region’s Member States except for Algeria 
are in sub-Saharan Africa, which has two thirds of all of the 
world’s cases of HIV.  Researchers who analysed data on HIV 
and hepatitis from 20 sub-Saharan African countries found a 
weighted mean prevalence rate of hepatitis B surface antigen 
(HBsAg) of 15% among people living with HIV, while that of 
antibodies to hepatitis C virus (HCV) was 7% among people 
living with HIV.6
Responses to the WHO/Alliance survey were received from 12 of 
the 46 Member States in the Region (26.1%) (Box 1).
a  Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and 
world region, 1990 and 2005. Vaccine, 2010, 28:6653–6657.
b   Aggarwal R. The global prevalence of hepatitis E virus infection and suscepti-
bility: a systematic review. Geneva, World Health Organization, 2010.
c  Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepati-
tis B virus infection: new estimates of age-specifi c HBsAg seroprevalence 
and endemicity. Vaccine, 2012, 30:2212–2219.
d  Mohd Hanafi ah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiol-
ogy of hepatitis C virus infection: new estimates of age-specifi c antibody 
to HCV seroprevalence. Hepatology, 2013, 57:1333–1342.
1  World population prospects: the 2010 revision. New York, United Nations, 
Department of Economic and Social Aff airs, Population Division, 2011.
2  World Health Statistics 2012. Geneva, WHO, 2012. Available at: http://www.who.
int/gho/publications/world_health_statistics/2012/en/ (accessed on 03 May 
2013).
 3  The African Health Monitor, April–June 2010; (12):22–29. Available at: http://ahm.
afro.who.int/issue12/pdf/AHM%2012Complete.pdf (accessed on 03 May 2013).
4  Global status report on noncommunicable diseases 2010. Geneva, WHO, 2011. 
Available at: http://whqlibdoc.who.int/publications/2011/9789240686458_eng.
pdf(accessed on 03 May 2013).
5  UNAIDS report on the global AIDS epidemic 2012. Geneva, 2012. Available at: 
http://www.unaids.org/en/media/unaids/contentassets/documents/epidemio 
logy/2012/gr2012/20121120_UNAIDS_Global_Report_2012_en.pdf (accessed 
on 03 May 2013).
6  Barth RE, Huijgen Q, Taljaard J, Hoepelman AI. Hepatitis B/C and HIV in sub-
Saharan Africa: an association between highly prevalent infectious diseases. A 
systematic review and meta-analysis. International Journal of Infectious Diseases, 
2010, 14(12):e1024–e1031.
Box 1. Responses to the 2012 Global Hepatitis Survey: WHO 
African Region
Member States that submitted surveys:
Member States that did not submit surveys: 
• Cameroon
• Chad
• Comoros
• Côte d’Ivoire
• Mali
• Algeria
• Angola
• Benin
• Botswana
• Burkina Faso
• Burundi
• Cape Verde
• Central African
Republic
• Congo
• Democratic Republic 
of the Congo
• Equatorial Guinea
• Mauritania
• Nigeria
• Rwanda
• Sierra Leone
• South Africa
• Eritrea
• Ethiopia
• Gabon
• Gambia
• Ghana
• Guinea
• Guinea-Bissau
• Kenya
• Lesotho
• Liberia
• Madagascar
• Malawi
• Mauritius
•  United Republic of
   Tanzania
• Zimbabwe
• Mozambique
• Namibia
• Niger
• Sao Tome and
Principe
• Senegal
• Seychelles
• Swaziland
• Togo
• Uganda
• Zambia
Viral hepatitis in the WHO African Region 
The African Region is estimated to have some of the 
highest prevalence rates for hepatitis A globally, with ≥90% 
of children in sub-Saharan Africa exposed to infection by 
the age of 10 years.a The prevalence of hepatitis E in the 
Region varies from <2%  in several countries to >20% in 
Central Africa.b
The prevalence of hepatitis B is estimated at 8% in West 
Africa and 5%–7% in central, eastern and southern 
Africa.c The prevalence of hepatitis C is even higher in 
some areas, reaching levels of up to 10%.d
National coordination
Two responding Member States (16.7%) reported the existence 
of a written national strategy or plan that focuses exclusively 
or primarily on the prevention and control of viral hepatitis 
(Figure 1). Both these Member States (South Africa and 
Mauritania) reported that it focuses exclusively on viral hepatitis.
Member States that reported the existence of a strategy or 
plan were asked about its specifi c components. South Africa 
reported the inclusion of components for vaccination, general 
prevention, prevention of transmission via injecting drug use, 
Chapter 3: W
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Figure 1. Responses to the question, “Is there a written 
national strategy or plan that focuses exclusively or primarily 
on the prevention and control of viral hepatitis?”
Yes
No
No response
No data
prevention of transmission in health-care settings, treatment 
and care, and coinfection with HIV. Mauritania reported the 
inclusion of components for raising awareness, surveillance, 
vaccination, general prevention, prevention of transmission via 
injecting drug use, prevention of transmission in health-care 
settings, treatment and care, and coinfection with HIV.
Four responding Member States (33.3%) reported that they 
have a governmental unit or department responsible solely for 
viral hepatitis-related activities. Member States that did so were 
asked to indicate the number of staff  members in the unit or 
department. Responses (N=4) ranged from 2 to 10 (median, 4.5), 
with Côte d’Ivoire reporting the largest number.
Member States were asked to report the number of people 
working full-time on hepatitis-related activities in all 
government agencies or bodies. Among the fi ve Member States 
that provided data for this question, the number ranged from 
0 to 7 (median, 3.0), with South Africa reporting the largest 
number.
Seven responding Member States (58.3%) reported that they 
have a viral hepatitis prevention and control programme 
that included activities targeting specifi c populations. The 
populations most commonly targeted were young children 
(57.1% of responding Member States within this subset) and 
health-care workers, including health-care waste handlers 
(57.1% of responding Member States within this subset).
Awareness-raising and partnerships
Four responding Member States (33.3%) reported that they 
held events for World Hepatitis Day 2012 (28 July). Since January 
2011, one responding Member State (8.3%) had funded some 
type of viral hepatitis public awareness campaign other than 
World Hepatitis Day. This Member State (Chad) reported that 
it addressed the following topics: general information about 
hepatitis and its transmission, vaccination for hepatitis A and 
hepatitis B, the importance of knowing one’s hepatitis B and 
hepatitis C status, and safer sex practices.
Six responding Member States (50.0%) reported that they 
collaborated with civil society groups within their countries 
to develop and implement the governmental viral hepatitis 
prevention and control programme. For example, Mali reported 
collaborating with SOS Hepatitis and Cameroon reported 
collaborating with Reseau Camerounais contre Hépatites Virales 
and Société Camerounaise de Gastro-Enterologie. (Further 
examples can be found in the summaries of country fi ndings 
later in this chapter.)
Evidence-based policy and data for action
Four responding Member States (33.3%) reported that they 
have routine surveillance for viral hepatitis; details appear in 
Table 1.
Nine responding Member States (75.0%) indicated that their 
countries have standard case defi nitions for hepatitis infection 
and three (25.0%) indicated that their countries have a central 
registry for reporting deaths, including hepatitis deaths.
Table 1. Types of surveillance in Member States reporting 
the existence of routine surveillance for viral hepatitis (N=4)
There is a national 
surveillance system for acute 
hepatitis infection for the 
following forms of hepatitis:
hepatitis A
hepatitis B
hepatitis C
hepatitis D
hepatitis E
There is a national 
surveillance system for 
chronic hepatitis infection 
for the following forms of 
hepatitis:
hepatitis B
hepatitis C
hepatitis D
Yes (%)
75.0
75.0
50.0
0
0
0
25.0
0
No (%)
0
0
25.0
50.0
50.0
75.0
50.0
50.0
Do not 
know 
(%)
0
0
0
25.0
25.0
0
0
0
No 
response 
(%)
25.0
25.0
25.0
25.0
25.0
25.0
25.0
50.0
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Two Member States reported on the proportion of hepatitis 
cases and deaths registered as “undiff erentiated” or “unclassifi ed” 
hepatitis. One Member State (Mali) reported this to be 15%–
20% for hepatitis B and 4.98% for hepatitis C. The other Member 
State (Mauritania) reported this to be 10%–20%. Additional 
survey fi ndings about surveillance are presented in Table 2.
Table 2. Data registration and surveillance (N=126)
Liver cancer cases are registered 
nationally
Cases with HIV/hepatitis 
coinfection are registered 
nationally
Hepatitis outbreaks are reported
If YES – Hepatitis outbreaks are 
further investigated (N=115)
Yes (%)
50.0
25.0
66.7
75.0
No (%)
33.3
50.0
16.7
25.0
Do not 
know 
(%)
16.7
8.3
16.7
0
No 
response 
(%)
0
16.7
0
0
Member States were asked how often hepatitis disease reports 
were published. Of the responding Member States, 16.7% 
reported that hepatitis disease reports are published annually, 
and 8.3% monthly. No hepatitis disease report is published by 
41.7% of responding Member States.
Two responding Member States (16.7%, Mauritania and 
Rwanda) reported the existence of a national public health 
research agenda for viral hepatitis.
Two responding Member States (16.7%, Côte d’Ivoire and 
Rwanda) reported that viral hepatitis serosurveys are conducted 
regularly. One of the two (Rwanda) indicated that serosurveys 
take place every two years. Both Member States with regular 
serosurveys reported that the most recent viral hepatitis 
serosurvey was carried out in either 2011 or 2012.
Prevention of transmission
Three responding Member States (25.0%) reported that they 
have a national policy for hepatitis A vaccination.
Two responding Member States (16.7%, Cameroon and Rwanda) 
reported that they have established the goal of eliminating 
hepatitis B (Figure 2). Member States with this goal were 
asked to specify the timeframe in which they seek to eliminate 
hepatitis B. Both Member States said that the timeframe was not 
specifi ed.
Member States were asked to report, for a given recent year, the 
percentage of newborn infants who had received the fi rst dose 
of hepatitis B vaccine within 24 hours of birth. Among the seven 
Member States that provided this information, all responses 
were 0%. Member States were also asked to report, for a given 
recent year, the percentage of one-year-olds (ages 12–23 
months) who had received three doses of hepatitis B vaccine. 
Figure 2. Responses to the question, “Has your government 
established the goal of eliminating hepatitis B?” (N=12)
No 
(66.7%)
Yes 
(16.7%)
Do not 
know 
(16.7%)
Among the eight Member States that provided this information, 
responses ranged from 50.0% to 97.0% (median, 83.0%).
Three responding Member States (25.0%) reported the 
existence of a national policy that specifi cally targets mother-to-
child transmission of hepatitis B. One Member State (Cameroon) 
indicated that the policy calls for health-care providers to follow 
up with all pregnant women found to have hepatitis B during 
pregnancy for the purpose of encouraging them to give birth 
at health-care facilities. The second Member State (Mauritania) 
indicated that the policy calls for counselling of all pregnant 
women found to have hepatitis B, and for delivery of the fi rst 
dose of hepatitis B vaccine to all infants within 24 hours of birth. 
The third Member State (Comoros) indicated that the policy 
calls for screening of all pregnant women for hepatitis B.
Four responding Member States (33.3%) reported the existence 
of a specifi c national strategy and/or policy/guidelines for 
preventing hepatitis B and hepatitis C infection in health-care 
settings.
One responding Member State (8.3%, South Africa) reported 
that health-care workers are vaccinated against hepatitis B 
prior to starting work that might put them at risk of exposure 
to blood.
Twelve responding Member States (100.0%) reported the 
existence of a national policy on injection safety in health-
care settings. These Member States were asked which types 
of syringes the policy recommends for therapeutic injections. 
Single-use syringes are recommended in 66.7% of policies, and 
auto-disable syringes in 58.3% (Figure 3).
Seven responding Member States (58.3%) reported that single-
use or auto-disable syringes, needles and cannulas are always 
available in all health-care facilities.
Member States were asked for offi  cial estimates of the number 
and percentage of unnecessary injections administered 
annually in health-care settings (e.g. injections that are given 
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Figure 3. Proportion of responding Member States with 
national policies on injection safety in health-care settings 
which recommend single-use syringes and auto-disable 
syringes for therapeutic injections (N=12)
a  Respondents could select both “single-use syringes” and “auto-disable syringes”.
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Single-use syringesa Auto-disable syringesa
when an equivalent oral medication is available). Eleven 
Member States reported that the fi gures are not known and one 
did not reply. Additional fi ndings relating to the prevention of 
hepatitis transmission are presented in Table 3.
Screening, care and treatment
Member States were asked how health professionals in their 
countries obtain the skills and competencies required to 
eff ectively care for people with viral hepatitis. Responding 
Member States most frequently indicated that these are acquired 
in schools for health professionals (pre-service education, 
58.3%). In addition, on-the-job training was identifi ed in 50.0% 
of responses, and postgraduate training in 50.0%.
Four responding Member States (33.3%) reported the existence 
of national clinical guidelines for the management of viral 
hepatitis (Figure 4). Two of these four Member States (South 
Africa and the United Republic of Tanzania) indicated that 
the guidelines include recommendations for cases with HIV 
coinfection. Six of nine responding Member States (66.7%) 
indicated that there are national clinical guidelines for the 
management of HIV, which include recommendations for 
coinfection with viral hepatitis.
Two responding Member States (16.7%, Côte d’Ivoire and 
Rwanda) indicated that they have national policies relating to 
screening and referral to care for hepatitis B and hepatitis C.
Regarding hepatitis B testing, 12 responding Member States 
(100.0%) indicated that people register by name for testing. 
Eleven members of this subset (91.7%) indicated that the 
names are kept confi dential. No responding Member State 
(0%) reported that the hepatitis B test is free of charge for all 
individuals. Six responding Member States (50.0%) reported 
Table 3. Hepatitis prevention: policies, practices and 
guidelines (N=12)
There is a national infection 
control policy for blood banks
All donated blood units 
(including family donations) and 
blood products nationwide are 
screened for hepatitis B
All donated blood units 
(including family donations) and 
blood products nationwide are 
screened for hepatitis C
There is a national policy relating 
to the prevention of viral 
hepatitis among people who 
inject drugs
The government has guidelines 
that address how hepatitis A 
and hepatitis E can be prevented 
through food and water safety
Yes (%)
100
100
83.3
25.0
25.0
No (%)
0
0
8.3
66.7
58.3
Do not 
know 
(%)
0
0
8.3
8.3
16.7
Figure 4. Responses to the question, “Are there national 
clinical guidelines for the management of viral hepatitis?” 
(N=12)
No 
(66.77%)
Yes 
(33.3%)
that the hepatitis B test is free of charge for members of specifi c 
groups. Groups identifi ed included blood donors, people living 
with HIV and pregnant women. Six responding Member States 
(50.0%) reported that the hepatitis B test is compulsory for 
members of specifi c groups. Groups identifi ed included blood 
donors, people living with HIV and pregnant women.
Regarding hepatitis C testing, eleven responding Member States 
(91.7%) indicated that people register by name for testing. All 
members of that subset (100%) indicated that the names are 
kept confi dential. No responding Member State (0%) reported 
that the hepatitis C test is free of charge for all individuals. Six 
responding Member States (50.0%) reported that the hepatitis 
C test is free of charge for members of specifi c groups. Groups 
identifi ed included blood donors. Six responding Member 
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States (50.0%) reported that the hepatitis C test is compulsory 
for members of specifi c groups. Groups identifi ed included 
blood donors.
Two responding Member States (16.7%) reported that publicly 
funded treatment is available for hepatitis B and three (25.0%) 
that it is available for hepatitis C. Information was not provided 
by any Member State regarding the amount spent on publicly 
funded treatment for hepatitis B and hepatitis C.
Nine responding Member States (75.0%) reported that at least 
one available drug for treating hepatitis B is on the national 
essential medicines list or subsidized by the government 
(Table 4). The drugs most commonly reported were lamivudine, 
interferon alpha and tenofovir.
Five responding Member States (41.7%) reported that at least 
one available drug for treating hepatitis C is on the national 
essential medicines list or subsidized by the government. The 
drugs most commonly reported were ribavirin, pegylated 
interferon and interferon alpha.
World Health Organization assistance
Member States were asked to indicate areas in which they 
might want assistance from WHO for the prevention and control 
of viral hepatitis. Respondents most commonly selected the 
following: increasing access to treatment (91.7%), developing 
the national plan for viral hepatitis prevention and control 
(91.7%), surveillance for viral hepatitis (91.7%) and increasing 
access to diagnostics (91.7%, Table 5). Responses from individual 
Member States appear in Annex C.
Lamivudine 
Interferon alpha 
Tenofovir
Pegylated interferon
Entecavir
Adefovir dipivoxil
Telbivudine
Ribavirin
Pegylated interferon
Interferon alpha
Telaprevir
Boceprevir
33.3
16.7
16.7
8.3
0.0
0.0
0.0
25.0
25.0
16.7
0.0
0.0
% of Member States reporting its 
inclusion (N=12)
% of Member States reporting its 
inclusion (N=12)
Drugs for treating 
hepatitis B
Drugs for treating 
hepatitis C
Table 4. Proportion of Member States reporting drugs for 
treating hepatitis B and C on national essential medicines 
lists or subsidized by governments
Awareness-raising, partnerships and resource mobilization (fi rst WHO strategic axis)
Developing the national plan for viral hepatitis prevention and control
Integrating viral hepatitis programmes into other health services
Awareness-raising
Evidence-based policy and data for action (second WHO strategic axis)
Viral hepatitis surveillance
Estimating the national burden of viral hepatitis
Developing tools to assess the eff ectiveness of interventions
Assessing the economic impact of viral hepatitis
Prevention of transmission (third WHO strategic axis)
Increasing coverage of the birth dose of the hepatitis B vaccine
Screening, care and treatment (fourth WHO strategic axis)
Increasing access to treatment
Increasing access to diagnostics
Improving laboratory quality
Developing education/training programmes for health professionals
91.7%
66.7%
83.3%
91.7%
75.0%
66.7%
58.3%
66.7% 
91.7%
91.7%
83.3%
75.0%
Table 5. Viral hepatitis control and prevention: areas in which Member States indicated interest in receiving WHO assistance 
(N=12)
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Cameroon
The Government of Cameroon reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. Information was not pro-
vided regarding how many people work 
full-time on hepatitis-related activities in 
all government agencies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c population: newborns.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 but has not funded any 
other public awareness campaign on viral 
hepatitis since January 2011.
The government collaborates with the fol-
lowing in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme: Re-
seau Camerounais contre Hépatites Virales 
and Société Camerounaise de Gastro-En-
terologie.
Evidence-based policy and data for 
action
There is no routine surveillance for viral 
hepatitis.
There are standard case defi nitions for 
hepatitis. Hepatitis deaths are not report-
ed to a central registry. Information was 
not provided regarding the percentage of 
hepatitis cases reported as “undiff erenti-
ated” or “unknown” hepatitis.
Liver cancer cases and cases with HIV/
hepatitis coinfection are not registered 
nationally. 
The government publishes hepatitis dis-
ease reports irregularly.
Hepatitis outbreaks are not required to 
be reported to the government. There is 
adequate laboratory capacity nationally 
to support outbreak investigations and 
other surveillance activities for hepatitis 
A, hepatitis B and hepatitis C, but not for 
hepatitis E.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is a national policy for hepatitis A 
vaccination. 
The government has established the goal 
of eliminating hepatitis B but the time-
frame is not specifi ed.
Information was not provided regarding 
the percentage of newborn infants nation-
ally in a given recent year who received 
the fi rst dose of hepatitis B vaccine within 
24 hours of birth or the percentage of one-
year-olds nationally (ages 12–23 months) 
in a given recent year who received three 
doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is no specifi c national strategy and/
or policy/guidelines for preventing hepa-
titis B and hepatitis C infection in health-
care settings. 
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities. 
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
20
Lower–middle-income
$2330
5.13%
$121.55
$36.01
51
0.482
19
4.5
Screening, care and treatment
It is not known how health professionals 
obtain the skills and competencies re-
quired to eff ectively care for people with 
viral hepatitis. 
There are national clinical guidelines for 
the management of viral hepatitis. In-
formation was not provided on whether 
these guidelines include recommenda-
tions for cases with HIV coinfection. There 
are national clinical guidelines for the 
management of HIV, which include rec-
ommendations for coinfection with viral 
hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are not 
provided free of charge, and are not com-
pulsory for members of any specifi c group.
Publicly funded treatment is not available 
for hepatitis B but is available for hepatitis 
C. It is not known who is eligible for pub-
licly funded treatment for hepatitis C. In-
formation was not provided regarding the 
amount spent by the government on such 
treatment for hepatitis C.
No drug for treating hepatitis B is on the 
national essential medicines list or subsi-
dized by the government. The following 
drugs for treating hepatitis C are on the 
national essential medicines list or subsi-
dized by the government: pegylated inter-
feron and lamivudine.
The Government of Cameroon welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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Chad
The Government of Chad reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. It has six staff  members. 
There are no people working full-time on 
hepatitis-related activities in any govern-
ment agency/body.
The government does not have a viral 
hepatitis prevention and control pro-
gramme that includes activities targeting 
specifi c populations.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 and has funded other 
viral hepatitis public awareness cam-
paigns since January 2011 (Annex A).
The government collaborates with the fol-
lowing in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme: As-
sociation SOS Hepatite Chad and Associa-
tion Soleil Levant. 
Evidence-based policy and data for 
action
There is no routine surveillance for viral 
hepatitis.
There are standard case defi nitions for 
hepatitis. Hepatitis deaths are not report-
ed to a central registry. The percentage of 
hepatitis cases reported as “undiff erentiat-
ed” or “unclassifi ed” hepatitis is not known.
Liver cancer cases and cases with HIV/
hepatitis coinfection are not registered 
nationally. 
The government does not publish hepati-
tis disease reports.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy for hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
It is not known what percentage of new-
born infants nationally in a given recent 
year received the fi rst dose of hepatitis B 
vaccine within 24 hours of birth or what 
percentage of one-year-olds (ages 12–23 
months) nationally in a given recent year 
received three doses of hepatitis B vaccine.
There is no national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B.
There is no specifi c national strategy and/
or policy/guidelines for preventing hepa-
titis B and hepatitis C infection in health-
care settings. 
There is a national policy on injection 
safety in health-care settings, which rec-
ommends single-use and auto-disable 
syringes for therapeutic injections. Single-
use or auto-disable syringes, needles and 
11.5
Low-income
$1360
4.53%
$61.67
$15.40
48
0.328
17
6
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
cannulas are always available in all health-
care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepati-
tis E can be prevented through food and 
water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education) and postgraduate training. 
There are no national clinical guidelines 
for the management of viral hepatitis. 
There are national clinical guidelines for 
the management of HIV, which include 
recommendations for coinfection with vi-
ral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are not 
free of charge and are not compulsory for 
members of any specifi c group.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
The following drug for treating hepatitis B 
is on the national essential medicines list 
or subsidized by the government: lami-
vudine. No drug for treating hepatitis C is 
on the national essential medicines list or 
subsidized by the government.
The Government of Chad welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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Comoros
The Government of Comoros reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. It is not known how 
many people work full-time on hepatitis-
related activities in all government agen-
cies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c population: children under the 
age of one year.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, but not for any type of chronic 
hepatitis.
There are standard case defi nitions for 
hepatitis. Hepatitis deaths are not report-
ed to a central registry.
It is not known whether liver cancer cases 
are registered nationally. Cases with HIV/
hepatitis coinfection are not registered 
nationally.
The government does not publish hepati-
tis disease reports. 
Hepatitis outbreaks are required to be 
reported to the government but are not 
further investigated. There is adequate 
laboratory capacity nationally to support 
outbreak investigations and other surveil-
lance activities for hepatitis A, hepatitis B 
and hepatitis C, but not for hepatitis E.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy for hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, no newborn infant in a given 
recent year received the fi rst dose of hepa-
titis B vaccine within 24 hours of birth 
and 86% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is no specifi c national strategy and/
or policy/guidelines for preventing hepa-
titis B and hepatitis C infection in health-
care settings.
There is a national policy on injection 
safety in health-care settings, which rec-
ommends single-use and auto-disable 
syringes for therapeutic injections. Single-
use or auto-disable syringes, needles and 
cannulas are always available in all health-
care facilities. 
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B, but not for hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
0.7
Low-income
$1110
4.51%
$49.11
$33.01
60
0.433
19
4.9
The government does not have guidelines 
that address how hepatitis A and hepati-
tis E can be prevented through food and 
water safety.
Screening, care and treatment
It is not known how health professionals 
obtain the skills and competencies re-
quired to eff ectively care for people with 
viral hepatitis. 
There are no national clinical guidelines 
for the management of viral hepatitis, or 
for the management of HIV, which include 
recommendations for coinfection with vi-
ral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are not 
free of charge for all individuals, but they 
are free of charge for blood donors and 
people living with HIV. Hepatitis B and 
hepatitis C tests are compulsory for blood 
donors, people living with HIV and preg-
nant women.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
The following drug for treating hepatitis B 
is on the national essential medicines list 
or subsidized by the government: lami-
vudine. No drug for treating hepatitis C is 
on the national essential medicines list or 
subsidized by the government.
The Government of Comoros welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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Côte d’Ivoire
The Government of Côte d’Ivoire reports 
as follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities: Programme National de 
Lutte contre les Hépatites Virales. It has 
10 staff  members. There are fi ve full-time 
equivalent staff  members who work on 
hepatitis-related activities in all govern-
ment agencies/bodies.
The government does not have a viral 
hepatitis prevention and control pro-
gramme that includes activities targeting 
specifi c populations.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 but has not funded 
other viral hepatitis public awareness 
campaigns since January 2011.
The government collaborates with the fol-
lowing in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme: Ré-
seau Ivoirien de Lutte contre les Hépatites 
Virales and Rotaract Côte d’Ivoire.
Evidence-based policy and data for 
action
There is no routine surveillance for viral 
hepatitis.
There are standard case defi nitions for 
hepatitis. Hepatitis deaths are not report-
ed to a central registry. Information was 
not provided regarding the percentage of 
hepatitis cases reported as “undiff erenti-
ated” or “unknown” hepatitis.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports annually. 
Hepatitis outbreaks are not required to be 
reported to the government. There is inad-
equate laboratory capacity nationally to 
support investigation of viral hepatitis out-
breaks and other surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target populations are children under the 
age of fi ve years, the general population, 
fi refi ghters and the military. The last sero-
survey was carried out in March 2012. 
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Information was not provided regarding 
the percentage of newborn infants na-
tionally in a given recent year who had 
received the fi rst dose of hepatitis B vac-
cine within 24 hours of birth. In a given 
recent year, 62% of one-year-olds (ages 
12–23 months) had received three doses 
of hepatitis B vaccine.
There is no national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B.
There is no specifi c national strategy and/
or policy/guidelines for preventing hepa-
titis B and hepatitis C infection in health-
care settings.
There is a national policy on injection 
safety in health-care settings, which rec-
ommends auto-disable syringes for thera-
peutic injections. Single-use or auto-disa-
ble syringes, needles and cannulas are not 
always available in all health-care facilities.
Information was not provided regard-
ing offi  cial government estimates of the 
20.2
Lower–middle-income
$1710
5.30%
$97.58
$21.07
50
0.400
19
4.4
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
number and percentage of unneces-
sary injections administered annually in 
health-care settings.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepati-
tis E can be prevented through food and 
water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
training workshops on the management 
of viral hepatitis. 
There are no national clinical guidelines 
for the management of viral hepatitis. 
There are national clinical guidelines for 
the management of HIV, which include 
recommendations for coinfection with vi-
ral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are not 
free of charge and are not compulsory for 
members of any specifi c group.
Publicly funded treatment is available for 
hepatitis B and hepatitis C. The following 
people are eligible: uninsured patients in 
Hospital Consultant Abidjan. Information 
was not provided regarding the amount 
spent by the government on such treat-
ment for hepatitis B and hepatitis C.
The following drug for treating hepatitis B 
is on the national essential medicines list 
or subsidized by the government: pegylat-
ed interferon. The following drug for treat-
ing hepatitis C is on the national essential 
medicines list or subsidized by the govern-
ment: pegylated interferon. 
The Government of Côte d’Ivoire wel-
comes assistance from WHO in one or 
more areas of viral hepatitis prevention 
and control (Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Mali
The Government of Mali reports as follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. It is not known how 
many people work full-time on hepatitis-
related activities in all government agen-
cies/bodies.
The government does not have a viral 
hepatitis prevention and control pro-
gramme that includes activities targeting 
specifi c populations.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government collaborates with the fol-
lowing in-country civil society group to 
develop and implement its viral hepatitis 
prevention and control programme: SOS 
Hepatitis.
Evidence-based policy and data for 
action
There is no routine surveillance for viral 
hepatitis.
There are no standard case defi nitions 
for hepatitis. Hepatitis deaths are not re-
ported to a central registry. Of the hepati-
tis B and hepatitis C cases, 15%–20% and 
4.98%, respectively, are reported as “undif-
ferentiated” or “unclassifi ed” hepatitis. 
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports annually.
It is not known whether hepatitis out-
breaks are required to be reported to the 
government. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
It is not known whether there is a national 
public health research agenda for viral 
hepatitis, or whether viral hepatitis sero-
surveys are conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination. 
It is not known whether the government 
has established the goal of eliminating 
hepatitis B.
It is not known what percentage of new-
born infants nationally in a given recent 
year received the fi rst dose of hepatitis B 
vaccine within 24 hours of birth or what 
percentage of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is no national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B.
There is no specifi c national strategy and/
or policy/guidelines for preventing hepa-
titis B and hepatitis C infection in health-
care settings.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
15.8
Low-income
$1040
4.98%
$55.58
$25.89
53
0.359
16
6.3
It is not known whether the government 
has guidelines that address how hepa-
titis A and hepatitis E can be prevented 
through food and water safety.
Screening, care and treatment
It is not known how health professionals 
obtain the skills and competencies re-
quired to eff ectively care for people with 
viral hepatitis. 
There are no national clinical guidelines 
for the management of viral hepatitis. 
There are national clinical guidelines for 
the management of HIV, which include 
recommendations for coinfection with vi-
ral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are not 
free of charge for all individuals, but they 
are free of charge for blood donors. Hepa-
titis B and hepatitis C tests are compulsory 
for blood donors.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
The following drug for treating hepatitis B 
is on the national essential medicines list 
or subsidized by the government: interfer-
on alpha. The following drugs for treating 
hepatitis C are on the national essential 
medicines list or subsidized by the govern-
ment: interferon alpha and ribavirin. 
The Government of Mali welcomes assist-
ance from WHO in one or more areas of viral 
hepatitis prevention and control (Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Mauritania
The Government of Mauritania reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses exclusively on the prevention 
and control of viral hepatitis. It includes 
components for raising awareness, surveil-
lance, vaccination, prevention in general, 
prevention of transmission via injecting 
drug use, prevention of transmission in 
health-care settings, treatment and care, 
and coinfection with HIV.
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities: Programme National 
de Lutte contre les Hépatites. It has three 
staff  members. There are three full-time 
equivalent staff  members who work on 
hepatitis-related activities in all govern-
ment agencies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
prisoners, people living with HIV and in-
digenous people.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 but has not funded 
other viral hepatitis public awareness 
campaigns since January 2011.
The government collaborates with the fol-
lowing in-country civil society group to 
develop and implement its viral hepatitis 
prevention and control programme: Asso-
ciation Mauritanienne de Lutte contre les 
Infections Virales.
Evidence-based policy and data for 
action
There is no routine surveillance for viral 
hepatitis.
There are no standard case defi nitions for 
hepatitis. It is not known whether deaths, 
including from hepatitis, are reported to a 
central registry. Of all hepatitis cases, 10%–
20% are reported as “undiff erentiated” or 
“unclassifi ed” hepatitis. 
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports.
It is not known whether hepatitis out-
breaks are required to be reported to the 
government. There is inadequate labora-
tory capacity nationally to support the in-
vestigation of viral hepatitis outbreaks and 
other surveillance activities.
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are not conducted regularly.
Prevention of transmission
There is a national policy for hepatitis A 
vaccination.
It is not known whether the government 
has established the goal of eliminating 
hepatitis B.
Nationally, no newborn infant in a given 
recent year received the fi rst dose of hepa-
titis B vaccine within 24 hours of birth 
and 73% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are not vac-
cinated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
3.5
Low-income
$2400
4.41%
$79.01
$41.96
58
0.453
20
4.5
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is a national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepati-
tis E can be prevented through food and 
water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education) and postgraduate training. 
There are no national clinical guidelines 
for the management of viral hepatitis. 
There are national clinical guidelines for 
the management of HIV, which include 
recommendations for coinfection with vi-
ral hepatitis.
Information was not provided on whether 
the government has national policies re-
lating to screening and referral to care for 
hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Information was not provided on whether 
hepatitis B or hepatitis C tests are free of 
charge for all individuals or compulsory for 
members of any specifi c group.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
No drug for treating hepatitis B or hepatitis 
C is on the national essential medicines list 
or subsidized by the government.
The Government of Mauritania welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Nigeria
The Government of Nigeria reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. It is not known how 
many people work full-time on hepatitis-
related activities in all government agen-
cies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c population: health-care workers 
(including health-care waste handlers).
Awareness-raising and partnerships
Information was not provided on whether 
the government held events for World 
Hepatitis Day 2012 or funded other viral 
hepatitis public awareness campaigns 
since January 2011.
Information was not provided on whether 
the government collaborates with in-
country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. Information was not provided about 
which specifi c types of acute and chronic 
hepatitis are monitored by surveillance 
systems.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Informa-
tion was not provided on the percentage 
of hepatitis cases reported as “undiff eren-
tiated” or “unknown” hepatitis.
Liver cancer cases are registered nation-
ally. Information was not provided on 
whether cases with HIV/hepatitis coinfec-
tion are registered nationally. 
The government publishes hepatitis dis-
ease reports monthly.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is inadequate labora-
tory capacity nationally to support inves-
tigation of viral hepatitis outbreaks and 
other surveillance activities.
Information was not provided on whether 
there is a national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are not conducted regularly.
Prevention of transmission
There is no national policy for hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Information was not provided regarding 
the percentage of newborn infants na-
tionally in a given recent year who had re-
ceived the fi rst dose of hepatitis B vaccine 
within 24 hours of birth or the percentage 
of one-year-olds nationally (ages 12–23 
months) in a given recent year who had 
received three doses of hepatitis B vaccine.
There is no national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B.
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. It is not known whether health-
care workers are vaccinated against hepa-
titis B prior to starting work that might put 
them at risk of exposure to blood.
There is a national policy on injection 
safety in health-care settings, which rec-
ommends auto-disable syringes for thera-
peutic injections. It is not known whether 
single-use or auto-disable syringes, nee-
dles and cannulas are always available in 
all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B. It is not known whether all do-
nated blood units (including family dona-
tions) and blood products nationwide are 
screened for hepatitis C.
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
162.5
Lower–middle-income
$2290
5.07%
$121.36
$45.98
54
0.459
18
5.5
It is not known whether there is a national 
policy relating to the prevention of viral 
hepatitis among people who inject drugs.
It is not known whether the government 
has guidelines that address how hepa-
titis A and hepatitis E can be prevented 
through food and water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, but 
information was not provided on whether 
these guidelines include recommenda-
tions for cases with HIV coinfection. In-
formation was not provided on whether 
there are national clinical guidelines for 
the management of HIV, which include 
recommendations for coinfection with vi-
ral hepatitis.
It is not known whether the government 
has national policies relating to screening 
and referral to care for hepatitis B or hepa-
titis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are not 
free of charge. Information was not pro-
vided on whether hepatitis B or hepatitis C 
tests are compulsory for members of any 
specifi c group.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
No drug for treating hepatitis B or hepatitis 
C is on the national essential medicines list 
or subsidized by the government.
The Government of Nigeria welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Rwanda
The Government of Rwanda reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. It has two staff  members. 
There are two full-time equivalent staff 
members who work on hepatitis-related 
activities in all government agencies/bod-
ies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people living with HIV, children under the 
age of one year and soldiers. 
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is no routine surveillance for viral 
hepatitis.
There are standard case defi nitions for 
hepatitis B. It is not known whether deaths, 
including from hepatitis, are reported to a 
central registry. The percentage of hepati-
tis cases reported as “undiff erentiated” or 
“unclassifi ed” hepatitis is not known.
It is not known whether liver cancer cases 
are registered nationally. Cases with HIV/
hepatitis coinfection are not registered 
nationally.
The government does not publish hepati-
tis disease reports.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak 
investigations and other surveillance ac-
tivities for hepatitis B and hepatitis C, but 
it is not known whether this is the case for 
hepatitis A and hepatitis E.
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target population is pregnant women. The 
last serosurvey was carried out in 2011. 
Prevention of transmission
There is no national policy for hepatitis A 
vaccination.
The government has established the goal 
of eliminating hepatitis B but did not pro-
vide information about a specifi c time-
frame for this.
Nationally, no newborn infant in a given 
recent year received the fi rst dose of hepa-
titis B vaccine within 24 hours of birth 
and 97% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are not vac-
cinated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection 
safety in health-care settings, which rec-
ommends the following types of syringes 
for therapeutic injections: single-use and 
auto-disable syringes. Single-use or auto-
disable syringes, needles and cannulas are 
always available in all health-care facilities.
10.9
Low-income
$1270
10.48%
$121.01
$60.59
59
0.429
19
5.4
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepati-
tis E can be prevented through food and 
water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-
service education), on-the-job training, 
postgraduate training and international 
conferences/workshops. 
There are no national clinical guidelines 
for the management of viral hepatitis. 
There are national clinical guidelines for 
the management of HIV, which include 
recommendations for coinfection with 
hepatitis B.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are not 
free of charge for all individuals, but they 
are free of charge and compulsory for 
blood donors. 
Publicly funded treatment is available for 
hepatitis B. The following group is eligible: 
people coinfected with HIV and hepatitis 
B. Publicly funded treatment is not avail-
able for hepatitis C. The amount spent by 
the government on publicly funded treat-
ment for hepatitis B is not known.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: lami-
vudine and tenofovir. No drug for treat-
ing hepatitis C is on the national essential 
medicines list or subsidized by the govern-
ment.
The Government of Rwanda welcomes 
assistance from WHO in one or more ar-
eas of viral hepatitis prevention and con-
trol (Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Sierra Leone
The Government of Sierra Leone reports 
as follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. It is not known how 
many people work full-time on hepatitis-
related activities in all government agen-
cies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c population: children under the 
age of one year.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is no routine surveillance for viral 
hepatitis.
There are standard case defi nitions for 
hepatitis. Hepatitis deaths are not report-
ed to a central registry. Information was 
not provided regarding the percentage of 
hepatitis cases reported as “undiff erenti-
ated” or “unknown” hepatitis.
Liver cancer cases and cases with HIV/
hepatitis coinfection are not registered 
nationally. 
The government does not publish hepati-
tis disease reports.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy for hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 0% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 91% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is no national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B.
There is no specifi c national strategy and/
or policy/guidelines for preventing hepa-
titis B and hepatitis C infection in health-
care settings. 
There is a national policy on injection 
safety in health-care settings, which rec-
ommends auto-disable syringes for thera-
peutic injections. Single-use or auto-disa-
ble syringes, needles and cannulas are not 
always available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepati-
tis E can be prevented through food and 
water safety.
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
6.0
Low-income
$840
13.07%
$107.25
$12.15
49
0.336
18
5.0
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are no national clinical guidelines 
for the management of viral hepatitis. It 
is not known whether there are national 
clinical guidelines for the management of 
HIV, which include recommendations for 
coinfection with viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are not 
free of charge for all individuals, but they 
are free of charge for children under the 
age of fi ve years, pregnant women and 
breastfeeding mothers. Hepatitis B and 
hepatitis C tests are compulsory for blood 
donors.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
The following drug for treating hepatitis B 
is on the national essential medicines list 
or subsidized by the government: lami-
vudine. No drug for treating hepatitis C is 
on the national essential medicines list or 
subsidized by the government.
The Government of Sierra Leone wel-
comes assistance from WHO in one or 
more areas of viral hepatitis prevention 
and control (Annex C).
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South Africa
The Government of South Africa reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses exclusively on the prevention 
and control of viral hepatitis. It includes 
components for vaccination, prevention 
in general, prevention of transmission via 
injecting drug use, prevention of transmis-
sion in health-care settings, treatment and 
care, and coinfection with HIV.
There is no designated governmental 
unit/department responsible solely for 
coordinating and/or carrying out viral 
hepatitis-related activities. There are seven 
full-time equivalent staff  members who 
work on hepatitis-related activities in all 
government agencies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c population: health-care workers 
(including health-care waste handlers).
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government collaborates with the fol-
lowing in-country civil society group to 
develop and implement its viral hepatitis 
prevention and control programme: the 
South African National Blood Service. 
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, and for chronic hepatitis C. 
There are standard case defi nitions for 
hepatitis. It is not known whether deaths, 
including from hepatitis, are reported to a 
central registry. The percentage of hepati-
tis cases reported as “undiff erentiated” or 
“unclassifi ed” hepatitis is not known.
It is not known whether liver cancer cases 
and cases with HIV/hepatitis coinfection 
are registered nationally. 
It is not known whether the government 
publishes hepatitis disease reports.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis A, hepatitis B and hepati-
tis C, but not for hepatitis E. 
It is not known whether there is a national 
public health research agenda for viral 
hepatitis. Viral hepatitis serosurveys are 
not conducted regularly.
Prevention of transmission
There is a national policy for hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, no newborn infant in a given 
recent year received the fi rst dose of hepa-
titis B vaccine within 24 hours of birth and 
50%–80% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine. 
There is no national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B.
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. It is not known whether single-
use or auto-disable syringes, needles and 
cannulas are always available in all health-
care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
50.5
Upper–middle-income
$10 710
8.94%
$934.95
$412.34
54
0.619
25
2.5
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is a national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are not 
free of charge for all individuals, but they 
are free of charge at public health-care fa-
cilities for people who do not have medi-
cal aid. Hepatitis B and hepatitis C tests are 
compulsory for health-care workers and 
sources of exposure following incidents of 
occupational exposure. 
Publicly funded treatment is not available 
for hepatitis B, but is available for hepatitis 
C. Information was not provided on who is 
eligible for such treatment for hepatitis C. 
The amount spent by the government on 
publicly funded treatment for hepatitis C 
is not known.
The following drug for treating hepatitis B 
is on the national essential medicines list 
or subsidized by the government: hepa-
titis B immune globulin. The following 
drugs for treating hepatitis C are on the 
national essential medicines list or subsi-
dized by the government: pegylated inter-
feron and ribavirin.
The Government of South Africa wel-
comes assistance from WHO in one or 
more areas of viral hepatitis prevention 
and control (Annex C).
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United Republic of Tanzania
The Government of the United Republic of 
Tanzania reports as follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. Information was not pro-
vided regarding how many people work 
full-time on hepatitis-related activities in 
all government agencies/bodies.
Information was not provided on whether 
the government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting specifi c popula-
tions.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
Information was not provided on whether 
the government collaborates with in-
country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme.
Evidence-based policy and data for 
action
Information was not provided on whether 
there is routine surveillance for viral hepa-
titis.
There are no standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Infor-
mation was not provided regarding the 
percentage of hepatitis cases reported as 
“undiff erentiated” or “unknown” hepatitis.
Liver cancer cases are registered nation-
ally. Information was not provided on 
whether cases with HIV/hepatitis coinfec-
tion are registered nationally.
The government publishes hepatitis dis-
ease reports.
Hepatitis outbreaks are required to be re-
ported to the government but are not fur-
ther investigated. 
There is inadequate laboratory capacity 
nationally to support investigation of viral 
hepatitis outbreaks and other surveillance 
activities.
It is not known whether there is a national 
public health research agenda for viral 
hepatitis. Viral hepatitis serosurveys are 
not conducted regularly.
Prevention of transmission
There is no national policy for hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, no newborn infant in a given 
recent year received the fi rst dose of hepa-
titis B vaccine within 24 hours of birth and 
more than 90% of one-year-olds (ages 12–
23 months) in a given recent year received 
three doses of the hepatitis B vaccine.
There is no national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B.
It is not known whether there is a specifi c 
national strategy and/or policy/guidelines 
for preventing hepatitis B and hepatitis C 
infection in health-care settings. Health-
care workers are not vaccinated against 
hepatitis B prior to starting work that 
might put them at risk of exposure to 
blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends auto-disable syringes for therapeu-
tic injections. Single-use or auto-disable 
syringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
46.2
Low-income
$1500
6.01%
$83.43
$56.17
55
0.466
18
5.5
There is a national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepati-
tis E can be prevented through food and 
water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through on-
the-job training. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for hepatitis B register by 
name and there is open access to their 
names. Information was not provided on 
whether people testing for hepatitis C reg-
ister by name. Hepatitis B and hepatitis C 
tests are not free of charge for all individu-
als, but they are free of charge for blood 
donors and for people with HIV and other 
chronic illnesses. Hepatitis B and hepatitis 
C tests are compulsory for blood donors.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
The following drug for treating hepatitis B 
is on the national essential medicines list 
or subsidized by the government: teno-
fovir. No drug for treating hepatitis C is 
on the national essential medicines list or 
subsidized by the government.
The Government of the United Republic of 
Tanzania welcomes assistance from WHO 
in one or more areas of viral hepatitis pre-
vention and control (Annex C).
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Zimbabwe
The Government of Zimbabwe reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. It is not known how 
many people work full-time on hepatitis-
related activities in all government agen-
cies/bodies.
The government does not have a viral 
hepatitis prevention and control pro-
gramme that includes activities targeting 
specifi c populations.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A and B, but not for any type of chronic 
hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. The per-
centage of hepatitis cases reported as “un-
diff erentiated” or “unclassifi ed” hepatitis is 
not known.
Liver cancer cases are registered nation-
ally, but cases with HIV/hepatitis coinfec-
tion are not.
The government does not publish hepati-
tis disease reports.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is inadequate labora-
tory capacity nationally to support inves-
tigation of viral hepatitis outbreaks and 
other surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy for hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, no newborn infant in a given 
recent year received the fi rst dose of hepa-
titis B vaccine within 24 hours of birth and 
more than 80% of one-year-olds (ages 12–
23 months) in a given recent year received 
three doses of hepatitis B vaccine.
There is no national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B.
There is no specifi c national strategy and/
or policy/guidelines for preventing hepa-
titis B and hepatitis C infection in health-
care settings. Health-care workers are not 
vaccinated against hepatitis B prior to 
starting work that might put them at risk 
of exposure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeu-
tic injections. Single-use or auto-disable 
syringes, needles and cannulas are not 
always available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
12.8
Low-income
--
--
--
--
49
0.376
19
3.3
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education) and on-the-job training. 
There are no national clinical guidelines 
for the management of viral hepatitis. 
There are national clinical guidelines for 
the management of HIV, which include 
recommendations for coinfection with vi-
ral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are not 
free of charge or compulsory for members 
of any specifi c group.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
The following drug for treating hepatitis B 
is on the national essential medicines list 
or subsidized by the government: inter-
feron alpha. The following drug for treat-
ing hepatitis C is on the national essential 
medicines list or subsidized by the govern-
ment: interferon alpha. 
The Government of Zimbabwe welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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Thirty-fi ve Member States make up the World Health 
Organization (WHO) Region of the Americas, which has a total 
population of 939 million.1 Most of the Region’s countries are 
low- and middle-income countries, but it also encompasses 
the high-income countries of Canada and the United States 
of America.2 The average life expectancy in the Region of the 
Americas in 2010 was 76.2 years, which represented a four-
year increase from 2005.3 By 2020, the Region will be home to 
almost 200 million people above the age of 60 years.3 Longer 
life expectancy and lifestyle changes have driven increases 
in noncommunicable diseases, and these diseases now cause 
more than three fourths of the deaths in the Region annually.4 
The Region of the Americas and the WHO European Region 
have the highest incidence rates of all types of cancer.5 Other 
notable public health issues in the Region of the Americas 
include road traffi  c accidents and violence. One quarter of the 
world’s 600 000 annual homicides occur there.3
The Region of the Americas stands out for its progress against 
vaccine-preventable diseases, and the high level of childhood 
vaccination coverage.3 Although communicable diseases cause 
only about 13% of deaths in the Region of the Americas, they 
impose a high burden of disease in some populations.3 A 2008 
literature review focusing on neglected tropical diseases in 
Latin America and the Caribbean concluded that the subregion 
may have a higher burden of disease from neglected tropical 
diseases such as hookworm infestation and Chagas disease than 
from malaria, tuberculosis or HIV.6 The Region of the Americas 
saw a decline in the rate of new HIV infections between 2001 
and 2009.3
a  Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and 
world region, 1990 and 2005. Vaccine, 2010, 28:6653–6657.
b  Aggarwal R. The global prevalence of hepatitis E virus infection and suscepti-
bility: a systematic review. Geneva, World Health Organization, 2010.
c  Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepati-
tis B virus infection: new estimates of age-specifi c HBsAg seroprevalence 
and endemicity. Vaccine, 2012, 30:2212–2219.
d  Mohd Hanafi ah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiol-
ogy of hepatitis C virus infection: new estimates of age-specifi c antibody 
to HCV seroprevalence. Hepatology, 2013, 57:1333–1342.
e  Pascarella S, Negro F. Hepatitis D virus: an update. Liver International, 
2011, 31:7–21.
f  Alvarado-Mora MV et al. Hepatitis B (HBV), hepatitis C (HCV) and hepatitis 
delta (HDV) viruses in the Colombian population – how is the epidemio-
logical situation? PLoS One, 2011, 6 (4):e18888.
1  World population prospects: the 2010 revision. New York, United Nations, 
Department of Economic and Social Aff airs, Population Division, 2011.
2  Country and lending groups [web site]. The World Bank. Available at: http://
data.worldbank.org/about/country-classifications/country-and-lending-
groups#Low_income (accessed on 26 February 2013).
3  Health in the Americas: 2012 edition. Regional outlook and country profi les. 
Washington, DC, WHO Regional Offi  ce for the Americas, 2012. Available at:  http://
www.paho.org/saludenlasamericas/docs/hia-2012-summary.pdf (accessed on 
05 May 2013).
4  Non-communicable diseases in the Americas: building a healthier future. 
Washington, DC, WHO Regional Offi  ce for the Americas, 2011. Available at: 
http://new.paho.org/hq/index.php?option=com_docman&task=doc_view 
&gid=14832&Itemid= (accessed on 05 May 2013).
5  Global status report on noncommunicable diseases 2010. Geneva, WHO, 2011. 
Available at: http://whqlibdoc.who.int/publications/2011/9789240686458_eng.
pdf= (accessed on 05 May 2013).
6  Hotez PJ et al. The neglected tropical diseases of Latin America and the 
Caribbean: a review of disease burden and distribution and a roadmap for 
control and elimination. PLoS Neglected Tropical Diseases, 2008, 2(9):e300. doi: 
10.1371/journal.pntd.0000300.
Viral hepatitis in the WHO Region of the Americas
Most countries in Latin America and the Caribbean (LAC) 
show intermediate endemicity for hepatitis A. However, 
the prevalence varies from region to region. For instance, 
the seroprevalence of anti-hepatitis A in persons between 
the ages of 15 and 19 years in the Caribbean and 
Andean regions (Peru, Ecuador, Bolivia) is 57% and 96%, 
respectively.a
A low prevalence and outbreaks of hepatitis E have 
been reported in some LAC countries. Although higher 
prevalence has been reported elsewhere, little is known 
about the epidemiology of this infection in the Region. 
For instance, studies in the Brazilian population show 
prevalence rates of around 3% in adults, while in Bolivia, 
the rates ranged from 1.7% to 16.2%.b
Recent data indicate that from 1990 to 2005, the 
prevalence of hepatitis B infection fell on average to below 
2% in the central and tropical Latin American regions, 
while it remained between 2% and 4% in the Caribbean, 
Andean and southern Latin American regions.c
In Andean, central, southern and tropical Latin American 
countries, approximately seven million adults are 
estimated to be anti-hepatitis C positive, meaning that 
they have been exposed to hepatitis C and could contract 
chronic infection.d
With respect to hepatitis D, a high prevalence of coinfection 
among hepatitis B cases has been observed in the 
Amazonian region.e For example, a study from Colombia 
showed that among hepatitis B-positive inhabitants, 5.2% 
were hepatitis D-positive and all except one were from 
the Amazonian region.f
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Responses to the WHO/Alliance survey were received from 27 of 
the 35 Member States in the Region (77.1%).
Box 1. Responses to the 2012 Global Hepatitis Survey: WHO 
Region of the Americas
Member States that submitted surveys:
Member States that did not submit surveys: 
•  Antigua and 
  Barbuda
• Argentina
• Bahamas
• Barbados
• Brazil
• Canada
• Colombia
• Costa Rica
• Cuba
•  Belize
•  Bolivia (Plurinational 
state of)
•  Chile
•  Dominican
  Republic
• Ecuador
• El Salvador
• Grenada
• Guatemala
• Guyana
• Honduras
• Jamaica
• Mexico
•  Dominica
•  Haiti
•  Saint Vincent and 
the Grenadines
• Nicaragua
• Panama
• Paraguay
• Peru
• Saint Kitts and Nevis
• Saint Lucia
• Suriname
•  United States
  of America
• Uruguay
•  Trinidad and Tobago
•  Venezuela (Bolivar-
ian Republic of)
National coordination
Nine responding Member States (33.3%) reported the existence 
of a written national strategy or plan that focuses exclusively 
or primarily on the prevention and control of viral hepatitis 
(Figure 1). Two of the nine Member States with a strategy or 
plan (Argentina and the United States of America) reported 
that it focuses exclusively on viral hepatitis, and fi ve (Brazil, 
Canada, Cuba, Peru and Suriname) reported that it addresses 
other diseases as well. Two countries (Ecuador and El Salvador) 
reported that the strategy or plan only addresses hepatitis B.
The nine Member States that reported the existence of a 
strategy or plan were asked about its specifi c components. All 
nine reported the inclusion of a component for vaccination. 
Eight reported the inclusion of components for surveillance 
and prevention of transmission in health-care settings. Seven 
reported the inclusion of components for general prevention, 
treatment and care, and coinfection with HIV. Six reported the 
inclusion of a component for raising awareness. Four reported 
the inclusion of a component for the prevention of transmission 
via injecting drug use.
Seven responding Member States (25.9%) reported that they 
have a governmental unit or department responsible solely 
for viral hepatitis-related activities. Member States that did so 
were asked to indicate the number of staff  members in the unit 
or department. Responses (N=4) ranged from 1 (Cuba) to 250 
(Brazil) (median, 54).
Member States were asked to report the number of people 
working full-time on hepatitis-related activities in all 
government agencies or bodies. Among the 13 Member States 
that provided data for this question, the numbers ranged from 0 
to 150 (median, 0), with the United States of America reporting 
the largest number.
Figure 1. Responses to the question, “Is there a written 
national strategy or plan that focuses exclusively or primarily 
on the prevention and control of viral hepatitis?”
Yes
No
No response
No data
Twenty responding Member States (74.1%) reported that 
they have a viral hepatitis prevention and control programme 
that includes activities targeting specifi c populations. The 
populations most commonly targeted were health-care 
workers, including health-care waste handlers (100% of 
responding Member States within this subset) and people 
living with HIV (60.0% of responding Member States within this 
subset). Six responding Member States reported the inclusion 
of activities targeting prisoners, and fi ve, the inclusion of 
activities targeting people who inject drugs. Groups identifi ed 
less frequently included migrants, indigenous populations, low-
income populations, those who are uninsured and those who 
are homeless.
Awareness-raising and partnerships
Twelve responding Member States (44.4%) reported that they 
had held events for World Hepatitis Day 2012 (28 July). Since 
January 2011, six responding Member States (22.2%) had 
funded some type of viral hepatitis public awareness campaign 
other than World Hepatitis Day (Table 1).
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Table 1. Topics of public awareness campaigns on viral 
hepatitis held in Member States since January 2011 (N=6)
General 
information about 
hepatitis and its 
transmission
Vaccination for 
hepatitis A and 
hepatitis B
Importance of 
knowing one’s 
hepatitis B and 
hepatitis C status
Safe water and 
good sanitation
Safer sex practices
Harm reduction 
for people who 
inject drugs
Safe workplace 
practices
Other a
CubaArgen-tina
X
X
X
X
X
X
X
X
X
X
X
Guate-
malaBrazil
 
 
 
 
 
 
X
X
X
X
X
X
Suri-
name
X
X
United 
States of 
America
X
X
X
X
X
X
a  Details can be found in the summaries of country fi ndings later in this chapter.
Eight responding Member States (29.6%) reported that 
they collaborated with civil society groups within their 
countries to develop and implement the governmental viral 
hepatitis prevention and control programme. For example, 
Canada reported collaborating with the Canadian Society for 
International Health, Canadian AIDS Treatment Information 
Exchange and University of British Columbia. Peru reported that 
it collaborated with Asociación Ciudadana de Lucha contra la 
Hepatitis. (Further examples can be found in the summaries of 
country fi ndings later in this chapter.)
Evidence-based policy and data for action
Twenty-four responding Member States (88.9%) reported that 
they have routine surveillance for viral hepatitis; details appear 
in Table 2.
Twenty-one responding Member States (77.8%) indicated that 
their countries have standard case defi nitions for hepatitis 
infection and 25 (92.6%) indicated that their countries have a 
central registry for the reporting of deaths, including hepatitis 
deaths.
Eight Member States reported on the proportion of hepatitis 
cases and deaths registered as “undiff erentiated” or “unclassifi ed” 
hepatitis. The reported proportion ranged from 0% to 60.0% 
(median, 27.5%). Additional survey fi ndings about surveillance 
are presented in Table 3.
Table 2. Types of surveillance in Member States that reported 
the existence of routine surveillance for viral hepatitis (N=24)
There is a national 
surveillance system for acute 
hepatitis infection for the 
following forms of hepatitis:
hepatitis A
hepatitis B
hepatitis C
hepatitis D
hepatitis E
There is a national 
surveillance system for 
chronic hepatitis infection 
for the following forms of 
hepatitis:
hepatitis B
hepatitis C
hepatitis D
Yes (%)
70.8
100
79.2
37.5
29.2
45.8
37.5
16.7
No (%)
20.8
0
12.5
45.8
54.2
50.0
54.2
70.8
Do not 
know 
(%)
0
0
0
0
0
0
0
0
No 
response 
(%)
8.3
0
8.3
16.7
16.7
4.2
8.3
12.5
Table 3. Data registration and surveillance (N=27)
Liver cancer cases are registered 
nationally
Cases with HIV/hepatitis 
coinfection are registered 
nationally
Hepatitis outbreaks are reported
If YES – Hepatitis outbreaks are 
further investigated (N=115)
Yes (%)
63.0
40.7
92.6
88.0
No (%)
18.5
51.9
3.7
8.0
Do not 
know 
(%)
7.4
7.4
3.7
0
No 
response 
(%)
11.1
0
0
4.0
Member States were asked how often hepatitis disease re-
ports are published. Of the responding Member States, 48.1% 
reported that hepatitis disease reports are published annually; 
11.1%, monthly; and 7.4%, weekly. No hepatitis disease report is 
published by 25.9% of responding Member States.
Five responding Member States (18.5%) (Argentina, Canada, 
Cuba, Guyana and Peru) reported the existence of a national 
public health research agenda for viral hepatitis.
Seven responding Member States (25.9%) reported that viral 
hepatitis serosurveys are conducted regularly. Among this 
subset, two (Canada and the United States of America) indicated 
that serosurveys take place every two years and one (Argentina) 
indicated that serosurveys take place twice annually. Of the 
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same subset, 57.1% reported that the most recent viral hepatitis 
serosurvey was carried out in either 2011 or 2012.
Prevention of transmission
Nine responding Member States (33.3%) reported that they 
have a national policy on hepatitis A vaccination.
Five responding Member States (18.5%) reported that 
they have established the goal of eliminating hepatitis B 
(Figure 2). Member States with this goal were asked to specify 
the timeframe in which they seek to eliminate hepatitis B. Of the 
three Member States that answered this question, two (Costa 
Rica and Suriname) said that the timeframe was not specifi ed 
while the third (Cuba) said 2013 for the paediatric population 
and 2015 for the rest of the population.
Figure 2. Responses to the question, “Has your government 
established the goal of eliminating hepatitis B?” (N=27)
No 
(70.4%)
Yes 
(18.5%)
Do not know 
(3.7%)
No response 
7.4%
Member States were asked to report, for a given recent year, 
the percentage of newborn infants who had received the fi rst 
dose of hepatitis B vaccine within 24 hours of birth. Among the 
18 Member States that provided this information, responses 
ranged from 0% to 100% (median, 33.5%). Member States were 
also asked to report, for a given recent year, the percentage of 
one-year-olds (ages 12–23 months) who had received three 
doses of hepatitis B vaccine. Among the 18 Member States that 
provided this information, responses ranged from 79.7% to 
100% (median, 94.0%).
Nineteen responding Member States (70.4%) reported the 
existence of a national policy that specifi cally targets mother-
to-child transmission of hepatitis B; details are presented in 
Table 4. More than two thirds of Member States with such a 
policy indicated that one component of the policy calls for 
screening of all pregnant women for hepatitis B.
Twenty responding Member States (74.1%) reported the 
existence of a specifi c national strategy and/or policy/guidelines 
for preventing hepatitis B and hepatitis C infection in health-
care settings.
Table 4. Activities called for in national policy targeting 
mother-to-child transmission of hepatitis B (N=19)
A
ll 
pr
eg
na
nt
 w
om
en
 a
re
 
sc
re
en
ed
 fo
r h
ep
at
iti
s B
A
ll 
pr
eg
na
nt
 w
om
en
 fo
un
d 
to
 
ha
ve
 h
ep
at
iti
s B
 a
re
 c
ou
ns
el
le
d
H
ea
lth
-c
ar
e 
pr
ov
id
er
s f
ol
lo
w
 
up
 w
ith
 a
ll 
pr
eg
na
nt
 w
om
en
 
fo
un
d 
to
 h
av
e 
he
pa
tit
is
 B
 
du
rin
g 
pr
eg
na
nc
y 
fo
r t
he
 
pu
rp
os
e 
of
 e
nc
ou
ra
gi
ng
 th
em
 
to
 g
iv
e 
bi
rt
h 
at
 h
ea
lth
-c
ar
e 
fa
ci
lit
ie
s
U
po
n 
de
liv
er
y,
 a
ll 
in
fa
nt
s 
bo
rn
 to
 w
om
en
 w
ith
 
he
pa
tit
is
 B
 re
ce
iv
e 
he
pa
tit
is
 B
 
im
m
un
og
lo
bu
lin
A
ll 
in
fa
nt
s r
ec
ei
ve
 th
e 
fi r
st
 d
os
e 
of
 h
ep
at
iti
s B
 v
ac
ci
ne
 w
ith
in
 2
4 
ho
ur
s o
f b
irt
h
Antigua and 
Barbuda
Argentina
Bahamas
Brazil
Canada
Colombia
Costa Rica
Cuba
Ecuador
Grenada
Guatemala
Guyana
Honduras
Jamaica
Panama
Peru
Suriname
United States 
of America
Uruguay
TOTAL
X
X
X
X
X
X
X
X
X
X
X
X
X
13
X
X
X
 
X
X
X
X
 
X
 
X
X
X
 
 
X
X
X
14
X
X
X
 
 
X
X
X
 
X
 
X
X
X
 
 
X
 
X
12
X
X
X
X
X
X
X
X
X
X
 
 
X
X
 
 
X
X
X
15
X
X
 
X
X
X
X
X
X
X
X
 
X
X
X
X
X
X
X
17
Nineteen responding Member States (70.4%) reported that 
health-care workers are vaccinated against hepatitis B prior to 
starting work that might put them at risk of exposure to blood.
Twenty-three responding Member States (85.2%) reported 
the existence of a national policy on injection safety in health-
care settings. These Member States were asked which types 
of syringes the policy recommends for therapeutic injections. 
Single-use syringes are recommended in 56.5% of policies, and 
auto-disable syringes in 47.8% (Figure 3).
Twenty-six responding Member States (96.3%) reported that 
single-use or auto-disable syringes, needles and cannulas are 
always available in all health-care facilities.
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Member States were asked for offi  cial estimates of the number 
and percentage of unnecessary injections administered 
annually in health-care settings (e.g. injections that are given 
when an equivalent oral medication is available). Twenty-one 
Member States reported that the fi gures are not known and 
four did not reply. Cuba reported that less than 5.0% of the total 
injections that are administered annually in health-care settings 
are unnecessary and Guyana reported that less than 14.0% are 
unnecessary.
Figure 3. Proportion of responding Member States with 
national policies on injection safety in health-care settings 
which recommend single-use syringes and auto-disable 
syringes for therapeutic injections (N=23)
a  Respondents could select both “single-use syringes” and “auto-disable syringes”.
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
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Single-use syringesa Auto-disable syringesa
Screening, care and treatment
Member States were asked how health professionals in their 
countries obtain the skills and competencies required to 
eff ectively care for people with viral hepatitis. Responding 
Member States most frequently indicated that these are acquired 
in schools for health professionals (pre-service education, 
74.1%). Additionally, on-the-job training was identifi ed in 70.4% 
of responses, and postgraduate training in 46.2%.a
Nine responding Member States (33.3%) reported the existence 
of national clinical guidelines for the management of viral 
hepatitis (Figure 4). Eight of these nine Member States indicated 
that the guidelines include recommendations for cases with 
HIV coinfection. Eight of 13 responding Member States (61.5%) 
indicated that there are national clinical guidelines for the 
management of HIV, which include recommendations for 
coinfection with viral hepatitis.
Fourteen responding Member States (51.9%) indicated that 
they have a national policy relating to screening and referral to 
care for hepatitis B. Ten (37.0%) reported having such a policy 
for hepatitis C.
Regarding hepatitis B testing, 25 responding Member States 
(92.6%) indicated that people register by name for testing. 
Twenty-one members of that subset (84.0%) indicated that the 
names are kept confi dential. Fourteen responding Member 
States (51.9%) reported that the hepatitis B test is free of 
charge for all individuals. Among the nine other Member States 
that answered the question, eight (88.9%) reported that the 
hepatitis B test is free of charge for members of specifi c groups. 
Groups identifi ed included blood donors, pregnant women and 
people living with HIV. Nine responding Member States (33.3%) 
reported that the hepatitis B test is compulsory for members of 
specifi c groups. Groups identifi ed included blood donors and 
pregnant women.
Table 5. Hepatitis prevention: policies, practices and 
guidelines (N=27)
There is a national infection 
control policy for blood banks
All donated blood units 
(including family donations) and 
blood products nationwide are 
screened for hepatitis B
All donated blood units 
(including family donations) and 
blood products nationwide are 
screened for hepatitis C
There is a national policy relating 
to the prevention of viral 
hepatitis among people who 
inject drugs
The government has guidelines 
that address how hepatitis A 
and hepatitis E can be prevented 
through food and water safety
Yes (%)
77.8
96.3
88.9
14.8
59.3
No (%)
7.4
0
0
63.0
25.9
Do not 
know 
(%)
11.1
0
7.4
14.8
7.4
No 
response 
(%)
3.7
3.7
3.7
7.4
7.4
a  N=26 (This response option was not included in the survey completed by 
Colombia.)
Figure 4. Responses to the question, “Are there national 
clinical guidelines for the management of viral hepatitis?” 
(N=27)
No 
(66.77%)
Yes 
(33.3%)
No response 
(4.0%)
Do not 
know 
7.1%
Chapter 4: W
H
O
 Region of the Am
ericas
36
GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Regarding hepatitis C testing, 22 responding Member States 
(81.5%) indicated that people register by name for testing. 
Eighteen members of that subset (81.8%) indicated that names 
are kept confi dential. Twelve responding Member States 
(44.4%) reported that the hepatitis C test is free of charge for 
all individuals. Among the nine other Member States that 
answered the question, fi ve (55.6%) reported that the hepatitis 
C test is free of charge for members of specifi c groups. Groups 
identifi ed included blood donors, pregnant women and people 
living with HIV. Seven responding Member States (25.9%) 
reported that the hepatitis C test is compulsory for members of 
specifi c groups. Groups identifi ed included blood donors and 
pregnant women.
Sixteen responding Member States (59.3%) reported that 
publicly funded treatment is available for hepatitis B and 13 
(48.1%) that it is available for hepatitis C. One responding 
Member State reported the amount spent on publicly funded 
treatment for hepatitis B and hepatitis C. Details can be found 
in the summaries of country fi ndings later in this chapter (see 
Argentina).
Twenty-two responding Member States (81.5%) reported that at 
least one available drug for treating hepatitis B is on the national 
essential medicines list or subsidized by the government 
(Table 6). The drugs most commonly reported were tenofovir, 
lamivudine and interferon alpha.
Lamivudine 
Interferon alpha 
Tenofovir
Pegylated interferon
Entecavir
Adefovir dipivoxil
Telbivudine
Ribavirin
Pegylated interferon
Interferon alpha
Telaprevir
Boceprevir
59.3
59.3
40.7
33.3
22.2
18.5
11.1
37.0
37.0
25.9
11.1
7.4
% of Member States reporting its 
inclusion (N=12)
% of Member States reporting its 
inclusion (N=12)
Drugs for treating 
hepatitis B
Drugs for treating 
hepatitis C
Table 6. Proportion of Member States reporting drugs for 
treating hepatitis B and C on national essential medicines 
lists or subsidized by governments
Twelve responding Member States (44.4%) reported that at 
least one available drug for treating hepatitis C is on the national 
essential medicines list or subsidized by the government. 
The drugs most commonly reported were interferon alpha, 
pegylated interferon and ribavirin.
World Health Organization assistance
Member States were asked to indicate areas in which they might 
want assistance from WHO for the prevention and control of viral 
hepatitis. Respondents most commonly selected the following: 
surveillance for viral hepatitis (74.1%) and estimating the 
national burden of viral hepatitis (70.4%) (Table 7). Responses 
from individual Member States appear in Annex C.
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Awareness-raising, partnerships and resource mobilization (fi rst WHO strategic axis)
Developing the national plan for viral hepatitis prevention and control
Integrating viral hepatitis programmes into other health services
Awareness-raising
Evidence-based policy and data for action (second WHO strategic axis)
Viral hepatitis surveillance
Estimating the national burden of viral hepatitis
Developing tools to assess the eff ectiveness of interventions
Assessing the economic impact of viral hepatitis
Prevention of transmission (third WHO strategic axis)
Increasing coverage of the birth dose of the hepatitis B vaccine
Screening, care and treatment (fourth WHO strategic axis)
Increasing access to treatment
Increasing access to diagnostics
Improving laboratory quality
Developing education/training programmes for health professionals
63.0%
59.3%
59.3%
74.1%
70.4%
51.9%
55.6%
33.3% 
37.0%
55.6%
46.2%a
63.0%
Table 7. Viral hepatitis control and prevention: areas in which Member States indicated interest in receiving WHO assistance 
(N=27)
a  N=26 (This response option was not included in the survey completed by Colombia.)
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Antigua and Barbuda
The Government of Antigua and Barbuda 
reports as follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. There are no people 
working full-time on hepatitis-related ac-
tivities in any government agency/body.
The government does not have a viral 
hepatitis prevention and control pro-
gramme that includes activities targeting 
specifi c populations.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, but not for any type of chronic 
hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. The per-
centage of hepatitis cases reported as “un-
diff erentiated” or “unclassifi ed” hepatitis is 
not known.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government does not publish hepati-
tis disease reports.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis B and hepatitis C, but not 
for hepatitis A and hepatitis E.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination. 
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 8% of newborn infants in a 
given recent year received the fi rst dose 
of hepatitis B vaccine within 24 hours of 
birth. It is not known what percentage 
of one-year-olds (ages 12–23 months) 
nationally in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is no specifi c national strategy and/
or policy/guidelines for preventing hepa-
titis B and hepatitis C infection in health-
care settings. Health-care workers are vac-
cinated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is no national policy on injection 
safety in health-care settings. Single-use 
or auto-disable syringes, needles and can-
nulas are always available in all health-care 
facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is no national infection control 
policy for blood banks. All donated blood 
units (including family donations) and 
blood products nationwide are screened 
for hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
0.09
Upper–middle-income
$17 900
6.03%
$990.55
$702.97
74
0.764
--
2.1
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis and for 
the management of HIV, which include 
recommendations for coinfection with vi-
ral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B, but not for hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are not 
free of charge for all individuals, but they 
are free of charge for blood donors. Infor-
mation was not provided on whether hep-
atitis B or hepatitis C tests are compulsory 
for members of any specifi c group.
Publicly funded treatment for hepatitis 
B and hepatitis C is available to all public 
hospital patients who contribute to the 
medical benefi ts scheme. The amount 
spent by the government on publicly 
funded treatment for hepatitis B and hep-
atitis C is not known.
The following drug for treating hepatitis 
B is on the national essential medicines 
list or is subsidized by the government: 
tenofovir. No drug for treating hepatitis C 
is on the national essential medicines list 
or subsidized by the government.
The Government of Antigua and Barbuda 
did not indicate a need for assistance from 
WHO in relation to viral hepatitis preven-
tion and control.
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Argentina
The Government of Argentina reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses exclusively on the prevention 
and control of viral hepatitis. It includes 
components for raising awareness, surveil-
lance, vaccination, prevention in general, 
prevention of transmission in health-care 
settings, treatment and care, and coinfec-
tion with HIV.
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. This programme is part 
of the AIDS and STD Directorate. Infor-
mation was not provided regarding how 
many staff  members this offi  ce has. There 
are eight full-time equivalent staff  mem-
bers who work on hepatitis-related activi-
ties in all government agencies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people living with HIV and the uninsured.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 and has funded other 
viral hepatitis public awareness cam-
paigns since January 2011 (Annex A).
The government collaborates with the fol-
lowing in-country civil society group to 
develop and implement its viral hepatitis 
prevention and control programme: Fun-
dación HCV Sin Fronteras.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B, C, D and E, and for the following types 
of chronic hepatitis: B, C and D.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Infor-
mation was not provided regarding the 
percentage of hepatitis cases reported as 
“undiff erentiated” or “unknown” hepatitis.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports annually.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target population is children. Information 
was not provided regarding when the last 
serosurvey was carried out.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination. 
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 94.4% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 92.5% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
40.8
Upper–middle-income
$17 130
8.10%
$1286.68
$702.56
75
0.797
30
2.2
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through on-
the-job training and postgraduate train-
ing. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection. There are national clini-
cal guidelines for the management of HIV, 
which include recommendations for coin-
fection with viral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals and are not com-
pulsory for members of any specifi c group.
Publicly funded treatment is available for 
hepatitis B and hepatitis C. The following 
groups are eligible: all people without so-
cial coverage. The government spends 40 
million pesos (US$ 8.8 million) annually on 
publicly funded treatment for hepatitis B 
and hepatitis C.
The following drugs for treating hepatitis B 
are on the national essential medicines list 
or subsidized by the government: pegylat-
ed interferon, lamivudine, entecavir and 
tenofovir. The following drugs for treating 
hepatitis C are included on the national 
essential medicines list or subsidized by 
the government: pegylated interferon and 
ribavirin.
The Government of Argentina welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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Bahamas
The Government of the Bahamas reports 
as follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. There are no people 
working full-time on hepatitis-related ac-
tivities in any government agency/body.
The government does not have a viral 
hepatitis prevention and control pro-
gramme that includes activities targeting 
specifi c populations.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, and for the following types of 
chronic hepatitis: B and C.
It is not known whether there are stand-
ard case defi nitions for hepatitis. Deaths, 
including from hepatitis, are reported to a 
central registry. The percentage of hepati-
tis cases reported as “undiff erentiated” or 
“unclassifi ed” hepatitis is not known.
Information was not provided on whether 
liver cancer cases are registered nationally. 
Cases with HIV/hepatitis coinfection are 
not registered nationally.
The government does not publish hepati-
tis disease reports.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis A, hepatitis B and hepati-
tis C, but it is not known if this is the case 
for hepatitis D and hepatitis E.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, less than 1% of newborn in-
fants in a given recent year received the 
fi rst dose of hepatitis B vaccine within 24 
hours of birth and 97% of one-year-olds 
(ages 12–23 months) in a given recent year 
received three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is no specifi c national strategy and/
or policy/guidelines for preventing hepa-
titis B and hepatitis C infection in health-
care settings.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends auto-disable syringes for therapeu-
tic injections. Single-use or auto-disable 
syringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
0.3
High-income
--
7.98%
$1988.45
$906.66
76
0.771
31
1.6
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are no national clinical guidelines 
for the management of viral hepatitis. 
There are national clinical guidelines for 
the management of HIV, which include 
recommendations for coinfection with 
viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are not 
free of charge for all individuals, but they 
are free of charge for children, indigent 
people, senior citizens and civil servants. 
Hepatitis B and hepatitis C tests are not 
compulsory for members of any specifi c 
group. 
Publicly funded treatment for hepatitis B 
and hepatitis C is available to all residents. 
The amount spent by the government on 
publicly funded treatment for hepatitis B 
and hepatitis C is not known.
The following drugs for treating hepatitis B 
are on the national essential medicines list 
or subsidized by the government: inter-
feron alpha, lamivudine, entecavir, telbivu-
dine and tenofovir. The following drugs for 
treating hepatitis C are on the national es-
sential medicines list or subsidized by the 
government: interferon alpha, ribavirin 
and telaprevir.
The Government of the Bahamas wel-
comes assistance from WHO in one or 
more areas of viral hepatitis prevention 
and control (Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Barbados
The Government of Barbados reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. There are no people 
working full-time on hepatitis-related ac-
tivities in any government agency/body.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
soldiers, police offi  cers, sanitary workers, 
infants and adolescents.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
B and C, but not for any type of chronic 
hepatitis.
There are no standard case defi nitions for 
hepatitis. It is not known whether deaths, 
including from hepatitis, are reported to a 
central registry. The percentage of hepati-
tis cases reported as “undiff erentiated” or 
“unclassifi ed” hepatitis is not known.
It is not known whether liver cancer cases 
are registered nationally. Cases with HIV/
hepatitis coinfection are not registered 
nationally.
The government publishes hepatitis dis-
ease reports monthly. 
Hepatitis outbreaks are not required to 
be reported to the government. There is 
adequate laboratory capacity nationally 
to support outbreak investigations and 
other surveillance activities for hepatitis B 
and hepatitis C, but this is not the case for 
hepatitis A and hepatitis E.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, no newborn infant in a given 
recent year received the fi rst dose of hepa-
titis B vaccine within 24 hours of birth 
and 95% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is no specifi c national strategy and/
or policy/guidelines for preventing hepa-
titis B and hepatitis C infection in health-
care settings.
There is no national policy on injection 
safety in health-care settings. Single-use 
or auto-disable syringes, needles and can-
nulas are always available in all health-care 
facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
0.3
High-income
--
7.97%
$1523.45
$990.36
76
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Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
It is not known whether there is a national 
infection control policy for blood banks. 
All donated blood units (including fam-
ily donations) and blood products na-
tionwide are screened for hepatitis B and 
hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepati-
tis E can be prevented through food and 
water safety.
Screening, care and treatment
It is not known how health professionals 
obtain the skills and competencies re-
quired to eff ectively care for people with 
viral hepatitis. 
There are no national clinical guidelines 
for the management of viral hepatitis or 
for HIV, which include recommendations 
for coinfection with viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; there is open 
access to their names. Hepatitis B and 
hepatitis C tests are free of charge for all 
individuals and are not compulsory for 
members of any specifi c group.
Publicly funded treatment is available for 
hepatitis B and hepatitis C. The following 
groups are eligible for such treatment for 
hepatitis B: nationals and residents; and for 
hepatitis C: nationals. The amount spent 
by the government on publicly funded 
treatment for hepatitis B and hepatitis C is 
not known.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: in-
terferon alpha, pegylated interferon, lami-
vudine and tenofovir. The following drugs 
for treating hepatitis C are on the national 
essential medicines list or subsidized by 
the government: interferon alpha and 
pegylated interferon.
The Government of Barbados welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Brazil
The Government of Brazil reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses primarily on the prevention 
and control of viral hepatitis, and also in-
tegrates other diseases. It includes compo-
nents for raising awareness, surveillance, 
vaccination, prevention in general, preven-
tion of transmission via injecting drug use, 
prevention of transmission in health-care 
settings, treatment and care, and coinfec-
tion with HIV.
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities: National Department of 
STD, AIDS and Viral Hepatitis. It has 250 
staff  members. It is not known how many 
people work full-time on hepatitis-related 
activities in all government agencies/bod-
ies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs, prisoners, sex 
workers, people living with HIV, the unin-
sured, indigenous people, pregnant wom-
en and men who have sex with men.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 and has funded other 
viral hepatitis public awareness campaigns 
since January 2011 (Annex A).
The government collaborates with in-
country civil society groups to develop and 
implement its viral hepatitis prevention 
and control programme. 
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: A, 
B, C, D and E, and for the following types of 
chronic hepatitis: B, C and D.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Informa-
tion was not provided on the percentage 
of hepatitis cases reported as “undiff erenti-
ated” or “unknown” hepatitis.
Liver cancer cases are not registered na-
tionally, but cases with HIV/hepatitis coin-
fection are. 
The government publishes hepatitis dis-
ease reports annually and in the case of 
outbreaks.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are conducted regularly; target 
populations include the general popula-
tion, adolescents, health professionals, 
pregnant women and tattooists. The last 
serosurvey was carried out in July 2012.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
It is not known what percentage of new-
born infants nationally in a given recent 
year received the fi rst dose of hepatitis B 
vaccine within 24 hours of birth or what 
percentage of one-year-olds (ages 12–23 
months) nationally in a given recent year 
received three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vaccinat-
ed against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
196.7
Upper–middle-income
$11 420
9.01%
$1028.29
$483.49
73
0.718
29
1.8
products nationwide are screened for hep-
atitis B and hepatitis C. 
There is a national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through on-
the-job training, postgraduate training and 
training for multidisciplinary teams. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals and are not com-
pulsory for members of any specifi c group.
Publicly funded treatment for hepatitis B 
and hepatitis C is available to the entire 
population. Information was not provided 
regarding the amount spent by the gov-
ernment on such treatment for hepatitis B 
and hepatitis C.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: in-
terferon alpha, pegylated interferon, lami-
vudine, adefovir dipivoxil, entecavir and 
tenofovir. The following drugs for treating 
hepatitis C are on the national essential 
medicines list or subsidized by the govern-
ment: interferon alpha, pegylated interfer-
on and ribavirin.
The Government of Brazil welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Canada
The Government of Canada reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses primarily on the prevention and 
control of viral hepatitis, and also integrates 
other diseases. It includes components for 
raising awareness, surveillance, vaccination, 
prevention in general, prevention of trans-
mission via injecting drug use, prevention 
of transmission in health-care settings, treat-
ment and care, and coinfection with HIV.
There is a designated governmental unit/
department responsible solely for coordinat-
ing and/or carrying out viral hepatitis-related 
activities. The name of this offi  ce was not pro-
vided. It is not known how many people work 
full-time on hepatitis-related activities in all 
government agencies/bodies.
The government has a viral hepatitis preven-
tion and control programme that includes 
activities targeting the following specifi c 
populations: health-care workers (including 
health-care waste handlers), people who in-
ject drugs, migrants, prisoners, the homeless, 
people living with HIV, low-income popula-
tions, indigenous people, ethnocultural pop-
ulations and youth.
Awareness-raising and partnerships
The government held events for World Hepa-
titis Day 2012 but has not funded other viral 
hepatitis public awareness campaigns since 
January 2011.
The government collaborates with the follow-
ing in-country civil society groups to develop 
and implement its viral hepatitis prevention 
and control programme: Canadian Society 
for International Health, Canadian AIDS Treat-
ment Information Exchange and University of 
British Columbia Hepatitis Services.
Evidence-based policy and data for 
action
There is a national surveillance system for the 
following types of acute hepatitis: A, B and C, 
and for the following types of chronic hepa-
titis: B and C.
There are standard case defi nitions for hepa-
titis. Deaths, including from hepatitis, are re-
ported to a central registry. Of hepatitis cases, 
0%–10.0% is reported as “undiff erentiated” or 
“unclassifi ed” hepatitis. 
Liver cancer cases are registered nationally, 
but cases with HIV/hepatitis coinfection are 
not.
The government publishes hepatitis disease 
reports annually. 
Hepatitis outbreaks are reported to local 
public health authorities and are further in-
vestigated only at the local level. There is ad-
equate laboratory capacity nationally to sup-
port investigation of viral hepatitis outbreaks 
and other surveillance activities.
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are conducted regularly; the target 
population is the general population. The 
last serosurvey was carried out from 2009 to 
2011.
Prevention of transmission
There is a national policy on hepatitis A vac-
cination.
The government has established the goal of 
eliminating hepatitis B but information was 
not provided about a specifi c timeframe for 
this goal.
Information was not provided on the per-
centage of newborn infants nationally in a 
given recent year who received the fi rst dose 
of hepatitis B vaccine within 24 hours of birth 
or the percentage of one-year-olds nationally 
(ages 12–23 months) in a given recent year 
who received three doses of hepatitis B vac-
cine.
There is a national policy that specifi cally tar-
gets mother-to-child transmission of hepati-
tis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis B 
and hepatitis C infection in health-care set-
tings. Health-care workers are vaccinated 
against hepatitis B prior to starting work that 
might put them at risk of exposure to blood.
There is a national policy on injection safety 
in health-care settings, which recommends 
34.3
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$39 660
11.29%
$4403.62
$3104.41
81
0.908
40
1.7
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
single-use syringes for therapeutic injections. 
Single-use or auto-disable syringes, nee-
dles and cannulas are always available in all 
health-care facilities.
Offi  cial government estimates of the number 
and percentage of unnecessary injections 
administered annually in health-care settings 
are not known.
There is a national infection control policy for 
blood banks. All donated blood units (includ-
ing family donations) and blood products 
nationwide are screened for hepatitis B and 
hepatitis C. 
There is a national policy relating to the pre-
vention of viral hepatitis among people who 
inject drugs.
The government has guidelines that address 
how hepatitis A and hepatitis E can be pre-
vented through food and water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care for 
people with viral hepatitis through schools 
for health professionals (pre-service educa-
tion), on-the-job training and postgraduate 
training.
There are national clinical guidelines for the 
management of viral hepatitis, which include 
recommendations for cases with HIV coinfec-
tion. 
The government has national policies relat-
ing to screening and referral to care for hepa-
titis B and hepatitis C. 
People testing for both hepatitis B and hepa-
titis C register by name; the names are kept 
confi dential within the system. Hepatitis B 
and hepatitis C tests are free of charge for 
all individuals, and are compulsory for blood 
donors and for some health-care workers in 
certain jurisdictions.
Publicly funded treatment is available for 
hepatitis B and hepatitis C. All Canadian resi-
dents are eligible for this. The amount spent 
by the government on such treatment for 
hepatitis B and hepatitis C is not known.
The following drugs for treating hepatitis B 
are on the national essential medicines list 
or subsidized by the government: interferon 
alpha, pegylated interferon, lamivudine, ade-
fovir dipivoxil, entecavir and telbivudine. The 
following drugs for treating hepatitis C are on 
the national essential medicines list or sub-
sidized by the government: pegylated inter-
feron, ribavirin, boceprevir and telaprevir.
The Government of Canada welcomes assist-
ance from WHO in one or more areas of viral 
hepatitis prevention and control (Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Colombia
The Government of Colombia reports as 
follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. There are three full-time 
equivalent staff  members who work on 
hepatitis-related activities in all govern-
ment agencies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people living with HIV and indigenous 
people.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate with 
in-country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A and B, but not for any type of chronic 
hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Sixty per 
cent of hepatitis cases are reported as “un-
diff erentiated” or “unclassifi ed” hepatitis.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports weekly and monthly.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination. 
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 82.7% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 85.4% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/
or policy for preventing hepatitis B and 
hepatitis C infection in health-care settings. 
Health-care workers are vaccinated against 
hepatitis B prior to starting work that might 
put them at risk of exposure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
Population (in millions) (2011)
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46.9
Upper–middle-income
$9560
7.59%
$712.59
$518.04
76
0.710
27
2.4
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education) and on-the-job training. 
There are national clinical guidelines for 
the management of viral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Information was not provided on whether 
hepatitis B or hepatitis C tests are free of 
charge for all individuals or compulsory for 
members of any specifi c group.
Publicly funded treatment is available for 
hepatitis B and hepatitis C. Information 
was not provided regarding who is eligible 
for this or the amount spent by the govern-
ment on such treatment.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: inter-
feron alpha, pegylated interferon, lamivu-
dine and tenofovir. The following drugs for 
treating hepatitis C are on the national es-
sential medicines list or subsidized by the 
government: interferon alpha, pegylated 
interferon and ribavirin.
The Government of Colombia welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Costa Rica
The Government of Costa Rica reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. There are no people 
working full-time on hepatitis-related ac-
tivities in any government agency/body.
The government does not have a viral 
hepatitis prevention and control pro-
gramme that includes activities targeting 
specifi c populations.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011. 
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B, C, D and E but not for any type of 
chronic hepatitis.
There are no standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Of hepa-
titis cases, 51% are reported as “undiff er-
entiated” or “unclassifi ed” hepatitis.
Liver cancer cases are registered nation-
ally, but cases with HIV/hepatitis coinfec-
tion are not.
The government publishes hepatitis dis-
ease reports annually.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities for hepatitis A, hepa-
titis B and hepatitis C. Information was not 
provided on whether this is the case for 
hepatitis E.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has established the goal 
of eliminating hepatitis B but has not de-
fi ned a timeframe for this goal.
Nationally, 91% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 84% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection 
safety in health-care settings. The policy 
recommends auto-disable syringes for 
therapeutic injections. Single-use or auto-
disable syringes, needles and cannulas are 
always available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
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There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are no national clinical guidelines 
for the management of viral hepatitis or 
for the management of HIV, which include 
recommendations for coinfection with 
viral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals. Information was 
not provided on whether hepatitis B or 
hepatitis C tests are compulsory for mem-
bers of any specifi c group.
Publicly funded treatment is available for 
hepatitis B and hepatitis C. All people di-
agnosed with hepatitis B and hepatitis 
C in the health services are eligible. The 
amount spent by the government on pub-
licly funded treatment for hepatitis B and 
hepatitis C is not known.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: 
interferon alpha, pegylated interferon, 
lamivudine and tenofovir. The following 
drugs for treating hepatitis C are included 
on the national essential medicines list or 
subsidized by the government: pegylated 
interferon and ribavirin.
The Government of Costa Rica welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Cuba
The Government of Cuba reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses primarily on the prevention 
and control of viral hepatitis, and also in-
tegrates other diseases. It includes compo-
nents for raising awareness, surveillance, 
vaccination, prevention in general, preven-
tion of transmission via injecting drug use, 
prevention of transmission in health-care 
settings, treatment and care, and coinfec-
tion with HIV.
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. It has one staff  member. 
The name of this offi  ce was not provided. 
There are 22 full-time equivalent staff 
members who work on hepatitis-related 
activities in all government agencies/bod-
ies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs, migrants, prison-
ers, people living with HIV and chronically 
ill patients.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 and has funded other 
viral hepatitis public awareness campaigns 
since January 2011 (Annex A).
The government does not collaborate with 
in-country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: A, 
B, C, D and E and for the following types of 
chronic hepatitis: B, C and D.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. No hepa-
titis case is reported as “undiff erentiated” or 
“unclassifi ed” hepatitis.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports annually, bi-annually and 
quarterly.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has established the goal 
of eliminating hepatitis B by 2013 for the 
paediatric population and by 2015 for the 
rest of the population.
Nationally, 100% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 100% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vaccinat-
ed against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection 
safety in health-care settings, which rec-
ommends single-use and auto-disable 
syringes for therapeutic injections. Single-
use or auto-disable syringes, needles and 
cannulas are always available in all health-
care facilities.
Less than 5% of injections administered 
annually in health-care settings are unnec-
essary, according to offi  cial government 
estimates. 
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
There is a national policy relating to the 
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prevention of viral hepatitis among people 
who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals. Hepatitis B tests 
are compulsory for pregnant women and 
organ and tissue donors, and hepatitis C 
tests for organ and tissue donors.
Publicly funded treatment is available for 
hepatitis B and hepatitis C. All people with 
medical prescriptions are eligible. Infor-
mation was not provided regarding the 
amount spent by the government on pub-
licly funded treatment for hepatitis B and 
hepatitis C.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: inter-
feron alpha, pegylated interferon, lamivu-
dine, adefovir dipivoxil and tenofovir. The 
following drugs for treating hepatitis C are 
on the national essential medicines list or 
subsidized by the government: interferon 
alpha, pegylated interferon and ribavirin.
The Government of Cuba welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Dominican Republic (the)
The Government of the Dominican 
Republic reports as follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. It is not known how 
many people work full-time on hepatitis-
related activities in all government agen-
cies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers) 
and newborns.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is no routine surveillance for viral 
hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. The per-
centage of hepatitis cases reported as “un-
diff erentiated” or “unclassifi ed” hepatitis is 
not known.
Liver cancer cases and cases with HIV/
hepatitis coinfection are not registered 
nationally. 
Information was not provided on whether 
the government publishes hepatitis dis-
ease reports.
Hepatitis outbreaks are required to be re-
ported to the government. Information 
was not provided on whether they are 
further investigated. There is adequate 
laboratory capacity nationally to support 
investigation of viral hepatitis outbreaks 
and other surveillance activities for hepa-
titis A, hepatitis B and hepatitis C. Informa-
tion was not provided on whether this is 
the case for hepatitis E.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination. 
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 82.1% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 79.7% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is no national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B.
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are not vac-
cinated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends auto-disable syringes for therapeu-
tic injections. Single-use or auto-disable 
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syringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
It is not known whether there is a national 
policy relating to the prevention of viral 
hepatitis among people who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepati-
tis E can be prevented through food and 
water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education). 
Information was not provided on whether 
there are national clinical guidelines for 
the management of viral hepatitis.
Information was not provided on whether 
the government has national policies re-
lating to screening and referral to care for 
hepatitis B or hepatitis C.
Information was not provided on whether 
people testing for hepatitis B or hepatitis C 
register by name, or whether the tests are 
free of charge for all individuals or compul-
sory for members of any specifi c group.
Publicly funded treatment is available for 
hepatitis B and hepatitis C. Information 
was not provided regarding who is eligi-
ble for this, or on the amount spent by the 
government on such treatment for hepati-
tis B and hepatitis C.
The following drug for treating hepatitis B 
is on the national essential medicines list 
or subsidized by the government: inter-
feron alpha. The following drug for treat-
ing hepatitis C is on the national essential 
medicines list or subsidized by the govern-
ment: interferon alpha.
The Government of the Dominican Re-
public welcomes assistance from WHO in 
one or more areas of viral hepatitis preven-
tion and control (Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Ecuador
The Government of Ecuador reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses exclusively on the prevention 
and control of hepatitis B. It includes com-
ponents for vaccination and treatment and 
care.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. It is not known how many 
people work full-time on hepatitis-related 
activities in all government agencies/bod-
ies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers) and 
sex workers.
Awareness-raising and partnerships
Information was not provided on whether 
the government held events for World 
Hepatitis Day 2012. It has not funded other 
viral hepatitis public awareness campaigns 
since January 2011.
The government does not collaborate with 
in-country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, but not for any type of chronic 
hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Informa-
tion was not provided on the percentage 
of hepatitis cases reported as “undiff erenti-
ated” or “unknown” hepatitis.
Liver cancer cases are registered nationally. 
It is not known whether cases with HIV/
hepatitis coinfection are registered nation-
ally.
The government does not publish hepati-
tis disease reports.
Hepatitis outbreaks are required to be 
reported to the government but are not 
further investigated. There is adequate 
laboratory capacity nationally to support 
outbreak investigations and other surveil-
lance activities for hepatitis A and hepatitis 
B. Information was not provided regarding 
whether this is the case for hepatitis C and 
hepatitis E.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 16.3% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 100% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vaccinat-
ed against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends auto-disable syringes for therapeu-
tic injections. Single-use or auto-disable 
syringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
It is not known whether there is a national 
infection control policy for blood banks. All 
donated blood units and blood products 
nationwide are screened for hepatitis B. It 
is not known whether all donated blood 
units (including family donations) and 
blood products nationwide are screened 
for hepatitis C. 
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There is no national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
It is not known whether the government 
has guidelines that address how hepa-
titis A and hepatitis E can be prevented 
through food and water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education). 
It is not known whether there are national 
clinical guidelines for the management of 
viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names are 
kept confi dential within the system. Hepa-
titis B tests are free of charge for all indi-
viduals, but not hepatitis C tests. Hepatitis 
B and hepatitis C tests are not compulsory 
for members of any specifi c group.
Publicly funded treatment for hepatitis B is 
available to some segments of the popula-
tion, but information was not provided on 
who is eligible and the amount spent by 
the government on such treatment. Pub-
licly funded treatment is not available for 
hepatitis C. 
The following drug for treating hepatitis B 
is on the national essential medicines list 
or subsidized by the government: lamivu-
dine. No drug for treating hepatitis C is on 
the national essential medicines list or sub-
sidized by the government.
The Government of Ecuador welcomes 
assistance from WHO in one or more ar-
eas of viral hepatitis prevention and con-
trol (Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
El Salvador
The Government of El Salvador reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses exclusively on the preven-
tion and control of hepatitis B. It includes 
components for surveillance, vaccination, 
prevention in general and prevention of 
transmission in health-care settings.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. It is not known how 
many people work full-time on hepatitis-
related activities in all government agen-
cies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c population: health-care workers 
(including health-care waste handlers).
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 but has not funded 
other viral hepatitis public awareness 
campaigns since January 2011.
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is a national surveillance system for 
the following types of acute hepatitis: A, 
B and C, but not for any type of chronic 
hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Fifty per 
cent of hepatitis cases are reported as “un-
diff erentiated” or “unclassifi ed” hepatitis.
Liver cancer cases are registered nation-
ally. It is not known whether cases with 
HIV/hepatitis coinfection are registered 
nationally.
The government does not publish hepati-
tis disease reports.
It is not known whether hepatitis out-
breaks are required to be reported to the 
government, or whether there is adequate 
laboratory capacity nationally to support 
investigation of viral hepatitis outbreaks 
and other surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
It is not known whether the government 
has established the goal of eliminating 
hepatitis B.
Nationally, 5% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 95% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is no national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B.
It is not known whether there is a specifi c 
national strategy and/or policy/guidelines 
for preventing hepatitis B and hepatitis C 
infection in health-care settings. Informa-
tion was not provided on whether health-
care workers are vaccinated against hepa-
titis B prior to starting work that might put 
them at risk of exposure to blood. 
There is a national policy on injection safe-
ty in health-care settings. Information was 
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not provided regarding the type of syring-
es the policy recommends for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B, but it is not known whether these 
are screened for hepatitis C.
It is not known whether there is a national 
policy relating to the prevention of viral 
hepatitis among people who inject drugs.
It is not known whether the government 
has guidelines that address how hepa-
titis A and hepatitis E can be prevented 
through food and water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education). 
It is not known whether there are national 
clinical guidelines for the management of 
viral hepatitis or for HIV, which include rec-
ommendations for coinfection with viral 
hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals and are not com-
pulsory for members of any specifi c group.
It is not known whether publicly funded 
treatment is available for hepatitis B or 
hepatitis C.
No drug for treating hepatitis B or hepatitis 
C is on the national essential medicines list 
or subsidized by the government. 
The Government of El Salvador welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Grenada
The Government of Grenada reports as 
follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. It is not known how many 
people work full-time on hepatitis-related 
activities in all government agencies/bod-
ies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people living with HIV and pregnant wom-
en.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate with 
in-country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: B 
and C, and for the following types of chron-
ic hepatitis: B and C.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Informa-
tion was not provided regarding the per-
centage of hepatitis cases reported as “un-
diff erentiated” or “unknown” hepatitis.
Liver cancer cases are registered nationally, 
but cases with HIV/hepatitis coinfection 
are not.
The government publishes hepatitis dis-
ease reports annually. 
Hepatitis outbreaks are required to be 
reported to the government but are not 
further investigated. There is adequate 
laboratory capacity nationally to support 
outbreak investigations and other surveil-
lance activities for hepatitis B and hepatitis 
C, but not for hepatitis A and hepatitis E.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 100% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 95% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Information was not provided on 
whether health-care workers are vaccinat-
ed against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
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Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through on-
the-job training. 
There are no national clinical guidelines 
for the management of viral hepatitis. In-
formation was not provided on whether 
there are national clinical guidelines for 
the management of HIV and whether they 
include recommendations for coinfection 
with viral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B, but not for hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; there is open 
access to the names. Hepatitis B tests are 
not free of charge for all individuals, but 
they are free of charge for antenatal wom-
en, health-care workers and people living 
with HIV. Information was not provided on 
whether hepatitis C tests are free of charge 
for all individuals. Hepatitis B and hepatitis 
C tests are not compulsory for members of 
any specifi c group.
Publicly funded treatment is available for 
hepatitis B. The following groups are eligi-
ble: pregnant women, health-care workers 
and people living with HIV. The amount 
spent by the government on such treat-
ment for hepatitis B is not known. Publicly 
funded treatment is not available for hepa-
titis C. 
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: lami-
vudine and tenofovir. No drug for treat-
ing hepatitis C is on the national essential 
medicines list or subsidized by the govern-
ment.
The Government of Grenada welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Guatemala
The Government of Guatemala reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hep-
atitis-related activities. Information was 
not provided on how many people work 
full-time on hepatitis-related activities in 
all government agencies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers) 
and newborns. 
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 and has funded other 
viral hepatitis public awareness cam-
paigns since January 2011 (Annex A).
The government collaborates with the fol-
lowing in-country civil society group to 
develop and implement its viral hepatitis 
prevention and control programme: Aso-
ciacion Guatemaltecadel Higado. 
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, but not for any type of chronic 
hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. 
Liver cancer cases are registered nation-
ally, but cases with HIV/hepatitis coinfec-
tion are not.
The government does not publish hepati-
tis disease reports.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis A, hepatitis B and hepa-
titis C. Information was not provided on 
whether this is the case for hepatitis E.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 31% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 87% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
14.8
--
$4760
6.85%
$324.92
$116.39
69
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sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection. There are national clini-
cal guidelines for the management of HIV, 
which include recommendations for coin-
fection with viral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name, but informa-
tion was not provided on whether their 
names are kept confi dential within the 
system or whether there is open access 
to their names. Hepatitis B and hepatitis C 
tests are free of charge for all individuals. 
Information was not provided on whether 
hepatitis B or hepatitis C tests are compul-
sory for members of any specifi c group.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
No drug for treating hepatitis B or hepatitis 
C is on the national essential medicines list 
or subsidized by the government. 
The Government of Guatemala welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Guyana
The Government of Guyana reports as 
follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. Information was not pro-
vided on how many people work full-time 
on hepatitis-related activities in all govern-
ment agencies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers) and 
people living with HIV.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government collaborates with the 
following in-country civil society groups 
to develop and implement its viral hepa-
titis prevention and control programme: 
groups for health-care workers and people 
living with HIV.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for acute as well as chronic hepatitis B. 
There are standard case defi nitions for 
hepatitis. Deaths, including from hepati-
tis, are reported to a central registry. The 
percentage of hepatitis cases reported as 
“undiff erentiated” or “unclassifi ed” hepati-
tis was not known.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports monthly.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis A, hepatitis B and hepatitis 
C, but not for hepatitis E.
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, no newborn infant in a given 
recent year received the fi rst dose of hepa-
titis B vaccine within 24 hours of birth. In 
a given recent year, 92% of one-year-olds 
(ages 12–23 months) received three doses 
of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vaccinat-
ed against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Less than 14% of injections administered 
annually in health-care settings are unnec-
essary, according to offi  cial government 
estimates. 
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
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0.8
Lower–middle-income
$3460
5.38%
$166.69
$142.35
67
0.633
24
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education) and on-the-job training. 
There are national clinical guidelines for 
the management of viral hepatitis. Infor-
mation was not provided on whether they 
include recommendations for cases with 
HIV coinfection. There are national clini-
cal guidelines for the management of HIV, 
which include recommendations for coin-
fection with viral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B but not for hepatitis C.
People testing for hepatitis B register by 
name; the names are kept confi dential 
within the system. Hepatitis B tests are free 
of charge for all individuals and are com-
pulsory for certain groups but information 
was not provided regarding which groups. 
Information was not provided on whether 
people testing for hepatitis C register by 
name, whether the tests are free of charge 
for all individuals or compulsory for mem-
bers of any specifi c group.
Publicly funded treatment for hepatitis B is 
available to the entire population, but not 
for hepatitis C. The amount spent by the 
government on such treatment for hepati-
tis B is not known.
The following drugs for treating hepatitis B 
are on the national essential medicines list 
or subsidized by the government: interfer-
on alpha, adefovir dipivoxil and tenofovir. It 
is not known which drugs for treating hep-
atitis C are on the national essential medi-
cines list or subsidized by the government. 
The Government of Guyana welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Honduras
The Government of Honduras reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is a designated governmental unit/
department responsible solely for coor-
dinating and/or carrying out hepatitis B-
related activities. The name of this offi  ce 
was not provided. Information was not 
provided on how many staff  members this 
offi  ce has. There are no people working 
full-time on hepatitis-related activities in 
any government agency/body.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers) 
and prisoners.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for acute hepatitis B but not for any type of 
chronic hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. The per-
centage of hepatitis cases reported as “un-
diff erentiated” or “unclassifi ed” hepatitis is 
not known.
It is not known whether liver cancer cases 
are registered nationally. Cases with HIV/
hepatitis coinfection are not registered 
nationally.
The government publishes hepatitis dis-
ease reports annually.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target population is blood donors. Infor-
mation was not provided regarding when 
the last serosurvey was carried out.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination. 
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 98% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 100% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
7.8
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mends auto-disable syringes for therapeu-
tic injections. Single-use or auto-disable 
syringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs. 
The government does not have guidelines 
that address how hepatitis A and hepati-
tis E can be prevented through food and 
water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through on-
the-job training. 
It is not known whether there are national 
clinical guidelines for the management of 
viral hepatitis. Information was not provid-
ed on whether there are national clinical 
guidelines for the management of HIV and 
whether they include recommendations 
for coinfection with viral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals, and are not com-
pulsory for members of any specifi c group.
It is not known whether publicly funded 
treatment is available for hepatitis B or 
hepatitis C.
No drug for treating hepatitis B or hepatitis 
C is on the national essential medicines list 
or subsidized by the government. 
The Government of Honduras welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Jamaica
The Government of Jamaica reports as 
follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. There are no people 
working full-time on hepatitis-related ac-
tivities in any government agency/body.
The government does not have a viral hep-
atitis prevention and control programme 
that includes activities targeting specifi c 
populations.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 but has not funded 
other viral hepatitis public awareness cam-
paigns since January 2011.
The government does not collaborate with 
in-country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: A, 
B, C, D and E, and for the following types of 
chronic hepatitis: B, C and D.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. The per-
centage of hepatitis cases reported as “un-
diff erentiated” or “unclassifi ed” hepatitis is 
not known.
Liver cancer cases and cases with HIV/
hepatitis coinfection are not registered na-
tionally. 
The government publishes hepatitis dis-
ease reports annually.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is inadequate laborato-
ry capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities. 
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination. 
The government has not established the 
goal of eliminating hepatitis B. 
Nationally, no newborn infant in a given 
recent year received the fi rst dose of hepa-
titis B vaccine within 24 hours of birth and 
92% of one-year-olds (ages 12–23 months) 
in a given recent year received three doses 
of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vaccinat-
ed against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
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2.8
Upper–middle-income
--
4.81%
$371.64
$198.85
71
0.727
27
2.3
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
It is not known whether there are national 
clinical guidelines for the management of 
viral hepatitis or for the management of 
HIV, and whether the latter include rec-
ommendations for coinfection with viral 
hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free 
of charge for all individuals and are com-
pulsory for blood donors and patients on 
dialysis.
Publicly funded treatment is available for 
hepatitis B and hepatitis C. People who 
seek care in the public health-care system 
are eligible for publicly funded treatment 
for hepatitis B but information on this for 
hepatitis C was not provided. The amount 
spent by the government on publicly fund-
ed treatment for hepatitis B and hepatitis C 
is not known.
The following drug for treating hepatitis B 
is on the national essential medicines list 
or subsidized by the government: lamivu-
dine. No drug for treating hepatitis C is on 
the national essential medicines list or sub-
sidized by the government. 
The Government of Jamaica welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Mexico
The Government of Mexico reports as 
follows.
National coordination
Information was not provided on whether 
there is a written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis.
Information was not provided on whether 
there is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities, or how many people 
work full-time on hepatitis-related activi-
ties in all government agencies/bodies.
Information was not provided on whether 
the government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting specifi c popula-
tions.
Awareness-raising and partnerships
Information was not provided on whether 
the government held events for World 
Hepatitis Day 2012 or funded other viral 
hepatitis public awareness campaigns 
since January 2011.
Information was not provided on whether 
the government collaborates with in-
country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B, C and D, but not for any type of chron-
ic hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Of the 
hepatitis cases, 10.2% are reported as “un-
diff erentiated” or “unclassifi ed” hepatitis.
Information was not provided on whether 
liver cancer cases are registered nationally. 
Cases with HIV/hepatitis coinfection are 
not registered nationally.
The government publishes hepatitis dis-
ease reports annually.
Hepatitis outbreaks are required to be 
reported to the government and are fur-
ther investigated. Information was not 
provided on whether there is adequate 
laboratory capacity nationally to support 
investigation of viral hepatitis outbreaks 
and other surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
Information was not provided on whether 
there is a national policy on hepatitis A 
vaccination or whether the government 
has established the goal of eliminating 
hepatitis B.
Information was not provided on the per-
centage of newborn infants nationally 
in a given recent year who received the 
fi rst dose of hepatitis B vaccine within 24 
hours of birth or the percentage of one-
year-olds nationally (ages 12–23 months) 
in a given recent year who received three 
doses of hepatitis B vaccine.
Information was not provided on whether 
there is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B.
Information was not provided on whether 
there is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings, or whether health-care workers 
are vaccinated against hepatitis B prior to 
starting work that might put them at risk 
of exposure to blood.
Information was not provided on wheth-
er there is a national policy on injection 
safety in health-care settings, or whether 
single-use or auto-disable syringes, nee-
114.8
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dles and cannulas are always available in 
all health-care facilities.
Information was not provided on offi  cial 
government estimates of the number 
and percentage of unnecessary injec-
tions administered annually in health-care 
settings.
Information was not provided on whether 
there is a national infection control policy 
for blood banks and whether all donated 
blood units (including family donations) 
and blood products nationwide are 
screened for hepatitis B and hepatitis C.
Information was not provided on whether 
there is a national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
Information was not provided on whether 
the government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Information was not provided on how 
health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis.
Information was not provided on whether 
there are national clinical guidelines for 
the management of viral hepatitis and for 
the management of HIV, and whether the 
latter include recommendations for coin-
fection with viral hepatitis.
Information was not provided on whether 
the government has national policies re-
lating to screening and referral to care for 
hepatitis B or hepatitis C.
Information was not provided on whether 
people testing for hepatitis B or hepatitis C 
register by name, and whether hepatitis B 
or hepatitis C tests are free of charge for all 
individuals or compulsory for members of 
any specifi c group.
Information was not provided on whether 
publicly funded treatment is available for 
hepatitis B or hepatitis C and, if so, who is 
eligible for this. 
Information was not provided on whether 
any drug for treating hepatitis B and hepa-
titis C is on the national essential medi-
cines list or subsidized by the government. 
The Government of Mexico did not indi-
cate a need for assistance from WHO in 
relation to viral hepatitis prevention and 
control.
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Nicaragua
The Government of Nicaragua reports as 
follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. It is not known how many 
people work full-time on hepatitis-related 
activities in all government agencies/bod-
ies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers) and 
people living with HIV.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012. It is not known wheth-
er the government has funded other viral 
hepatitis public awareness campaigns 
since January 2011.
The government collaborates with in-
country civil society groups to develop and 
implement its viral hepatitis prevention 
and control programme, but the identity 
of these partners was not provided.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, but not for any type of chronic 
hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. 
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports as warranted.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis A, hepatitis B and hepatitis 
C. Information was not provided on wheth-
er this is the case for hepatitis E.
There is no national public health research 
agenda for viral hepatitis. It is not known 
whether viral hepatitis serosurveys are 
conducted regularly.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Information was not provided on the per-
centage of newborn infants nationally in 
a given recent year who received the fi rst 
dose of hepatitis B vaccine within 24 hours 
of birth or the percentage of one-year-olds 
nationally (ages 12–23 months) in a given 
recent year who received three doses of 
hepatitis B vaccine.
There is no national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B.
It is not known whether there is a specifi c 
national strategy and/or policy/guidelines 
for preventing hepatitis B and hepatitis C 
infection in health-care settings. Health-
care workers are not vaccinated against 
hepatitis B prior to starting work that might 
put them at risk of exposure to blood.
There is a national policy on injection 
safety in health-care settings, which rec-
ommends single-use and auto-disable 
syringes for therapeutic injections. Single-
use or auto-disable syringes, needles and 
cannulas are always available in all health-
care facilities.
Information was not provided regard-
ing offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
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Information was not provided on whether 
there is a national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
Information was not provided on whether 
the government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education) and on-the-job training. 
Information was not provided on whether 
there are national clinical guidelines for the 
management of viral hepatitis or for the 
management of HIV, and whether the lat-
ter include recommendations for coinfec-
tion with viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals and are compul-
sory for donors.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
The following drug for treating hepatitis B 
is on the national essential medicines list or 
subsidized by the government: interferon 
alpha. No drug for treating hepatitis C is on 
the national essential medicines list or sub-
sidized by the government.
The Government of Nicaragua welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Panama
The Government of Panama reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hep-
atitis-related activities. Information was 
not provided on how many people work 
full-time on hepatitis-related activities in 
all government agencies/bodies.
The government does not have a viral 
hepatitis prevention and control pro-
gramme that includes activities targeting 
specifi c populations.
Awareness-raising and partnerships
It is not known whether the government 
held events for World Hepatitis Day 2012 
or funded other viral hepatitis public 
awareness campaigns since January 2011.
Information was not provided on whether 
the government collaborates with in-
country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B, C, D and E. Information was not pro-
vided on whether there is a national sur-
veillance system for any type of chronic 
hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Informa-
tion was not provided on the percentage 
of hepatitis cases reported as “undiff eren-
tiated” or “unknown” hepatitis.
Information was not provided on whether 
liver cancer cases are registered nationally. 
Cases with HIV/hepatitis coinfection are 
not registered nationally.
The government publishes hepatitis dis-
ease reports annually.
Hepatitis outbreaks are required to be 
reported to the government and are fur-
ther investigated. Information was not 
provided on whether there is adequate 
laboratory capacity nationally to support 
investigation of viral hepatitis outbreaks 
and other surveillance activities.
Information was not provided on whether 
there is a national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are not conducted regularly.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 89% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 94% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends auto-disable syringes for therapeu-
tic injections. Single-use or auto-disable 
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syringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
It is not known whether there is a national 
policy relating to the prevention of viral 
hepatitis among people who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education) and on-the-job training. 
Information was not provided on whether 
there are national clinical guidelines for 
the management of viral hepatitis. There 
are no national clinical guidelines for the 
management of HIV, which include rec-
ommendations for coinfection with viral 
hepatitis.
Information was not provided on whether 
the government has national policies re-
lating to screening and referral to care for 
hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Information was not provided on whether 
hepatitis B or hepatitis C tests are free of 
charge for all individuals, but they are 
compulsory for blood donors.
Information was not provided on whether 
publicly funded treatment is available for 
hepatitis B or C. 
No drug for treating hepatitis B or hepatitis 
C is on the national essential medicines list 
or subsidized by the government. 
The Government of Panama welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Paraguay
The Government of Paraguay reports as 
follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. Information was not pro-
vided on how many people work full-time 
on hepatitis-related activities in all govern-
ment agencies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people living with HIV and patients on 
haemodialysis.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate with 
in-country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme.
Evidence-based policy and data for 
action
There is no routine surveillance for viral 
hepatitis.
There are no standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Informa-
tion was not provided on the percentage 
of hepatitis cases reported as “undiff erenti-
ated” or “unknown” hepatitis.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government does not publish hepati-
tis disease reports.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis A, hepatitis B and hepatitis 
C, but not for hepatitis E.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target populations are people who inject 
drugs, sex workers and men who have sex 
with men. Information was not provided 
on when the last serosurvey was carried 
out.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Information was not provided regarding 
the percentage of newborn infants nation-
ally in a given recent year who received the 
fi rst dose of hepatitis B vaccine within 24 
hours of birth or the percentage of one-
year-olds nationally (ages 12–23 months) 
in a given recent year who received three 
doses of hepatitis B vaccine.
There is no national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B.
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vaccinat-
ed against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends auto-disable syringes for therapeu-
tic injections. Single-use or auto-disable 
syringes, needles and cannulas are always 
available in all health-care facilities.
Information was not provided on offi  cial 
government estimates of the number and 
percentage of unnecessary injections ad-
ministered annually in health-care settings.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
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There is no national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education) and on-the-job training. 
There are no national clinical guidelines for 
the management of viral hepatitis. There 
are national clinical guidelines for the man-
agement of HIV, which include recommen-
dations for coinfection with viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name, and there 
is open access to their names. Hepatitis B 
and hepatitis C tests are free of charge for 
all individuals and are not compulsory for 
members of any specifi c group.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: lami-
vudine and tenofovir. No drug for treat-
ing hepatitis C is on the national essential 
medicines list or subsidized by the govern-
ment.
The Government of Paraguay welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Peru
The Government of Peru reports as follows.
National coordination
There is a written national strategy or plan 
that focuses primarily on the prevention and 
control of viral hepatitis, and also integrates 
other diseases. It includes components for 
raising awareness, surveillance, vaccination, 
prevention in general, prevention of trans-
mission in health-care settings, treatment 
and care, and coinfection with HIV.
There is a designated governmental unit/
department responsible solely for coordinat-
ing and/or carrying out viral hepatitis-related 
activities: Estrategia Sanitaria Nacional de Pre-
vención y Control de ITS, VIH/SIDA y Hepatitis 
B. It has eight staff  members. There are eight 
full-time equivalent staff  members who work 
on hepatitis-related activities in all govern-
ment agencies/bodies.
The government has a viral hepatitis preven-
tion and control programme that includes 
activities targeting the following specifi c 
populations: health-care workers (including 
health-care waste handlers) and indigenous 
people.
Awareness-raising and partnerships
The government held events for World Hepa-
titis Day 2012 but has not funded other viral 
hepatitis public awareness campaigns since 
January 2011.
The government collaborates with the fol-
lowing in-country civil society group to de-
velop and implement its viral hepatitis pre-
vention and control programme: Asociación 
Ciudadana de Lucha contra la Hepatitis.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepati-
tis. There is a national surveillance system for 
acute and chronic hepatitis B. 
There are standard case defi nitions for hepa-
titis. Hepatitis deaths are not reported to a 
central registry. The percentage of hepatitis 
cases reported as “undiff erentiated” or “un-
classifi ed” hepatitis is not known.
Liver cancer cases and cases with HIV/hepati-
tis coinfection are registered nationally. 
The government publishes hepatitis disease 
reports as warranted.
Hepatitis outbreaks are required to be report-
ed to the government and are further investi-
gated. There is adequate laboratory capacity 
nationally to support outbreak investigations 
and other surveillance activities for hepatitis 
A, hepatitis B and hepatitis C. Information was 
not provided regarding whether this is the 
case for hepatitis E.
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are conducted regularly; the target 
populations are the general population, the 
Amazonian indigenous population and men 
who have sex with men. The last serosurvey 
was carried out in 2011. 
Prevention of transmission
There is no national policy on hepatitis A vac-
cination.
The government has not established the goal 
of eliminating hepatitis B.
Nationally, 36% of newborn infants in a given 
recent year received the fi rst dose of hepatitis 
B vaccine within 24 hours of birth and 90% of 
one-year-olds (ages 12–23 months) in a given 
recent year received three doses of hepatitis 
B vaccine.
There is a national policy that specifi cally tar-
gets mother-to-child transmission of hepati-
tis B (Annex B). 
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis B 
and hepatitis C infection in health-care set-
tings. Health-care workers are vaccinated 
against hepatitis B prior to starting work that 
might put them at risk of exposure to blood.
There is a national policy on injection safety 
in health-care settings, which recommends 
auto-disable syringes for therapeutic injec-
tions. Single-use or auto-disable syringes, 
needles and cannulas are always available in 
all health-care facilities.
Offi  cial government estimates of the number 
and percentage of unnecessary injections 
administered annually in health-care settings 
are not known.
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There is a national infection control policy for 
blood banks. All donated blood units (includ-
ing family donations) and blood products 
nationwide are screened for hepatitis B and 
hepatitis C. 
There is no national policy relating to the pre-
vention of viral hepatitis among people who 
inject drugs. 
The government does not have guidelines 
that address how hepatitis A and hepatitis 
E can be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care for 
people with viral hepatitis through schools for 
health professionals (pre-service education). 
There are national clinical guidelines for the 
management of viral hepatitis, which include 
recommendations for cases with HIV coin-
fection. Information was not provided on 
whether there are national clinical guidelines 
for the management of HIV and whether they 
include recommendations for coinfection 
with viral hepatitis.
The government has national policies relat-
ing to screening and referral to care for hepa-
titis B, but information was not provided on 
whether this is the case for hepatitis C.
People testing for hepatitis B register by 
name; the names are kept confi dential within 
the system. Hepatitis B tests are not free of 
charge for all individuals, but they are free of 
charge for indigenous populations. Hepatitis 
B tests are not compulsory for members of 
any specifi c group. Information was not pro-
vided on whether people testing for hepatitis 
C register by name, whether the tests are free 
of charge for all individuals, or are compulso-
ry for members of any specifi c group.
Publicly funded treatment is available for 
hepatitis B but not for hepatitis C. Informa-
tion was not provided on the amount spent 
by the government on publicly funded treat-
ment for hepatitis B. 
The following drugs for treating hepatitis B 
are on the national essential medicines list 
or subsidized by the government: interferon 
alpha, entecavir and tenofovir. The following 
drugs for treating hepatitis C are on the na-
tional essential medicines list or subsidized 
by the government: pegylated interferon and 
ribavirin.
The Government of Peru welcomes assist-
ance from WHO in one or more areas of viral 
hepatitis prevention and control (Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Saint Kitts and Nevis
The Government of Saint Kitts and Nevis 
reports as follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities and there are no people 
working full-time on hepatitis-related ac-
tivities in any government agency/body.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities relating to hepatitis B vac-
cination for health-care workers.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate with 
in-country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute and chron-
ic hepatitis: B and C. 
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. The per-
centage of hepatitis cases reported as “un-
diff erentiated” or “unclassifi ed” hepatitis is 
not known. 
Liver cancer cases and cases with HIV/
hepatitis coinfection are not registered na-
tionally. 
The government publishes hepatitis dis-
ease reports annually. 
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis A, hepatitis B and hepatitis 
C, but not for hepatitis E.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Information was not provided on the per-
centage of newborn infants nationally in 
a given recent year who received the fi rst 
dose of hepatitis B vaccine within 24 hours 
of birth or the percentage of one-year-olds 
nationally (ages 12–23 months) in a given 
recent year who received three doses of 
hepatitis B vaccine.
There is no national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B.
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vaccinat-
ed against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
It is not known whether there is a national 
infection control policy for blood banks. All 
donated blood units (including family do-
nations) and blood products nationwide 
are screened for hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
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The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education). 
It is not known whether there are national 
clinical guidelines for the management of 
viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names are 
kept confi dential within the system. Hepa-
titis B and hepatitis C tests are not free of 
charge for all individuals, but hepatitis B 
tests are free of charge for antenatal wom-
en in the public system and blood donors. 
Hepatitis B and hepatitis C tests are not 
compulsory for members of any specifi c 
group.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C. 
The following drugs for treating hepatitis 
B drugs are on the national essential medi-
cines list or subsidized by the government: 
lamivudine and tenofovir. No drug for 
treating hepatitis C is on the national es-
sential medicines list or subsidized by the 
government.
The Government of Saint Kitts and Nevis 
welcomes assistance from WHO in one or 
more areas of viral hepatitis prevention 
and control (Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Saint Lucia
The Government of Saint Lucia reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. It is not known how 
many people work full-time on hepatitis-
related activities in all government agen-
cies/bodies.
The government does not have a viral 
hepatitis prevention and control pro-
gramme that includes activities targeting 
specifi c populations.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is no routine surveillance for viral 
hepatitis.
There are no standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Informa-
tion was not provided on the percentage 
of hepatitis cases reported as “undiff eren-
tiated” or “unknown” hepatitis.
Liver cancer cases and cases with HIV/
hepatitis coinfection are not registered 
nationally. 
The government does not publish hepati-
tis disease reports.
Hepatitis A outbreaks are required to be 
reported to the government and are fur-
ther investigated. There is inadequate 
laboratory capacity nationally to support 
investigation of viral hepatitis outbreaks 
and other surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination. 
The government has not established the 
goal of eliminating hepatitis B.
It is not known what percentage of new-
born infants nationally in a given recent 
year received the fi rst dose of hepatitis B 
vaccine within 24 hours of birth or what 
percentage of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is no national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B.
There is no specifi c national strategy and/
or policy/guidelines for preventing hepa-
titis B and hepatitis C infection in health-
care settings.
There is no national policy on injection 
safety in health-care settings. Single-use 
or auto-disable syringes, needles and can-
nulas are always available in all health-care 
facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
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There is no national infection control 
policy for blood banks. All donated blood 
units (including family donations) and 
blood products nationwide are screened 
for hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepati-
tis E can be prevented through food and 
water safety.
Screening, care and treatment
It is not known how health professionals 
obtain the skills and competencies re-
quired to eff ectively care for people with 
viral hepatitis. 
There are no national clinical guidelines 
for the management of viral hepatitis. It 
is not known whether there are national 
clinical guidelines for the management of 
HIV and whether they include recommen-
dations for coinfection with viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for hepatitis B register by 
name; the names are kept confi dential 
within the system. Hepatitis B tests are 
not free of charge for all individuals, but 
they are free of charge for blood donors 
and pregnant women. Hepatitis B tests 
are compulsory for pregnant women. In-
formation was not provided on whether 
people testing for hepatitis C register by 
name, whether the test is free of charge for 
all individuals or whether it is compulsory 
for members of any specifi c group.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: lami-
vudine and tenofovir. No drug for treat-
ing hepatitis C is on the national essential 
medicines list or subsidized by the govern-
ment.
The Government of Saint Lucia welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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Suriname
The Government of Suriname reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses primarily on the prevention 
and control of viral hepatitis, and also in-
tegrates other diseases. It includes compo-
nents for surveillance, vaccination, preven-
tion of transmission in health-care settings 
and coinfection with HIV.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. There are no people 
working full-time on hepatitis-related ac-
tivities in any government agency/body.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people living with HIV and pregnant wom-
en.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 and has funded other 
viral hepatitis public awareness campaigns 
since January 2011 (Annex A).
The government does not collaborate with 
in-country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme.
Evidence-based policy and data for 
action
There is routine hospital-based surveillance 
for viral hepatitis. The surveillance system 
registers all patients who have a diagnosis 
of hepatitis (either acute or chronic).
It is not known whether there are stand-
ard case defi nitions for hepatitis. Deaths, 
including from hepatitis, are reported to a 
central registry. Information was not pro-
vided regarding the percentage of hepa-
titis cases reported as “undiff erentiated” or 
“unknown” hepatitis.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports regularly.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis A, hepatitis B and hepatitis 
C, but not for hepatitis E.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination. 
The government has established the goal 
of eliminating hepatitis B but information 
was not provided about a specifi c time-
frame for this goal.
It is not known what percentage of new-
born infants nationally in a given recent 
year received the fi rst dose of hepatitis B 
vaccine within 24 hours of birth. In a given 
recent year, 86% of one-year-olds (ages 
12–23 months) received three doses of 
hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vaccinat-
ed against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
It is not known whether there is a national 
policy relating to the prevention of viral 
hepatitis among people who inject drugs.
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The government does not have guidelines 
that address how hepatitis A and hepatitis 
E can be prevented through food and wa-
ter safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis and for 
the management of HIV, which include 
recommendations for coinfection with vi-
ral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C for pregnant 
women. 
People testing for both hepatitis B and 
hepatitis C register by name; the names are 
kept confi dential within the system. Hepa-
titis B and hepatitis C tests are not free of 
charge for all individuals, but they are free 
of charge and compulsory for blood do-
nors. 
Publicly funded treatment is available for 
hepatitis B and hepatitis C, but information 
was not provided on who is eligible for this. 
The amount spent by the government on 
such treatment for hepatitis B and hepatitis 
C is not known.
The following drug for treating hepatitis B 
is on the national essential medicines list or 
subsidized by the government: tenofovir. 
No drug for treating hepatitis C is on the 
national essential medicines list or subsi-
dized by the government.
The Government of Suriname welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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United States of America
The Government of the United States of 
America reports as follows.
National coordination
There is a written national strategy or plan 
that focuses exclusively on the prevention 
and control of viral hepatitis. It includes com-
ponents for raising awareness, surveillance, 
vaccination, prevention in general, preven-
tion of transmission via injecting drug use, 
prevention of transmission in health-care 
settings, treatment and care, and coinfection 
with HIV.
There is a designated governmental unit/
department responsible solely for coordinat-
ing and/or carrying out viral hepatitis-related 
activities: the Division of Viral Hepatitis within 
the National Center for HIV/AIDS, Viral Hepati-
tis, STD, and TB Prevention (US Centers for Dis-
ease Control and Prevention). It has 100 staff  
members. There are 150 full-time equivalent 
staff  members who work on hepatitis-related 
activities in all government agencies/bodies.
The government has a viral hepatitis preven-
tion and control programme that includes 
activities targeting the following specifi c 
populations: health-care workers (including 
health-care waste handlers), people who in-
ject drugs, migrants, prisoners, the homeless, 
people living with HIV, low-income popula-
tions, the uninsured, immigrants and refu-
gees, people born between 1945 and 1965, 
Asian–Americans, military veterans, and peo-
ple who have chronic hepatitis C and live in 
areas underserved by treatment specialists.
Awareness-raising and partnerships
The government held events for World Hepa-
titis Day 2012 and has funded other viral 
hepatitis public awareness campaigns since 
January 2011 (Annex A).
The government collaborates with the follow-
ing in-country civil society groups to develop 
and implement its viral hepatitis prevention 
and control programme: Viral Hepatitis Ac-
tion Coalition, National Viral Hepatitis Round-
table, and Asia and Pacifi c Alliance to Elimi-
nate Viral Hepatitis.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepati-
tis. There is a national surveillance system for 
the following types of acute hepatitis: A, B, C 
and D and for the following types of chronic 
hepatitis: B and C.
There are standard case defi nitions for hepa-
titis. Deaths, including from hepatitis, are re-
ported to a central registry. No hepatitis case 
is reported as “undiff erentiated” or “unclassi-
fi ed” hepatitis.
Liver cancer cases are registered nationally, 
but cases with HIV/hepatitis coinfection are 
not. 
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investigation 
of viral hepatitis outbreaks and other surveil-
lance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the tar-
get populations are children over the age of 
six years and the general population. The last 
serosurvey was carried out in 2011.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination.
The government has established the goal of 
eliminating hepatitis B but information was 
not provided about a specifi c timeframe for 
this goal.
Nationally, 58% of newborn infants in a given 
recent year received the fi rst dose of hepatitis 
B vaccine within 24 hours of birth and 90% of 
one-year-olds (ages 12–23 months) in a given 
recent year received three doses of hepatitis 
B vaccine.
There is a national policy that specifi cally tar-
gets mother-to-child transmission of hepati-
tis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis B 
and hepatitis C infection in health-care set-
tings. Health-care workers are vaccinated 
against hepatitis B prior to starting work that 
might put them at risk of exposure to blood.
There is a national policy on injection safety 
in health-care settings, which recommends 
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single-use syringes for therapeutic injections. 
Single-use or auto-disable syringes, nee-
dles and cannulas are always available in all 
health-care facilities.
Offi  cial government estimates of the number 
and percentage of unnecessary injections 
administered annually in health-care settings 
are not known.
There is a national infection control policy for 
blood banks. All donated blood units (includ-
ing family donations) and blood products 
nationwide are screened for hepatitis B and 
hepatitis C. 
There is a national policy relating to the pre-
vention of viral hepatitis among people who 
inject drugs.
The government has guidelines that address 
how hepatitis A and hepatitis E can be pre-
vented through food and water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care for 
people with viral hepatitis through schools 
for health professionals (pre-service educa-
tion), on-the-job training, postgraduate train-
ing and continuing medical education. 
There are national clinical guidelines for the 
management of viral hepatitis, which in-
clude recommendations for cases with HIV 
coinfection. 
The government has national policies relat-
ing to screening and referral to care for hepa-
titis B and hepatitis C. 
People testing for both hepatitis B and hepa-
titis C register by name; the names are kept 
confi dential within the system. Hepatitis B 
and hepatitis C tests are not free of charge 
and are not compulsory for members of any 
specifi c group.
Publicly funded treatment is not available for 
hepatitis B or hepatitis C. 
The following drugs for treating hepatitis B 
are on the national essential medicines list 
or subsidized by the government: interferon 
alpha, pegylated interferon, lamivudine, 
adefovir dipivoxil, entecavir, telbivudine and 
tenofovir. The following drugs for treating 
hepatitis C are on the national essential medi-
cines list or subsidized by the government: 
interferon alpha, pegylated interferon, ribavi-
rin, boceprevir and telaprevir.
The Government of the United States of 
America did not indicate a need for assist-
ance from WHO in relation to viral hepatitis 
prevention and control.
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Uruguay
The Government of Uruguay reports as 
follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. Information was not pro-
vided regarding how many people work 
full-time on hepatitis-related activities in all 
government agencies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs, prisoners and 
people living with HIV.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 but has not funded 
other viral hepatitis public awareness cam-
paigns since January 2011.
The government does not collaborate with 
in-country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: A, 
B, C, D and E but not for any type of chronic 
hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Of hepati-
tis cases, 0.03% are reported as “undiff eren-
tiated” or “unclassifi ed” hepatitis.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports annually. 
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis A, hepatitis B and hepatitis 
C. Information was not provided on wheth-
er this is the case for hepatitis E.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Information was not provided on the per-
centage of newborn infants nationally in 
a given recent year who received the fi rst 
dose of hepatitis B vaccine within 24 hours 
of birth or the percentage of one-year-olds 
nationally (ages 12–23 months) in a given 
recent year who received three doses of 
hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis B 
and hepatitis C infection in health-care set-
tings. Health-care workers are vaccinated 
against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends auto-disable syringes for therapeu-
tic injections. Single-use or auto-disable 
syringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
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Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection. There are national clini-
cal guidelines for the management of HIV, 
which include recommendations for coin-
fection with viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names are 
kept confi dential within the system. Hepa-
titis B and hepatitis C tests are not free of 
charge for all individuals, but they are free 
of charge for donors, people who have 
been in accidents and pregnant women. 
Hepatitis B and hepatitis C tests are com-
pulsory for patients with kidney disease, 
donors and pregnant women.
Publicly funded treatment is not available 
for hepatitis B, but is available for hepatitis 
C. Eligibility for publicly funded treatment 
for hepatitis C is extended to everyone 
through the national resources fund. Infor-
mation was not provided on the amount 
spent by the government on such treat-
ment for hepatitis C.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: 
pegylated interferon and lamivudine. The 
following drugs for treating hepatitis C are 
on the national essential medicines list or 
subsidized by the government: pegylated 
interferon and ribavirin.
The Government of Uruguay welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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Chapter 5:
WHO Eastern Mediterranean 
Region
Chapter 5: W
H
O
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editerranean Region
Twenty-two Member States make up the World Health 
Organization (WHO) Eastern Mediterranean Region, which 
has a total population of 605 million.1 More than two thirds 
of the Region’s age-standardized mortality in 2008 was 
attributable to noncommunicable diseases,2  and deaths from 
noncommunicable diseases are expected to increase by more 
than 20% by 2020.3 Although the overall HIV prevalence in the 
Region is only an estimated 0.2%, the estimated annual number 
of new HIV infections increased from 2001 to 2010, and almost 
90 000 children and adults were newly infected in 2010.4,5 
Almost half of the population of the Eastern Mediterranean 
Region lives in malaria risk areas; health system capacity for 
a  Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and 
world region, 1990 and 2005. Vaccine, 2010, 28:6653–6657.
b  Rein DB et al. The global burden of hepatitis E virus genotypes 1 and 2 in 
2005. Hepatology, 2012, 55:988–997.
c  WHO Regional Offi  ce for the Eastern Mediterranean. The growing threats 
of hepatitis B and hepatitis C in the Eastern Mediterranean Region: a call 
for action. Presented at the Fifty-sixth session of the WHO Regional 
Committee for the Eastern Mediterranean. Fez, Morocco, 5–8 October 
2009 [Document no: EM/ RC/56/3]. Available at:  http://applications.emro.
who.int/docs/EM_RC56_3_en.pdf (accessed on 07 June 2013).
d  Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of 
hepatitis B virus infection: new estimates of age-specifi c HBsAg 
seroprevalence and endemicity. Vaccine, 2012, 30:2212–2219.
1  World population prospects: the 2010 revision. New York, United Nations, 
Department of Economic and Social Aff airs, Population Division, 2011.
2  World health statistics 2012. Geneva, WHO, 2012. Available at: http://apps.who.
int/iris/bitstream/10665/44844/1/9789241564441_eng.pdf (accessed on 11 May 
2013).
3  Global status report on noncommunicable diseases 2010. Geneva, WHO, 2011. 
Available at: http://whqlibdoc.who.int/publications/2011/9789240686458_eng.
pdf (accessed on 11 May 2013).
4  UNAIDS report on the global AIDS epidemic 2012. Geneva, UNAIDS, 2012. Available 
at: http://www.unaids.org/en/media/unaids/contentassets/documents/ epidem 
iology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_en.pdf (accessed 
on 11 May 2013).
5  The work of WHO in the Eastern Mediterranean Region: annual report of the Regional 
Director, 1 January–31 December 2011. Cairo, WHO Regional Offi  ce for the Eastern 
Mediterranean, 2012. Available at: http://applications.emro.who.int/docs/RD_
Annual_Report_2012_en_14587.pdf (accessed on 11 May 2013).
6  Causes of death 2008 summary tables. Geneva, Health Statistics and Informatics 
Department, World Health Organization, May 2011. Available at: http://www.
who.int/entity/gho/mortality_burden_disease/global_burden_disease_
DTH6_2008.xls (accessed on 11 May 2013).
7  Global overview 2011: people internally displaced by confl ict and violence. Geneva, 
Internal Displacement Monitoring Centre, April 2012. Available at: http://www.
internal-displacement.org/publications/global-overview-2011.pdf (accessed on 
11 May 2013).
Viral hepatitis in the WHO Eastern Mediterranean 
Region 
The prevalence of hepatitis A in the Region has decreased 
in recent decades; where studies from the 1980s reported 
100% exposure rate by the age of 10 years, more recent 
studies indicate a modest decrease to 50% of children 
exposed by the age of 15 years.a 
The prevalence of hepatitis E infection is high (>15%) in 
Sudan, South Sudan, Pakistan and Somalia; however, the 
burden is highly uncertain.b
It is estimated that approximately 4.3 million people are 
infected with hepatitis B and 800 000 people are infected 
with hepatitis C annually in the Region.c In North Africa 
and the Middle Eastern region, low–intermediate (2%–
4%) prevalence  of hepatitis B was reported across all age 
groups in 2005.d
The prevalence of hepatitis C is estimated to be 1%–4.6%, 
with levels as high as 15% and higher than 20% in parts of 
Egypt and Pakistan, respectively. Overall, an estimated 17 
million people in the Region suffer from chronic hepatitis C 
infection.c
responding to malaria is limited.5 Tuberculosis caused 17% of all 
deaths from infectious and parasitic diseases in 2008.6 Five of 
the Region’s countries are among the ten countries in the world 
that host the largest proportions of internally displaced persons 
per population, which places an additional strain on their health 
systems.7
Responses to the WHO/Alliance survey were received from 17 of 
the 22 Member States in the region (77.3%).
Box 1. Responses to the 2012 Global Hepatitis Survey: WHO 
Eastern Mediterranean Region
Member States that submitted surveys:
Member States that did not submit surveys: 
•  Afghanistan
•  Bahrain
•  Djibouti
•  Egypt
•  Iran (Islamic Republic of)
•  Iraq
•  Libya
•  Morocco
•  Saudi Arabia
•  Jordan
•  Kuwait
•  Lebanon
•  Oman
•  Pakistan
•  Qatar
•  Tunisia
•  United Arab Emirates
•  Somalia
•  South Sudan
•  Sudan
•  Syrian Arab Republic
•  Yemen
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National coordination
Nine responding Member States (52.9%) reported the existence 
of a written national strategy or plan that focuses exclusively 
or primarily on the prevention and control of viral hepatitis 
(Figure 1). Six of the nine Member States with a strategy or plan 
(Bahrain, Egypt, Iraq, Jordan, Kuwait and Lebanon) reported 
that it focuses exclusively on viral hepatitis, and two (Oman and 
Sudan) reported that it addresses other diseases as well. One 
country (Iran) reported that the strategy or plan addresses only 
hepatitis B and hepatitis C.
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Figure 1. Responses to the question, “Is there a written 
national strategy or plan that focuses exclusively or primarily 
on the prevention and control of viral hepatitis?”
Yes
No
No response
No data
The nine Member States that reported the existence of a 
strategy or plan were asked about its specifi c components. All 
nine reported the inclusion of components for surveillance and 
general prevention. Eight reported the inclusion of components 
for vaccination, prevention of transmission in health-care 
settings and prevention of transmission via injecting drug 
use. Seven reported the inclusion of a component for raising 
awareness, six reported the inclusion of a component for 
treatment and care, and three reported the inclusion of a 
component for coinfection with HIV.
Ten responding Member States (58.8%) reported that they have 
a governmental unit or department responsible solely for viral 
hepatitis-related activities. Member States that did so were 
asked to indicate the number of staff  members in the unit or 
department. Responses (N=9) ranged from 2 to 44 (median, 4), 
with Iraq reporting the largest number.
Table 1. Topics of public awareness campaigns on viral 
hepatitis held in Member States since January 2011 (N=7)
General 
information 
about hepatitis 
and its 
transmission
Vaccination for 
hepatitis A and 
hepatitis B
Importance of 
knowing one’s 
hepatitis B and 
hepatitis C 
status
Safe water 
and good 
sanitation
Safer sex 
practices
Harm 
reduction for 
people who 
inject drugs
Safe workplace 
practices
Other a
Iraq
X
X
 
X
 
 
X
 
X
 
 
 
 
 
X
 
X
X
X
 
 
 
X
 
X
X
X
X
X
X
X
 
 
 
 
 
 
 
 
X
X
X
X
 
 
 
X
 
X
X
X
 
 
 
X
X
JordanIranEgypt Oman QatarPaki-stan
a  Details can be found in the summaries of country fi ndings later in this chapter.
Member States were asked to report the number of people 
working full-time on hepatitis-related activities in all 
government agencies or bodies. Among the six Member States 
that provided data for this question, the number ranged from 0 
to 47 (median, 3), with Iran reporting the largest number.
Ten responding Member States (58.8%) reported that they have 
a viral hepatitis prevention and control programme that includes 
activities targeting specifi c populations. The populations most 
commonly targeted are health-care workers, including health-
care waste handlers (100% of responding Member States within 
this subset) and prisoners (80.0% of responding Member States 
within this subset). Six responding Member States reported the 
inclusion of activities targeting people who inject drugs and 
fi ve reported the inclusion of activities targeting people living 
with HIV. Groups identifi ed less frequently included migrants, 
indigenous populations, low-income populations, those who 
are uninsured and those who are homeless.
Awareness-raising and partnerships
Eight responding Member States (47.1%) reported that they 
had held events for World Hepatitis Day 2012 (28 July). Since 
January 2011, seven responding Member States (41.2%) had 
funded some type of viral hepatitis public awareness campaign 
other than World Hepatitis Day (Table 1).
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Five responding Member States (29.4%) reported that they 
collaborated with civil society groups within their countries 
to develop and implement the governmental viral hepatitis 
prevention and control programme. For example, Lebanon 
reported collaborating with the Lebanese Red Cross and 
Lebanese Scouts, while Qatar reported collaborating with the 
Qatar Red Crescent Society. (Further examples can be found in 
the summaries of country fi ndings later in this chapter.)
Evidence-based policy and data for action
Fifteen responding Member States (88.2%) reported that they 
have routine surveillance for viral hepatitis; details appear in 
Table 2.
Table 2. Types of surveillance in Member States that reported 
the existence of routine surveillance for viral hepatitis (N=15)
There is a national 
surveillance system for acute 
hepatitis infection for the 
following forms of hepatitis:
hepatitis A
hepatitis B
hepatitis C
hepatitis D
hepatitis E
There is a national 
surveillance system for 
chronic hepatitis infection 
for the following forms of 
hepatitis:
hepatitis B
hepatitis C
hepatitis D
Yes (%)
86.7
86.3
86.3
40.0
53.3
46.7
46.7
26.7
No (%)
0
13.3
13.7
33.3
26.7
53.3
53.3
60.0
Do not 
know 
(%)
0
0
0
0
0
0
0
0
No 
response 
(%)
13.3
0
0
26.7
20.0
0
0
13.3
Table 3. Data registration and surveillance (N=17)
Liver cancer cases are registered 
nationally
Cases with HIV/hepatitis 
coinfection are registered 
nationally
Hepatitis outbreaks are reported
If YES – Hepatitis outbreaks are 
further investigated (N=115)
Yes (%)
70.6
47.1
100
94.1
No (%)
23.5
47.1
0
5.9
Do not 
know 
(%)
5.9
5.9
0
0
No 
response 
(%)
0
0
0
0
Sixteen responding Member States (94.1%) indicated that their 
countries have standard case defi nitions for hepatitis infection 
and 11 (64.7%) indicated that their countries have a central 
registry for the reporting of deaths, including hepatitis deaths.
Nine Member States reported on the proportion of hepatitis 
cases and deaths registered as “undiff erentiated” or “unclassifi ed” 
hepatitis. The reported proportions ranged from 0% to 100% 
(median, 7.0%). Additional survey fi ndings about surveillance 
are presented in Table 3.
Member States were asked how often hepatitis disease reports 
are published. Of the responding Member States, 35.3% 
reported that they publish hepatitis disease reports annually; 
17.6%, monthly; and 23.5%, weekly. No hepatitis disease report 
is published by 17.6% of responding Member States.
Nine responding Member States (52.9%) reported the existence 
of a national public health research agenda for viral hepatitis.
Four responding Member States (23.5%) reported that viral 
hepatitis serosurveys are conducted regularly. Among this 
subset of responding Member States, one (Kuwait) indicated 
that serosurveys take place every year. The same Member State 
reported that the most recent viral hepatitis serosurvey was 
carried out in 2011.
Prevention of transmission
Four responding Member States (23.5%) reported that they 
have a national policy on hepatitis A vaccination.
Five responding Member States (29.4%) reported that they have 
established the goal of eliminating hepatitis B (Figure 2). Member 
States with this goal were asked to specify the timeframe in 
which they seek to eliminate hepatitis B. Of the two Member 
States that answered this question, one (Bahrain) said 2015 and 
one (Lebanon) said 2020.
Figure 2. Responses to the question, “Has your government 
established the goal of eliminating hepatitis B?” (N=17)
No 
(58.8%)
Yes 
(29.4%)
No response 
11.8%
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Table 4. Activities called for in national policy targeting 
mother-to-child transmission of hepatitis B (N=11)
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Figure 3. Proportion of responding Member States with 
national policies on injection safety in health-care settings 
which recommend single-use syringes and auto-disable 
syringes for therapeutic injections (N=13)
a  Respondents could select both “single-use syringes” and “auto-disable syringes”.
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Single-use
syringesa
Auto-disable 
syringesa
Do not know
Member States were asked to report, for a given recent year, 
the percentage of newborn infants who had received the fi rst 
dose of hepatitis B vaccine within 24 hours of birth. Among the 
13 Member States that provided this information, responses 
ranged from 0% to 100% (median, 90.0%). Member States were 
also asked to report, for a given recent year, the percentage of 
one-year-olds (ages 12–23 months) who had received three 
doses of hepatitis B vaccine. Among the 14 Member States that 
provided this information, responses ranged from 0% to 100% 
(median, 91.0%).
Eleven responding Member States (64.7%) reported the 
existence of a national policy that specifi cally targets mother-to-
child transmission of hepatitis B; details are presented in Table 4. 
Slightly less than half of the Member States with such a policy 
indicated that one component of the policy calls for screening 
of all pregnant women for hepatitis B.
Eleven responding Member States (64.7%) reported the 
existence of a specifi c national strategy and/or policy/guidelines 
for preventing hepatitis B and hepatitis C infection in health-
care settings.
Nine responding Member States (52.9%) reported that health-
care workers are vaccinated against hepatitis B prior to starting 
work that might put them at risk of exposure to blood.
Thirteen responding Member States (76.5%) reported the 
existence of a national policy on injection safety in health-
care settings. These Member States were asked which types 
of syringes the policy recommends for therapeutic injections. 
Single-use syringes are recommended in 84.6% of policies, and 
auto-disable syringes in 23.1% (Figure 3).
Fourteen responding Member States (82.4%) reported that 
single-use or auto-disable syringes, needles and cannulas are 
always available in all health-care facilities.
Member States were asked for offi  cial estimates of the number 
and percentage of unnecessary injections administered 
annually in health-care settings (e.g. injections that are given 
when an equivalent oral medication is available). Sixteen 
Member States reported that the fi gures are not known and 
one (Pakistan) reported that 20.0% of the total injections 
administered annually in health-care settings are unnecessary.
Additional fi ndings relating to the prevention of hepatitis 
transmission are presented in Table 5.
Screening, care and treatment
Member States were asked how health professionals in their 
countries obtain the skills and competencies required to 
eff ectively care for people with viral hepatitis. Responding 
Member States most frequently indicated that these are 
obtained in schools for health professionals (pre-service 
education, 82.4%). Additionally, on-the-job training was 
identifi ed in 70.6% of responses, and postgraduate training in 
52.9%.
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Table 5. Hepatitis prevention: policies, practices and 
guidelines (N=17)
There is a national infection 
control policy for blood banks
All donated blood units 
(including family donations) and 
blood products nationwide are 
screened for hepatitis B
All donated blood units 
(including family donations) and 
blood products nationwide are 
screened for hepatitis C
There is a national policy relating 
to the prevention of viral 
hepatitis among people who 
inject drugs
The government has guidelines 
that address how hepatitis A 
and hepatitis E can be prevented 
through food and water safety
Yes (%)
76.5
82.4
100
23.5
41.2
No (%)
17.6
11.8
0
76.5
58.8
Do not 
know 
(%)
5.9
0
0
0
0
No 
response 
(%)
0
5.9
0
0
0
Nine responding Member States (52.9%) reported the existence 
of national clinical guidelines for the management of viral 
hepatitis (Figure 4). Five of these nine Member States indicated 
that the guidelines include recommendations for cases with 
HIV coinfection. Six of 12 responding Member States (50.0%) 
indicated that there are national clinical guidelines for the 
management of HIV, which include recommendations for 
coinfection with viral hepatitis.
Eight responding Member States (47.1%) indicated that they 
have a national policy relating to screening and referral to care 
for hepatitis B. Eight (47.1%) reported having such a policy for 
hepatitis C.
Regarding hepatitis B testing, 16 responding Member States 
(94.1%) indicated that people register by name for testing. 
Twelve members of that subset (75.0%) indicated that the 
names are kept confi dential. Seven responding Member States 
(41.2%) reported that the hepatitis B test is free of charge for all 
individuals. Among the ten other Member States, fi ve (50.0%) 
reported that the test is free of charge for members of specifi c 
groups. Groups identifi ed included blood donors, health-
care workers and patients on haemodialysis. Nine responding 
Member States (52.9%) reported that the hepatitis B test is 
compulsory for members of specifi c groups. Groups identifi ed 
included blood donors, health-care workers, patients on 
haemodialysis and prisoners.
Regarding hepatitis C testing, 16 responding Member States 
(94.1%) indicated that people register by name for testing. 
Twelve members of that subset (75.0%) indicated that the 
names are kept confi dential. Seven responding Member States 
(41.2%) reported that the hepatitis C test is free of charge for all 
Figure 4. Responses to the question, “Are there national 
clinical guidelines for the management of viral hepatitis?” 
(N=17)
No 
(41.2%)
Yes 
(52.9%)
Do not 
know 
5.9%
individuals. Among the ten other Member States, fi ve (50.0%) 
reported that the test is free of charge for members of specifi c 
groups. Groups identifi ed included blood donors, health-
care workers and patients on haemodialysis. Nine responding 
Member States (52.9%) reported that the hepatitis C test is 
compulsory for members of specifi c groups. Groups identifi ed 
included blood donors, health-care workers, patients on 
haemodialysis and prisoners.
Lamivudine 
Interferon alpha 
Tenofovir
Pegylated interferon
Entecavir
Adefovir dipivoxil
Telbivudine
Ribavirin
Pegylated interferon
Interferon alpha
Telaprevir
Boceprevir
64.7
64.7
52.9
41.2
35.3
23.5
17.6
64.7
64.7
47.1
11.8
11.8
% of Member States reporting its 
inclusion (N=12)
% of Member States reporting its 
inclusion (N=12)
Drugs for treating 
hepatitis B
Drugs for treating 
hepatitis C
Table 6. Proportion of Member States reporting drugs for 
treating hepatitis B and C on national essential medicines 
lists or subsidized by governments
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Awareness-raising, partnerships and resource mobilization (fi rst WHO strategic axis)
Developing the national plan for viral hepatitis prevention and control
Integrating viral hepatitis programmes into other health services
Awareness-raising
Evidence-based policy and data for action (second WHO strategic axis)
Viral hepatitis surveillance
Estimating the national burden of viral hepatitis
Developing tools to assess the eff ectiveness of interventions
Assessing the economic impact of viral hepatitis
Prevention of transmission (third WHO strategic axis)
Increasing coverage of the birth dose of the hepatitis B vaccine
Screening, care and treatment (fourth WHO strategic axis)
Increasing access to treatment
Increasing access to diagnostics
Improving laboratory quality
Developing education/training programmes for health professionals
82.4%
64.7%
76.5%
64.7%
76.5%
82.4%
82.4%
41.2% 
76.5%
70.6%
70.6%
76.5%
Table 7. Viral hepatitis control and prevention: areas in which Member States indicated interest in receiving WHO assistance 
(N=17)
Eleven responding Member States (64.7%) reported that 
publicly funded treatment is available for hepatitis B and 11 
(64.7%) that publicly funded treatment is available for hepatitis 
C. Four responding Member States reported the amount spent 
on publicly funded treatment for hepatitis B and hepatitis C. 
Details can be found in the summaries of country fi ndings later 
in this chapter (see Bahrain, Egypt, Pakistan and Syrian Arab 
Republic).
Thirteen responding Member States (76.5%) reported that at 
least one available drug for treating hepatitis B is on the national 
essential medicines list or subsidized by the government 
(Table 6). The drugs most commonly reported were interferon 
alpha, pegylated interferon and lamivudine.
Twelve responding Member States (70.6%) reported that at 
least one available drug for treating hepatitis C is on the national 
essential medicines list or subsidized by the government. The 
drugs most commonly reported were ribavirin, pegylated 
interferon and interferon alpha.
World Health Organization assistance
Member States were asked to indicate areas in which they might 
want assistance from WHO for the prevention and control of viral 
hepatitis. Respondents most commonly selected the following: 
developing the national plan for viral hepatitis prevention and 
control (82.4%), developing tools to assess the eff ectiveness 
of interventions (82.4%) and assessing the economic impact 
of viral hepatitis (82.4%) (Table 7). Responses from individual 
Member States appear in Annex C.
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Afghanistan
The Government of Afghanistan reports as 
follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. Information was not pro-
vided on how many people work full-time 
on hepatitis-related activities in all govern-
ment agencies/bodies.
The government does not have a viral hep-
atitis prevention and control programme 
that includes activities targeting specifi c 
populations.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate with 
in-country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: A, 
B, C and D, but not for any type of chronic 
hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. All hepa-
titis cases (100%) are reported as “undiff er-
entiated” or “unclassifi ed” hepatitis. 
Liver cancer cases and cases with HIV/
hepatitis coinfection are not registered na-
tionally. 
The government does not publish hepati-
tis disease reports.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is inadequate laborato-
ry capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, no newborn infant in a given 
recent year received the fi rst dose of hepa-
titis B vaccine within 24 hours of birth and 
82% of one-year-olds (ages 12–23 months) 
in a given recent year received three doses 
of hepatitis B vaccine.
There is no national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B.
There is no specifi c national strategy and/
or policy/guidelines for preventing hepati-
tis B and hepatitis C infection in health-care 
settings.
There is a national policy on injection safe-
ty in health-care settings, but information 
was not provided on the type of syringes 
it recommends for therapeutic injections. 
It is not known whether single-use or auto-
disable syringes, needles and cannulas are 
always available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
32.4
Low-income
$1140
7.58%
$44.47
$5.18
48
0.398
17
6.3
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
There is a national HIV policy that includes 
a policy relating to the prevention of viral 
hepatitis among people who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepatitis 
E can be prevented through food and wa-
ter safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are no national clinical guidelines 
for the management of viral hepatitis or 
for the management of HIV, which include 
recommendations for coinfection with vi-
ral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
Information was not provided on whether 
people testing for hepatitis B register by 
name. People testing for hepatitis C do not 
register by name. Hepatitis B and hepatitis 
C tests are not free of charge for all individ-
uals, but they are free of charge for blood 
donors and injecting drug users. Hepatitis 
B and hepatitis C tests are not compulsory 
for members of any specifi c group.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C. 
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: inter-
feron alpha and pegylated interferon. The 
following drugs for treating hepatitis C are 
on the national essential medicines list or 
subsidized by the government: interferon 
alpha and pegylated interferon. 
The Government of Afghanistan welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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Bahrain
The Government of Bahrain reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses exclusively on the prevention 
and control of viral hepatitis. It includes 
components for surveillance, vaccination, 
prevention in general, prevention of trans-
mission via injecting drug use, prevention 
of transmission in health-care settings, 
and treatment and care.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. It is not known how 
many people work full-time on hepatitis-
related activities in all government agen-
cies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs, prisoners and 
people living with HIV.
Awareness-raising and partnerships
It is not known whether the government 
held events for World Hepatitis Day 2012 
or funded other viral hepatitis public 
awareness campaigns since January 2011. 
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme. 
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B, C, D and E, and for the following types 
of chronic hepatitis: B, C and D.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. No hepa-
titis case is reported as “undiff erentiated” 
or “unclassifi ed” hepatitis.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports every three months.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are not conducted regularly.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination. 
The government has established the goal 
of eliminating hepatitis B by2015. 
Nationally in 2011, all newborn children of 
hepatitis B-infected mothers and mothers 
of unknown status received the fi rst dose 
of hepatitis B vaccine within 24 hours of 
birth, and 99.8% of one-year-olds (ages 
12–23 months) received three doses of 
hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is a national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
1.3
High-income
--
4.97%
$1083.06
$794.15
74
0.806
30
2.5
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, but 
these do not include recommendations 
for cases with HIV coinfection.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals and are not com-
pulsory for members of any specifi c group.
Publicly funded treatment for hepatitis 
B and hepatitis C is available to all Bah-
raini citizens. The government spends 
BD 273 377 (US$ 725 332) annually on 
hepatitis B and hepatitis C drugs. Other 
treatment costs are publicly funded as 
well, but the total amount spent on hepa-
titis is not known.
The following drugs for treating hepatitis B 
are on the national essential medicines list 
or subsidized by the government: pegylat-
ed interferon, lamivudine, entecavir and 
tenofovir. The following drugs for treating 
hepatitis C are on the national essential 
medicines list or subsidized by the govern-
ment: pegylated interferon and ribavirin. 
The Government of Bahrain welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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Djibouti
The Government of Djibouti reports as 
follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. There are three full-time 
equivalent staff  members who work on 
hepatitis-related activities in all govern-
ment agencies/bodies.
The government does not have a viral hep-
atitis prevention and control programme 
that includes activities targeting specifi c 
populations.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 but has not funded 
other viral hepatitis public awareness cam-
paigns since January 2011.
The government does not collaborate with 
in-country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme.
Evidence-based policy and data for 
action
There is no routine surveillance for viral 
hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Of hepa-
titis cases, 7% are reported as “undiff erenti-
ated” or “unclassifi ed” hepatitis.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports annually.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
Information was not provided on whether 
the government has established the goal 
of eliminating hepatitis B.
Nationally, 90% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 75% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is no specifi c national strategy and/
or policy/guidelines for preventing hepati-
tis B and hepatitis C infection in health-care 
settings.
There is no national policy on injection 
safety in health-care settings. Single-use 
or auto-disable syringes, needles and can-
nulas are always available in all health-care 
facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
0.9
Lower–middle-income
$2450
7.24%
$170.01
$110.99
60
0.430
21
3.8
injections administered annually in health-
care settings are not known.
There is no national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis C, but not for hepatitis B.
There is no national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepatitis 
E can be prevented through food and wa-
ter safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education). 
There are no national clinical guidelines for 
the management of viral hepatitis. There 
are national clinical guidelines for the man-
agement of HIV, which include recommen-
dations for coinfection with viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name, and there is 
open access to their names. Hepatitis B and 
hepatitis C tests are not free of charge for all 
individuals but are free for certain groups; 
information was not provided regarding 
which groups. Hepatitis B and hepatitis C 
tests are not compulsory for members of 
any specifi c group.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
No drug for treating hepatitis B or hepatitis 
C is on the national essential medicines list 
or subsidized by the government.
The Government of Djibouti welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Egypt
The Government of Egypt reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses exclusively on the prevention 
and control of viral hepatitis. It includes 
components for raising awareness, surveil-
lance, vaccination, prevention in general, 
prevention of transmission via injecting 
drug use, prevention of transmission in 
health-care settings, and treatment and 
care.
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities: Hepatitis Unit, Preven-
tive Sector, Ministry of Health. It has three 
staff  members. There are three full-time 
equivalent staff  members who work on 
hepatitis-related activities in all govern-
ment agencies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers) 
and patients on dialysis.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012, but has fund-
ed other viral hepatitis public awareness 
campaigns since January 2011 (Annex A).
The government collaborates with the fol-
lowing in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme: Ter-
ros, Misr-elkheir and the Sawiris Founda-
tion. 
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, but not for any type of chronic 
hepatitis. 
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Of hepa-
titis cases, 69% are reported as “undiff er-
entiated” or “unclassifi ed” hepatitis. 
Liver cancer cases are registered nation-
ally, but cases with HIV/hepatitis coinfec-
tion are not.
The government publishes hepatitis dis-
ease reports annually. 
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis A, hepatitis B and hepati-
tis C, but not for hepatitis E.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target population is people aged 15–59 
years. The last serosurvey was carried out 
in 2008.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has established the goal 
of eliminating hepatitis B in children under 
fi ve years of age, but did not provide infor-
mation about a specifi c timeframe for this.
Nationally, no newborn infant in a given 
recent year received the fi rst dose of hepa-
titis B vaccine within 24 hours of birth 
and 95% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vaccinat-
ed against hepatitis B.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
82.5
Lower–middle-income
$6120
4.66%
$288.57
$107.94
71
0.644
24
2.7
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through on-
the-job training and postgraduate train-
ing. 
There are national clinical guidelines for 
the management of viral hepatitis but it is 
not known whether they include recom-
mendations for cases with HIV coinfection.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals and are compul-
sory for patients on dialysis, visa applicants 
and blood donors.
Publicly funded treatment for hepatitis B 
and hepatitis C is available to all people 
with health insurance and for those sup-
ported by the governmental treatment 
programme. 
The government spends about LE 800 mil-
lion (US$ 131.8 million) annually on pub-
licly funded treatment for hepatitis B and 
hepatitis C.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: 
pegylated interferon and lamivudine. The 
following drugs for treating hepatitis C are 
on the national essential medicines list or 
subsidized by the government: pegylated 
interferon and ribavirin. 
The Government of Egypt welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Iran (Islamic Republic of)
The Government of Iran reports as follows.
National coordination
There is a written national strategy or plan 
that focuses exclusively on the prevention 
and control of hepatitis B and hepatitis C. 
It includes components for raising aware-
ness, surveillance, vaccination, prevention 
in general, prevention of transmission via 
injecting drug use, prevention of transmis-
sion in health-care settings, and treatment 
and care.
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities: the Viral Hepatitis Unit. 
It has fi ve staff  members. There are 47 full-
time equivalent staff  members who work 
on hepatitis-related activities in all govern-
ment agencies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs, prisoners and 
people living with HIV.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 and has funded other 
viral hepatitis public awareness campaigns 
since January 2011 (Annex A).
Information was not provided on whether 
the government collaborates with in-
country civil society groups to develop and 
implement its viral hepatitis prevention 
and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: B 
and C, and for the following types of chron-
ic hepatitis: B, C and D.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. The per-
centage of hepatitis cases reported as “un-
diff erentiated” or “unclassifi ed” hepatitis is 
not known.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally.
The government publishes hepatitis dis-
ease reports monthly. 
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis A, hepatitis B and hepatitis 
C. Information was not provided on wheth-
er this is the case for hepatitis E. 
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target populations include the general 
population and people who inject drugs. 
Information was not provided on when the 
last serosurvey was carried out.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination. 
The government has established the goal 
of eliminating hepatitis B but did not pro-
vide information about a specifi c time-
frame for this.
Nationally, 98% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth. 
Information was not provided on the per-
centage of one-year-olds nationally (ages 
12–23 months) in a given recent year who 
received three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vaccinat-
ed against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection 
safety in health-care settings, which rec-
ommends single-use and auto-disable 
syringes for therapeutic injections. Single-
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
74.8
Upper–middle-income
$11 420
5.60%
$836.28
$335.61
73
0.707
27
1.7
use or auto-disable syringes, needles and 
cannulas are always available in all health-
care facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
There is a national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepatitis 
E can be prevented through food and wa-
ter safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education) and on-the-job training. 
There are national clinical guidelines for 
the management of viral hepatitis but they 
do not include recommendations for cases 
with HIV coinfection. There are national 
clinical guidelines for the management of 
HIV, which include recommendations for 
coinfection with viral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names are 
kept confi dential within the system. Hepa-
titis B and hepatitis C tests are not free of 
charge and are not compulsory for mem-
bers of any specifi c group.
Publicly funded treatment for hepatitis B 
and hepatitis C is available to insurance 
companies.
Information was not provided on the 
amount spent by the government on pub-
licly funded treatment for hepatitis B and 
hepatitis C.
Information was not provided on whether 
any drug for treating hepatitis B or hepati-
tis C is on the national essential medicines 
list or subsidized by the government.
Information was not provided on whether 
the Government of Iran has a need for as-
sistance from WHO in relation to viral hepa-
titis prevention and control.
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Iraq
The Government of Iraq reports as follows.
National coordination
There is a written national strategy or plan 
that focuses exclusively on the prevention 
and control of viral hepatitis. It includes 
components for raising awareness, surveil-
lance, vaccination, prevention in general, 
prevention of transmission via injecting 
drug use, and prevention of transmission 
in health-care settings.
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities: Viral Hepatitis Section, 
Communicable Disease Control Center, 
Ministry of Health. It has 44 staff  mem-
bers. There are 44 full-time equivalent staff  
members who work on hepatitis-related 
activities in all government agencies/
bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
migrants, prisoners, low-income popu-
lations, indigenous people, pregnant 
women, patients on haemodialysis and 
those with thalassaemia, and preoperative 
patients.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 and has funded other 
viral hepatitis public awareness cam-
paigns since January 2011 (Annex A).
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B, C, D and E, and for the following types 
of chronic hepatitis: B, C and D.
There are standard case defi nitions for 
hepatitis. Hepatitis deaths are not report-
ed to a central registry. Information was 
not provided on the percentage of hepa-
titis cases reported as “undiff erentiated” or 
“unknown” hepatitis.
It is not known whether liver cancer cases 
are registered nationally. Cases with HIV/
hepatitis coinfection are not registered 
nationally.
The government publishes hepatitis 
disease reports weekly, monthly and 
annually.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis B and hepatitis C, but not 
for hepatitis A and hepatitis E.
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target population is the general popula-
tion. The last serosurvey was carried out in 
2005–2006. 
Prevention of transmission
There is a national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B. 
Nationally, 88% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 89% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of the hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection 
safety in health-care settings, which rec-
ommends single-use and auto-disable 
syringes for therapeutic injections. Single-
use or auto-disable syringes, needles and 
cannulas are always available in all health-
care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
32.7
Lower–middle-income
$3750
8.42%
$340.13
$118.35
66
0.573
18
4.7
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
It is not known whether there are national 
clinical guidelines for the management of 
viral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name, and there is 
open access to their names. Hepatitis B 
and hepatitis C tests are free of charge for 
all individuals and compulsory for blood 
donors.
Publicly funded treatment for hepatitis B 
and hepatitis C is available to all patients 
who need it. The amount spent by the 
government on such treatment for hepa-
titis B and hepatitis C is not known.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: 
interferon alpha, pegylated interferon, 
lamivudine and adefovir dipivoxil. The fol-
lowing drugs for treating hepatitis C are 
on the national essential medicines list or 
subsidized by the government: interferon 
alpha, pegylated interferon and ribavirin.
The Government of Iraq welcomes as-
sistance from WHO in one or more ar-
eas of viral hepatitis prevention and con-
trol (Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Jordan
The Government of Jordan reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses exclusively on the prevention 
and control of viral hepatitis. It includes 
components for raising awareness, surveil-
lance, vaccination, prevention in general, 
prevention of transmission via injecting 
drug use, prevention of transmission in 
health-care settings, treatment and care, 
and coinfection with HIV.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. It is not known how many 
people work full-time on hepatitis-related 
activities in all government agencies/bod-
ies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
prisoners, people living with HIV and close 
contacts of people who are positive for 
hepatitis B or hepatitis C.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 and has funded other 
viral hepatitis public awareness campaigns 
since January 2011 (Annex A).
The government collaborates with in-
country civil society groups to develop and 
implement its viral hepatitis prevention 
and control programme, but information 
was not provided on the identity of these.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, and for the following types of 
chronic hepatitis: B and C.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. No hepa-
titis case is reported as “undiff erentiated” or 
“unclassifi ed” hepatitis.
Liver cancer cases are registered nationally, 
but it is not known whether cases with HIV/
hepatitis coinfection are.
The government publishes hepatitis dis-
ease reports annually. 
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities. 
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, no newborn infant in a given 
recent year received the fi rst dose of hepa-
titis B vaccine within 24 hours of birth and 
97% of one-year-olds (ages 12–23 months) 
in a given recent year received three doses 
of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vaccinat-
ed against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
6.3
Upper–middle-income
$5930
8.04%
$448.45
$303.41
71
0.698
21
3.1
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names are 
kept confi dential within the system. Hepa-
titis B and hepatitis C tests are not free of 
charge for all individuals, but they are free 
of charge for health-care workers and close 
contacts of people who are positive for 
hepatitis B or hepatitis C. Hepatitis B and 
hepatitis C tests are compulsory for health-
care workers.
Publicly funded treatment for hepatitis B 
and hepatitis C is available to Jordanians 
who seek treatment but have no insur-
ance. Information was not provided on the 
amount spent by the government on pub-
licly funded treatment for hepatitis B and 
hepatitis C.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: inter-
feron alpha, pegylated interferon, lamivu-
dine, adefovir dipivoxil and entecavir. The 
following drugs for treating hepatitis C are 
on the national essential medicines list or 
subsidized by the government: interferon 
alpha, pegylated interferon and ribavirin.
The Government of Jordan welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Kuwait
The Government of Kuwait reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses exclusively on the prevention 
and control of viral hepatitis. It includes 
components for raising awareness, surveil-
lance,  vaccination,  prevention in general, 
prevention of transmission via injecting 
drug use, prevention of transmission in 
health-care settings, treatment and care, 
and coinfection with HIV.
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities: Fighting Epidemics Unit, 
Preventive Medicine Department. It has 
eight staff  members. It is not known how 
many people work full-time on hepatitis-
related activities in all government agen-
cies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs, migrants, pris-
oners,  people living with HIV,  indigenous 
people, new army and police recruits, 
pregnant women and new employees. 
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012. Information was 
not provided on whether the government 
has funded other viral hepatitis public 
awareness campaigns since January 2011.
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B, C, D and E, but not for chronic hepa-
titis B or hepatitis C. Information was not 
provided on whether there is a national 
surveillance system for chronic hepatitis D.
There are standard case defi nitions for 
hepatitis. It is not known whether deaths, 
including from hepatitis, are reported to a 
central registry. No hepatitis case is report-
ed as “undiff erentiated” or “unclassifi ed” 
hepatitis.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports monthly.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target populations are children, the gen-
eral population and people who inject 
drugs. The last serosurvey was carried out 
in 2011.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination. 
The government has established the goal 
of eliminating hepatitis B but did not pro-
vide information about a specifi c time-
frame for this.
Nationally, 95% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 95% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
2.8
High-income
$53 720
2.63%
$1132.54
$910.20
78
0.760
28
2.3
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
There is a national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepati-
tis E can be prevented through food and 
water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals, and are compul-
sory for health-care workers, immigrants, 
pregnant women, prisoners, new recruits 
in the army and police, and new employ-
ees.
Publicly funded treatment for hepatitis B 
and hepatitis C is available to the entire 
population. The amount spent by the gov-
ernment on such treatment for hepatitis B 
and hepatitis C is not known.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: 
interferon alpha, pegylated interferon, 
lamivudine, entecavir and telbivudine. The 
following drugs for treating hepatitis C are 
on the national essential medicines list or 
subsidized by the government: interferon 
alpha, pegylated interferon, ribavirin, bo-
ceprevir and telaprevir.
The Government of Kuwait welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Lebanon
The Government of Lebanon reports 
as follows.
National coordination
There is a written national strategy or plan 
that focuses exclusively on the prevention 
and control of viral hepatitis. It includes 
components for raising awareness,  surveil-
lance,  vaccination,  prevention in general, 
prevention of transmission via injecting 
drug use, prevention of transmission in 
health-care settings,  treatment and care, 
and coinfection with HIV.
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities: the National Program for 
Prevention of Viral Hepatitis. It has three 
staff  members. There are three full-time 
equivalent staff  members who work on 
hepatitis-related activities in all govern-
ment agencies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs and prisoners.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government collaborates with the fol-
lowing in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme: the 
Lebanese Red Cross, SIDC, Hep B and Leba-
nese Scouts.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, and for the following types of 
chronic hepatitis: B and C.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. The per-
centage of hepatitis cases reported as “un-
diff erentiated” or “unclassifi ed” hepatitis is 
not known.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports annually. 
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis A, hepatitis B and hepatitis 
C, but not for hepatitis E. 
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly. 
Prevention of transmission
There is no national policy on hepatitis A 
vaccination. 
The government has established the goal 
of eliminating hepatitis B by 2020.
Nationally, 90% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 80% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine. 
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vaccinat-
ed against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection safe-
ty in health-care settings. It is not known 
what types of syringes the policy recom-
mends for therapeutic injections. Single-
use or auto-disable syringes, needles and 
cannulas are always available in all health-
care facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
4.3
Upper–middle-income
$14 470
7.03%
$980.43
$383.95
74
0.739
29
1.8
injections administered annually in health-
care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
It is not known how health professionals 
obtain the skills and competencies re-
quired to eff ectively care for people with 
viral hepatitis. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection. There are national clini-
cal guidelines for the management of HIV, 
which include recommendations for coin-
fection with viral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names are 
kept confi dential within the system. Hepa-
titis B and hepatitis C tests are not free of 
charge and not compulsory for members 
of any specifi c group. 
Publicly funded treatment is available for 
hepatitis B and hepatitis C. The following 
people are eligible for publicly funded 
treatment for hepatitis B: patients with no 
social security coverage. Information was 
not provided on who is eligible for such 
treatment for hepatitis C. Information was 
not provided on the amount spent by the 
government on publicly funded treatment 
for hepatitis B and hepatitis C.
The following drugs for treating hepatitis B 
are on the national essential medicines list 
or subsidized by the government: pegylat-
ed interferon, lamivudine, entecavir and 
tenofovir. The following drugs for treating 
hepatitis C are on the national essential 
medicines list or subsidized by the govern-
ment: pegylated interferon and ribavirin.
The Government of Lebanon welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Oman
The Government of Oman reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses primarily on the prevention 
and control of viral hepatitis, but also inte-
grates other diseases. It includes compo-
nents for surveillance, vaccination, preven-
tion in general, prevention of transmission 
via injecting drug use, and prevention of 
transmission in health-care settings. 
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. There are no people 
working full-time on hepatitis-related ac-
tivities in any government agency/body.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c population: health-care workers 
(including health-care waste handlers).
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012, but has fund-
ed other viral hepatitis public awareness 
campaigns since January 2011 (Annex A).
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B, C, D and E, but not for any type of 
chronic hepatitis.
There are standard case defi nitions for 
hepatitis. Hepatitis deaths are not report-
ed to a central registry. Of hepatitis cases, 
21.1% are reported as “undiff erentiated” or 
“unclassifi ed” hepatitis.
Liver cancer cases are registered nation-
ally, but cases with HIV/hepatitis coinfec-
tion are not.
The government publishes hepatitis dis-
ease reports weekly. 
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 98% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 99% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known. 
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
2.8
High-income
$25 720
2.77%
$597.59
$478.87
74
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25
2.3
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Country classifi cation (2012)
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Human Development Index (2011)
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The government does not have guidelines 
that address how hepatitis A and hepati-
tis E can be prevented through food and 
water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education). 
There are no national clinical guidelines 
for the management of viral hepatitis or 
for the management of HIV, which include 
recommendations for coinfection with vi-
ral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name, and there 
is open access to their names. Hepatitis 
B and hepatitis C tests are free of charge 
for all individuals and are compulsory for 
donors, patients on dialysis, prisoners, ex-
patriate workers and health-care workers. 
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: in-
terferon alpha, pegylated interferon and 
lamivudine. The following drugs for treat-
ing hepatitis C are on the national essen-
tial medicines list or subsidized by the 
government: interferon alpha, pegylated 
interferon and ribavirin.
The Government of Oman welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Pakistan
The Government of Pakistan reports as 
follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis.
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities: Provincial Hepatitis Con-
trol Programs. It is not known how many 
staff  members this offi  ce has, or how many 
people work full-time on hepatitis-related 
activities in all government agencies/bod-
ies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs, prisoners and 
people living with HIV. 
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 and has funded other 
viral hepatitis public awareness campaigns 
since January 2011 (Annex A).
The government does not collaborate with 
in-country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for acute hepatitis A, but not for any type of 
chronic hepatitis.
There are standard case defi nitions for 
hepatitis. Hepatitis deaths are not reported 
to a central registry. Information was not 
provided regarding the percentage of hep-
atitis cases reported as “undiff erentiated” 
or “unknown” hepatitis.
Liver cancer cases are not registered na-
tionally, but cases with HIV/hepatitis coin-
fection are.
The government has published one hepa-
titis disease report that described a nation-
al hepatitis prevalence study conducted in 
2008.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, no newborn infant in a given 
recent year received the fi rst dose of hepa-
titis B vaccine within 24 hours of birth and 
56% of one-year-olds (ages 12–23 months) 
in a given recent year received three doses 
of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vaccinat-
ed against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is no national policy on injection 
safety in health-care settings. Single-use 
or auto-disable syringes, needles and can-
nulas are not always available in all health-
care facilities.
Twenty per cent of injections administered 
annually in health-care settings are unnec-
essary, according to offi  cial government 
estimates. 
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
176.7
Lower–middle-income
$2870
2.20%
$58.72
$22.59
63
0.504
22
3.4
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis C, but not for hepatitis B.
There is no national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection. There are national clini-
cal guidelines for the management of HIV, 
which include recommendations for coin-
fection with viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name, and there 
is open access to their names. Hepatitis B 
and hepatitis C tests are not free of charge 
and not compulsory for members of any 
specifi c group.
Publicly funded treatment for hepatitis B 
and hepatitis C is available to patients who 
cannot pay for treatment. The government 
spends PRs 200–300 million (US$ 2.1–3.2 
million) per province annually on publicly 
funded treatment for hepatitis B and hepa-
titis C.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: inter-
feron alpha, pegylated interferon, lamivu-
dine and entecavir. The following drugs for 
treating hepatitis C are on the national es-
sential medicines list or subsidized by the 
government: interferon alpha, pegylated 
interferon and ribavirin.
The Government of Pakistan welcomes 
assistance from WHO in one or more ar-
eas of viral hepatitis prevention and con-
trol (Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Qatar
The Government of Qatar reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities, but its name was not 
provided. It has three staff  members. There 
are 15 full-time equivalent staff  members 
who work on hepatitis-related activities in 
all government agencies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs, migrants, prison-
ers and expatriates.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 and has funded other 
viral hepatitis public awareness cam-
paigns since January 2011 (Annex A).
The government collaborates with the fol-
lowing in-country civil society group to 
develop and implement its viral hepatitis 
prevention and control programme: the 
Qatar Red Crescent Society.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B, C and E, and for the following types 
of chronic hepatitis: B and C. Information 
was not provided on whether there is a 
national surveillance system for chronic 
hepatitis D.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Of hepa-
titis cases, 0.38% is reported as “undiff er-
entiated” or “unclassifi ed” hepatitis. 
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports annually and also internally 
every six months.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are not conducted regularly.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 100% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 95% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepati-
1.9
High-income
$86 440
1.81%
$1622.47
$1256.65
78
0.831
32
2.3
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
tis E can be prevented through food and 
water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals and compulsory 
for pregnant women, couples planning to 
marry, prisoners and expatriates. Hepatitis 
C tests are compulsory for certain groups 
but information was not provided regard-
ing which groups.
Publicly funded treatment for hepatitis B 
and hepatitis C is available to the entire 
population. The amount spent by the gov-
ernment on such treatment for hepatitis B 
and hepatitis C is not known.
The following drugs for treating hepatitis B 
are on the national essential medicines list 
or subsidized by the government: inter-
feron alpha, pegylated interferon, lamivu-
dine, adefovir, entecavir, telbivudine and 
tenofovir. The following drugs for treating 
hepatitis C are on the national essential 
medicines list or subsidized by the govern-
ment: interferon alpha, pegylated interfer-
on, ribavirin, boceprevir and telaprevir.
The Government of Qatar welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Somalia
The Government of Somalia reports as 
follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. It is not known how many 
people work full-time on hepatitis-related 
activities in all government agencies/bod-
ies.
The government does not have a viral hep-
atitis prevention and control programme 
that includes activities targeting specifi c 
populations.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012, but has not funded 
other viral hepatitis public awareness cam-
paigns since January 2011.
The government does not collaborate with 
in-country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme.
Evidence-based policy and data for 
action
There is no routine surveillance for viral 
hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. The per-
centage of hepatitis cases reported as “un-
diff erentiated” or “unclassifi ed” hepatitis is 
not known.
Liver cancer cases are registered nationally, 
but cases with HIV/hepatitis coinfection 
are not.
The government does not publish hepati-
tis disease reports.
Hepatitis outbreaks are required to be 
reported to the government but are not 
further investigated. There is adequate 
laboratory capacity nationally to support 
investigation of viral hepatitis outbreaks 
and other surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, no newborn infant in a given 
recent year received the fi rst dose of hepa-
titis B vaccine within 24 hours of birth and 
no one-year-old (ages 12–23 months) in a 
given recent year received three doses of 
hepatitis B vaccine.
There is no national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B.
There is no specifi c national strategy and/
or policy/guidelines for preventing hepati-
tis B and hepatitis C infection in health-care 
settings. 
There is no national policy on injection 
safety in health-care settings. Single-use 
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
9.6
Low-income
--
--
--
--
51
--
18
6.3
or auto-disable syringes, needles and can-
nulas are always available in all health-care 
facilities. 
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
There is no national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B, but information was not provided 
on whether this is the case for hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepatitis 
E can be prevented through food and wa-
ter safety.
Screening, care and treatment
It was not known how health profession-
als obtain the skills and competencies re-
quired to eff ectively care for people with 
viral hepatitis. 
There are no national clinical guidelines 
for the management of viral hepatitis, 
but there are for the management of HIV, 
which include recommendations for coin-
fection with viral hepatitis.
People testing for both hepatitis B and 
hepatitis C register by name; the names are 
kept confi dential within the system. Hepa-
titis B and hepatitis C tests are not free of 
charge and not compulsory for members 
of any specifi c group.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
No drug for treating hepatitis B or hepatitis 
C is on the national essential medicines list 
or subsidized by the government. 
The Government of Somalia welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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South Sudan
The Government of South Sudan reports 
as follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities: Emergency Prepared-
ness and Response Department. It has fi ve 
staff  members. It is not known how many 
people work full-time on hepatitis-related 
activities in all government agencies/bod-
ies.
The government does not have a viral 
hepatitis prevention and control pro-
gramme that includes activities targeting 
specifi c populations.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
B, C and E, but not for any type of chronic 
hepatitis.
There are no standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. The per-
centage of hepatitis cases reported as “un-
diff erentiated” or “unclassifi ed” hepatitis is 
not known.
Liver cancer cases are registered nation-
ally, but cases with HIV/hepatitis coinfec-
tion are not.
The government does not publish hepati-
tis disease reports.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is inadequate labora-
tory capacity nationally to support inves-
tigation of viral hepatitis outbreaks and 
other surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
It is not known what percentage of new-
born infants nationally in a given recent 
year received the fi rst dose of hepatitis B 
vaccine within 24 hours of birth or what 
percentage of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is no national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B.
There is no specifi c national strategy and/
or policy/guidelines for preventing hepa-
titis B and hepatitis C infection in health-
care settings.
There is no national policy on injection 
safety in health-care settings. Single-use 
or auto-disable syringes, needles and can-
nulas are always available in all health-care 
facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is no national infection control 
policy for blood banks. All donated blood 
units (including family donations) and 
blood products nationwide are screened 
for hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
--
Lower–middle-income
--
--
--
--
--
--
--
--
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
The government does not have guidelines 
that address how hepatitis A and hepati-
tis E can be prevented through food and 
water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education) and on-the-job training. 
There are no national clinical guidelines 
for the management of viral hepatitis, 
but there are for the management of HIV, 
which include recommendations for coin-
fection with viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are not 
free of charge for all individuals, but they 
are free of charge and compulsory for 
blood donors. 
Publicly funded treatment for hepatitis B 
and hepatitis C is available to the entire 
population. The amount spent by the gov-
ernment on such treatment for hepatitis B 
and hepatitis C is not known.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: lami-
vudine and tenofovir. No drug for treat-
ing hepatitis C is on the national essential 
medicines list or subsidized by the govern-
ment.
The Government of South Sudan wel-
comes assistance from WHO in one or 
more areas of viral hepatitis prevention 
and control (Annex C).
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Sudan
The Government of Sudan reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses primarily on the prevention 
and control of viral hepatitis, and also in-
tegrates other diseases. It includes com-
ponents for raising awareness, surveillance 
and prevention in general. 
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. Information was not pro-
vided regarding how many people work 
full-time on hepatitis-related activities in all 
government agencies/bodies.
The government does not have a viral hep-
atitis prevention and control programme 
that includes activities targeting specifi c 
populations.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012, but has not funded 
other viral hepatitis public awareness cam-
paigns since January 2011.
The government does not collaborate with 
in-country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for acute hepatitis A, but not for any type of 
chronic hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Of hepati-
tis cases, 90% are reported as “undiff erenti-
ated” or “unclassifi ed” hepatitis. 
Liver cancer cases and cases with HIV/
hepatitis coinfection are not registered na-
tionally. 
The government publishes hepatitis dis-
ease reports weekly. 
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is inadequate laborato-
ry capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, no newborn infant in a given 
recent year received the fi rst dose of hepa-
titis B vaccine within 24 hours of birth and 
93% of one-year-olds (ages 12–23 months) 
in a given recent year received three doses 
of hepatitis B vaccine.
There is no national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B.
There is no specifi c national strategy and/
or policy/guidelines for preventing hepati-
tis B and hepatitis C infection in health-care 
settings.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeu-
tic injections. Single-use or auto-disable 
syringes, needles and cannulas are always 
available in all health-care facilities.
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
44.6
Lower–middle-income
$2120
6.32%
$141.39
$42.16
59
0.408
20
4.4
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepatitis 
E can be prevented through food and wa-
ter safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education) and on-the-job training. 
There are no national clinical guidelines 
for the management of viral hepatitis, or 
for the management of HIV, which include 
recommendations for coinfection with vi-
ral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals and compulsory 
for blood donors.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
The following drug for treating hepatitis B 
is on the national essential medicines list or 
subsidized by the government: ribavirin.
The Government of Sudan welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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Syrian Arab Republic
The Government of the Syrian Arab 
Republic reports as follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities: the Viral Hepatitis Con-
trol Unit. It has four staff  members. It is not 
known how many people work full-time 
on hepatitis-related activities in all govern-
ment agencies/bodies.
Information was not provided on wheth-
er the government has a viral hepati-
tis prevention and control programme 
that includes activities targeting specifi c 
populations.
Awareness-raising and partnerships
Information was not provided on whether 
the government held events for World 
Hepatitis Day 2012 or has funded other vi-
ral hepatitis public awareness campaigns 
since January 2011.
The government collaborates with the 
following in-country civil society groups 
to develop and implement its viral hepa-
titis prevention and control programme: 
Syrian Red Crescent Society and Syrian 
Family Planning Association.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B, C, D and E, and for the following types 
of chronic hepatitis: B, C and D.
There are standard case defi nitions for 
hepatitis. Hepatitis deaths are not report-
ed to a central registry. Information was 
not provided on the percentage of hepa-
titis cases reported as “undiff erentiated” or 
“unknown” hepatitis.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports quarterly.
Hepatitis outbreaks are required to be 
reported to the government and are fur-
ther investigated. Information was not 
provided on whether there is adequate 
laboratory capacity nationally to support 
investigation of viral hepatitis outbreaks 
and other surveillance activities.
There is a national public health research 
agenda for viral hepatitis. Information was 
not provided on whether viral hepatitis 
serosurveys are conducted regularly.
Prevention of transmission
Information was not provided on whether 
there is a national policy for hepatitis A 
vaccination or whether the government 
has established the goal of eliminating 
hepatitis B.
Information was not provided on the per-
centage of newborn infants nationally 
in a given recent year who received the 
fi rst dose of hepatitis B vaccine within 24 
hours of birth or the percentage of one-
year-olds nationally (ages 12–23 months) 
in a given recent year who received three 
doses of hepatitis B vaccine.
Information was not provided on whether 
there is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B.
Information was not provided on whether 
there is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
20.8
Lower–middle-income
$5080
3.41%
$174.20
$80.13
74
0.632
21
2.9
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, but 
they do not include recommendations for 
cases with HIV coinfection.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are not 
free of charge for all individuals, but they 
are free of charge for blood donors. Hepa-
titis B and hepatitis C tests are compul-
sory for blood donors, couples planning 
to marry, patients on haemodialysis and 
those who undergo frequent haemotrans-
fusion.
Publicly funded treatment for hepatitis 
B and hepatitis C is available to Syrian 
citizens and refugees. The government 
spends LS 700 000 (US$ 11 112) per pa-
tient annually on publicly funded treat-
ment for hepatitis B and hepatitis C.
The following drugs for treating hepatitis B 
are on the national essential medicines list 
or subsidized by the government: inter-
feron alpha, pegylated interferon, lamivu-
dine, adefovir dipivoxil, entecavir, telbivu-
dine and tenofovir. The following drugs for 
treating hepatitis C are on the national es-
sential medicines list or subsidized by the 
government: interferon alpha, pegylated 
interferon and ribavirin.
The Government of the Syrian Arab Re-
public welcomes assistance from WHO in 
one or more areas of viral hepatitis preven-
tion and control (Annex C).
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Yemen
The Government of Yemen reports as 
follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis. 
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities: Disease Control and Sur-
veillance, General Directorate. It has two 
staff  members. It is not known how many 
people work full-time on hepatitis-related 
activities in all government agencies/
bodies.
The government does not have a viral hep-
atitis prevention and control programme 
that includes activities targeting specifi c 
populations.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate with 
in-country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C. Information was not provided 
on whether there is a national surveillance 
system for acute hepatitis D or hepatitis E. 
There is no national surveillance system for 
any type of chronic hepatitis.
There are standard case defi nitions for hep-
atitis. Hepatitis deaths are not reported to a 
central registry. The percentage of hepati-
tis cases reported as “undiff erentiated” or 
“unclassifi ed” hepatitis is not known.
Liver cancer cases and cases with HIV/
hepatitis coinfection are not registered na-
tionally. 
The government publishes hepatitis dis-
ease reports weekly.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
It is not known whether there is a national 
public health research agenda for viral 
hepatitis. Viral hepatitis serosurveys are not 
conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, no newborn infant in a given 
recent year received the fi rst dose of hepa-
titis B vaccine within 24 hours of birth and 
81% of one-year-olds (ages 12–23 months) 
in a given recent year received three doses 
of hepatitis B vaccine.
There is no national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B.
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are not vac-
cinated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection 
safety in health-care settings, which rec-
ommends single-use and auto-disable 
syringes for therapeutic injections. Single-
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
24.8
Lower–middle-income
$2170
5.18%
$122.18
$29.52
65
0.462
4
5.2
use or auto-disable syringes, needles and 
cannulas are not always available in all 
health-care facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
It is not known whether there is a national 
infection control policy for blood banks. All 
donated blood units (including family do-
nations) and blood products nationwide 
are screened for hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepatitis 
E can be prevented through food and wa-
ter safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education). 
There are no national clinical guidelines for 
the management of viral hepatitis. Infor-
mation was not provided on whether there 
are national clinical guidelines for the man-
agement of HIV, which include recommen-
dations for coinfection with viral hepatitis. 
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names are 
kept confi dential within the system. Hepa-
titis B and hepatitis C tests are not free of 
charge or compulsory for members of any 
specifi c group.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
No drug for treating hepatitis B or hepatitis 
C is on the national essential medicines list 
or subsidized by the government. 
The Government of Yemen welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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Viral hepatitis in the WHO European Region  
The seroprevalence and incidence of hepatitis A vary 
geographically, increasing from west (<50% exposed 
by the age of 30 years) to east (≥50% exposed by the 
age of 30 years).a Although the total number of cases is 
decreasing, hepatitis A infection is still an important public 
health threat in the Region, with a potential for outbreaks.b
Hepatitis E is responsible for fewer than 5% of cases of 
acute hepatitis in western Europe and, in most studies, 
antibodies against hepatitis E have been found in a small 
proportion (0%–10%) of healthy persons; for other parts of 
Europe, the prevalence is higher, reaching up to 27.8%.c
In the WHO European Region, over 13 million adults are 
living with hepatitis B and 15 million with hepatitis C.d This 
data suggest that almost one in fi fty adults is infected 
with hepatitis B and a similar proportion of people have 
chronic hepatitis C. Most of those infected in the WHO 
European Region live in eastern European and central 
Asian countries: 66% of those with hepatitis B and 64% of 
those with hepatitis C.d
People who inject drugs are the most affected (15% for 
hepatitis B and 44% for hepatitis C), but infection is also 
common in other vulnerable population groups such as 
men who have sex with men (8.7% and 4.2%, respectively), 
and sex workers (3.3% and 11%, respectively).d By 
comparison, rates in the general population of countries 
in the European Region outside the European Union and 
European Free Trade Association are 3.8% for hepatitis B 
and 2.3 % for hepatitis C.d
The 53 Member States of the World Health Organization (WHO) 
European Region together have a population of 899 million, 
with the Russian Federation accounting for approximately one 
six of this total.1 The European Region, which includes 45 high-
income and upper–middle-income countries,2 is characterized 
by increasing life expectancy and a health profi le shaped more 
by noncommunicable than by communicable diseases. At the 
same time, the widely varying social, political and economic 
circumstances of diff erent countries translate into markedly 
diff erent health needs and health outcomes at the national and 
subnational levels.
While the European Region’s under-fi ve mortality rate of 7.9 per 
1000 live births is the lowest in the world, some countries in 
the Region have considerably higher and lower rates.3 Average 
life expectancy for the Region reached 76 years in 2010, with 
a 13-year diff erence between the lowest and highest national 
averages (69 and 82 years, respectively).3 By 2050, more 
than one fourth of the Region’s population will be aged 65 
years or older.3 This trend is one factor driving the increase in 
noncommunicable disease rates in the European Region, but 
lifestyle factors are also thought to play a major role in shaping 
the health of the population. The European Region has the 
highest prevalence of tobacco use among all WHO regions, as 
well as the highest alcohol consumption. 3 
Noncommunicable diseases account for some 80% of deaths in 
the European Region, with circulatory diseases causing almost 
half of all mortality.3 In 28 countries of the European Region, 
cancer is the leading cause of premature death. Among men, 
the forms of cancer resulting in the highest mortality are lung, 
colon, stomach and prostate cancer; among women, they are 
breast, lung, stomach, colon, cervical and ovarian cancer3. 
Communicable diseases that contribute notably to the disease 
burden include viral hepatitis, tuberculosis, HIV infection and 
sexually transmitted infections.3 Tuberculosis causes more than 
40% of all deaths from communicable diseases,3 and some 
countries in central and eastern Europe have an especially high 
burden of multidrug-resistant tuberculosis.4 Although new 
HIV infections are decreasing globally, the eastern part of the 
European Region has the fastest-growing HIV epidemic in the 
world,4 a trend driven largely by injecting drug use.5
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Responses to the WHO/Alliance survey were received from 44 of 
the 53 Member States in the European Region (83.0%).
Box 1. Responses to the 2012 Global Hepatitis Survey: WHO 
European Region
Member States that submitted surveys:
Member States that did not submit surveys: 
• Albania
• Andorra
• Armenia
• Austria
• Azerbaijan
• Belarus
• Belgium
• Bulgaria
• Croatia
• Cyprus
• Czech Republic
• Denmark
• Estonia
• Finland
• France
• Georgia
• Germany
•  Bosnia and 
Herzegovina
• Greece
• Iceland
• Hungary
• Ireland
• Israel
• Italy
• Kyrgyzstan
• Latvia
• Lithuania
• Luxembourg
• Malta
• Montenegro
• Netherlands
• Poland
•  Republic of 
Moldova
•  Russian Federation
• San Marino
• Serbia
• Kazakhstan
• Monaco
• Norway
• Portugal
• Slovakia
• Slovenia
• Spain
• Sweden
• Switzerland
• Tajikistan
•  The former Yugoslav
• Republic of Mac-
edonia
• Turkey
• Ukraine
•  United Kingdom of 
Great Britain and 
Northern Ireland
• Uzbekistan
• Romania
• Turkmenistan
National coordination
Thirteen responding Member States (29.5%) reported the 
existence of a written national strategy or plan that focuses 
exclusively or primarily on the prevention and control of 
viral hepatitis (Figure 1). Four of the 13 Member States with a 
strategy or plan (the Czech Republic, France, Kyrgyzstan and 
the Republic of Moldova) reported that it focuses exclusively 
on viral hepatitis, and seven (Armenia, Austria, Denmark, Israel, 
Russian Federation, Slovenia and Uzbekistan) reported that it 
addresses other diseases as well. One country (Turkey) reported 
that the strategy or plan addresses only hepatitis B, and one (the 
United Kingdom of Great Britain and Northern Ireland) reported 
that it addresses only hepatitis C.
The 13 Member States that reported the existence of a strategy 
or plan were asked about its specifi c components. All 13 reported 
the inclusion of a component for prevention of transmission 
in health-care settings. Twelve reported the inclusion of 
components for surveillance, vaccination and prevention 
of transmission via injecting drug use. Eleven reported the 
inclusion of components for general prevention, and treatment 
and care. Eight reported the inclusion of components for raising 
awareness and coinfection with HIV.
Seven responding Member States (15.9%) reported that they 
have a governmental unit or department responsible solely for 
viral hepatitis-related activities.a Member States that did so were 
Figure 1. Responses to the question, “Is there a written national strategy or plan that focuses exclusively or primarily on the 
prevention and control of viral hepatitis?”
Yes
No
No response
No data
a  One Member State responded that there is no governmental unit but a special 
national multidisciplinary expert team responsible for hepatitis-related activities.
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asked to indicate the number of staff  members in the unit or 
department. Responses (N=5) ranged from 2 to 7 (median, 3), 
with the Republic of Moldova reporting the largest number.
Member States were asked to report the number of people 
working full-time on hepatitis-related activities in all 
government agencies or bodies. Among the 13 Member States 
that provided data for this question, the number ranged from 0 
to 213 (median, 1.5), with Armenia reporting the largest number.
Thirty-four responding Member States (77.3%) reported that 
they have a viral hepatitis prevention and control programme 
that includes activities targeting specifi c populations. The 
populations most commonly targeted are people who inject 
drugs (91.2% of responding Member States within this subset) 
and health-care workers, including health-care waste handlers 
(94.1% of responding Member States within this subset). 
Twenty-one responding Member States reported the inclusion 
of activities targeting people living with HIV, and 17 reported 
the inclusion of activities targeting prisoners. Groups identifi ed 
less frequently included migrants, indigenous populations, low-
income populations, those who are uninsured and those who 
are homeless.
Table 2. Types of surveillance in Member States that reported 
the existence of routine surveillance for viral hepatitis (N=43)
There is a national 
surveillance system for acute 
hepatitis infection for the 
following forms of hepatitis:
hepatitis A
hepatitis B
hepatitis C
hepatitis D
hepatitis E
There is a national 
surveillance system for 
chronic hepatitis infection 
for the following forms of 
hepatitis:
hepatitis B
hepatitis C
hepatitis D
Yes (%)
100
100
95.3
46.5
55.8
65.1
62.8
30.2
No (%)
0
0
4.7
41.9
30.2
32.6
34.9
62.8
Do not 
know 
(%)
0
0
0
0
0
0
0
0
No 
response 
(%)
0
0
0
11.6
14.0
2.3
2.3
7.0
Table 1. Topics of public awareness campaigns on viral 
hepatitis held in Member States since January 2011 (N=10)
General 
information 
about hepatitis 
and its 
transmission
Vaccination for 
hepatitis A and 
hepatitis B
Importance of 
knowing one’s 
hepatitis B and 
hepatitis C 
status
Safe water 
and good 
sanitation
Safer sex 
practices
Harm 
reduction for 
people who 
inject drugs
Safe workplace 
practices
X
X
X
X
X
X
X
X
X
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X
X
X
X
X
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X
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Awareness-raising and partnerships
Seventeen responding Member States (38.6%) reported that 
they had held events for World Hepatitis Day 2012 (28 July). 
Since January 2011, ten responding Member States (22.7%) had 
funded some type of viral hepatitis public awareness campaign 
other than World Hepatitis Day (Table 1).
Twenty-nine responding Member States (65.9%) reported 
that they collaborated with civil society groups within their 
countries to develop and implement the governmental viral 
hepatitis prevention and control programme. For example, 
Armenia reported collaborating with the Armenian Hepatitis 
Forum and the Netherlands reported collaborating with the 
National Hepatitis Centrum. (Further examples can be found in 
the summaries of country fi ndings later in this chapter.)
Evidence-based policy and data for action
Forty-three responding Member States (97.7%) reported that 
they have routine surveillance for viral hepatitis; details appear 
in Table 2.
Forty-two responding Member States (95.5%) indicated that 
their countries have standard case defi nitions for hepatitis 
infection and 42 (95.5%) indicated that their countries have a 
central registry for the reporting of deaths, including hepatitis 
deaths.
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Table 3. Data registration and surveillance (N=44)
Liver cancer cases are registered 
nationally
Cases with HIV/hepatitis 
coinfection are registered 
nationally
Hepatitis outbreaks are reported
If YES – Hepatitis outbreaks are 
further investigated (N=115)
Yes (%)
79.5
65.9
95.5
100
No (%)
18.2
34.1
4.5
0
Do not 
know 
(%)
2.3
0
0
0
No 
response 
(%)
0
0
0
0
Twenty-nine Member States reported on the proportion of 
hepatitis cases and deaths registered as “undiff erentiated” or 
“unclassifi ed” hepatitis. The reported proportions ranged from 
0% to 21.0% (median, 1.0%).a Additional survey fi ndings about 
surveillance are presented in Table 3.
a  These fi gures represent data from 29 of the 30 Member States. Data from the 
Russian Federation are not included here because they were reported in a 
diff erent way. See the Russian Federation country fi ndings later in this chapter for 
information about undiff erentiated/unclassifi ed hepatitis in that Member State.
Member States were asked how often hepatitis disease reports 
are published. Of the responding Member States, 47.7% 
reported that they publish hepatitis disease reports annually; 
36.4%, monthly; and 13.6%, weekly. No hepatitis disease report 
is published by 11.4% of responding Member States.
Eight responding Member States (18.2%) reported the existence 
of a national public health research agenda for viral hepatitis.
Twenty responding Member States (45.5%) reported that 
besides routine surveillance of viral hepatitis, serosurveys are 
conducted regularly. The majority of the surveys targeted the 
general population, pregnant women, men who have sex 
with men, and people who inject drugs. Among this subset of 
responding Member States, 20.0% indicated that serosurveys 
take place at least once per year and, of the same subset, 40.0% 
reported that the most recent viral hepatitis serosurvey was 
carried out in either 2011 or 2012.
Prevention of transmission
Thirty responding Member States (68.2%) reported that they 
have a national policy on hepatitis A vaccination.
Seven responding Member States (15.9%) reported that they 
have established the goal of eliminating or reducing hepatitis 
B (Figure 2). Member States with this goal were asked to specify 
the timeframe in which they seek to eliminate or reduce 
hepatitis B. Among the three Member States that answered this 
question, Latvia reported a target of reducing the proportion of 
acute hepatitis B cases among children by 2011–2012, and the 
Republic of Moldova and Sweden reported targets of reducing 
hepatitis B by 2016.
a  Three Member States (Latvia, Republic of Moldova and Sweden) that answered 
”yes” to this question added comments indicating that their goals relate to 
reducing rather than eliminating hepatitis B.
Figure 2. Responses to the question, “Has your government 
established the goal of eliminating hepatitis B?” (N=44)
No 
(77.3%)
Yes a 
(15.9%)
No response 
2.3%
Do not know 
4.5%
Member States were asked to report, for a given recent year, 
the percentage of newborn infants who had received the fi rst 
dose of hepatitis B vaccine within 24 hours of birth. Among the 
28 Member States that provided this information, responses 
ranged from 0% to 100% (median, 93.5%). Member States were 
also asked to report, for a given recent year, the percentage of 
one-year-olds (ages 12–23 months) who had received three 
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Albania
Andorra
Armenia
Austria
Azerbaijan
Belarus
Belgium
Belarus
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Georgia
Germany
Hungary
Ireland
Israel
Italy
Kyrgyzstan
Latvia
Lithuania
Luxembourg
Malta
Montenegro
Netherlands
Poland
Republic of Moldova
Russian Federation
San Marino
Serbia
Slovakia
Slovenia
Spain
Sweden
The former Yugoslav 
Republic of Macedonia
Turkey
Ukraine
United Kingdom of 
Great Britain and 
Northern Ireland
TOTAL
Table 4. Activities called for in national policy targeting mother-to-child transmission of hepatitis B (N=41)
All pregnant 
women are 
screened for 
hepatitis B
All pregnant 
women found to 
have hepatitis B 
are counselled
Health-care providers 
follow up with all pregnant 
women found to have 
hepatitis B during preg-
nancy for the purpose of 
encouraging them to give 
birth at health-care facilities
Upon delivery, 
all infants born 
to women with 
hepatitis B 
receive hepatitis B 
immunoglobulin
All infants 
receive the fi rst 
dose of hepatitis 
B vaccine within 
24 hours of birth
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Table 5. Hepatitis prevention: policies, practices and 
guidelines (N=44)
There is a national infection 
control policy for blood banks
All donated blood units 
(including family donations) and 
blood products nationwide are 
screened for hepatitis B
All donated blood units 
(including family donations) and 
blood products nationwide are 
screened for hepatitis C
There is a national policy relating 
to the prevention of viral 
hepatitis among people who 
inject drugs
The government has guidelines 
that address how hepatitis A 
and hepatitis E can be prevented 
through food and water safety
Yes (%)
95.5
95.5
97.7
56.8
56.8
No (%)
2.3
2.3
0
27.3
31.8
Do not 
know 
(%)
0
0
0
11.4
9.1
No 
response 
(%)
2.3
2.3
2.3
4.5
2.3
Member States were asked for offi  cial estimates of the number 
and percentage of unnecessary injections administered 
annually in health-care settings (e.g. injections that are given 
when an equivalent oral medication is available). Forty-three 
Member States reported that the fi gures are not known and 
one (Denmark) reported that no unnecessary injection is 
administered annually in health-care settings.
Additional fi ndings relating to the prevention of hepatitis 
transmission are presented in Table 5.
Screening, care and treatment
Member States were asked how health professionals in their 
countries obtain the skills and competencies required to 
eff ectively care for people with viral hepatitis. Responding 
Member States most frequently indicated that these are 
obtained in schools for health professionals (pre-service 
education, 81.8%). Additionally, on-the-job training was 
identifi ed in 79.5% of responses, and postgraduate training in 
75.0%.
Twenty-nine responding Member States (65.9%) reported the 
existence of national clinical guidelines for the management 
of viral hepatitis (Figure 4). Sixteen of these 29 Member States 
indicated that the guidelines include recommendations for cases 
with HIV coinfection. Nineteen of 29 responding Member States 
(65.5%) indicated that there are national clinical guidelines for 
the management of HIV, which include recommendations for 
coinfection with viral hepatitis.
Figure 3. Proportion of responding Member States with 
national policies on injection safety in health-care settings 
which recommend single-use syringes and auto-disable 
syringes for therapeutic injections (N=39)
a  Respondents could select both “single-use syringes” and “auto-disable syringes”.
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Single-use
syringesa
Auto-disable 
syringesa
Do not know
doses of hepatitis B vaccine. Among the 38 Member States that 
provided this information, responses ranged from 30.0% to 
99.3% (median, 95.0%).
Forty-one responding Member States (93.2%) reported the 
existence of a national policy that specifi cally targets mother-to-
child transmission of hepatitis B; details are presented in Table 4. 
Three fourths of Member States with such a policy indicated that 
one component of the policy calls for screening of all pregnant 
women for hepatitis B.
Thirty-seven responding Member States (84.1%) reported 
the existence of a specifi c national strategy and/or policy/
guidelines for preventing hepatitis B and hepatitis C infection 
in health-care settings.
Thirty-seven responding Member States (84.1%) reported that 
health-care workers are vaccinated against hepatitis B prior to 
starting work that might put them at risk of exposure to blood.
Thirty-nine responding Member States (88.6%) reported the 
existence of a national policy on injection safety in health-
care settings. These Member States were asked which types 
of syringes the policy recommends for therapeutic injections. 
Single-use syringes are recommended in 79.5% of policies, and 
auto-disable syringes in 12.8% (Figure 3).
Forty-one responding Member States (93.2%) reported that 
single-use or auto-disable syringes, needles and cannulas are 
always available in all health-care facilities.
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Figure 4. Responses to the question, “Are there national 
clinical guidelines for the management of viral hepatitis?” 
(N=44)
No 
(27.3%)
Yes 
(65.9%)
No 
response 
2.3%
Do not know 
4.5%
Lamivudine 
Interferon alpha 
Tenofovir
Pegylated interferon
Entecavir
Adefovir dipivoxil
Telbivudine
Ribavirin
Pegylated interferon
Interferon alpha
Telaprevir
Boceprevir
84.1
77.3
75.0
61.4
54.5
50.0
38.6
86.4
79.5
68.2
38.6
38.6
% of Member States reporting its 
inclusion (N=12)
% of Member States reporting its 
inclusion (N=12)
Drugs for treating 
hepatitis B
Drugs for treating 
hepatitis C
Table 6. Proportion of Member States reporting drugs for 
treating hepatitis B and C on national essential medicines 
lists or subsidized by governments
Twenty-two responding Member States (50.0%) indicated that 
they have a national policy relating to screening and referral to 
care for hepatitis B. Twenty-one (47.7%) reported that they have 
such a policy for hepatitis C.
Regarding hepatitis B testing, 40 responding Member States 
(90.9%) indicated that people register by name for testing. 
Thirty-six members of that subset (90.0%) indicated that the 
names are kept confi dential. Nineteen responding Member 
States (43.2%) reported that the hepatitis B test is free of charge 
for all individuals. Among the 25 other Member States, 19 
(76.0%) reported that the hepatitis B test is free of charge for 
members of specifi c groups. Groups identifi ed included blood 
donors, health-care workers, prisoners, pregnant women, 
people who inject drugs and people living with HIV. Twenty-
four responding Member States (54.5%) reported that the 
hepatitis B test is compulsory for members of specifi c groups. 
Groups identifi ed included blood donors, health-care workers, 
pregnant women and patients on haemodialysis.
Regarding hepatitis C testing, 40 responding Member States 
(90.9%) indicated that people register by name for testing. 
Thirty-six members of that subset (90.0%) indicated that the 
names are kept confi dential. Twenty responding Member States 
(45.5%) reported that the hepatitis C test is free of charge for 
all individuals. Among the 24 other Member States, 18 (75.0%) 
reported that the hepatitis C test is free of charge for members 
of specifi c groups. Groups identifi ed included blood donors, 
health-care workers, prisoners, pregnant women, people who 
inject drugs and people living with HIV. Twenty-two responding 
Member States (50.0%) reported that the hepatitis C test is 
compulsory for members of specifi c groups. Groups identifi ed 
included blood donors, health-care workers, pregnant women 
and patients on haemodialysis.
Thirty-six responding Member States (81.8%) reported that 
publicly funded treatment is available for hepatitis B and 34 
(77.3%) that it is available for hepatitis C. Eight responding 
Member States reported the amount spent on publicly funded 
treatment for hepatitis B and hepatitis C. Details can be found 
in the summaries of country fi ndings later in this chapter (see 
Armenia, Croatia, Germany, Lithuania, Poland, San Marino, 
Spain and Turkey).
Thirty-eight responding Member States (86.4%) reported that at 
least one available drug for treating hepatitis B is on the national 
essential medicines list or subsidized by the government. The 
drugs most commonly reported were lamivudine, interferon 
alpha, tenofovir and pegylated interferon (Table 6).
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Awareness-raising, partnerships and resource mobilization (fi rst WHO strategic axis)
Developing the national plan for viral hepatitis prevention and control
Integrating viral hepatitis programmes into other health services
Awareness-raising
Evidence-based policy and data for action (second WHO strategic axis)
Viral hepatitis surveillance
Estimating the national burden of viral hepatitis
Developing tools to assess the eff ectiveness of interventions
Assessing the economic impact of viral hepatitis
Prevention of transmission (third WHO strategic axis)
Increasing coverage of the birth dose of the hepatitis B vaccine
Screening, care and treatment (fourth WHO strategic axis)
Increasing access to treatment
Increasing access to diagnostics
Improving laboratory quality
Developing education/training programmes for health professionals
38.6%
29.5%
27.3%
22.7%
34.1%
22.7%
38.6%
9.1% 
25.0%
22.7%
20.9%a
34.1%
Table 7. Viral hepatitis control and prevention: areas in which governments indicated interest in receiving WHO assistance 
(N=44)
a  N=43 (This response option was not included in the survey completed by Belarus.)
Thirty-nine responding Member States (88.6%) reported that at 
least one available drug for treating hepatitis C is on the national 
essential medicines list or subsidized by the government. 
The drugs most commonly reported were interferon alpha, 
pegylated interferon and ribavirin.
World Health Organization assistance
Member States were asked to indicate areas in which they might 
want assistance from WHO for the prevention and control of viral 
hepatitis. Respondents most commonly selected the following: 
developing the national plan for viral hepatitis prevention and 
control (39.5%), and assessing the economic impact of viral 
hepatitis (39.5%) (Table 7). Responses from individual Member 
States appear in Annex C.
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The Government of Albania reports as 
follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis. 
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities: Department of Infection 
and Disease Control. It has fi ve staff  mem-
bers. There are two full-time equivalent 
staff  members who work on hepatitis-re-
lated activities in all government agencies/
bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people living with HIV, students and preg-
nant women.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 but has not funded 
other viral hepatitis public awareness cam-
paigns since January 2011.
The government does not collaborate with 
in-country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, but not for any type of chronic 
hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Of hepati-
tis cases, 21% are reported as “undiff erenti-
ated” or “unclassifi ed” hepatitis. 
Liver cancer cases are not registered na-
tionally, but cases with HIV/hepatitis coin-
fection are.
The government publishes hepatitis dis-
ease reports monthly. 
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target populations are the general popu-
lation, men who have sex with men, preg-
nant women and health-care workers. The 
last serosurvey was carried out in 2003. 
Prevention of transmission
There is no national policy on hepatitis A 
vaccination. 
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 97.4% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 99.1% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vaccinat-
ed against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeu-
tic injections. Single-use or auto-disable 
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
3.2
Lower–middle-income
$8820
5.66%
$577.28
$225.38
73
0.739
30
1.5
syringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
It is not known whether there is a national 
policy relating to the prevention of viral 
hepatitis among people who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepatitis 
E can be prevented through food and wa-
ter safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
It is not known whether there are national 
clinical guidelines for the management of 
viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals. Information was 
not provided on whether hepatitis B or 
hepatitis C tests are compulsory for mem-
bers of any specifi c group.
It is not known whether publicly funded 
treatment is available for hepatitis B or 
hepatitis C and, if so, the amount spent by 
the government on such treatment.
The following drug for treating hepatitis B 
is on the national essential medicines list or 
subsidized by the government: interferon 
alpha. The following drug for treating hep-
atitis C is on the national essential medi-
cines list or subsidized by the government: 
interferon alpha.
The Government of Albania welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
Albania
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Andorra
The Government of Andorra reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. There are no people 
working full-time on hepatitis-related ac-
tivities in any government agency/body.
Information was not provided on whether 
the government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting specifi c popula-
tions.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, but not for any type of chronic 
hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. No hepa-
titis case is reported as “undiff erentiated” 
or “unclassifi ed” hepatitis. 
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports annually.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 93% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 99% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection 
safety in health-care settings, which rec-
ommends single-use and auto-disable 
syringes for therapeutic injections. Single-
use or auto-disable syringes, needles and 
cannulas are always available in all health-
care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
In response to questions about screening 
of blood, the respondent stated, “In An-
dorra there are no blood banks. We work 
in collaboration with Spain and France, 
following their rules.” No further informa-
tion was provided on whether there is a 
national infection control policy for blood 
banks, or whether all donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C.
Information was not provided on whether 
there is a national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
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The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education). 
Information was not provided on whether 
there are national clinical guidelines for 
the management of viral hepatitis. There 
are no national clinical guidelines for the 
management of HIV, which include rec-
ommendations for coinfection with viral 
hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are not 
free of charge and are not compulsory for 
members of any specifi c group.
Publicly funded treatment for hepatitis B 
and hepatitis C is available to the entire 
population. The amount spent by the gov-
ernment on such treatment is not known.
The following drugs for treating hepatitis B 
are on the national essential medicines list 
or subsidized by the government: inter-
feron alpha, pegylated interferon, lamivu-
dine, adefovir dipivoxil, entecavir, telbivu-
dine and tenofovir. The following drugs for 
treating hepatitis C are on the national es-
sential medicines list or subsidized by the 
government: interferon alpha, pegylated 
interferon, ribavirin, boceprevir and tel-
aprevir.
The Government of Andorra did not in-
dicate a need for assistance from WHO in 
relation to viral hepatitis prevention and 
control.
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The Government of Armenia reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses primarily on the prevention and 
control of viral hepatitis, and also integrates 
other diseases. It includes components for 
raising awareness, surveillance, vaccination, 
prevention in general, prevention of trans-
mission via injecting drug use, prevention 
of transmission in health-care settings, treat-
ment and care, and coinfection with HIV.
There is no designated governmental unit/
department responsible solely for coordinat-
ing and/or carrying out viral hepatitis-related 
activities. There are 213 full-time equivalent 
staff  members who work on hepatitis-related 
activities in all government agencies/bodies. 
The government has a viral hepatitis preven-
tion and control programme that includes 
activities targeting the following specifi c 
populations: health-care workers (including 
health-care waste handlers), people who in-
ject drugs and people living with HIV.
Awareness-raising and partnerships
The government held events for World Hepa-
titis Day 2012 and has funded other viral 
hepatitis public awareness campaigns since 
January 2011 (Annex A).
The government collaborates with the follow-
ing in-country civil society group to develop 
and implement its viral hepatitis prevention 
and control programme: the Armenian Hepa-
titis Forum.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepatitis. 
There is a national surveillance system for the 
following types of acute hepatitis: A, B, C, D 
and E, but not for any type of chronic hepa-
titis.
There are standard case defi nitions for hepa-
titis. Deaths, including from hepatitis, are re-
ported to a central registry. Of hepatitis cases, 
2.8% are reported as “undiff erentiated” or “un-
classifi ed” hepatitis.
Liver cancer cases and cases with HIV/hepati-
tis coinfection are registered nationally. 
The government publishes hepatitis disease 
reports monthly. 
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investigation 
of viral hepatitis outbreaks and other surveil-
lance activities.
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis sero-
surveys are conducted regularly. The target 
populations are health-care workers at risk 
of parenterally transmitted hepatitis, donors 
and pregnant women. Information was not 
provided on when the last serosurvey was 
carried out.
Prevention of transmission
There is a national policy on hepatitis A vac-
cination. 
The government has not established the goal 
of eliminating hepatitis B.
Nationally, 96% of newborn infants in a given 
recent year received the fi rst dose of hepatitis 
B vaccine within 24 hours of birth and 95% of 
one-year-olds (ages 12–23 months) in a given 
recent year received three doses of hepatitis 
B vaccine.
There is a national policy that specifi cally tar-
gets mother-to-child transmission of hepati-
tis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis B 
and hepatitis C infection in health-care set-
tings. Health-care workers are vaccinated 
against hepatitis B prior to starting work that 
might put them at risk of exposure to blood.
There is a national policy on injection safety 
in health-care settings, which recommends 
single-use and auto-disable syringes for ther-
apeutic injections. Single-use or auto-disable 
syringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the number 
and percentage of unnecessary injections 
administered annually in health-care settings 
are not known. 
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
3.1
Lower–middle-income
$6100
4.40%
$238.52
$96.92
70
0.806
32
1.7
There is a national infection control policy for 
blood banks. All donated blood units (includ-
ing family donations) and blood products 
nationwide are screened for hepatitis B and 
hepatitis C. 
There is a national policy relating to the pre-
vention of viral hepatitis among people who 
inject drugs.
The government has guidelines that address 
how hepatitis A and hepatitis E can be pre-
vented through food and water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care for 
people with viral hepatitis through schools 
for health professionals (pre-service educa-
tion), on-the-job training, postgraduate train-
ing and thematic workshops.
There are no national clinical guidelines for 
the management of viral hepatitis, but there 
are for the management of HIV, which include 
recommendations for coinfection with viral 
hepatitis.
The government has national policies relat-
ing to screening and referral to care for hepa-
titis B and hepatitis C. 
People testing for both hepatitis B and hepa-
titis C register by name; the names are kept 
confi dential within the system. Hepatitis B 
and hepatitis C tests are not free of charge for 
all individuals, but they are free of charge for 
patients with acute hepatitis, blood donors 
and pregnant women in the city of Yerevan. 
Hepatitis B and hepatitis C tests are compul-
sory for patients with hepatitis, people liv-
ing with HIV, health-care workers at risk of 
parenterally transmitted hepatitis and preg-
nant women in Yerevan.
Publicly funded treatment is available for 
acute hepatitis B and hepatitis C. 
The government spends dram 120 000–
150 000 (US$ 298–373) per patient in sum on 
publicly funded treatment for hepatitis B and 
hepatitis C.
The following drugs for treating hepatitis B 
are on the national essential medicines list 
or subsidized by the government: interferon 
alpha, pegylated interferon and lamivudine. 
The following drugs for treating hepatitis C 
are on the national essential medicines list or 
subsidized by the government: interferon al-
pha, pegylated interferon and ribavirin.
The Government of Armenia welcomes assist-
ance from WHO in one or more areas of viral 
hepatitis prevention and control (Annex C).
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Austria
The Government of Austria reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses primarily on the prevention 
and control of viral hepatitis, and also in-
tegrates other diseases. It includes com-
ponents for raising awareness, surveil-
lance, vaccination, prevention in general, 
prevention of transmission via injecting 
drug use, prevention of transmission in 
health-care settings, treatment and care, 
and coinfection with HIV. 
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. It is not known how 
many people work full-time on hepatitis-
related activities in all government agen-
cies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs and people living 
with HIV.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011. 
The government collaborates with in-
country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme. Information 
was not provided about the identity of 
civil society partners.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B, C, D and E, and for the following types 
of chronic hepatitis: B, C and D.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. The per-
centage of hepatitis cases reported as “un-
diff erentiated” or “unclassifi ed” hepatitis is 
not known.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports monthly. 
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, less than 1% of newborn in-
fants in a given recent year received the 
fi rst dose of hepatitis B vaccine within 24 
hours of birth and 95% of one-year-olds 
(ages 12–23 months) in a given recent year 
received three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection 
safety in health-care settings, which rec-
ommends single-use and auto-disable 
syringes for therapeutic injections. Single-
use or auto-disable syringes, needles and 
cannulas are always available in all health-
care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is a national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
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Information was not provided on whether 
the government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education). 
There are national clinical guidelines for 
the management of viral hepatitis, but 
they do not include recommendations for 
cases with HIV coinfection. There are na-
tional clinical guidelines for the manage-
ment of HIV, which include recommenda-
tions for coinfection with viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals and are not com-
pulsory for members of any specifi c group. 
Publicly funded treatment is available for 
hepatitis B and hepatitis C. Information 
was not provided on who is eligible for 
this. The amount spent by the government 
on publicly funded treatment for hepatitis 
B and hepatitis C is not known.
The following drugs for treating hepatitis B 
are on the national essential medicines list 
or subsidized by the government: inter-
feron alpha, lamivudine and tenofovir. The 
following drugs for treating hepatitis C are 
on the national essential medicines list or 
subsidized by the government: interferon 
alpha and ribavirin.
The Government of Austria did not indi-
cate a need for assistance from WHO in 
relation to viral hepatitis prevention and 
control.
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The Government of Azerbaijan reports as 
follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis.
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities: Republican Centre of 
Hygiene and Epidemiology, Department 
of Intestinal Infections. It has three staff  
members. There is one full-time equivalent 
staff  member who works on hepatitis-re-
lated activities in all government agencies/
bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c population: pregnant women.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 but has not funded 
other viral hepatitis public awareness cam-
paigns since January 2011.
The government collaborates with the fol-
lowing in-country civil society group to 
develop and implement its viral hepatitis 
prevention and control programme: Vish-
nevskaya-Rostropovich Foundation.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, but not for any type of chronic 
hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. No hepa-
titis case is reported as “undiff erentiated” or 
“unclassifi ed” hepatitis.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports monthly. 
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis A, hepatitis B and hepatitis 
C, but not for hepatitis E.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target populations are pregnant women, 
blood donors and medical staff . Informa-
tion was not provided on when the last 
serosurvey was carried out.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 99% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 96% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is no specifi c national strategy and/
or policy/guidelines for preventing hepati-
tis B and hepatitis C infection in health-care 
settings. Health-care workers are not vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends auto-disable syringes for therapeu-
tic injections. Single-use or auto-disable 
syringes, needles and cannulas are always 
available in all health-care facilities.
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
9.3
Upper–middle-income
$8960
5.88%
$579.07
$117.49
68
0.733
30
2.2
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education) and postgraduate training. 
There are no national clinical guidelines for 
the management of viral hepatitis. Infor-
mation was not provided on whether there 
are national clinical guidelines for the man-
agement of HIV, which include recommen-
dations for coinfection with viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals, and are compul-
sory for pregnant women, blood donors 
and medical staff .
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
The following drugs for treating hepatitis B 
are on the national essential medicines list 
or subsidized by the government: lamivu-
dine and tenofovir. The following drug for 
treating hepatitis C is on the national es-
sential medicines list or subsidized by the 
government: ribavirin.
The Government of Azerbaijan welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C). 
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Belarus
The Government of Belarus reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. There are 20–25 full-
time equivalent staff  members who work 
on hepatitis-related activities in all govern-
ment agencies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: people who inject 
drugs, prisoners, people living with HIV, 
sex workers and men who have sex with 
men.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 and has funded other 
viral hepatitis public awareness cam-
paigns since January 2011 (Annex A).
The government collaborates with the fol-
lowing in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme: NGO 
“Positive Movement” and Belarusian Red 
Cross.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B, C, D and E, and for the following types 
of chronic hepatitis: B, C and D.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Infor-
mation was not provided regarding the 
percentage of hepatitis cases reported as 
“undiff erentiated” or “unknown” hepatitis.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports monthly and annually.
Hepatitis outbreaks are reported to the 
government and are further investigated. 
There is adequate laboratory capacity na-
tionally to support investigation of out-
breaks and other surveillance activities. 
Information was not provided on whether 
there is a national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target populations are people who in-
ject drugs, men who have sex with men, 
pregnant women, people living with HIV, 
health-care workers, members of the mili-
tary and prisoners. Information was not 
provided on when the last serosurvey was 
carried out.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 100% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 98%–100% of one-year-olds (ages 12–
23 months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/
or policy for preventing hepatitis B and 
hepatitis C infection in health-care set-
tings. Health-care workers are vaccinated 
against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is a national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
9.6
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The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety. 
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals and are compul-
sory for members of some specifi c groups 
but these groups were not identifi ed.
Publicly funded treatment is available for 
hepatitis B and C. Information was not 
provided on who is eligible for publicly 
funded treatment for hepatitis B. Publicly 
funded treatment for hepatitis C is avail-
able only to people with acute infection 
(not those with chronic infection). Infor-
mation was not provided on the amount 
spent by the government on such treat-
ment for hepatitis B and hepatitis C.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list: interferon alpha, pegylated interferon, 
lamivudine and tenofovir. The following 
drugs for treating hepatitis C are on the 
national essential medicines list: interferon 
alpha, pegylated interferon and ribavirin.
The Government of Belarus welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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The Government of Belgium reports as 
follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. It is not known how many 
people work full-time on hepatitis-related 
activities in all government agencies/bod-
ies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
newborns and unvaccinated adolescents.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government collaborates with the fol-
lowing in-country civil society groups to 
develop and implement the vaccination 
component of its viral hepatitis prevention 
and control programme: well baby clinics, 
school health services, and organizations 
for health-care providers who are involved 
in vaccination, such as paediatricians and 
other physicians.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, but not for any type of chronic 
hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. The per-
centage of hepatitis cases reported as “un-
diff erentiated” or “unclassifi ed” hepatitis is 
not known.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports annually.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are conducted regularly; the tar-
get population is the general population. 
The last serosurvey was carried out in 2006. 
Prevention of transmission
There is a national policy on hepatitis A 
vaccination. 
The government has not established the 
goal of eliminating hepatitis B.
Information was not provided on the per-
centage of newborn infants nationally in 
a given recent year who received the fi rst 
dose of hepatitis B vaccine within 24 hours 
of birth. In a given recent year, 91% of one-
year-olds (ages 12–23 months) received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vaccinat-
ed against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
10.8
High-income
$39 190
10.71%
$4025.11
$3008.52
80
0.886
41
1.8
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
There is a national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
It is not known whether the government 
has guidelines that address how hepa-
titis A and hepatitis E can be prevented 
through food and water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals and are not com-
pulsory for members of any specifi c group.
Publicly funded treatment for hepatitis B 
and hepatitis C is available to the entire 
population. Information was not provided 
on the amount spent by the government 
on such treatment.
The following drugs for treating hepatitis B 
are on the national essential medicines list 
or subsidized by the government: interfer-
on alpha, pegylated interferon, lamivudine, 
adefovir dipivoxil, entecavir and tenofovir. 
The following drugs for treating hepatitis 
C are on the national essential medicines 
list or subsidized by the government: inter-
feron alpha, pegylated interferon, ribavirin, 
boceprevir and telaprevir.
The Government of Belgium welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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Bulgaria
The Government of Bulgaria reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hep-
atitis-related activities. Information was 
not provided on how many people work 
full-time on hepatitis-related activities in 
all government agencies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c population: health-care workers 
(including health-care waste handlers).
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 but has not funded 
other viral hepatitis public awareness 
campaigns since January 2011.
The government collaborates with the 
following in-country civil society groups 
to develop and implement its viral hepa-
titis prevention and control programme: 
Hepasist National Association to Fight 
Hepatitis and Hepactive Association to 
Fight Hepatitis.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B, C, D and E, but not for any type of 
chronic hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Less than 
5% of hepatitis cases are reported as “un-
diff erentiated” or “unclassifi ed” hepatitis.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports weekly. 
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis A, hepatitis B, and hepati-
tis C, but not for hepatitis E.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target population is the general popula-
tion. The last serosurvey was carried out 
in 2011. 
Prevention of transmission
There is a national policy on hepatitis A 
vaccination. 
The government has established the goal 
of eliminating hepatitis B but does not 
have a specifi c timeframe for this.
Nationally, 98.6% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 96.0% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is a national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
7.4
Upper–middle-income
$14 160
6.87%
$434.89
$236.97
74
0.771
42
1.5
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through on-
the-job training and postgraduate train-
ing. 
There are national clinical guidelines for 
the management of viral hepatitis, but 
they do not include recommendations for 
cases with HIV coinfection. There are na-
tional clinical guidelines for the manage-
ment of HIV, which include recommenda-
tions for coinfection with viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are not 
free of charge for all individuals, but are 
free of charge for injecting drug users, 
men who have sex with men, prisoners 
and sex workers. Hepatitis B and hepatitis 
C tests are not compulsory for members of 
any specifi c group.
Publicly funded treatment for hepatitis B 
and hepatitis C is available to all people 
with health insurance. Information was 
not provided on the amount spent by the 
government on such treatment.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: 
interferon alpha, pegylated interferon, 
lamivudine, adefovir dipivoxil, entecavir 
and telbivudine. The following drugs for 
treating hepatitis C are on the national es-
sential medicines list or subsidized by the 
government: interferon alpha, pegylated 
interferon and ribavirin.
The Government of Bulgaria welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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The Government of Croatia reports as 
follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis. 
There is no designated governmental 
unit/department responsible solely for 
coordinating and/or carrying out viral 
hepatitis-related activities. Information was 
not provided on how many people work 
full-time on hepatitis-related activities in all 
government agencies/bodies.
The government has a viral hepatitis 
prevention and control programme that 
includes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs, prisoners and 
people living with HIV.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 and has funded other 
viral hepatitis public awareness campaigns 
since January 2011 (Annex A).
The government collaborates with the 
following in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme: 
HULOH Hepatos, HUHIV.
Evidence-based policy and data for 
action
There is routine surveillance for viral 
hepatitis. There is a national surveillance 
system for the following types of acute 
hepatitis: A, B, C, D and E, and for the 
following types of chronic hepatitis: B, C 
and D.
There are standard case defi nitions 
for hepatitis. Deaths, including from 
hepatitis, are reported to a central registry. 
Of hepatitis cases, 1%–5% is reported 
as “undiff erentiated” or “unclassifi ed” 
hepatitis.
Liver cancer cases and cases with HIV/
hepatitis coinfection are registered 
nationally. 
The government publishes hepatitis 
disease reports monthly and annually.
Hepatitis outbreaks are required to be 
reported to the government and are 
further investigated. There is adequate 
laboratory capacity nationally to support 
investigation of viral hepatitis outbreaks 
and other surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are not conducted regularly.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 96% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 96% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/
or policy/guidelines for preventing 
hepatitis B and hepatitis C infection in 
health-care settings. Health-care workers 
are vaccinated against hepatitis B prior to 
starting work that might put them at risk of 
exposure to blood.
There is a national policy on injection 
safety in health-care settings, which 
recommends single-use syringes for 
therapeutic injections. Single-use or auto-
disable syringes, needles and cannulas are 
always available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
4.3
High-income
$18 760
7.76%
$1066.72
$1284.54
76
0.834
42
1.5
injections administered annually in health-
care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C.
There is a national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
The government has guidelines that 
address how hepatitis A and hepatitis E 
can be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-
service education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection.
The government has national policies 
relating to screening and referral to care for 
hepatitis B and hepatitis C. 
Whether or not people who test for 
hepatitis B or hepatitis C register by name 
depends on the setting. If they do register 
by name, these are kept confi dential within 
the system. Hepatitis B and hepatitis C tests 
are free of charge for all individuals and 
compulsory for blood and organ donors.
Publicly funded treatment for hepatitis B 
is available to the entire population, while 
for hepatitis C it is available to all people 
who have public health insurance. The 
government spends approximately HRK 20 
million (US$ 3.4 million) annually on such 
treatment for hepatitis B and hepatitis C.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: 
pegylated interferon, lamivudine, 
telbivudine and tenofovir. The following 
drugs for treating hepatitis C are on 
the national essential medicines list or 
subsidized by the government: pegylated 
interferon and ribavirin.
The Government of Croatia welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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Cyprus
The Government of Cyprus reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. There are no people 
working full-time on hepatitis-related ac-
tivities in any government agency/body.
The government does not have a viral 
hepatitis prevention and control pro-
gramme that includes activities targeting 
specifi c populations.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B, C, D and E, and for the following types 
of chronic hepatitis: B, C and D.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. No hepa-
titis case is reported as “undiff erentiated” 
or “unclassifi ed” hepatitis.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports annually. 
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is no national public health research 
agenda for viral hepatitis. It is not known 
whether viral hepatitis serosurveys are 
conducted regularly.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination. 
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 0.4% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 96% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are not vac-
cinated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepati-
tis E can be prevented through food and 
water safety.
1.1
--
$30 970
5.97%
$1841.64
$764.40
81
0.866
34
1.5
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through on-
the-job training. 
There are national clinical guidelines for 
the management of viral hepatitis. It is not 
known whether they include recommen-
dations for cases with HIV coinfection.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name, and there 
is open access to their names. Hepati-
tis B and hepatitis C tests are not free of 
charge for all individuals, but they are free 
of charge for people living with HIV, preg-
nant women, blood donors and people 
infected with either hepatitis B or hepa-
titis C. Information was not provided on 
whether hepatitis B or hepatitis C tests are 
compulsory for members of any specifi c 
group.
Publicly funded treatment for hepatitis B 
and hepatitis C is available to the entire 
population. The amount spent by the gov-
ernment on such treatment is not known.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: in-
terferon alpha, pegylated interferon, lami-
vudine, adefovir dipivoxil, entecavir, telbi-
vudine and tenofovir. The following drugs 
for treating hepatitis C are on the national 
essential medicines list or subsidized by 
the government: pegylated interferon and 
ribavirin.
The Government of Cyprus welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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The Government of the Czech Republic 
reports as follows.
National coordination
There is a written national strategy or plan 
that focuses exclusively on the prevention 
and control of viral hepatitis. It includes 
components for surveillance, vaccination, 
prevention in general, prevention of trans-
mission via injecting drug use, prevention 
of transmission in health-care settings, and 
treatment and care.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. It is not known how many 
people work full-time on hepatitis-related 
activities in all government agencies/bod-
ies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs, workers at cen-
tres for people who inject drugs, new-
borns, adolescents, medical students, 
nurses and workers in selected social serv-
ices, prison workers, emergency services 
workers, patients on regular dialysis, new 
clients in residences for people with poor 
health, and contacts of hepatitis B-infected 
patients and hepatitis B surface antigen 
(HBsAg)-positive carriers. 
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government collaborates with the fol-
lowing in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme: pa-
tient associations.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: A, 
B, C and E, but not for any type of chronic 
hepatitis. 
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Less than 
1% of hepatitis cases are reported as “un-
diff erentiated” or “unclassifi ed” hepatitis.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports weekly, monthly and annually.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly. The 
most recent serosurvey was conducted in 
2001 and targeted the general population.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination. 
The government has not established the 
goal of eliminating hepatitis B.
Nationally, less than 1% of newborn in-
fants in a given recent year received the 
fi rst dose of hepatitis B vaccine within 24 
hours of birth and 99% of one-year-olds 
(ages 12–23 months) in a given recent year 
received three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
It is not known whether there is a specifi c 
national strategy and/or policy/guidelines 
for preventing hepatitis B and hepatitis C 
infection in health-care settings. Health-
care workers are vaccinated against hepa-
titis B prior to starting work that might put 
them at risk of exposure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
10.5
High-income
$24 370
7.88%
$2050.95
$1716.16
77
0.917
39
1.5
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
There is a national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection. It is not known whether 
there are national clinical guidelines for the 
management of HIV, which include rec-
ommendations for coinfection with viral 
hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names are 
kept confi dential within the system. Hepa-
titis B and hepatitis C tests are not free of 
charge for all individuals, though they are 
for certain groups, but information was not 
provided regarding which groups. Hepati-
tis B and hepatitis C tests are compulsory 
for members of some specifi c groups but 
these groups were not identifi ed.
Publicly funded treatment for hepatitis B 
and hepatitis C is available to all people 
with national health insurance. Information 
was not provided on the amount spent by 
the government on such treatment.
Information was not provided on whether 
any drug for treating hepatitis B or hepati-
tis C is on the national essential medicines 
list or subsidized by the government. 
The Government of the Czech Republic 
did not indicate a need for assistance from 
WHO in relation to viral hepatitis preven-
tion and control.
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Denmark
The Government of Denmark reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses primarily on the prevention 
and control of viral hepatitis, and also in-
tegrates other diseases. It includes compo-
nents for surveillance, vaccination, preven-
tion in general, prevention of transmission 
via injecting drug use, prevention of trans-
mission in health-care settings, treatment 
and care, and coinfection with HIV.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. One third of one full-time 
staff  position in all government agencies/
bodies is allocated to work on hepatitis-
related activities.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs and pregnant 
women.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011. 
The government collaborates with the 
following in-country civil society groups 
to develop and implement its viral hepa-
titis prevention and control programme: 
Gadejuristen and AIDS-Fondet.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, and for the following types of 
chronic hepatitis: B and C.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. The per-
centage of hepatitis cases reported as “un-
diff erentiated” or “unclassifi ed” hepatitis is 
not known.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports annually.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target populations are people who inject 
drugs, pregnant women and children of 
infected mothers. Information was not 
provided on when the last serosurvey was 
carried out.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B. 
Nationally, 90% of newborn children of 
hepatitis B-infected mothers in a given 
recent year received the fi rst dose of hepa-
titis B vaccine within 24 hours of birth and 
64% of one-year-old children (ages 12–23 
months) of hepatitis B-infected mothers in 
a given recent year received three doses of 
hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection 
safety in health-care settings, but it is not 
known what type of syringes it recom-
mends for therapeutic injections. Single-
use or auto-disable syringes, needles and 
cannulas are always available in all health-
care facilities.
No injection administered annually in 
health-care settings is unnecessary, ac-
cording to offi  cial government estimates.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
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There is a national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals and not compul-
sory for members of any specifi c group.
Publicly funded treatment for hepatitis B 
and hepatitis C is available to the entire 
population. Information was not provided 
on the amount spent by the government 
on such treatment.
The following drugs for treating hepatitis B 
are on the national essential medicines list 
or subsidized by the government: inter-
feron alpha, pegylated interferon, lamivu-
dine, adefovir dipivoxil, entecavir, telbivu-
dine and tenofovir. The following drugs for 
treating hepatitis C are on the national es-
sential medicines list or subsidized by the 
government: interferon alpha, pegylated 
interferon, ribavirin, boceprevir and tel-
aprevir.
The Government of Denmark did not in-
dicate a need for assistance from WHO in 
relation to viral hepatitis prevention and 
control.
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The Government of Estonia reports as 
follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. There are no people 
working full-time on hepatitis-related ac-
tivities in any government agency/body.
The government does not have a viral hep-
atitis prevention and control programme 
that includes activities targeting specifi c 
populations.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate with 
in-country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: A, 
B, C, D and E, and for the following types of 
chronic hepatitis: B, C and D.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Less than 
1% of hepatitis cases are reported as “un-
diff erentiated” or “unclassifi ed” hepatitis. 
Liver cancer cases are not registered na-
tionally, but cases with HIV/hepatitis coin-
fection are.
The government publishes hepatitis dis-
ease reports monthly and annually.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis A, hepatitis B and hepatitis 
C, but not for hepatitis E.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination. 
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 88% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 94% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vaccinat-
ed against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
1.3
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40
1.7
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education). 
There are national clinical guidelines for 
the management of viral hepatitis, but it 
is not known whether they include recom-
mendations for cases with HIV coinfection.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names are 
kept confi dential within the system. Hepa-
titis B and hepatitis C tests are not free of 
charge for all individuals, but they are for 
pregnant women, prisoners, donors and 
people with medical insurance. Hepatitis 
B and hepatitis C tests are compulsory for 
blood donors.
Publicly funded treatment for hepatitis 
B and hepatitis C is available to people 
covered by the Estonian Health Insurance 
Fund. Information was not provided on the 
amount spent by the government on such 
treatment.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: inter-
feron alpha and pegylated interferon. The 
following drugs for treating hepatitis C are 
on the national essential medicines list or 
subsidized by the government: interferon 
alpha, pegylated interferon and ribavirin.
The Government of Estonia welcomes 
assistance from WHO in one or more ar-
eas of viral hepatitis prevention and con-
trol (Annex C).
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Finland
The Government of Finland reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. It is not known how 
many people work full-time on hepatitis-
related activities in all government agen-
cies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs, migrants and 
prisoners.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government collaborates with the 
following in-country civil society groups 
to develop and implement its viral hepa-
titis prevention and control programme: 
A-Clinic Foundation and Helsinki Deacon-
ess Institute.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A and B, and for the following types of 
chronic hepatitis: B, C and D.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. The per-
centage of hepatitis cases reported as “un-
diff erentiated” or “unclassifi ed” hepatitis is 
not known.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports annually.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target populations are people who inject 
drugs, men who have sex with men, sex 
workers and pregnant women. The last se-
rosurvey was carried out in 2010.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
It is not known what percentage of new-
born infants nationally in a given recent 
year received the fi rst dose of hepatitis B 
vaccine within 24 hours of birth or what 
percentage of one-year-olds (ages 12–23 
months) nationally in a given recent year 
received three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
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Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education) and postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, but 
they do not include recommendations for 
cases with HIV coinfection. There are na-
tional clinical guidelines for the manage-
ment of HIV, which include recommenda-
tions for coinfection with viral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals and are not com-
pulsory for members of any specifi c group. 
Publicly funded treatment for hepatitis B is 
available to the entire population. All legal 
residents are eligible for publicly funded 
treatment for hepatitis C, but there is pre-
screening according to clinically set crite-
ria, and being an active IDU is among the 
contraindications for starting treatment. 
The amount spent by the government on 
publicly funded treatment for hepatitis B 
and hepatitis C is not known.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: 
interferon alpha, pegylated interferon, 
lamivudine and adefovir dipivoxil. The fol-
lowing drugs for treating hepatitis C are 
on the national essential medicines list or 
subsidized by the government: interferon 
alpha, pegylated interferon, ribavirin, bo-
ceprevir and telaprevir.
The Government of Finland welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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The Government of France reports as follows.
National coordination
There is a written national strategy or plan 
that focuses exclusively on the prevention 
and control of viral hepatitis. It includes com-
ponents for raising awareness, surveillance, 
vaccination, prevention in general, preven-
tion of transmission via injecting drug use, 
prevention of transmission in health-care set-
tings, and treatment and care.
There is a designated governmental unit/
department responsible solely for coordinat-
ing and/or carrying out viral hepatitis-related 
activities: Bureau Infections par le VIH, IST et 
Hépatites (DGS-RI2). Information was not pro-
vided on how many staff  members this offi  ce 
has. It is not known how many people work 
full-time on hepatitis-related activities in all 
government agencies/bodies.
The government has a viral hepatitis preven-
tion and control programme that includes 
activities targeting the following specifi c 
populations: health-care workers (including 
health-care waste handlers), people who in-
ject drugs, migrants, prisoners and people 
living with HIV.
Awareness-raising and partnerships
The government held events for World Hepa-
titis Day 2012 but has not funded other viral 
hepatitis public awareness campaigns since 
January 2011. 
The government collaborates with the fol-
lowing in-country civil society groups to de-
velop and implement its viral hepatitis pre-
vention and control programme: Federation 
SOS-Hépatites, Hépatites Infos Services and 
Collectif Hépatites Virales.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepatitis. 
There is a national surveillance system for the 
following types of acute hepatitis: A and B, 
and for chronic hepatitis B. 
There are standard case defi nitions for hepa-
titis. Deaths, including from hepatitis, are re-
ported to a central registry. The percentage of 
hepatitis cases reported as “undiff erentiated” 
or “unclassifi ed” hepatitis is not known.
Liver cancer cases are not registered nation-
ally, but cases with HIV/hepatitis coinfection 
are.
The government publishes hepatitis disease 
reports annually.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investigation 
of outbreaks and other surveillance activities.
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are conducted regularly; the target 
populations are the general population, pris-
oners, people who inject drugs and men who 
have sex with men. The last serosurvey was 
carried out in 2011.
Prevention of transmission
There is a national policy on hepatitis A vac-
cination.
The government has not established the goal 
of eliminating hepatitis B.
It is not known what percentage of newborn 
infants nationally in a given recent year re-
ceived the fi rst dose of hepatitis B vaccine 
within 24 hours of birth. In a given recent year, 
53% of one-year-olds (ages 12–23 months) 
received three doses of hepatitis B vaccine.
There is a national policy that specifi cally tar-
gets mother-to-child transmission of hepati-
tis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis B 
and hepatitis C infection in health-care set-
tings. Health-care workers are vaccinated 
against hepatitis B prior to starting work that 
might put them at risk of exposure to blood.
There is a national policy on injection safety 
in health-care settings, which recommends 
single-use syringes for therapeutic injections. 
Single-use or auto-disable syringes, nee-
dles and cannulas are always available in all 
health-care facilities.
Offi  cial government estimates of the number 
and percentage of unnecessary injections 
administered annually in health-care settings 
are not known.
Population (in millions) (2011)
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Life expectancy at birth (in years) (2009)
Human Development Index (2011)
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Total fertility rate per woman (2010)
63.1
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There is a national infection control policy for 
blood banks. All donated blood units (includ-
ing family donations) and blood products 
nationwide are screened for hepatitis B and 
hepatitis C. 
There is a national policy relating to the pre-
vention of viral hepatitis among people who 
inject drugs.
The government has guidelines that address 
how hepatitis A and hepatitis E can be pre-
vented through food and water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care for 
people with viral hepatitis through schools 
for health professionals (pre-service educa-
tion), on-the-job training and postgraduate 
training. 
There are national clinical guidelines for the 
management of viral hepatitis, but they do 
not include recommendations for cases with 
HIV coinfection. There are national clinical 
guidelines for the management of HIV, which 
include recommendations for coinfection 
with viral hepatitis.
The government has national policies relat-
ing to screening and referral to care for hepa-
titis B and hepatitis C. 
People testing for both hepatitis B and hepa-
titis C register by name; the names are kept 
confi dential within the system. Hepatitis B 
tests are not free of charge for all individu-
als, but they are free of charge in specifi c 
preventive centres. Hepatitis C tests are free 
of charge for all individuals. Hepatitis B tests 
are compulsory for people who begin health 
professional studies and for pregnant wom-
en. Hepatitis C tests are not compulsory for 
members of any specifi c group.
Publicly funded treatment for hepatitis B and 
hepatitis C is available to all participants in 
the national health insurance programme 
(“Sécurité Sociale”).
In 2009, the national health insurance pro-
gramme spent approximately €450 mil-
lion (US$ 578.7 million) for the treatment of 
chronic hepatitis B and hepatitis C.
The following drugs for treating hepatitis B 
are on the national essential medicines list 
or subsidized by the government: interferon 
alpha, pegylated interferon, lamivudine, 
adefovir dipivoxil, entecavir, telbivudine and 
tenofovir. The following drugs for treating 
hepatitis C are on the national essential medi-
cines list or subsidized by the government: 
interferon alpha, pegylated interferon, ribavi-
rin, boceprevir and telaprevir.
The Government of France welcomes assist-
ance from WHO in one or more areas of viral 
hepatitis prevention and control (Annex C).
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Georgia
The Government of Georgia reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. It has three staff  mem-
bers. It is part of the Surveillance Division 
of the Communicable Diseases Depart-
ment within the National Center for Dis-
ease Control and Public Health. There are 
65 full-time equivalent staff  members who 
work on hepatitis-related activities in all 
government agencies/bodies.
The government does not have a viral 
hepatitis prevention and control pro-
gramme that includes activities targeting 
specifi c populations.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 but has not funded 
other viral hepatitis public awareness 
campaigns since January 2011.
The government collaborates with the fol-
lowing in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme: Be-
moni Public Union, Center for Information 
and Counseling on Reproductive Health 
Tanadgoma, and Curatio International 
Foundation.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B, C and E, and for the following types of 
chronic hepatitis: B and C.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. The per-
centage of hepatitis cases reported as “un-
diff erentiated” or “unclassifi ed” hepatitis is 
not known.
Liver cancer cases are not registered na-
tionally, but cases with HIV/hepatitis coin-
fection are.
The government publishes hepatitis dis-
ease reports annually.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 93% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 89% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is no specifi c national strategy and/
or policy/guidelines for preventing hepa-
titis B and hepatitis C infection in health-
care settings. Health-care workers are not 
vaccinated against hepatitis B prior to 
starting work that might put them at risk 
of exposure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
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There is a national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepati-
tis E can be prevented through food and 
water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection. 
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names are 
kept confi dential within the system. Hepa-
titis B and hepatitis C tests are not free of 
charge for all individuals, but they are free 
of charge for pregnant women and blood 
donors. Hepatitis B and hepatitis C tests 
are compulsory for blood donors.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
The following drugs for treating hepatitis B 
are on the national essential medicines list 
or subsidized by the government: inter-
feron alpha, pegylated interferon, lamivu-
dine, adefovir dipivoxil and tenofovir. The 
following drugs for treating hepatitis C are 
on the national essential medicines list or 
subsidized by the government: interferon 
alpha, pegylated interferon, ribavirin, bo-
ceprevir and telaprevir.
The Government of Georgia welcomes 
assistance from WHO in one or more ar-
eas of viral hepatitis prevention and con-
trol (Annex C).
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Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
82.2
High-income
$40 230
11.64%
$4332.34
$3339.32
80
0.940
44
1.4
Germany
The Government of Germany reports as 
follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. There is one full-time 
equivalent staff  member who works on 
hepatitis-related activities in all govern-
ment agencies/bodies.
The government does not have a viral hep-
atitis prevention and control programme 
that includes activities targeting specifi c 
populations. However, hepatitis B vacci-
nation is recommended for people who 
inject drugs, prisoners and people living 
with HIV.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011. 
The government does not collaborate with 
in-country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B, C, D and E, and for chronic hepatitis C.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Informa-
tion was not provided on the percentage 
of hepatitis cases reported as “undiff erenti-
ated” or “unknown” hepatitis.
Liver cancer cases are registered nationally, 
but cases with HIV/hepatitis coinfection 
are not.
The government publishes hepatitis dis-
ease reports annually.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target populations are children aged 3–17 
years and the general population. The last 
serosurvey was carried out in 2009–2011.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination, which recommends vaccina-
tion for health-care workers (including 
health-care waste handlers).
The government has not established the 
goal of eliminating hepatitis B.
Information was not provided on the per-
centage of newborn infants nationally in 
a given recent year who received the fi rst 
dose of hepatitis B vaccine within 24 hours 
of birth. In a given recent year, 90%–91% 
of one-year-olds (ages 12–23 months) re-
ceived three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood. Hepatitis B vaccination is 
also recommended for health-care waste 
handlers.
There is a national policy on injection safety 
in health-care settings but it is not known 
what type of syringes it recommends for 
therapeutic injections. Single-use or auto-
disable syringes, needles and cannulas are 
always available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs. 
The government does not have guidelines 
that address how hepatitis A and hepatitis 
E can be prevented through food and wa-
ter safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education) and on-the-job training. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B, but not for hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals and are not com-
pulsory for members of any specifi c group.
Publicly funded treatment for hepatitis B 
and hepatitis C is available to all people 
with national health insurance. In 2010, 
the government spent €7.8 million (US$ 
10 million) on outpatient care for hepatitis 
B and €1.8 million (US$ 2.3 million) on out-
patient care for hepatitis C, not including 
drug costs. 
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: inter-
feron alpha, pegylated interferon, lamivu-
dine, adefovir dipivoxil, entecavir, telbivu-
dine and tenofovir. The following drugs for 
treating hepatitis C are on the national es-
sential medicines list or subsidized by the 
government: interferon alpha, pegylated 
interferon, ribavirin, boceprevir and tel-
aprevir.
The Government of Germany did not in-
dicate a need for assistance from WHO in 
relation to viral hepatitis prevention and 
control.
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Hungary
The Government of Hungary reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. It is not known how 
many people work full-time on hepatitis-
related activities in all government agen-
cies/bodies.
The government does not have a viral 
hepatitis prevention and control pro-
gramme that includes activities targeting 
specifi c populations.
Awareness-raising and partnerships
It is not known whether the government 
held events for World Hepatitis Day 2012 
or has funded other viral hepatitis public 
awareness campaigns since January 2011.
The government collaborates with the fol-
lowing in-country civil society group to 
develop and implement its viral hepatitis 
prevention and control programme: Máj-
moly Foundation.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B, C, D and E. Information was not pro-
vided on whether there is a national sur-
veillance system for any type of chronic 
hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Informa-
tion was not provided on the percentage 
of hepatitis cases reported as “undiff eren-
tiated” or “unknown” hepatitis.
Liver cancer cases are registered nation-
ally, but cases with HIV/hepatitis coinfec-
tion are not.
The government publishes hepatitis dis-
ease reports weekly.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
It is not known whether there is a national 
public health research agenda for viral 
hepatitis. Viral hepatitis serosurveys are 
not conducted regularly.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
It is not known what percentage of new-
born infants nationally in a given recent 
year received the fi rst dose of hepatitis B 
vaccine within 24 hours of birth or what 
percentage of one-year-olds (ages 12–23 
months) nationally in a given recent year 
received three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection 
safety in health-care settings, but it is not 
known what type of syringes it recom-
mends for therapeutic injections. Single-
use or auto-disable syringes, needles and 
cannulas are always available in all health-
care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
10.0
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It is not known whether there is a national 
policy relating to the prevention of viral 
hepatitis among people who inject drugs. 
It is not known whether the government 
has guidelines that address how hepa-
titis A and hepatitis E can be prevented 
through food and water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through on-
the-job training and postgraduate train-
ing. 
There are national clinical guidelines for 
the management of viral hepatitis. It is not 
known whether there are national clinical 
guidelines for the management of HIV, 
which include recommendations for coin-
fection with viral hepatitis.
It is not known whether the government 
has national policies relating to screening 
and referral to care for hepatitis B or hepa-
titis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are not 
free of charge, and are compulsory for cer-
tain health-care professionals.
Publicly funded treatment is available for 
hepatitis B and hepatitis C, but informa-
tion was not provided on who is eligible 
for such treatment. The amount spent by 
the government on publicly funded treat-
ment for hepatitis B and hepatitis C is not 
known.
It is not known whether any drug for treat-
ing hepatitis B or hepatitis C is on the 
national essential medicines list or subsi-
dized by the government.
It is not known whether the Government 
of Hungary has a need for assistance from 
WHO in relation to viral hepatitis preven-
tion and control.
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Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
4.5
High-income
$34 180
9.19%
$3703.96
$2561.56
80
0.959
35
2.1
Ireland
The Government of Ireland reports as 
follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. It is not known how many 
people work full-time on hepatitis-related 
activities in all government agencies/bod-
ies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs, migrants and 
prisoners.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011. 
The government collaborates with the fol-
lowing in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme: Posi-
tive Action, Transfusion Positive and Irish 
Haemophilia Society.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B, and C, and for the following types of 
chronic hepatitis: B and C.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. No hepa-
titis case is reported as “undiff erentiated” or 
“unclassifi ed” hepatitis.
Liver cancer cases are registered nationally, 
but cases with HIV/hepatitis coinfection 
are not.
The government publishes hepatitis dis-
ease reports quarterly. 
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis A, hepatitis B and hepatitis 
C, but it is not known whether this is the 
case for hepatitis E.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
It is not known what percentage of new-
born infants nationally in a given recent 
year received the fi rst dose of hepatitis B 
vaccine within 24 hours of birth. Nationally, 
90% of one-year-olds (ages 12–23 months) 
in a given recent year received three doses 
of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vaccinat-
ed against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
It is not known whether there is a national 
policy on injection safety in health-care 
settings, and what type of syringes it rec-
ommends for therapeutic injections. It is 
not known whether single-use or auto-
disable syringes, needles and cannulas are 
always available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
Information was not provided on whether 
there is a national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepatitis 
E can be prevented through food and wa-
ter safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education) and postgraduate training. 
There are no national clinical guidelines for 
the management of viral hepatitis. It is not 
known whether there are national clinical 
guidelines for the management of HIV, 
which include recommendations for coin-
fection with viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names are 
kept confi dential within the system. Hepa-
titis B and hepatitis C tests are not free of 
charge for all individuals, but they are free 
of charge for people attending public clin-
ics for drug users, women in antenatal care, 
people with sexually transmitted infec-
tions, and people seeking asylum. Hepati-
tis B and hepatitis C tests are not compul-
sory for members of any specifi c group.
Publicly funded treatment is available for 
hepatitis B and hepatitis C. The following 
group is eligible for such treatment for 
hepatitis B: people with a medical card. 
The following group is eligible for such 
treatment for hepatitis C: people with a 
medical card or a Health Amendment Act 
card. Information was not provided on the 
amount spent by the government on pub-
licly funded treatment for hepatitis B and 
hepatitis C.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: inter-
feron alpha, pegylated interferon, lamivu-
dine, adefovir dipivoxil and entecavir. The 
following drugs for treating hepatitis C are 
on the national essential medicines list or 
subsidized by the government: interferon 
alpha, pegylated interferon, ribavirin, bo-
ceprevir and telaprevir.
The Government of Ireland did not indicate 
a need for assistance from WHO in relation 
to viral hepatitis prevention and control.
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Israel
The Government of Israel reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses primarily on the prevention 
and control of viral hepatitis, and also in-
tegrates other diseases. It includes compo-
nents for surveillance, vaccination, preven-
tion of transmission via injecting drug use, 
prevention of transmission in health-care 
settings, treatment and care, and coinfec-
tion with HIV.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. It is not known how 
many people work full-time on hepatitis-
related activities in all government agen-
cies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs, people living 
with HIV and travellers.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, but not for any type of chronic 
hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Of hepa-
titis cases, 1% is reported as “undiff erenti-
ated” or “unclassifi ed” hepatitis. 
Liver cancer cases are registered nation-
ally, but cases with HIV/hepatitis coinfec-
tion are not.
The government publishes hepatitis dis-
ease reports weekly. 
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis A, hepatitis B and hepati-
tis C, but not for hepatitis E. 
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 98% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 98% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is a national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
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Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, but 
information was not provided on whether 
they include recommendations for cases 
with HIV coinfection. There are national 
clinical guidelines for the management of 
HIV, which include recommendations for 
coinfection with viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free 
of charge for all individuals, and are com-
pulsory for blood donors and health-care 
workers.
Publicly funded treatment is available for 
hepatitis B and hepatitis C. Information 
was not provided regarding who is eligi-
ble for this. The amount spent by the gov-
ernment on publicly funded treatment for 
hepatitis B and hepatitis C is not known.
The following drugs for treating hepatitis B 
are on the national essential medicines list 
or subsidized by the government: inter-
feron alpha, pegylated interferon, lamivu-
dine, adefovir dipivoxil, entecavir, telbivu-
dine and tenofovir. The following drugs for 
treating hepatitis C are on the national es-
sential medicines list or subsidized by the 
government: interferon alpha, pegylated 
interferon, ribavirin, boceprevir and tel-
aprevir. 
The Government of Israel did not indicate 
a need for assistance from WHO in relation 
to viral hepatitis prevention and control.
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60.8
High-income
$32 400
9.53%
$3021.72
$2345.36
82
0.914
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Italy
The Government of Italy reports as follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. Information was not pro-
vided on how many people work full-time 
on hepatitis-related activities in all govern-
ment agencies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs, prisoners, part-
ners of carriers of HBsAg and hepatitis C 
virus, people cohabiting with carriers of 
HBsAg or hepatitis C virus, people under-
going multiple blood transfusions, people 
with haemophilia, people undergoing 
haemodialysis, people with chronic skin 
lesions of the hands (eczema, psoriasis), 
travellers to hepatitis B-endemic areas, po-
lice offi  cers, fi refi ghters, public offi  cials and 
garbage disposal workers.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 but has not funded 
other viral hepatitis public awareness cam-
paigns since January 2011.
The government does not collaborate with 
in-country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme. 
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: A, 
B, C, D and E, but not for any type of chronic 
hepatitis.
There are standard case defi nitions for hep-
atitis. Deaths, including from hepatitis, are 
reported to a central registry. In response 
to a question asking what percentage 
of hepatitis cases are reported as “undif-
ferentiated” or “unclassifi ed”, the follow-
ing information was provided: incidence 
rate/100 000 of unclassifi ed hepatitis: 0.1. 
Liver cancer cases and cases with HIV/
hepatitis coinfection are not registered na-
tionally. 
The government publishes hepatitis dis-
ease reports annually.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, all newborn children of hepa-
titis B-infected mothers in a given recent 
year received the fi rst dose of hepatitis B 
vaccine within 24 hours of birth, and 95% 
of one-year-olds (ages 12–23 months) in a 
given recent year received three doses of 
hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is no specifi c national strategy and/
or policy/guidelines for preventing hepati-
tis B and hepatitis C infection in health-care 
settings.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
There is a national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education) and postgraduate training. 
There are no national clinical guidelines for 
the management of viral hepatitis. Infor-
mation was not provided on whether there 
are national clinical guidelines for the man-
agement of HIV, which include recommen-
dations for coinfection with viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for hepatitis B and hepatitis 
C do not register by name. Hepatitis B and 
hepatitis C tests are free of charge for all in-
dividuals. Information was not provided on 
whether hepatitis B or hepatitis C tests are 
compulsory for members of any specifi c 
group. 
Publicly funded treatment is available for 
hepatitis B and hepatitis C. Information 
was not provided regarding who is eligible 
for this. Information was not provided on 
the amount spent by the government on 
publicly funded treatment for hepatitis B 
and hepatitis C.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: inter-
feron alpha, pegylated interferon, lamivu-
dine, adefovir dipivoxil, entecavir, telbivu-
dine and tenofovir. The following drugs for 
treating hepatitis C are on the national es-
sential medicines list or subsidized by the 
government: interferon alpha, pegylated 
interferon, ribavirin, boceprevir and tel-
aprevir.
The Government of Italy did not indicate a 
need for assistance from WHO in relation to 
viral hepatitis prevention and control.
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Kyrgyzstan
The Government of Kyrgyzstan reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses exclusively on the prevention 
and control of viral hepatitis. It includes 
components for surveillance, vaccination, 
prevention of transmission via injecting 
drug use, prevention of transmission in 
health-care settings, and treatment and 
care.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. It is not known how 
many people work full-time on hepatitis-
related activities in all government agen-
cies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: people who inject 
drugs and people living with HIV.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government collaborates with the fol-
lowing in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme: non-
governmental organizations that work 
with sex workers, prisoners and people 
who inject drugs.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B, C and D, and for the following types 
of chronic hepatitis: B, C and D.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Of hepa-
titis cases, 20% are reported as “undiff er-
entiated” or “unclassifi ed” hepatitis.
Liver cancer cases are not registered na-
tionally, but cases with HIV/hepatitis coin-
fection are. 
The government publishes hepatitis dis-
ease reports monthly.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis A, hepatitis B, hepatitis C 
and hepatitis D, but not for hepatitis E.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination. 
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 93%–95% of newborn infants 
in a given recent year received the fi rst 
dose of hepatitis B vaccine within 24 hours 
of birth and 98% of one-year-olds (ages 
12–23 months) in a given recent year re-
ceived three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is no specifi c national strategy 
and/or policy/guidelines for preventing 
hepatitis B and hepatitis C infection in 
health-care settings. Information was not 
provided on whether health-care workers 
are vaccinated against hepatitis B prior to 
starting work that might put them at risk 
of exposure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is no national infection control 
policy for blood banks. All donated blood 
units (including family donations) and 
blood products nationwide are screened 
for hepatitis C, but not for hepatitis B. 
5.4
Low-income
$2180
6.18%
$140.26
$78.80
66
0.734
24
2.7
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
There is a national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection. There are national clini-
cal guidelines for the management of HIV, 
which include recommendations for coin-
fection with viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are not 
free of charge and are not compulsory for 
members of any specifi c group.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: in-
terferon alpha, pegylated interferon, lami-
vudine and tenofovir. The following drugs 
for treating hepatitis C are on the national 
essential medicines list or subsidized by 
the government: pegylated interferon and 
ribavirin.
The Government of Kyrgyzstan welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
2.2
Upper–middle-income
$17 700
6.68%
$1092.52
$667.99
72
0.857
40
1.5
Latvia
The Government of Latvia reports as 
follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. It is not known how many 
people work full-time on hepatitis-related 
activities in all government agencies/
bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs, infants, ado-
lescents, patients on dialysis and blood 
donors.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012, but has not funded 
other viral hepatitis public awareness cam-
paigns since January 2011.
The government collaborates with the 
following in-country civil society groups 
to develop and implement its viral hepa-
titis prevention and control programme: 
Association HIV Latvia and the Hepatitis 
Association.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: A, 
B, C and E, and for the following types of 
chronic hepatitis: B and C.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Of hepa-
titis cases, 3% are reported as “undiff erenti-
ated” or “unclassifi ed” hepatitis.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports monthly and annually.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
It is not known whether there is a national 
public health research agenda for viral 
hepatitis. Viral hepatitis serosurveys are 
not conducted regularly. The most recent 
serosurvey was conducted in 2000 and tar-
geted pregnant women, boarding school 
students and new members of the military.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has established the goal 
of reducing hepatitis B among children by 
2011–2012.
Information was not provided on the per-
centage of newborn infants in a given 
recent year who received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth. 
Nationally, 91% of one-year-olds (ages 12–
23 months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vaccinat-
ed against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepatitis 
E can be prevented through food and wa-
ter safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education) and on-the-job training. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection. Information was not pro-
vided on whether there are national clini-
cal guidelines for the management of HIV, 
which include recommendations for coin-
fection with viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names are 
kept confi dential within the system. Hepa-
titis B and hepatitis C tests are not free of 
charge for all individuals, but they are free 
of charge at syringe exchange points for 
people who inject drugs. Hepatitis B and 
hepatitis C tests are not compulsory for 
members of any specifi c group.
Publicly funded treatment is available for 
people chronically infected with hepatitis 
B and hepatitis C. For people with chronic 
hepatitis B, public funding covers inpatient 
hospital treatment. For people with chron-
ic hepatitis C, public funding covers 75% 
of all treatment costs. The amount spent 
by the government on such treatment for 
hepatitis B and hepatitis C is not known.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: inter-
feron alpha and lamivudine. The following 
drugs for treating hepatitis C are on the 
national essential medicines list or subsi-
dized by the government: interferon alpha, 
pegylated interferon and ribavirin.
The Government of Latvia welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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Lithuania
The Government of Lithuania reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. It is not known how 
many people work full-time on hepatitis-
related activities in all government agen-
cies/bodies.
The government does not have a viral 
hepatitis prevention and control pro-
gramme that includes activities targeting 
specifi c populations.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012, but has not funded 
other viral hepatitis public awareness 
campaigns since January 2011. 
The government collaborates with in-
country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme. Information 
was not provided about the identity of the 
civil society partners. 
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B, C, D and E, and for the following types 
of chronic hepatitis: B, C and D.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Of hepa-
titis cases, 7% are reported as “undiff eren-
tiated” or “unclassifi ed” hepatitis.
Liver cancer cases are registered nation-
ally, but cases with HIV/hepatitis coinfec-
tion are not.
The government does not publish hepati-
tis disease reports.
Hepatitis outbreaks are not required to be 
reported to the government. There is ad-
equate laboratory capacity nationally to 
support investigation of viral hepatitis out-
breaks and other surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 96% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 95% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood. 
There is a national policy on injection 
safety in health-care settings. Information 
was not provided on the type of syringes 
it recommends for therapeutic injections. 
Single-use or auto-disable syringes, nee-
dles and cannulas are always available in 
all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepati-
tis E can be prevented through food and 
water safety.
3.3
Upper–middle-income
$19 640
7.04%
$1299.46
$954.93
73
0.853
39
1.5
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection. Information was not pro-
vided on whether there are national clini-
cal guidelines for the management of HIV, 
which include recommendations for coin-
fection with viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are not 
free of charge and are not compulsory for 
members of any specifi c group.
All people with health insurance are eligi-
ble for publicly funded treatment for hep-
atitis B and hepatitis C. The government 
spends LTL 14.6 million (€4.3 million; US$ 
5.6 million) annually on hepatitis B and 
hepatitis C medications, and LTL 2.1 mil-
lion (€624 000; US$ 800 000) annually on 
hepatitis B and hepatitis C outpatient and 
inpatient services. 
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: in-
terferon alpha, pegylated interferon, lami-
vudine, adefovir dipivoxil, entecavir and 
tenofovir. The following drugs for treating 
hepatitis C are on the national essential 
medicines list or subsidized by the gov-
ernment: interferon alpha, pegylated in-
terferon and ribavirin.
The Government of Lithuania welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
0.5
High-income
$64 260
7.77%
$6743.02
$5691.67
81
0.854
39
1.6
Luxembourg
The Government of Luxembourg reports 
as follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. It is not known how many 
people work full-time on hepatitis-related 
activities in all government agencies/
bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs and prisoners.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate with 
in-country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, and for the following types of 
chronic hepatitis: B and C.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. The per-
centage of hepatitis cases reported as “un-
diff erentiated” or “unclassifi ed” hepatitis is 
not known.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government does not publish hepati-
tis disease reports.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination. 
It is not known whether the government 
has established the goal of eliminating 
hepatitis B.
It is not known what percentage of new-
born infants nationally in a given recent 
year received the fi rst dose of hepatitis B 
vaccine within 24 hours of birth. Nationally, 
94% of one-year-olds (ages 12–23 months) 
in a given recent year received three doses 
of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vaccinat-
ed against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
There is a national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
It is not known whether the government 
has guidelines that address how hepa-
titis A and hepatitis E can be prevented 
through food and water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are no national clinical guidelines 
for the management of viral hepatitis or 
for the management of HIV, which include 
recommendations for coinfection with vi-
ral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names are 
kept confi dential within the system. Hepa-
titis B and hepatitis C tests are not free of 
charge. Hepatitis B tests are compulsory 
for health-care workers, who should sub-
sequently be vaccinated. Hepatitis C tests 
are not compulsory for members of any 
specifi c group.
Publicly funded treatment is available for 
hepatitis B and hepatitis C. People insured 
by the national health insurance system 
are eligible. The amount spent by the gov-
ernment on publicly funded treatment for 
hepatitis B and hepatitis C is not known.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: inter-
feron alpha, pegylated interferon, lamivu-
dine, adefovir dipivoxil and tenofovir. The 
following drugs for treating hepatitis C are 
on the national essential medicines list or 
subsidized by the government: interferon 
alpha, pegylated interferon, ribavirin, bo-
ceprevir and telaprevir.
The Government of Luxembourg did not 
indicate a need for assistance from WHO 
in relation to viral hepatitis prevention and 
control.
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Malta
The Government of Malta reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis. 
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. It is not known how 
many people work full-time on hepatitis-
related activities in all government agen-
cies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs, prisoners and 
people living with HIV.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012, but has not funded 
other viral hepatitis public awareness 
campaigns since January 2011.
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, and for the following types of 
chronic hepatitis: B and C. 
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Informa-
tion was not provided on the percentage 
of hepatitis cases reported as “undiff eren-
tiated” or “unknown” hepatitis.
Liver cancer cases are registered nation-
ally, but cases with HIV/hepatitis coinfec-
tion are not.
The government does not publish hepati-
tis disease reports.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis A, hepatitis B and hepati-
tis C, but not for hepatitis E.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination. 
The government has established the goal 
of eliminating hepatitis B but does not 
have a specifi c timeframe for this.
Nationally, 15% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 82% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
0.4
High-income
$24 480
8.65%
$2261.40
$1480.73
80
0.866
39
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Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
The government does not have guidelines 
that address how hepatitis A and hepati-
tis E can be prevented through food and 
water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education). 
There are no national clinical guidelines 
for the management of viral hepatitis, but 
physicians have adopted the European 
clinical guidelines for the management 
of viral hepatitis. Information was not pro-
vided on whether there are national clini-
cal guidelines for the management of HIV, 
which include recommendations for coin-
fection with viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals and are not com-
pulsory for members of any specifi c group.
Publicly funded treatment is available for 
hepatitis B and hepatitis C. Information 
was not provided on who is eligible for this 
and the amount spent by the government 
on publicly funded treatment for hepatitis 
B and hepatitis C.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: in-
terferon alpha and lamivudine. The fol-
lowing drug for treating hepatitis C is on 
the national essential medicines list or 
subsidized by the government: interferon 
alpha.
The Government of Malta did not indicate 
a need for assistance from WHO in relation 
to viral hepatitis prevention and control.
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Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
0.6
Upper–middle-income
$13 700
9.11%
$1155.27
$776.01
75
0.831
36
1.7
Montenegro
The Government of Montenegro reports as 
follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. It is not known how many 
people work full-time on hepatitis-related 
activities in all government agencies/bod-
ies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs and children.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government collaborates with the fol-
lowing in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme: NGO 
Juventas and NGO Cazas.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: A, 
B, C, D and E, and for the following types of 
chronic hepatitis: B and C.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Of hepati-
tis cases, 18% are reported as “undiff erenti-
ated” or “unclassifi ed” hepatitis.
Liver cancer cases are not registered na-
tionally, but cases with HIV/hepatitis coin-
fection are.
The government publishes hepatitis dis-
ease reports in the annual report on com-
municable diseases in Montenegro.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target populations are people who inject 
drugs, men who have sex with men, sex 
workers and prisoners. The last serosurvey 
was carried out in 2011.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination. 
The government has not established the 
goal of eliminating hepatitis B.
Information was not provided on the per-
centage of newborn infants nationally in 
a given recent year who received the fi rst 
dose of hepatitis B vaccine within 24 hours 
of birth. In a given recent year, 91% of one-
year-olds (ages 12–23 months) received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vaccinat-
ed against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
It is not known whether the government 
has guidelines that address how hepa-
titis A and hepatitis E can be prevented 
through food and water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education) and on-the-job training. 
There are no national clinical guidelines for 
the management of viral hepatitis. It is not 
known whether there are national clinical 
guidelines for the management of HIV, 
which include recommendations for coin-
fection with viral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free 
of charge for all individuals covered by 
national health insurance, and are compul-
sory for blood, organ and tissue donors.
Publicly funded treatment is available for 
hepatitis B and hepatitis C. The following 
people are eligible: individuals covered 
by national health insurance. The amount 
spent by the government on publicly fund-
ed treatment for hepatitis B and hepatitis C 
is not known.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: 
pegylated interferon and lamivudine. The 
following drugs for treating hepatitis C are 
on the national essential medicines list or 
subsidized by the government: pegylated 
interferon and ribavirin.
The Government of Montenegro wel-
comes assistance from WHO in one or 
more areas of viral hepatitis prevention 
and control (Annex C).
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Netherlands (the)
The Government of the Netherlands 
reports as follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hep-
atitis-related activities. There are two to 
three full-time equivalent staff  members 
who work on hepatitis-related activities in 
all government agencies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs, migrants, pris-
oners, sex workers, people living with HIV 
and men who have sex with men.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 and has funded other 
viral hepatitis public awareness cam-
paigns since January 2011 (Annex A).
The government collaborates with the fol-
lowing in-country civil society group to 
develop and implement its viral hepatitis 
prevention and control programme: Na-
tional Hepatitis Centrum. 
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, and for chronic hepatitis B.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Of hepa-
titis cases, 2% are reported as “undiff eren-
tiated” or “unclassifi ed” hepatitis.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports annually.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target populations are the general popula-
tion and prisoners. The last serosurvey was 
carried out in 2010.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 99% of newborn infants in a 
given recent year received the fi rst dose 
of hepatitis B vaccine within 24 hours of 
birth. It is not known what percentage 
of one-year-olds (ages 12–23 months) 
nationally in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is no national policy on injection 
safety in health-care settings, although 
there is a policy on needle-stick injuries. 
Single-use or auto-disable syringes, nee-
dles and cannulas are always available in 
all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C.
There is a national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
16.7
High-income
$43 140
11.92%
$5037.83
$3991.24
81
0.944
41
1.8
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection. There are national clini-
cal guidelines for the management of HIV, 
which include recommendations for coin-
fection with viral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for hepatitis B and hepati-
tis C do not register by name. Hepatitis B 
and hepatitis C tests are not free of charge 
for all individuals. Hepatitis B tests are free 
of charge for patients attending sexu-
ally transmitted infection (STI) clinics who 
meet specifi c criteria. Hepatitis C tests are 
free of charge for people living with HIV 
and men who have sex with men. Hepati-
tis B and hepatitis C tests are not compul-
sory for members of any specifi c group.
Publicly funded treatment for hepatitis B 
and hepatitis C is available to all people 
with social health insurance. The amount 
spent by the government on such treat-
ment for hepatitis B and hepatitis C is not 
known.
It is not known whether any drug for treat-
ing hepatitis B or hepatitis C is on the 
national essential medicines list or subsi-
dized by the government.
The Government of the Netherlands did 
not indicate a need for assistance from 
WHO in relation to viral hepatitis preven-
tion and control.
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Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
38.3
High-income
$20 430
7.46%
$1476.06
$1071.94
76
0.853
38
1.4
Poland
The Government of Poland reports as 
follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. It is not known how many 
people work full-time on hepatitis-related 
activities in all government agencies/
bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers); 
people who inject drugs; people living 
with HIV; household contacts and other 
contacts of hepatitis B-infected persons; 
pre-surgical patients; and people at risk 
due to lifestyle, occupation, age and chron-
ic diseases.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate with 
in-country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: A, 
B, C, D and E, and for the following types of 
chronic hepatitis: B, C and D.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Of hepa-
titis cases, 2% are reported as “undiff erenti-
ated” or “unclassifi ed” hepatitis.
Liver cancer cases are registered nationally, 
but cases with HIV/hepatitis coinfection 
are not.
The government publishes hepatitis dis-
ease reports. Information was not provided 
on how often these are published.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis A, hepatitis B and hepatitis 
C, but not for hepatitis E.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
It is not known what percentage of new-
born infants nationally in a given recent 
year received the fi rst dose of hepatitis B 
vaccine within 24 hours of birth. In a given 
recent year, 98% of one-year-olds (ages 
12–23 months) received three doses of 
hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vaccinat-
ed against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection safe-
ty in health-care settings. It is not known 
what type of syringes it recommends for 
therapeutic injections. Single-use or auto-
disable syringes, needles and cannulas are 
always available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known. 
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
There is a national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepati-
tis E can be prevented through food and 
water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for the 
management of viral hepatitis, but they do 
not include recommendations for cases 
with HIV coinfection. There are national 
clinical guidelines for the management of 
HIV, which include recommendations for 
coinfection with viral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names are 
kept confi dential within the system. Hepa-
titis B and hepatitis C tests are not free of 
charge for all individuals, but they are free 
of charge for blood and organ donors, 
pregnant women, and everyone who has 
public health insurance and is referred by a 
doctor. Hepatitis B and hepatitis C tests are 
compulsory for blood and organ donors.
Publicly funded treatment is available for 
hepatitis B and hepatitis C. Publicly insured 
patients are eligible for this based on medi-
cal indications. The government spent Zl 
65.5 million (US$ 20.1 million) on publicly 
funded treatment for hepatitis B in 2011. 
The amount spent by the government 
on such treatment for hepatitis C is not 
known.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: in-
terferon alpha, pegylated interferon, lami-
vudine, adefovir dipivoxil, entecavir and 
tenofovir. The following drugs for treating 
hepatitis C are included on the national es-
sential medicines list or subsidized by the 
government: interferon alpha, pegylated 
interferon and ribavirin.
The Government of Poland welcomes 
assistance from WHO in one or more ar-
eas of viral hepatitis prevention and con-
trol (Annex C).
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Republic of Moldova (the)
The Government of the Republic of Moldova 
reports as follows.
National coordination
There is a written national strategy or plan 
that focuses exclusively on the prevention 
and control of viral hepatitis. It includes com-
ponents for raising awareness, surveillance, 
vaccination, prevention in general, preven-
tion of transmission via injecting drug use, 
prevention of transmission in health-care 
settings, treatment and care, and coinfection 
with HIV.
There is a designated governmental unit/de-
partment responsible solely for coordinating 
and/or carrying out viral hepatitis-related ac-
tivities: the National Center for Public Health 
Laboratory for Epidemiology of Viral Hepati-
tis. It has seven staff  members. There are 29 
full-time equivalent staff  members who work 
on hepatitis-related activities in all govern-
ment agencies/bodies.
The government has a viral hepatitis preven-
tion and control programme that includes 
activities targeting the following specifi c 
populations: health-care workers (including 
health-care waste handlers), people who in-
ject drugs, migrants, prisoners, people living 
with HIV, contacts of people with acute and 
chronic viral hepatitis, and medical students.
Awareness-raising and partnerships
The government held events for World Hepa-
titis Day 2012 and has funded other viral 
hepatitis public awareness campaigns since 
January 2011 (Annex A).
The government collaborates with the fol-
lowing in-country civil society group to de-
velop and implement its viral hepatitis pre-
vention and control programme: Politics and 
Analytics in Health.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepatitis. 
There is a national surveillance system for the 
following types of acute hepatitis: A, B, C, D 
and E, and for the following types of chronic 
hepatitis: B, C and D.
There are standard case defi nitions for hepa-
titis. Deaths, including from hepatitis, are re-
ported to a central registry. Of hepatitis cases, 
7.6% are reported as “undiff erentiated” or “un-
classifi ed” hepatitis.
Liver cancer cases are registered nationally, 
but cases with HIV/hepatitis coinfection are 
not.
The government publishes hepatitis disease 
reports monthly and annually.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investigation 
of viral hepatitis outbreaks and other surveil-
lance activities.
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are conducted regularly; the target 
populations are children under the age of 17 
years, the general population, people who in-
ject drugs, patients on haemodialysis, blood 
donors and family members of those with 
hepatitis B and hepatitis C. The last serosur-
vey was carried out in 2012. 
Prevention of transmission
There is no national policy on hepatitis A vac-
cination.
The government has established the goal of 
reducing hepatitis B to a level that achieves 
parity with the European Union average by 
2016.
Nationally, 99.5% of newborn infants in a giv-
en recent year received the fi rst dose of hepa-
titis B vaccine within 24 hours of birth and 
99.3% of one-year-olds (ages 12–23 months) 
in a given recent year received three doses of 
hepatitis B vaccine.
There is a national policy that specifi cally tar-
gets mother-to-child transmission of hepati-
tis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis B 
and hepatitis C infection in health-care set-
tings. Health-care workers are vaccinated 
against hepatitis B prior to starting work that 
might put them at risk of exposure to blood.
There is no national policy on injection safety 
in health-care settings. Single-use or auto-
disable syringes, needles and cannulas are 
always available in all health-care facilities.
Offi  cial government estimates of the number 
and percentage of unnecessary injections 
administered annually in health-care settings 
are not known.
There is a national infection control policy for 
blood banks. All donated blood units (includ-
ing family donations) and blood products 
nationwide are screened for hepatitis B and 
hepatitis C.
3.5
Lower–middle-income
$3640
11.68%
$360.40
$165.05
69
0.746
35
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Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
There is a national policy relating to the pre-
vention of viral hepatitis among people who 
inject drugs.
The government has guidelines that address 
how hepatitis A and hepatitis E can be pre-
vented through food and water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care for 
people with viral hepatitis through schools 
for health professionals (pre-service educa-
tion), on-the-job training, postgraduate train-
ing, and at conferences and seminars. 
There are national clinical guidelines for the 
management of viral hepatitis, but they do 
not include recommendations for cases with 
HIV coinfection. There are national clinical 
guidelines for the management of HIV, which 
include recommendations for coinfection 
with viral hepatitis.
The government has national policies relat-
ing to screening and referral to care for hepa-
titis B and hepatitis C. 
People testing for both hepatitis B and hepa-
titis C register by name, and there is open ac-
cess to their names. Hepatitis B and hepatitis 
C tests are free of charge for all individuals, 
and are compulsory for health-care workers, 
patients on haemodialysis, donors and those 
in regular contact with people infected with 
hepatitis B or hepatitis C.
Publicly funded treatment for hepatitis B and 
hepatitis C is available to all people with na-
tional health insurance. The amount spent 
by the government on such treatment is not 
known.
The following drugs for treating hepatitis B 
are on the national essential medicines list or 
subsidized by the government: pegylated in-
terferon and lamivudine. The following drugs 
for treating hepatitis C are on the national 
essential medicines list or subsidized by the 
government: pegylated interferon and riba-
virin.
The Government of the Republic of Moldova 
welcomes assistance from WHO in one or 
more areas of viral hepatitis prevention and 
control (Annex C).
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Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
142.8
Upper–middle-income
$20 560
5.07%
$998.36
$619.73
68
0.777
38
1.5
Russian Federation (the)
The Government of the Russian Federation 
reports as follows.
National coordination
There is a written national strategy or plan 
that focuses primarily on the prevention and 
control of viral hepatitis, and also integrates 
other diseases. It includes components for 
raising awareness, surveillance, vaccination, 
prevention in general, prevention of trans-
mission via injecting drug use, prevention 
of transmission in health-care settings, treat-
ment and care, and coinfection with HIV.
The following designated governmental 
units/departments are responsible solely 
for coordinating and/or carrying out viral 
hepatitis-related activities: Central Research 
Institute of Epidemiology Reference Center 
for Viral Hepatitis and Expert Group on Viral 
Hepatitis of the Ministry of Health. Informa-
tion was not provided regarding the number 
of staff  members. It is not known how many 
people work full-time on hepatitis-related 
activities in all government agencies/bodies.
The government has a viral hepatitis preven-
tion and control programme that includes 
activities targeting the following specifi c 
populations: health-care workers (including 
health-care waste handlers), people who 
inject drugs, people living with HIV, food in-
dustry workers, and sewage and sanitation 
workers.
Awareness-raising and partnerships
The government held events for World Hepa-
titis Day 2012 and has funded other viral 
hepatitis public awareness campaigns since 
January 2011 (Annex A).
The government collaborates with the fol-
lowing in-country civil society group to de-
velop and implement its viral hepatitis pre-
vention and control programme: Together 
against Hepatitis.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepatitis. 
There is a national surveillance system for the 
following types of acute hepatitis: A, B and C, 
and for the following types of chronic hepa-
titis: B and C.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Of acute 
and chronic hepatitis cases, 5.7% and 1.3%, 
respectively, are reported as “undiff erenti-
ated” or “unclassifi ed” hepatitis. 
Liver cancer cases and cases with HIV/hepati-
tis coinfection are registered nationally. 
The government publishes hepatitis disease 
reports monthly and annually.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activities 
for hepatitis A, hepatitis B and hepatitis C but 
not for hepatitis E. 
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis sero-
surveys are conducted regularly. Target pop-
ulations include children, the general popu-
lation, people who inject drugs and select 
populations such as health-care workers and 
patients who are thought to be at increased 
risk for viral hepatitis. The last serosurvey was 
carried out in 2012.
Prevention of transmission
There is a national policy on hepatitis A vac-
cination.
The government has established the goal of 
eliminating hepatitis B but the timeframe has 
not yet been set.
It is not known what percentage of newborn 
infants nationally in a given recent year re-
ceived the fi rst dose of hepatitis B vaccine 
within 24 hours of birth. In a given recent year, 
97.3% of one-year-olds (ages 12–23 months) 
received three doses of hepatitis B vaccine.
There is a national policy that specifi cally tar-
gets mother-to-child transmission of hepati-
tis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis B 
and hepatitis C infection in health-care set-
tings. Health-care workers are vaccinated 
against hepatitis B prior to starting work that 
might put them at risk of exposure to blood.
There is a national policy on injection safety 
in health-care settings, which recommends 
single-use syringes for therapeutic injections. 
Single-use or auto-disable syringes, nee-
dles and cannulas are always available in all 
health-care facilities.
Offi  cial government estimates of the number 
and percentage of unnecessary injections 
administered annually in health-care settings 
are not known.
There is a national infection control policy for 
blood banks. All donated blood units (includ-
ing family donations) and blood products 
nationwide are screened for hepatitis B and 
hepatitis C. 
There is a national policy relating to the pre-
vention of viral hepatitis among people who 
inject drugs.
The government has guidelines that address 
how hepatitis A and hepatitis E can be pre-
vented through food and water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care for 
people with viral hepatitis through schools 
for health professionals (pre-service educa-
tion), on-the-job training and postgraduate 
training. 
It is not known whether there are national 
clinical guidelines for the management of 
viral hepatitis, but there are for the manage-
ment of HIV, which include recommenda-
tions for coinfection with viral hepatitis.
The government has national policies relat-
ing to screening and referral to care for hepa-
titis B and hepatitis C. 
People testing for both hepatitis B and hepa-
titis C register by name; the names are kept 
confi dential within the system. Hepatitis B 
and hepatitis C tests are not free of charge for 
all individuals, but they are free of charge for 
donors, pregnant women, recipients of blood 
and blood components, and newborns of 
women with acute and chronic hepatitis 
B. Hepatitis B and hepatitis C tests are com-
pulsory for selected populations, including 
health-care workers and patients who are 
thought to be at increased risk for viral hepa-
titis.
Publicly funded treatment is available for 
hepatitis B and hepatitis C. The amount spent 
by the government on such treatment is not 
known.
The following drugs for treating hepatitis B 
are on the national essential medicines list 
or subsidized by the government: interferon 
alpha, pegylated interferon, lamivudine, en-
tecavir and telbivudine. The following drugs 
for treating hepatitis C are on the national 
essential medicines list or subsidized by the 
government: interferon alpha, pegylated in-
terferon and ribavirin.
The Government of the Russian Federation 
welcomes assistance from WHO in one or 
more areas of viral hepatitis prevention and 
control (Annex C).
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San Marino
The Government of San Marino reports as 
follows.
National coordination 
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis. 
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hep-
atitis-related activities. Information was 
not provided on how many people work 
full-time on hepatitis-related activities in 
all government agencies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c population: health-care workers 
(including health-care waste handlers).
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011. 
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme. 
Evidence-based policy and data for 
action 
There is no routine surveillance for viral 
hepatitis. 
There are no standard case defi nitions for 
hepatitis. Information was not provided 
on whether deaths, including from hepa-
titis, are reported to a central registry. No 
hepatitis case is reported as “undiff erenti-
ated” or “unclassifi ed” hepatitis.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government does not publish hepati-
tis disease reports. 
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities. 
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission 
There is no national policy on hepatitis A 
vaccination. 
The government has not established the 
goal of eliminating hepatitis B.
Nationally, less than 1% of newborn in-
fants in a given recent year received the 
fi rst dose of hepatitis B vaccine within 24 
hours of birth and 89% of one-year-olds 
(ages 12–23 months) in a given recent year 
received three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B). 
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood. 
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepati-
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tis E can be prevented through food and 
water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through on-
the-job training. 
There are no national clinical guidelines 
for the management of viral hepatitis. In-
formation was not provided on whether 
there are national clinical guidelines for 
the management of HIV, which include 
recommendations for coinfection with vi-
ral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals and are compul-
sory for blood donors.
Publicly funded treatment is available for 
hepatitis B and hepatitis C. Information 
was not provided on who is eligible for 
this or on the amount spent by the gov-
ernment on publicly funded treatment for 
hepatitis B and hepatitis C.
The following drugs for treating hepatitis B 
are on the national essential medicines list 
or subsidized by the government: inter-
feron alpha, pegylated interferon, lamivu-
dine, adefovir dipivoxil and entecavir. The 
following drugs for treating hepatitis C are 
on the national essential medicines list or 
subsidized by the government: interferon 
alpha, pegylated interferon and ribavirin.
The Government of San Marino welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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Serbia
The Government of Serbia reports as 
follows.
National coordination 
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis. 
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. It is not known how many 
people work full-time on hepatitis-related 
activities in all government agencies/bod-
ies. 
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs and people living 
with HIV.
Awareness-raising and partnerships 
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011. 
The government collaborates with the fol-
lowing in-country civil society group to 
develop and implement its viral hepatitis 
prevention and control programme: NGO 
HRONOS.
Evidence-based policy and data for 
action 
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: A, 
B, C and E, and for the following types of 
chronic hepatitis: B and C.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Less than 
1% of hepatitis cases are reported as “un-
diff erentiated” or “unclassifi ed” hepatitis.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports annually.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis A, hepatitis B and hepatitis 
C, but not for hepatitis E.
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target populations are men who have sex 
with men, sex workers and Roma youth. 
The last serosurvey was carried out in 2010.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
It is not known what percentage of new-
born infants nationally in a given recent 
year received the fi rst dose of hepatitis B 
vaccine within 24 hours of birth. In a given 
recent year, 96% of one-year-olds (ages 
12–23 months) received three doses of 
hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vaccinat-
ed against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
It is not known whether there is a national 
policy relating to the prevention of viral 
hepatitis among people who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate specialization. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection. There are national clini-
cal guidelines for the management of HIV, 
which include recommendations for coin-
fection with viral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names are 
kept confi dential within the system. Hepa-
titis B and hepatitis C tests are not free of 
charge for all individuals, but they are free 
of charge for pregnant women, people liv-
ing with HIV, patients who are referred and 
patients on haemodialysis. Hepatitis B and 
hepatitis C tests are compulsory for blood 
donors, voluntary donors of tissues and 
organs, pregnant women and patients on 
haemodialysis.
Publicly funded treatment for hepatitis B 
and hepatitis C is available to all people 
with health insurance. Information was not 
provided on the amount spent by the gov-
ernment on such treatment.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: inter-
feron alpha, lamivudine, adefovir dipivoxil 
and tenofovir. The following drugs for 
treating hepatitis C are on the national es-
sential medicines list or subsidized by the 
government: pegylated interferon and 
ribavirin. 
The Government of Serbia welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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Slovakia
The Government of Slovakia reports as 
follows.
National coordination 
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis. 
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. It is not known how 
many people work full-time on hepatitis-
related activities in all government agen-
cies/bodies. 
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs and people living 
with HIV.
Awareness-raising and partnerships 
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011. 
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme. 
Evidence-based policy and data for 
action 
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B, C, D and E, and for the following types 
of chronic hepatitis: B, C and D. 
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. The per-
centage of hepatitis cases reported as “un-
diff erentiated” or “unclassifi ed” hepatitis is 
not known. 
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports monthly.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
It is not known whether there is a national 
public health research agenda for viral 
hepatitis or whether viral hepatitis sero-
surveys are conducted regularly.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination. 
It is not known whether the government 
has established the goal of eliminating 
hepatitis B.
Information was not provided on the per-
centage of newborn infants nationally 
in a given recent year who received the 
fi rst dose of hepatitis B vaccine within 24 
hours of birth or the percentage of one-
year-olds nationally (ages 12–23 months) 
in a given recent year who received three 
doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is no specifi c national strategy 
and/or policy/guidelines for preventing 
hepatitis B and hepatitis C infection in 
health-care settings. Information was not 
provided on whether health-care workers 
are vaccinated against hepatitis B prior to 
starting work that might put them at risk 
of exposure to blood.
It is not known whether there is a national 
policy on injection safety in health-care 
settings. Single-use or auto-disable syring-
es, needles and cannulas are always avail-
able in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
It is not known whether there is a national 
policy relating to the prevention of viral 
hepatitis among people who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepati-
tis E can be prevented through food and 
water safety.
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Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis. It is not 
known whether there are national clinical 
guidelines for the management of HIV, 
which include recommendations for coin-
fection with viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals and are not com-
pulsory for members of any specifi c group.
Publicly funded treatment is available 
for hepatitis B, but information was not 
provided on who is eligible for this. In-
formation was not provided on whether 
publicly funded treatment is available for 
hepatitis C, or on the amount spent by the 
government on such treatment for hepati-
tis B and hepatitis C.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: 
pegylated interferon, lamivudine, adefovir 
dipivoxil, entecavir, telbivudine and teno-
fovir. The following drugs for treating hep-
atitis C are on the national essential medi-
cines list or subsidized by the government: 
interferon alpha, pegylated interferon, 
ribavirin, boceprevir and telaprevir.
The Government of Slovakia welcomes 
assistance from WHO in one or more ar-
eas of viral hepatitis prevention and con-
trol (Annex C).
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Slovenia
The Government of Slovenia reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses primarily on the prevention and 
control of viral hepatitis, and also integrates 
other diseases. It includes components for 
raising awareness, surveillance, vaccination, 
prevention in general, prevention of trans-
mission via injecting drug use, prevention 
of transmission in health-care settings, treat-
ment and care, and coinfection with HIV.
There is a designated governmental unit/
department responsible solely for coordinat-
ing and/or carrying out viral hepatitis-related 
activities. It is a special national multidisci-
plinary expert team. However, there are no 
people working full-time on hepatitis-related 
activities in any government agency/body.
The government has a viral hepatitis preven-
tion and control programme that includes 
activities targeting the following specifi c 
populations: health-care workers (including 
health-care waste handlers), people who in-
ject drugs, prisoners, people living with HIV 
and people undergoing immunosuppressive 
therapy.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not fund-
ed other viral hepatitis public awareness 
campaigns since January 2011. However, an 
expert team sanctioned by the government 
has prepared events for World Hepatitis Day 
since 2008. These have included mass media 
awareness campaigns on prevention and 
control, as well as anonymous free testing for 
hepatitis B and hepatitis C.
The government collaborates with the fol-
lowing in-country civil society groups to de-
velop and implement its viral hepatitis pre-
vention and control programme: Stigma and 
Legebitra.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepatitis. 
There is a national surveillance system for the 
following types of acute hepatitis: A, B, C, D 
and E, and for the following types of chronic 
hepatitis: B, C and D.
There are standard case defi nitions for hepa-
titis. Deaths, including from hepatitis, are re-
ported to a central registry. No hepatitis case 
is reported as “undiff erentiated” or “unclassi-
fi ed” hepatitis.
Liver cancer cases and cases with HIV/hepati-
tis coinfection are registered nationally. 
The government publishes hepatitis disease 
reports monthly.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investigation 
of viral hepatitis outbreaks and other surveil-
lance activities.
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted every six to 12 
months; the target populations are the gen-
eral population, people who inject drugs, 
blood donors, health-care workers and preg-
nant women. Information was not provided 
on when the last serosurvey was carried out.
Prevention of transmission
There is a national policy on hepatitis A vac-
cination. 
The government has not established the goal 
of eliminating hepatitis B.
Information was not provided on the per-
centage of newborn infants nationally in a 
given recent year who received the fi rst dose 
of hepatitis B vaccine within 24 hours of birth 
or the percentage of one-year-olds nationally 
(ages 12–23 months) in a given recent year 
who received three doses of hepatitis B vac-
cine.
There is a national policy that specifi cally tar-
gets mother-to-child transmission of hepati-
tis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis B 
and hepatitis C infection in health-care set-
tings. Health-care workers are vaccinated 
against hepatitis B prior to starting work that 
might put them at risk of exposure to blood.
There is a national policy on injection safety 
in health-care settings, which recommends 
single-use syringes for therapeutic injections. 
Single-use or auto-disable syringes, needles 
and cannulas are always available in all 
health-care facilities.
Offi  cial government estimates of the number 
and percentage of unnecessary injections 
administered annually in health-care settings 
are not known.
There is a national infection control policy for 
blood banks. All donated blood units (includ-
ing family donations) and blood products 
nationwide are screened for hepatitis B and 
hepatitis C. 
There is a national policy relating to the pre-
vention of viral hepatitis among people who 
inject drugs.
The government has guidelines that address 
how hepatitis A and hepatitis E can be pre-
vented through food and water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care for 
people with viral hepatitis through schools 
for health professionals (pre-service educa-
tion), on-the-job training, postgraduate train-
ing and viral hepatitis conferences. 
There are national clinical guidelines for the 
management of viral hepatitis, which include 
recommendations for cases with HIV coin-
fection. There are national clinical guidelines 
for the management of HIV, which include 
recommendations for coinfection with viral 
hepatitis. 
The government has national policies relat-
ing to screening and referral to care for hepa-
titis B and hepatitis C. 
People testing for both hepatitis B and hepa-
titis C register by name, and there is open ac-
cess to their names. Hepatitis B and hepatitis 
C tests are not free of charge for all individu-
als, but they are free of charge for pregnant 
women, prisoners, people who inject drugs 
and family members of hepatitis B carriers. 
Hepatitis B and hepatitis C tests are compul-
sory for health-care workers.
Publicly funded treatment is available for 
hepatitis B and hepatitis C. Everyone with 
national health insurance is eligible for this. 
Information was not provided on the amount 
spent by the government on such treatment. 
The following drugs for treating hepatitis B 
are on the national essential medicines list 
or subsidized by the government: interferon 
alpha, pegylated interferon, lamivudine, 
adefovir dipivoxil, entecavir, telbivudine and 
tenofovir. The following drugs for treating 
hepatitis C are on the national essential medi-
cines list or subsidized by the government: in-
terferon alpha, pegylated interferon, ribavirin 
and boceprevir.
The Government of Slovenia welcomes assist-
ance from WHO in one or more areas of viral 
hepatitis prevention and control (Annex C).
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Spain
The Government of Spain reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hep-
atitis-related activities. Information was 
not provided on how many people work 
full-time on hepatitis-related activities in 
all government agencies/bodies.
The government has a viral hepatitis pre-
vention and control programme that 
includes activities targeting the follow-
ing specifi c populations: health workers 
(including health-care waste handlers), 
people who inject drugs and people living 
with HIV.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, but not for any type of chronic 
hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Of hepa-
titis cases, 27% are reported as “undiff er-
entiated” or “unclassifi ed” hepatitis. 
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports annually. 
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak 
investigations and other surveillance ac-
tivities for hepatitis A, B and C, but it is not 
known whether this is the case for hepa-
titis E.
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are not conducted regularly.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination. 
Information was not provided on whether 
the government has established the goal 
of eliminating hepatitis B.
Nationally, 96.6% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 96.6% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is a national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
46.5
High-income
$31 400
9.54%
$3027.24
$2204.28
82
0.878
40
1.5
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection. There are national clini-
cal guidelines for the management of HIV, 
which include recommendations for coin-
fection with viral hepatitis. 
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for hepatitis B and hepatitis 
C do not register by name. Hepatitis B and 
hepatitis C tests are free of charge for all 
individuals and are compulsory for blood 
donors. 
Publicly funded treatment for hepatitis B 
and hepatitis C is available to all people 
with health insurance. The government 
spends €13 329 (US$ 17 140) on such 
treatment for hepatitis B per patient per 
year, and €39 940 (US$ 51 359) for hepati-
tis C per patient per year.
The following drugs for treating hepatitis B 
are on the national essential medicines list 
or subsidized by the government: inter-
feron alpha, pegylated interferon, lamivu-
dine, adefovir dipivoxil, entecavir, telbivu-
dine and tenofovir. The following drugs for 
treating hepatitis C are on the national es-
sential medicines list or subsidized by the 
government: interferon alpha, pegylated 
interferon, ribavirin, boceprevir and tel-
aprevir.
The Government of Spain did not indicate 
a need for assistance from WHO in relation 
to viral hepatitis prevention and control.
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Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
9.4
High-income
$42 200
9.63%
$3756.86
$3046.78
81
0.936
41
1.9
Sweden
The Government of Sweden reports as 
follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis.
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities: Swedish Institute for 
Communicable Disease Control, Coordina-
tion of HIV and STI Prevention Unit. It has 
two staff  members. It is not known how 
many people work full-time on hepatitis-
related activities in all government agen-
cies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs, migrants, prison-
ers, people living with HIV, men who have 
sex with men, and partners and children of 
hepatitis B-infected people.
Awareness-raising and partnerships 
The government held events for World 
Hepatitis Day 2012 and has funded other 
viral hepatitis public awareness campaigns 
since January 2011 (Annex A). 
The government collaborates with the fol-
lowing in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme: Con-
victus; the Swedish Drug Users Union; and 
the Swedish Federation for Rights, Inde-
pendence, Health and Equality.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: A, 
B, C, D and E, and for the following types of 
chronic hepatitis: B, C and D. 
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. No hepa-
titis case is reported as “undiff erentiated” or 
“unclassifi ed” hepatitis.
Liver cancer cases are registered nationally, 
but cases with HIV/hepatitis coinfection 
are not. 
The government publishes hepatitis dis-
ease reports annually and, if needed, dur-
ing outbreaks. 
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of outbreaks and other surveillance 
activities. 
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target population is children aged 14–16 
years. The last serosurvey was carried out 
in 2007.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has established the goal 
of reducing hepatitis B by 2016.
It is not known what percentage of new-
born infants nationally in a given recent 
year received the fi rst dose of hepatitis B 
vaccine within 24 hours of birth, or what 
percentage of one-year-olds (ages 12–23 
months) nationally in a given recent year 
received three doses of hepatitis B vaccine. 
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vaccinat-
ed against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends auto-disable syringes for therapeu-
tic injections. Single-use or auto-disable 
syringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
There is a national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepatitis 
E can be prevented through food and wa-
ter safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection. Information was not pro-
vided on whether there are national clini-
cal guidelines for the management of HIV, 
which include recommendations for coin-
fection with viral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals and are compul-
sory for blood donors.
Publicly funded treatment for hepatitis B 
and hepatitis C is available to the entire 
population. The amount spent by the gov-
ernment on such treatment is not known.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: inter-
feron alpha, pegylated interferon, lamivu-
dine, adefovir dipivoxil, entecavir, telbivu-
dine and tenofovir. The following drugs for 
treating hepatitis C are on the national es-
sential medicines list or subsidized by the 
government: interferon alpha, pegylated 
interferon, ribavirin, boceprevir and tel-
aprevir.
The Government of Sweden did not in-
dicate a need for assistance from WHO in 
relation to viral hepatitis prevention and 
control.
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Switzerland
The Government of Switzerland reports as 
follows.
National coordination 
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis. 
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hep-
atitis-related activities. Information was 
not provided on how many people work 
full-time on hepatitis-related activities in 
all government agencies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c population: people who inject 
drugs. 
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government collaborates with the fol-
lowing in-country civil society group to 
develop and implement its viral hepatitis 
prevention and control programme: Swiss 
Experts in Viral Hepatitis (SEVHep). 
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, and for the following types of 
chronic hepatitis: B and C.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. No hepa-
titis case is reported as “undiff erentiated” 
or “unclassifi ed” hepatitis.
Liver cancer cases and cases with HIV/
hepatitis coinfection are not registered 
nationally. 
The government publishes hepatitis dis-
ease reports weekly.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of outbreaks and other surveillance 
activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Information was not provided on the per-
centage of newborn infants nationally in 
a given recent year who received the fi rst 
dose of hepatitis B vaccine within 24 hours 
of birth. In a given recent year, 30% of one-
year-olds (ages 12–23 months) received 
three doses of hepatitis B vaccine.
There is no national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B, but there are recommenda-
tions about this issue.
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is no national policy on injection 
safety in health-care settings. Single-use 
or auto-disable syringes, needles and can-
nulas are always available in all health-care 
facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is a national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
7.7
High-income
$52 570
11.52%
$5394.04
$3183.56
82
0.926
41
1.5
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, but 
they do not include recommendations 
for cases with HIV coinfection. There are 
no national clinical guidelines for the 
management of HIV, which include rec-
ommendations for coinfection with viral 
hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are not 
free of charge for all individuals, but they 
are free of charge for health-care workers, 
and organ and blood donors. Hepatitis B 
and hepatitis C tests are not compulsory 
for members of any specifi c group.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: 
pegylated interferon, lamivudine, adefovir 
dipivoxil, entecavir, telbivudine and teno-
fovir. The following drugs for treating hep-
atitis C are on the national essential medi-
cines list or subsidized by the government: 
pegylated interferon, ribavirin, boceprevir 
and telaprevir.
The Government of Switzerland did not 
indicate a need for assistance from WHO 
in relation to viral hepatitis prevention and 
control.
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Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
7.0
Low-income
$1937
5.98%
$128.43
$34.24
68
0.726
20
3.3
Tajikistan
The Government of Tajikistan reports as 
follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. Information was not pro-
vided on how many people work full-time 
on hepatitis-related activities in all govern-
ment agencies/bodies.
The government does not have a viral hep-
atitis prevention and control programme 
that includes activities targeting specifi c 
populations.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate with 
in-country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: A, 
B, C, D and E, and for the following types of 
chronic hepatitis: B and C.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. No hepa-
titis case is reported as “undiff erentiated” or 
“unclassifi ed” hepatitis.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports annually.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of outbreaks and other surveillance 
activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target populations are people who inject 
drugs, men who have sex with men, sex 
workers, prisoners, pregnant women and 
people living with HIV. The last serosurvey 
was carried out in 2011.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 98% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 96% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is no national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B.
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vaccinat-
ed against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeu-
tic injections. Single-use or auto-disable 
syringes, needles and cannulas are not 
always available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
It is not known whether there is a national 
policy relating to the prevention of viral 
hepatitis among people who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are no national clinical guidelines 
for the management of viral hepatitis, 
but there are for the management of HIV, 
which include recommendations for coin-
fection with viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names are 
kept confi dential within the system. Hepa-
titis B and hepatitis C tests are not free of 
charge for all individuals, but they are free 
of charge for people living with HIV and 
blood donors. Hepatitis B and hepatitis C 
tests are compulsory for blood donors and 
medical staff .
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
No drug for treating hepatitis B is on the 
national essential medicines list or subsi-
dized by the government. The following 
drug for treating hepatitis C is on the na-
tional essential medicines list or subsidized 
by the government: ribavirin.
The Government of Tajikistan welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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The Government of the former Yugoslav 
Republic of Macedonia reports as follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. It is not known how 
many people work full-time on hepatitis-
related activities in all government agen-
cies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs and people living 
with HIV.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government collaborates with the fol-
lowing in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme: Hep-
ta and HOPS.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, but not for any type of chronic 
hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Of hepa-
titis cases, 9% are reported as “undiff eren-
tiated” or “unclassifi ed” hepatitis.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports weekly.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis A, hepatitis B and hepati-
tis C, but not for hepatitis E.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has established the goal 
of eliminating hepatitis B but did not pro-
vide information about a specifi c time-
frame for this.
Nationally, 98% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 96% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C.
There is a national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
2.1
Upper–middle-income
$11 090
7.09%
$790.97
$504.26
74
0.776
36
1.4
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, but 
they do not include recommendations for 
cases with HIV coinfection. There are na-
tional clinical guidelines for the manage-
ment of HIV, which include recommenda-
tions for coinfection with viral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are not 
free of charge for all individuals, but they 
are free of charge for people who inject 
drugs, blood donors and people living 
with HIV. Hepatitis B and hepatitis C tests 
are not compulsory for members of any 
specifi c group.
Publicly funded treatment is available for 
hepatitis B and hepatitis C, but informa-
tion was not provided on who is eligible 
for this, or on the amount spent by the 
government on such treatment.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: in-
terferon alpha, pegylated interferon and 
lamivudine. The following drugs for treat-
ing hepatitis C are on the national essen-
tial medicines list or subsidized by the 
government: interferon alpha, pegylated 
interferon and ribavirin.
The Government of the former Yugoslav 
Republic of Macedonia welcomes as-
sistance from WHO in one or more ar-
eas of viral hepatitis prevention and con-
trol (Annex C).
The former Yugoslav 
Republic of Macedonia
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Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
73.6
Upper–middle-income
$16 940
6.74%
$1029.14
$773.95
75
0.704
28
2.1
Turkey
The Government of Turkey reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses exclusively on the preven-
tion and control of hepatitis B. It includes 
components for raising awareness, surveil-
lance, vaccination, prevention in general, 
prevention of transmission via injecting 
drug use, and prevention of transmission 
in health-care settings.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. It is not known how many 
people work full-time on hepatitis-related 
activities in all government agencies/
bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs and prisoners.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012, but has funded 
other viral hepatitis public awareness cam-
paigns since January 2011 (Annex A).
The government collaborates with the fol-
lowing in-country civil society group to 
develop and implement its viral hepatitis 
prevention and control programme: Viral 
Hepatitle Savaşım Derneği.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: A, 
B, C, D and E, but not for any type of chronic 
hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. The per-
centage of hepatitis cases reported as “un-
diff erentiated” or “unclassifi ed” hepatitis is 
not known.
Liver cancer cases are registered nationally, 
but cases with HIV/hepatitis coinfection 
are not.
The government publishes hepatitis dis-
ease reports monthly.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of outbreaks and other surveillance 
activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 97% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 96% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vaccinat-
ed against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C.
There is a national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are no national clinical guidelines 
for the management of viral hepatitis or 
for the management of HIV, which include 
recommendations for coinfection with vi-
ral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name, and there is 
open access to their names. Hepatitis B and 
hepatitis C tests are not free of charge for 
all individuals, but they are free of charge 
for all of the defi ned risk groups. Hepatitis 
B and hepatitis C tests are compulsory for 
blood donors, transplant providers and 
preoperative patients.
Publicly funded treatment for hepatitis 
B and hepatitis C is available to everyone 
under the age of 18 years and to those 18 
years or older if they have health insurance. 
(In Turkey, 99% of people have health in-
surance.) The government spends €85 mil-
lion (US$ 109.3 million) annually on drugs 
for publicly funded treatment for hepati-
tis B and hepatitis C. It is not known how 
much the government spends on other 
components of publicly funded treatment.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: inter-
feron alpha, pegylated interferon, lamivu-
dine, adefovir dipivoxil, entecavir, telbivu-
dine and tenofovir. The following drugs for 
treating hepatitis C are on the national es-
sential medicines list or subsidized by the 
government: interferon alpha, pegylated 
interferon, ribavirin, boceprevir and tel-
aprevir.
The Government of Turkey did not indicate 
a need for assistance from WHO in relation 
to viral hepatitis prevention and control.
Ch
ap
te
r 6
: W
H
O
 E
ur
op
ea
n 
Re
gi
on
143
GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Ukraine
The Government of Ukraine reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. It is not known how 
many people work full-time on hepatitis-
related activities in all government agen-
cies/bodies.
The government does not have a viral 
hepatitis prevention and control pro-
gramme that includes activities targeting 
specifi c populations.
Awareness-raising and partnerships
It is not known whether the government 
held events for World Hepatitis Day 2012. 
It has not funded other viral hepatitis pub-
lic awareness campaigns since January 
2011.
The government collaborates with the fol-
lowing in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme: NGO 
“Stop Hepatitis” and Offi  ce IRF in Ukraine.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, and for the following types of 
chronic hepatitis: B and C.
There are no standard case defi nitions for 
hepatitis. Hepatitis deaths are not report-
ed to a central registry. Information was 
not provided on the percentage of hepa-
titis cases reported as “undiff erentiated” or 
“unknown” hepatitis.
Liver cancer cases are registered nation-
ally, but cases with HIV/hepatitis coinfec-
tion are not.
The government does not publish hepati-
tis disease reports.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis A, hepatitis B and hepati-
tis C, but information was not provided on 
whether this is the case for hepatitis E.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target population is people who inject 
drugs. The last serosurvey was carried out 
in 2011.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 70% of newborn infants in a 
given recent year received the fi rst dose 
of hepatitis B vaccine within 24 hours of 
birth. Among children who had received 
the fi rst dose within 24 hours of birth, 
70%–80% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
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The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are no national clinical guidelines 
for the management of viral hepatitis, 
but there are for the management of HIV, 
which include recommendations for coin-
fection with viral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are not 
free of charge for all individuals, but they 
are free of charge for pregnant women, 
blood donors and military conscripts. 
Hepatitis B and hepatitis C tests are com-
pulsory for pregnant women, blood do-
nors and military conscripts.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: in-
terferon alpha, pegylated interferon, lami-
vudine and tenofovir. The following drugs 
for treating hepatitis C are on the national 
essential medicines list or subsidized by 
the government: pegylated interferon and 
ribavirin.
The Government of Ukraine welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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62.4
High-income
$36 010
9.64%
$3479.56
$2918.89
80
0.879
40
1.9
The Government of the United Kingdom of 
Great Britain and Northern Ireland reports 
as follows.
National coordination
There is a written national strategy or plan 
that focuses exclusively on the preven-
tion and control of hepatitis C. It includes 
components for raising awareness, surveil-
lance, prevention in general, prevention of 
transmission via injecting drug use, pre-
vention of transmission in health-care set-
tings, treatment and care, and coinfection 
with HIV.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. It is not known how many 
people work full-time on hepatitis-related 
activities in all government agencies/
bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs, migrants, prison-
ers, the homeless, people living with HIV, 
people at risk for STI and pregnant women 
(antenatal screening).
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012, but has funded 
other viral hepatitis public awareness cam-
paigns since January 2011 (Annex A).
The government collaborates with the fol-
lowing in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme: Hepa-
titis C Trust, Addaction, British Liver Trust, 
Exchange Supplies, Needle Exchange Fo-
rum and Injecting Advice.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: A, 
B, C and E, and for the following types of 
chronic hepatitis: B and C.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. No hepa-
titis case is reported as “undiff erentiated” or 
“unclassifi ed” hepatitis.
Liver cancer cases are registered nationally, 
but cases with HIV/hepatitis coinfection 
are not.
The government publishes hepatitis dis-
ease reports quarterly and annually. 
Hepatitis outbreaks are not required to 
be reported to the government. There is 
adequate laboratory capacity nationally 
to support investigation of outbreaks and 
other surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target populations are people who inject 
drugs, female sex workers and men who 
have sex with men. The last serosurvey was 
carried out in 2011.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Information was not provided on the per-
centage of newborn infants nationally in 
a given recent year who received the fi rst 
dose of hepatitis B vaccine within 24 hours 
of birth or the percentage of one-year-olds 
nationally (ages 12–23 months) in a given 
recent year who received three doses of 
hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vaccinat-
ed against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection 
safety in health-care settings, but it is not 
known what type of syringes it recom-
mends for therapeutic injections. It is not 
known whether single-use or auto-disable 
syringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
There is a national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are no national clinical guidelines 
for the management of viral hepatitis, 
but there are for the management of HIV, 
which include recommendations for coin-
fection with viral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals, and are compul-
sory for health-care workers who wish to 
do exposure-prone procedures.
Publicly funded treatment for hepatitis B 
and hepatitis C is available to the entire 
population. The amount spent by the gov-
ernment on such treatment is not known.
The following drugs for treating hepatitis B 
are on the national essential medicines list 
or subsidized by the government: interfer-
on alpha, pegylated interferon, lamivudine, 
adefovir dipivoxil, entecavir and tenofovir. 
The following drugs for treating hepatitis 
C are on the national essential medicines 
list or subsidized by the government: inter-
feron alpha, pegylated interferon, ribavirin, 
boceprevir and telaprevir.
The Government of the United Kingdom of 
Great Britain and Northern Ireland did not 
indicate a need for assistance from WHO in 
relation to viral hepatitis prevention and 
control.
United Kingdom of Great Britain 
and Northern Ireland (the)
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Uzbekistan
The Government of Uzbekistan reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses primarily on the prevention 
and control of viral hepatitis, and also in-
tegrates other diseases. It includes com-
ponents for vaccination, prevention in 
general and prevention of transmission in 
health-care settings.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. It is not known how 
many people work full-time on hepatitis-
related activities in all government agen-
cies/bodies.
The government does not have a viral 
hepatitis prevention and control pro-
gramme that includes activities targeting 
specifi c populations.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, and for the following types of 
chronic hepatitis: B, C and D.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. The per-
centage of hepatitis cases reported as “un-
diff erentiated” or “unclassifi ed” hepatitis is 
not known.
It is not known whether liver cancer cases 
are registered nationally. Cases with HIV/
hepatitis coinfection are not registered 
nationally.
The government publishes hepatitis dis-
ease reports monthly.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of outbreaks and other surveillance 
activities.
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, approximately 90% of newborn 
infants in a given recent year received the 
fi rst dose of hepatitis B vaccine within 24 
hours of birth and approximately 90% of 
one-year-olds (ages 12–23 months) in a 
given recent year received three doses of 
hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is no specifi c national strategy 
and/or policy/guidelines for preventing 
hepatitis B and hepatitis C infection in 
health-care settings. Information was not 
provided on whether health-care workers 
are vaccinated against hepatitis B prior to 
starting work that might put them at risk 
of exposure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
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There is a national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education) and postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection. There are national clini-
cal guidelines for the management of HIV, 
which include recommendations for coin-
fection with viral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name, and there is 
open access to their names. Hepatitis B 
and hepatitis C tests are not free of charge. 
Information was not provided on whether 
hepatitis B or hepatitis C tests are free of 
charge for any specifi c group. Hepatitis B 
and hepatitis C tests are not compulsory 
for members of any specifi c group.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
No drug for treating hepatitis B or hepatitis 
C is on the national essential medicines list 
or subsidized by the government.
The Government of Uzbekistan welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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Viral hepatitis in the WHO South-East Asia Region   
The endemicity of hepatitis A in the Region ranges from 
low (<50% exposed by the age of 30 years) in the eastern 
areas to high (>90% exposed by the age of 10 years) in the 
southern areas.a
Approximately 14 million cases of hepatitis E infection 
occur annually in the Region, which accounts for more 
than half the global burden. Indeed, the prevalence of 
hepatitis E is estimated to be above 25% in those >50 
years of age.b
The seroprevalence of hepatitis B in the young age 
groups of 0–14 years is 1.2%–1.4%. However, in adults, the 
serpoprevalence is higher, at above 5%.c
There are up to 50 million people with chronic hepatitis C 
infection in the South Asia.d Because of the asymptomatic 
nature of chronic hepatitis B and hepatitis C, most people 
infected with these are not aware of their status until they 
have symptoms of cirrhosis or liver cancer many years 
later.c,d
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Eleven Member States make up the World Health Organization 
(WHO) South-East Asia Region, which has a total population of 
1.83 billion.1 India, with a population of 1.24 billion, accounts 
for approximately two thirds of the Region’s population.1 
The South-East Asia Region hosts one fourth of the world’s 
population and carries about 30% of the world’s total disease 
burden.2 In 2009, life expectancy at birth for the South-East Asia 
Region was 65 years.3
The greatest contributors to morbidity and mortality are 
noncommunicable diseases: cardiovascular diseases and cancer 
account for about 30% and 9% of deaths, respectively.4 Age-
standardized mortality rates (2008) indicate that communicable 
diseases account for about 30% of deaths.1 The South-East Asia 
Region has high child mortality, with three fourths of these 
deaths resulting from diarrhoeal diseases, pneumonia and 
neonatal conditions.5 The Region is home to more than two 
thirds of the world’s malnourished children.5 Unsafe water and 
inadequate sanitation and hygiene pose major health risks to 
both children and adults; the Region has the highest incidence 
of diarrhoeal disease in the world.5
Responses to the WHO/Alliance survey were received from all 
11 Member States in the South-East Asia Region (100%).
Box 1. Responses to the 2012 Global Hepatitis Survey: WHO 
South-East Asia Region
Member States that submitted surveys:
• Bangladesh
• Bhutan
•  Democratic People’s 
Republic of Korea
• India
• Indonesia
• Maldives
• Myanmar
• Nepal
• Sri Lanka
• Thailand
• Timor-Leste
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National coordination
Four responding Member States (36.4%) reported the existence 
of a written national strategy or plan that focuses exclusively 
or primarily on the prevention and control of viral hepatitis 
(Figure 1). Three of the four Member States with a strategy 
or plan (Democratic People’s Republic of Korea, India and 
Indonesia) reported that it focuses exclusively on viral hepatitis, 
and one (Myanmar) reported that it addresses other diseases as 
well.
Figure 1. Responses to the question, “Is there a written 
national strategy or plan that focuses exclusively or primarily 
on the prevention and control of viral hepatitis?”
Yes
No
No data
The four Member States that reported the existence of a strategy 
or plan were asked about its specifi c components. All four 
reported the inclusion of components for raising awareness, 
surveillance, vaccination, general prevention, prevention of 
transmission in health-care settings, and treatment and care. 
Three reported the inclusion of a component for the prevention 
of transmission via injecting drug use.
Three responding Member States (27.3%) reported that they 
have a governmental unit or department responsible solely for 
viral hepatitis-related activities. Member States that did so were 
asked to indicate the number of staff  members in the unit or 
department. Responses ranged from 4 to 20 (median, 4), with 
Myanmar reporting the largest number.
Member States were asked to report the number of people 
working full-time on hepatitis-related activities in all 
government agencies or bodies. Among the three Member 
States that provided data for this question, the number ranged 
from 0 to 49 (median, 30.5), with Myanmar reporting the largest 
number.
Nine responding Member States (81.8%) reported that they have 
a viral hepatitis prevention and control programme that includes 
activities targeting specifi c populations. The populations most 
commonly targeted were health-care workers, including health-
care waste handlers (77.8% of responding Member States within 
this subset) and people who inject drugs (44.4% of responding 
Member States within this subset). The following populations 
were each targeted by one third of responding Member States 
within this subset: migrants, prisoners and people living with 
HIV. Groups identifi ed less frequently included indigenous 
populations, low-income populations, those who are uninsured 
and those who are homeless.
Awareness-raising and partnerships
One responding Member State (9.1%) reported that it had held 
events for World Hepatitis Day 2012 (28 July). Since January 
2011, three responding Member States (27.3%) had funded 
some type of viral hepatitis public awareness campaign other 
than World Hepatitis Day (Table 1). 
Four responding Member States (36.4%) reported that they 
collaborated with civil society groups within their countries 
to develop and implement the governmental viral hepatitis 
prevention and control programme. For example, Bangladesh 
reported collaborating with the Liver Foundation of Bangladesh, 
and Myanmar reported collaborating with health-care provider 
associations and with the Myanmar Red Cross Association.
(Further examples can be found in the summaries of country 
fi ndings later in this chapter.)
Table 1. Topics of public awareness campaigns on viral 
hepatitis held in Member States since January 2011 (N=3)
General information 
about hepatitis and 
its transmission
Vaccination for 
hepatitis A and 
hepatitis B
Importance of 
knowing one’s 
hepatitis B and 
hepatitis C status
Safe water and 
good sanitation
Safer sex practices
Harm reduction for 
people who inject 
drugs
Safe workplace 
practices
Myanmar
Democratic People’s 
Republic of 
Korea
X
X
X
X
X
X
X
X
X
X
Indonesia
X
X
X
X
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Table 2. Types of surveillance in Member States that reported 
the existence of routine surveillance for viral hepatitis (N=6)
There is a national 
surveillance system for acute 
hepatitis infection for the 
following forms of hepatitis:
hepatitis A
hepatitis B
hepatitis C
hepatitis D
hepatitis E
There is a national 
surveillance system for 
chronic hepatitis infection 
for the following forms of 
hepatitis:
hepatitis B
hepatitis C
hepatitis D
Yes (%)
83.3 
100 
83.3 
33.3 
33.3 
33.3 
33.3 
0 
No (%)
0 
0 
0 
33.3 
33.3 
66.7 
66.7 
83.3 
Do not 
know 
(%)
0
0
0
0
0
0
0
0
No 
response 
(%)
16.7 
0 
16.7 
33.3 
33.3 
0 
0 
16.7 
Table 3. Data registration and surveillance (N=11)
Liver cancer cases are registered 
nationally
Cases with HIV/hepatitis 
coinfection are registered 
nationally
Hepatitis outbreaks are reported
If YES – Hepatitis outbreaks are 
further investigated (N=115)
Yes (%)
63.6 
45.5 
81.8 
100 
No (%)
36.4 
36.4 
18.2 
0 
Do not 
know 
(%)
0 
18.2 
0 
0 
No 
response 
(%)
0 
0 
0 
0 
Evidence-based policy and data for action
Six responding Member States (54.5%) reported that they have 
routine surveillance for viral hepatitis; details appear in Table 2. 
Seven responding Member States (63.6%) indicated that their 
countries have standard case defi nitions for hepatitis infection 
and seven (63.6%) indicated that their countries have a central 
registry for the reporting of deaths, including hepatitis deaths.
Two Member States reported on the proportion of hepatitis 
cases and deaths registered as “undiff erentiated” or “unclassifi ed” 
hepatitis. One reported this to be 25.1% and the other less 
than 5.0%. Additional survey fi ndings about surveillance are 
presented in Table 3.
Member States were asked how often hepatitis disease reports 
are published. Of the responding Member States, 45.5% said 
that reports are not published. Among the six Member States 
with published reports, one said reports are published weekly, 
one weekly and annually, two monthly and annually, and one 
annually. The sixth said reports are published in journal articles.
Three responding Member States (27.3%, Democratic People’s 
Republic of Korea, Indonesia and Myanmar) reported the 
existence of a national public health research agenda for viral 
hepatitis.
Two responding Member States (18.2%, the Democratic 
People’s Republic of Korea and Myanmar) reported that viral 
hepatitis serosurveys are conducted regularly. Myanmar 
indicated that serosurveys take place at least once per year. The 
Democratic People’s Republic of Korea said that its serosurveys 
target children under the age of 17 years, while Myanmar said 
that its serosurveys target children over the age of 5 years and 
the general population. The most recent serosurvey in the 
Democratic People’s Republic of Korea was conducted in 2009, 
and the most recent one in Myanmar was conducted in 2010.
Prevention of transmission
No responding Member State reported that they have a national 
policy on hepatitis A vaccination.
Two responding Member States (18.2%) reported that 
they have established the goal of eliminating hepatitis B 
(Figure 2). Member States with this goal were asked to specify 
the timeframe in which they seek to eliminate hepatitis B. The 
Democratic People’s Republic of Korea said by 2016, and Sri 
Lanka said by 2015.
Member States were asked to report, for a given recent year, 
the percentage of newborn infants who had received the fi rst 
dose of hepatitis B vaccine within 24 hours of birth. Among 
the seven governments providing this information, responses 
ranged from 0% to 99.9% (median, 75.4%). Governments were 
Figure 2. Responses to the question, “Has your government 
established the goal of eliminating hepatitis B?” (N=11)
No 
(81.8%)
Yes 
(18.2%)
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Table 4. Activities called for in national policy targeting 
mother-to-child transmission of hepatitis B (N=7)
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also asked to report, for a given recent year, the percentage of 
one-year-olds (ages 12–23 months) who had received three 
doses of hepatitis B vaccine. Among the eight governments 
providing this information, responses ranged from 38.0% to 
99.0% (median, 93.9%).
Seven responding governments (63.6%) reported the existence 
of a national policy that specifi cally targets mother-to-child 
transmission of hepatitis B; details are presented in Table 4. Five 
governments with such a policy indicated that one component 
of the policy calls for screening of all pregnant women for 
hepatitis B. Seven governments with such a policy indicated 
that one component of the policy calls for administering the 
second and third doses of hepatitis B vaccine to all infants 
within 12 months of birth.
Five responding Member States (45.5%) reported the existence 
of a specifi c national strategy and/or policy for preventing 
hepatitis B and hepatitis C infection in health-care settings.
Five responding Member States (45.5%) reported that health-
care workers are vaccinated against hepatitis B prior to starting 
work that might put them at risk of exposure to blood.
Ten responding Member States (90.9%) reported the existence 
of a national policy on injection safety in health-care settings. 
These ten Member States were asked which types of syringes 
Figure 3. Proportion of responding Member States with 
national policies on injection safety in health-care settings 
which recommend single-use syringes and auto-disable 
syringes for therapeutic injections (N=10)
a  Respondents could select both “single-use syringes” and “auto-disable syringes”.
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Single-use syringesa Auto-disable syringesa
the policy recommends for therapeutic injections. Single-use 
syringes are recommended in 90.0% of policies, and auto-
disable syringes in half of policies (Figure3).
Ten responding Member States (90.9%) reported that single-
use or auto-disable syringes, needles and cannulas are always 
available in all health-care facilities.
Member States were asked for offi  cial estimates of the number 
and percentage of unnecessary injections administered 
annually in health-care settings (e.g. injections that are given 
when an equivalent oral medication is available). Ten Member 
States reported that the fi gures are not known and one did not 
reply.
Additional fi ndings relating to the prevention of hepatitis 
transmission are presented in Table 5.
Screening, care and treatment
Member States were asked how health professionals in their 
countries obtain the skills and competencies required to 
eff ectively care for people with viral hepatitis. Eight Member 
States indicated that these are obtained in schools for health 
professionals (pre-service education) and on-the-job training.
Four responding Member States (36.4%) reported the existence 
of national clinical guidelines for the management of viral 
hepatitis (Figure 4). Two of these four responding Member States 
(50.0%) indicated that the guidelines include recommendations 
for cases with HIV coinfection.
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Table 5. Hepatitis prevention: policies, practices and 
guidelines (N=11)
There is a national infection 
control policy for blood banks
All donated blood units 
(including family donations) and 
blood products nationwide are 
screened for hepatitis B
All donated blood units 
(including family donations) and 
blood products nationwide are 
screened for hepatitis C
There is a national policy relating 
to the prevention of viral 
hepatitis among people who 
inject drugs
The government has guidelines 
that address how hepatitis A 
and hepatitis E can be prevented 
through food and water safety
Yes (%)
100  
90.9  
81.8  
18.2  
45.5  
No (%)
0  
9.1  
9.1  
63.6  
54.5  
Do not 
know (%)
0  
0  
9.1  
18.2  
0  
Figure 4. Responses to the question, “Are there national 
clinical guidelines for the management of viral hepatitis?” 
(N=11)
No 
(54.5%)
Yes 
(36.4%)
Do not 
know 
9.1%
Three responding Member States (27.3%) indicated that they 
have a national policy relating to screening and referral to care 
for hepatitis B. Two (18.2%) reported having such a policy for 
hepatitis C.
Regarding hepatitis B testing, ten responding Member States 
(90.9%) indicated that people register by name for testing. Eight 
of the ten members of that subset (80.0%) indicated that the 
names are kept confi dential. Five responding Member States 
(45.5%) reported that the hepatitis B test is free of charge for all 
individuals. Among the six other Member States, Myanmar and 
Thailand reported that the hepatitis B test is free of charge for 
members of specifi c groups. Groups identifi ed included blood 
donors and pregnant women. Six responding Member States 
(54.5%) reported that the hepatitis B test is compulsory for 
members of specifi c groups. Groups identifi ed included blood 
donors and people living with HIV.
Regarding hepatitis C testing, ten responding Member States 
(90.9%) indicated that people register by name for testing. Eight 
of the ten members of that subset (80.0%) indicated that the 
names are kept confi dential. Five responding Member States 
(45.5%) reported that the hepatitis C test is free of charge for all 
individuals. Among the six other Member States, Myanmar and 
Thailand reported that the hepatitis C test is free of charge for 
members of specifi c groups. Groups identifi ed included blood 
donors and pregnant women. Six responding Member States 
(54.5%) reported that the hepatitis C test is compulsory for 
members of specifi c groups. Groups identifi ed included blood 
donors and people living with HIV.
Six responding Member States (54.5%) reported that publicly 
funded treatment is available for hepatitis B and six (54.5%) 
that publicly funded treatment is available for hepatitis C. 
Information was not provided by any Member State regarding 
the amount spent on publicly funded treatment for hepatitis B 
and hepatitis C.
Nine responding Member States (81.8%) reported that at least 
one available drug for treating hepatitis B is on the national 
essential medicines list (Table 6). The drugs most commonly 
reported were lamivudine, interferon alpha, tenofovir and 
pegylated interferon.
Seven responding Member States (63.6%) reported that at least 
one available drug for treating hepatitis C is on the national 
essential medicines list. The drugs most commonly reported 
were interferon alpha, pegylated interferon and ribavirin.
World Health Organization assistance
Member States were asked to indicate areas in which they might 
want assistance from WHO for the prevention and control of viral 
hepatitis. Respondents most commonly selected the following: 
developing the national plan for viral hepatitis prevention and 
control (81.8%), estimating the national burden of viral hepatitis 
(81.8%) and conducting viral hepatitis surveillance (81.8%)
(Table 7). Responses from individual Member States appear in 
Annex C.
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Lamivudine 
Interferon alpha 
Tenofovir
Pegylated interferon
Entecavir
Adefovir dipivoxil
Telbivudine
Ribavirin
Pegylated interferon
Interferon alpha
Telaprevir
Boceprevir
63.6  
45.5  
45.5  
36.4  
36.4  
36.4  
27.3  
54.5  
45.5  
45.5  
27.3  
18.2  
% of Member States reporting its 
inclusion (N=12)
% of Member States reporting its 
inclusion (N=12)
Drugs for treating 
hepatitis B
Drugs for treating 
hepatitis C
Table 6. Proportion of Member States reporting drugs for 
treating hepatitis B and C on national essential medicines 
lists or subsidized by governments
Awareness-raising, partnerships and resource mobilization (fi rst WHO strategic axis)
Developing the national plan for viral hepatitis prevention and control
Integrating viral hepatitis programmes into other health services
Awareness-raising
Evidence-based policy and data for action (second WHO strategic axis)
Viral hepatitis surveillance
Estimating the national burden of viral hepatitis
Developing tools to assess the eff ectiveness of interventions
Assessing the economic impact of viral hepatitis
Prevention of transmission (third WHO strategic axis)
Increasing coverage of the birth dose of the hepatitis B vaccine
Screening, care and treatment (fourth WHO strategic axis)
Increasing access to treatment
Increasing access to diagnostics
Improving laboratory quality
Developing education/training programmes for health professionals
81.8%
63.6%
72.7%
81.8%
81.8%
63.6%
54.5%
54.5% 
54.5%
63.6%
0%a
63.6%
Table 7. Viral hepatitis control and prevention: areas in which Member States indicated interest in receiving WHO assistance 
(N=11)
a  N=26 (This response option was not included in the survey completed by Member States of the South-East Asia Region.)
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Bangladesh
The Government of Bangladesh reports as 
follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. It is not known how many 
people work full-time on hepatitis-related 
activities in all government agencies/bod-
ies.
The government does not have a viral hep-
atitis prevention and control programme 
that includes activities targeting specifi c 
populations.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government collaborates with the fol-
lowing in-country civil society group to 
develop and implement its viral hepatitis 
prevention and control programme: Liver 
Foundation of Bangladesh.
Evidence-based policy and data for 
action
There is no routine surveillance for viral 
hepatitis. 
There are no standard case defi nitions for 
hepatitis. Hepatitis deaths are not reported 
to a central registry. The percentage of 
hepatitis cases reported as “undiff erentiat-
ed” or “unclassifi ed” hepatitis is not known.
Liver cancer cases and cases with HIV/
hepatitis coinfection are not registered na-
tionally.  
The government publishes hepatitis dis-
ease reports in journals.
Hepatitis outbreaks are not reported to the 
government. There is inadequate labora-
tory capacity nationally to support investi-
gation of outbreaks and other surveillance 
activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Information was not provided on the per-
centage of newborn infants nationally in 
a given recent year who received the fi rst 
dose of hepatitis B vaccine within 24 hours 
of birth or the percentage of one-year-olds 
nationally (ages 12–23 months) in a given 
recent year who received three doses of 
hepatitis B vaccine.
There is no national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B.
There is no specifi c national strategy and/
or policy for preventing hepatitis B and 
hepatitis C infection in health-care settings. 
Health-care workers are not vaccinated 
against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is no national policy on injection 
safety in health-care settings. Single-use 
or auto-disable syringes, needles and can-
nulas are always available in all health-care 
facilities.
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
150.4
Low-income
$1940
3.48%
$148.45
$66.43
65
0.500
24
2.2
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
There is a national infection control policy 
for blood banks. Not all donated blood 
units and blood products nationwide are 
screened for hepatitis B. It is not known 
whether all donated blood units (including 
family donations) and blood products na-
tionwide are screened for hepatitis C.
There is no national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepatitis 
E can be prevented through food and wa-
ter safety.
Screening, care and treatment
It is not known how health professionals 
obtain the skills and competencies re-
quired to eff ectively care for people with 
viral hepatitis. 
There are no national clinical guidelines for 
the management of viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for hepatitis B and hepatitis 
C do not register by name. Hepatitis B and 
hepatitis C tests are not free of charge, and 
are compulsory for blood donors.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C. 
The following drugs for treating hepati-
tis B drugs are on the national essential 
medicines list: interferon alpha, pegylated 
interferon, lamivudine, adefovir dipivoxil, 
entecavir, telbivudine and tenofovir. The 
following drugs for treating hepatitis C are 
on the national essential medicines list: in-
terferon alpha, pegylated interferon, riba-
virin, boceprevir and telaprevir.
The Government of Bangladesh welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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Bhutan
The Government of Bhutan reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. It is not known how 
many people work full-time on hepatitis-
related activities in all government agen-
cies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs, migrants, prison-
ers, the homeless, people living with HIV, 
low-income populations, the uninsured, 
indigenous people and pregnant women.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for acute hepatitis B, but not for any type 
of chronic hepatitis.
There are no standard case defi nitions for 
hepatitis. Hepatitis deaths are not report-
ed to a central registry. The percentage of 
hepatitis cases reported as “undiff erentiat-
ed” or “unclassifi ed” hepatitis is not known.
Liver cancer cases are not registered na-
tionally, but cases with HIV/hepatitis coin-
fection are. 
The government publishes hepatitis dis-
ease reports annually.
Hepatitis outbreaks are reported to the 
government and are further investigated. 
There is adequate laboratory capacity na-
tionally to support investigation of viral 
hepatitis outbreaks and other surveillance 
activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 29% of newborn infants in a 
given recent year received the fi rst dose 
of hepatitis B vaccine within 24 hours of 
birth, based on a policy introduced in mid-
2011, and 93% of one-year-olds (ages 12–
23 months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is no specifi c national strategy and/
or policy for preventing hepatitis B and 
hepatitis C infection in health-care set-
tings. However, health-care workers are 
vaccinated against hepatitis B prior to 
starting work that might put them at risk 
of exposure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
0.7
Lower–middle-income
$5570
5.19%
$274.76
$238.57
63
0.552
25
2.4
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is a national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepati-
tis E can be prevented through food and 
water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education) and on-the-job training. 
There are no national clinical guidelines 
for the management of viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name, and there 
is open access to their names. Hepatitis 
B and hepatitis C tests are free of charge 
for all individuals, and are compulsory for 
blood donors and people living with HIV.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
The following drug for treating hepatitis B 
is on the national essential medicines list: 
lamivudine. No drug for treating hepatitis 
C is on the national essential medicines 
list.
The Government of Bhutan welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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Democratic People’s 
Republic of Korea
The Government of the Democratic 
People’s Republic of Korea reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses exclusively on the prevention 
and control of viral hepatitis. It includes 
components for raising awareness, surveil-
lance, vaccination, prevention in general, 
prevention of transmission in health-care 
settings, and treatment and care. 
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. The name of this offi  ce 
was not provided. It has four staff  mem-
bers. It is not known how many people 
work full-time on hepatitis-related activi-
ties in all government agencies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c population: health-care workers, 
including health-care waste handlers. 
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012, but has funded 
other viral hepatitis public awareness cam-
paigns since January 2011 (Annex A). 
The government collaborates with the fol-
lowing in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme: mass 
media and community and social organi-
zations.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, and for the following types of 
chronic hepatitis: B and C.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Informa-
tion was not provided on the percentage 
of hepatitis cases reported as “undiff erenti-
ated” or “unknown” hepatitis.
Liver cancer cases are registered nationally, 
but cases with HIV/hepatitis coinfection 
are not. 
The government does not publish hepati-
tis disease reports. 
Hepatitis outbreaks are reported to the 
government and are further investigated. 
There is adequate laboratory capacity na-
tionally to support investigation of viral 
hepatitis outbreaks and other surveillance 
activities. 
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target population is children under the age 
of 17 years. The last serosurvey was carried 
out in 2009. 
Prevention of transmission
There is no national policy on hepatitis A 
vaccination. 
The government has established the goal 
of eliminating hepatitis B by 2016.
Nationally, more than 90% of newborn 
infants in a given recent year received the 
fi rst dose of hepatitis B vaccine within 24 
hours of birth and more than 90% of one-
year-olds (ages 12–23 months) in a given 
recent year received three doses of hepa-
titis B vaccine. 
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B). 
There is a specifi c national strategy and/
or policy for preventing hepatitis B and 
hepatitis C infection in health-care settings. 
However, health-care workers are not vac-
cinated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection 
safety in health-care settings, which rec-
ommends single-use and auto-disable sy-
ringes for therapeutic injections. However, 
single-use or auto-disable syringes, nee-
dles and cannulas are not always available 
in all health-care facilities. 
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
24.5
Low-income
--
--
--
$45.68
70
--
33
2.0
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B, but not for hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs. 
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety. 
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education) and on-the-job training. 
There are national clinical guidelines for 
the management of viral hepatitis, but 
they do not include recommendations for 
cases with HIV coinfection. 
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals and are not com-
pulsory for members of any specifi c group. 
Publicly funded treatment is available for 
hepatitis B and hepatitis C. Information 
was not provided on who is eligible for 
this. Information was not provided on the 
amount spent by the government on pub-
licly funded treatment. 
The following drugs for treating hepatitis B 
are on the national essential medicines list: 
interferon alpha and pegylated interferon. 
The following drugs for treating hepatitis C 
are on the national essential medicines list: 
interferon alpha and pegylated interferon. 
The Government of the Democratic Peo-
ple’s Republic of Korea welcomes assist-
ance from WHO in one or more areas of 
viral hepatitis prevention and control 
(Annex C).
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India
The Government of India reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses exclusively on the prevention 
and control of viral hepatitis. It includes 
components for raising awareness, surveil-
lance, vaccination, prevention in general, 
prevention of transmission via injecting 
drug use, prevention of transmission in 
health-care settings, and treatment and 
care. 
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. It has four staff  members. 
It is not known how many people work 
full-time on hepatitis-related activities in 
all government agencies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c population: health-care workers, 
including health-care waste handlers.
Awareness-raising and partnerships
It is not known whether the government 
held events for World Hepatitis Day 2012 
or funded other viral hepatitis public 
awareness campaigns since January 2011.
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is no routine surveillance for viral 
hepatitis. 
There are standard case defi nitions for 
hepatitis. Hepatitis deaths are not report-
ed to a central registry. The percentage of 
hepatitis cases reported as “undiff erentiat-
ed” or “unclassifi ed” hepatitis is not known. 
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government does not publish hepati-
tis disease reports.
Hepatitis outbreaks are reported to the 
government and are further investigated. 
There is inadequate laboratory capacity 
nationally to support investigation of viral 
hepatitis outbreaks and other surveillance 
activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
It is not known what percentage of new-
born infants nationally in a given recent 
year received the fi rst dose of hepatitis B 
vaccine within 24 hours of birth or what 
percentage of one-year-olds (ages 12–23 
months) nationally in a given recent year 
received three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
It is not known whether there is a specifi c 
national strategy and/or policy for prevent-
ing hepatitis B and hepatitis C infection in 
health-care settings. However, health-care 
workers are vaccinated against hepatitis B 
prior to starting work that might put them 
at risk of exposure to blood. 
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends auto-disable syringes for therapeu-
tic injections. Single-use or auto-disable 
syringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
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(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
It is not known whether there is a national 
policy relating to the prevention of viral 
hepatitis among people who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through on-
the-job training. 
It is not known whether there are national 
clinical guidelines for the management of 
viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals and are compul-
sory for blood donors.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
The following drug for treating hepatitis B 
is on the national essential medicines list: 
lamivudine. The following drug for treat-
ing hepatitis C is on the national essential 
medicines list: ribavirin. 
The Government of India welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
The Government of Indonesia reports as 
follows. 
National coordination
There is a written national strategy or plan 
that focuses exclusively on the prevention 
and control of viral hepatitis. It includes 
components for raising awareness, surveil-
lance, vaccination, prevention in general, 
prevention of transmission via injecting 
drug use, prevention of transmission in 
health-care settings, and treatment and 
care. 
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. There are 12 full-time 
equivalent staff  members who work on 
hepatitis-related activities in all govern-
ment agencies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c population: health-care workers, 
including health-care waste handlers.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 and has funded other 
viral hepatitis public awareness campaigns 
since January 2011 (Annex A).
Information was not provided on whether 
the government collaborates with in-
country civil society groups to develop and 
implement its viral hepatitis prevention 
and control programme.
Evidence-based policy and data for 
action
There is no routine surveillance for viral 
hepatitis. 
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Informa-
tion was not provided on the percentage 
of hepatitis cases reported as “undiff erenti-
ated” or “unknown” hepatitis.
Liver cancer cases are registered nationally, 
but it is not known whether cases with HIV/
hepatitis coinfection are.
The government publishes hepatitis dis-
ease reports monthly and annually. 
Hepatitis outbreaks are reported to the 
government and are further investigated. 
There is adequate laboratory capacity na-
tionally to support investigation of out-
breaks and other surveillance activities.
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly. 
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Information was not provided on the per-
centage of newborn infants nationally in 
a given recent year who received the fi rst 
dose of hepatitis B vaccine within 24 hours 
of birth. Nationally, 94% of one-year-olds 
(ages 12–23 months) in a given recent year 
received three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is no specifi c national strategy and/
or policy for preventing hepatitis B and 
hepatitis C infection in health-care settings. 
Health-care workers are not vaccinated 
against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection 
safety in health-care settings, which rec-
ommends single-use and auto-disable 
syringes for therapeutic injections. Single-
use or auto-disable syringes, needles and 
cannulas are always available in all health-
care facilities.
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Information was not provided on offi  cial 
government estimates of the number and 
percentage of unnecessary injections ad-
ministered annually in health-care settings. 
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
It is not known whether there is a national 
policy relating to the prevention of viral 
hepatitis among people who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education) and on-the-job training. 
There are no national clinical guidelines for 
the management of viral hepatitis. 
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names are 
kept confi dential within the system. Hepa-
titis B and hepatitis C tests are not free of 
charge. Information was not provided on 
whether hepatitis B or hepatitis C tests are 
compulsory for members of any specifi c 
group.
Government employees are eligible for 
publicly funded treatment for hepatitis B 
and hepatitis C. Information was not pro-
vided on the amount spent by the govern-
ment on such treatment.
The following drugs for treating hepatitis B 
are on the national essential medicines list: 
pegylated interferon, lamivudine, adefovir 
dipivoxil and telbivudine. The following 
drugs for treating hepatitis C are on the 
national essential medicines list: pegylated 
interferon and ribavirin.
The Government of Indonesia welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Maldives
The Government of the Maldives reports 
as follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hep-
atitis-related activities. Information was 
not provided on how many people work 
full-time on hepatitis-related activities in 
all government agencies/bodies. 
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: people who inject 
drugs, migrants and prisoners.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government collaborates with the fol-
lowing in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme: non-
governmental organizations that work 
with injecting drug users and other high-
risk populations.
Evidence-based policy and data for 
action
There is no routine surveillance for viral 
hepatitis.
There are no standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. The per-
centage of hepatitis cases reported as “un-
diff erentiated” or “unclassifi ed” hepatitis is 
not known.
Liver cancer cases are not registered 
nationally, but cases with HIV/hepatitis 
coinfection are.
The government does not publish hepati-
tis disease reports.
Hepatitis outbreaks are not reported to the 
government. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 98% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 96% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/
or policy for preventing hepatitis B and 
hepatitis C infection in health-care set-
tings. Health-care workers are vaccinated 
against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
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There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs. 
The government does not have guidelines 
that address how hepatitis A and hepati-
tis E can be prevented through food and 
water safety. 
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through on-
the-job training. 
There are no national clinical guidelines 
for the management of viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free 
of charge for all individuals and are com-
pulsory for pregnant women, pre-surgical 
patients and foreign nationals applying for 
work visas. 
Publicly funded treatment for hepatitis B 
and hepatitis C is available to the entire 
population. The amount spent by the gov-
ernment on such treatment is not known.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list: lamivudine and tenofovir. No drug for 
treating hepatitis C is on the national es-
sential medicines list.
The Government of the Maldives wel-
comes assistance from WHO in one or 
more areas of viral hepatitis prevention 
and control (Annex C).
Chapter 7: W
H
O
 South-East Asia Region
160
GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
The Government of Myanmar reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses primarily on the prevention 
and control of viral hepatitis, and also in-
tegrates other diseases. It includes compo-
nents for raising awareness, surveillance, 
vaccination, prevention in general, preven-
tion of transmission via injecting drug use, 
prevention of transmission in health-care 
settings, and treatment and care.
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. It has 20 staff  members. 
There are 49 full-time equivalent staff 
members who work on hepatitis-related 
activities in all government agencies/
bodies. 
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs, migrants, prison-
ers, the homeless, people living with HIV, 
low-income populations, the uninsured 
and indigenous people.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012, but has funded 
other viral hepatitis public awareness cam-
paigns since January 2011 (Annex A).
The government collaborates with the fol-
lowing in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme: Myan-
mar Medical Association, Myanmar Health 
Assistant Association, Myanmar Nurses’ 
Association, Myanmar Maternal and Child 
Welfare Association and Myanmar Red 
Cross Association.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, and for the following types of 
chronic hepatitis: B and C.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Less than 
5% of hepatitis cases are reported as “un-
diff erentiated” or “unclassifi ed” hepatitis.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports monthly and annually.
Hepatitis outbreaks are reported to the 
government and are further investigated. 
There is adequate laboratory capacity na-
tionally to support investigation of viral 
hepatitis outbreaks and other surveillance 
activities.
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
most recent one was in 2010.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B. 
Nationally, 10% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 38% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/
or policy for preventing hepatitis B and 
hepatitis C infection in health-care settings. 
Health-care workers are vaccinated against 
hepatitis B prior to starting work that might 
put them at risk of exposure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
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Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C.
There is a national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training, post-
graduate training and continuing medical 
education activities.
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names are 
kept confi dential within the system. Hepa-
titis B and hepatitis C tests are not free of 
charge for everyone, but they are free for 
pregnant women and blood donors. Hepa-
titis B and hepatitis C tests are compulsory 
for pregnant women, blood donors and 
people applying for employment.
Publicly funded treatment is available for 
hepatitis B and hepatitis C. Information 
was not provided on who is eligible for it, 
or on the amount spent by the govern-
ment on such treatment.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list: interferon alpha, pegylated interferon, 
lamivudine, adefovir dipivoxil, entecavir, 
telbivudine and tenofovir. The following 
drugs for treating hepatitis C are on the 
national essential medicines list: interferon 
alpha, pegylated interferon and ribavirin.
The Government of Myanmar welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Nepal
The Government of Nepal reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis. 
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. It is not known how 
many people work full-time on hepatitis-
related activities in all government agen-
cies/bodies. 
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: people who inject 
drugs and people living with HIV. 
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme. 
Evidence-based policy and data for 
action
There is no routine surveillance for viral 
hepatitis. 
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Informa-
tion was not provided on the percentage 
of hepatitis cases reported as “undiff eren-
tiated” or “unknown” hepatitis.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government does not publish hepati-
tis disease reports. 
Hepatitis outbreaks are reported to the 
government and are further investigated. 
There is adequate laboratory capacity na-
tionally to support investigation of viral 
hepatitis outbreaks and other surveillance 
activities. 
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination. 
The government has not established the 
goal of eliminating hepatitis B.
It is not known what percentage of new-
born infants nationally in a given recent 
year received the fi rst dose of hepatitis B 
vaccine within 24 hours of birth or what 
percentage of one-year-olds (ages 12–23 
months) nationally in a given recent year 
received three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B). 
There is no specifi c national strategy and/
or policy for preventing hepatitis B and 
hepatitis C infection in health-care set-
tings. Health-care workers are not vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities. 
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs. 
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The government does not have guidelines 
that address how hepatitis A and hepati-
tis E can be prevented through food and 
water safety. 
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education) and on-the-job training. 
There are no national clinical guidelines 
for the management of viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name, and there is 
open access to their names. Hepatitis B 
and hepatitis C tests are not free of charge 
and are not compulsory for members of 
any specifi c group.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C. 
The following drugs for treating hepatitis 
B are on the national essential medicines 
list: interferon alpha, pegylated interferon, 
lamivudine, adefovir dipivoxil, entecavir, 
telbivudine and tenofovir. The following 
drugs for treating hepatitis C are on the 
national essential medicines list: interfer-
on alpha, pegylated interferon, ribavirin, 
boceprevir and telaprevir.
The Government of Nepal welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
The Government of Sri Lanka reports as 
follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis. 
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. Information was not pro-
vided on how many people work full-time 
on hepatitis-related activities in all govern-
ment agencies/bodies. 
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: children (through the 
Expanded Programme on Immunization) 
and health-care workers, including health-
care waste handlers. 
Awareness-raising and partnerships
The government held a conference for 
World Hepatitis Day 2012, but has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011. 
The government does not collaborate with 
in-country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme. 
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: A, 
B, C, D and E, but not for any type of chronic 
hepatitis. 
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. The per-
centage of hepatitis cases reported as “un-
diff erentiated” or “unclassifi ed” hepatitis is 
not known. 
Liver cancer cases are registered nationally, 
but it is not known whether cases with HIV/
hepatitis coinfection are.
The government publishes hepatitis dis-
ease reports weekly, as well as in a quar-
terly epidemiological bulletin.
Hepatitis outbreaks are reported to the 
government and are further investigated. 
There is inadequate laboratory capacity 
nationally to support investigation of viral 
hepatitis outbreaks and other surveillance 
activities. 
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly. 
Prevention of transmission
There is no national policy on hepatitis A 
vaccination. 
The government has established the goal 
of eliminating hepatitis B by 2015. 
Nationally, no newborn infant in a given re-
cent year received the fi rst dose of hepati-
tis B vaccine within 24 hours of birth. How-
ever, 99% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is no national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B. 
There is a specifi c national strategy and/
or policy for preventing hepatitis B and 
hepatitis C infection in health-care set-
tings. Health-care workers are vaccinated 
against hepatitis B prior to starting work 
that might put them at risk of exposure 
to blood; vaccinations are arranged with-
in groups and are provided on request 
through pharmacies. 
There is a national policy on injection 
safety in health-care settings, which rec-
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Lower–middle-income
$5520
2.95%
$148.45
$66.43
71
0.691
31
2.3
ommends single-use and auto-disable 
syringes for therapeutic injections. Single-
use or auto-disable syringes, needles and 
cannulas are always available in all health-
care facilities. 
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known. 
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs. 
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety. 
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education) and on-the-job training. 
There are national clinical guidelines for 
the management of viral hepatitis, but it 
is not known whether they include recom-
mendations for cases with HIV coinfection. 
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names are 
kept confi dential within the system. Hepa-
titis B and hepatitis C tests are not free of 
charge and are not compulsory for mem-
bers of any specifi c group. 
Publicly funded treatment is not available 
for hepatitis B or hepatitis C. 
The following drug for treating hepatitis B 
is on the national essential medicines list: 
interferon alpha. The following drug for 
treating hepatitis C is on the national es-
sential medicines list: interferon alpha.
The Government of Sri Lanka welcomes 
assistance from WHO in one or more ar-
eas of viral hepatitis prevention and con-
trol (Annex C).
Sri Lanka
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Thailand
The Government of Thailand reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. There are no people 
working full-time on hepatitis-related ac-
tivities in any government agency/body.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c population: health-care workers, 
including health-care waste handlers.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B, C, D and E, but not for any type of 
chronic hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Of hepa-
titis cases, 25% are reported as “undiff er-
entiated” or “unclassifi ed” hepatitis.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports weekly and annually. 
Hepatitis outbreaks are reported to the 
government and are further investigated. 
There is adequate laboratory capacity na-
tionally to support investigation of viral 
hepatitis outbreaks and other surveillance 
activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are not conducted regularly. 
The most recent serosurvey, which tar-
geted the general population, was carried 
out in 2004.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 99% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 98% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy for preventing hepatitis B and hepa-
titis C infection in health-care settings, but 
it addresses only vaccination for health-
care workers. Health-care workers are not 
vaccinated against hepatitis B prior to 
starting work that might put them at risk 
of exposure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepati-
tis E can be prevented through food and 
water safety.
69.5
Upper–middle-income
$8360
3.88%
$329.71
$247.42
70
0.682
34
1.6
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
technical seminars.
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B, but not for hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are not 
free of charge for all individuals, but they 
are for pregnant women, blood donors 
and civil servants. Hepatitis C tests are free 
of charge for blood donors. Hepatitis B 
and hepatitis C tests are compulsory for 
blood donors.
Publicly funded treatment is available for 
hepatitis B and hepatitis C. Patients under 
the universal coverage scheme are eligi-
ble. However, only lamivudine and tenofo-
vir are included in the universal coverage 
package for hepatitis B, and major drugs 
for treating hepatitis C are not included. 
The amount spent by the government on 
publicly funded treatment for hepatitis B 
and hepatitis C is not known.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list: lamivudine and tenofovir. No drug for 
treating hepatitis C is on the national es-
sential medicines list. 
The Government of Thailand welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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The Government of Timor-Leste reports as 
follows.
National coordination
There is no written national strategy or plan 
that focuses exclusively or primarily on the 
prevention and control of viral hepatitis. 
There is no designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. It is not known how many 
people work full-time on hepatitis-related 
activities in all government agencies/
bodies. 
The government does not have a viral hep-
atitis prevention and control programme 
that includes activities targeting specifi c 
populations. 
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011. 
The government does not collaborate with 
in-country civil society groups to develop 
and implement its viral hepatitis preven-
tion and control programme. 
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, but not for any type of chronic 
hepatitis. 
There are no standard case defi nitions for 
hepatitis. Hepatitis deaths are not reported 
to a central registry. The percentage of 
hepatitis cases reported as “undiff erentiat-
ed” or “unclassifi ed” hepatitis is not known. 
Liver cancer cases and cases with HIV/
hepatitis coinfection are not regis-
tered nationally.  
The government does not publish hepati-
tis disease reports. 
Hepatitis outbreaks are reported to the 
government and are further investigated. 
There is inadequate laboratory capacity 
nationally to support investigation of viral 
hepatitis outbreaks and other surveillance 
activities. 
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly. 
Prevention of transmission
There is no national policy on hepatitis A 
vaccination. 
The government has not established the 
goal of eliminating hepatitis B.
Nationally, no newborn infant in a given 
recent year received the fi rst dose of hepa-
titis B vaccine within 24 hours of birth. In 
a given recent year, 67% of one-year-olds 
(ages 12–23 months) received three doses 
of hepatitis B vaccine. 
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B). 
There is no specifi c national strategy and/
or policy for preventing hepatitis B and 
hepatitis C infection in health-care settings. 
Health-care workers are not vaccinated 
against hepatitis B prior to starting work 
that might put them at risk of exposure to 
blood.
There is a national policy on injection safe-
ty in health-care settings, but this policy 
is only for the immunization programme. 
It recommends single-use syringes for 
therapeutic injections. Single-use or auto-
disable syringes, needles and cannulas are 
always available in all health-care facilities. 
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
1.2
Lower–middle-income
$5200
9.12%
$83.98
$46.88
67
0.495
17
6.2
Offi  cial government estimates of the 
number and percentage of unnecessary 
injections administered annually in health-
care settings are not known. 
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for hep-
atitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among people 
who inject drugs. 
The government does not have guidelines 
that address how hepatitis A and hepatitis 
E can be prevented through food and wa-
ter safety. 
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education) and on-the-job training. 
There are no national clinical guidelines for 
the management of viral hepatitis. 
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals and are not com-
pulsory for members of any specifi c group. 
Publicly funded treatment is available for 
hepatitis B and hepatitis C. Information 
was not provided on the amount spent by 
the government on such treatment. 
Information was not provided on whether 
any drug for treating hepatitis B or hepati-
tis C is on the national essential medicines 
list.
The Government of Timor-Leste welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
Timor-Leste
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Viral hepatitis in the WHO Western Pacifi c Region   
Very low prevalence rates (<50% of population exposed 
by the age of 30 years) for hepatitis A have been 
consistently reported from high-income Asia–Pacifi c 
countries and Australasia (Australia and New Zealand). 
Very little information is available from island nations in 
the Region, though they appear, on average, to have an 
intermediate prevalence rate.a
Similarly, for hepatitis E, studies are scarce; however, 
prevalence estimates above 5% are not reported in the 
Region.b
In this Region, with the exception of Australia, Japan and 
New Zealand where the chronic hepatitis B infection rate 
varies from 2% to 4%, countries have an estimated rate of 
5%–7% or more.c
The Region accounts for 48% of global liver cancer cases 
among men and 62% among women. Moreover, liver 
cancer is the third most common cause of cancer mortality 
among men in the Region.d
For hepatitis C infection, prevalence estimates are 2.6% for 
the Region.e Although strategies have been implemented 
to reduce the risk factors for hepatitis C infection, unsafe 
blood transfusion, unsafe injections and injecting drug 
use are the major routes of transmission in the Region.
Twenty-seven Member States make up the Western Pacifi c 
Region, which has a total population of 1.8 billion. The 
population of China accounts for approximately three fourths 
of this total.1
The Western Pacifi c Region encompasses countries at diff erent 
levels of socioeconomic development, and includes six high-
income countries.2 It also includes geographically isolated 
Pacifi c Island Countries with poor infrastructure.3 Health 
indicators for the Region vary widely. Across countries, the 
median life expectancy at birth is 70 years. However, it is 8–11 
years lower in fi ve countries of the Region, while Japan’s life 
expectancy of 83 years is the highest in the world.4 Similarly, 
the median under-fi ve mortality rate across countries is 19 per 
1000 population, while the highest country rate is 83 per 1000 
population (Papua New Guinea) and the lowest is 3 per 1000 
(Japan and Singapore).4
Noncommunicable diseases caused 80% of deaths in the 
Western Pacifi c Region in 2008,5 with cardiovascular diseases 
accounting for almost half of the deaths from noncommunicable 
diseases.6 Among WHO regions, the Western Pacifi c Region 
has the highest prevalence of daily tobacco smoking among 
men (46%); it also has the highest rates of lung cancer among 
both sexes (combined).7 Alcohol is another major risk factor, 
particularly in low- and middle-income countries in the Region.4 
Liver cancer rates in the Region are far higher than in other 
regions.7
Responses to the WHO/Alliance survey were received from 15 of 
the 27 Member States in the Region (55.6%).
Box 1. Responses to the 2012 Global Hepatitis Survey: WHO 
Western Pacifi c Region
Member States that submitted surveys:
Member States that did not submit surveys: 
• Australia
• Brunei Darussalam
• Cambodia
• China
• Japan
• Kiribati
• Cook Islands
• Fiji
• Marshall Islands
•  Micronesia (Federated 
States of)
•  Lao People’s 
Democratic 
Republic
• Malaysia
• Mongolia
• New Zealand
• Nauru
• Niue
• Palau
• Philippines
• Papua New Guinea
• Singapore
• Solomon Islands
• Tonga
• Viet Nam
•  Republic of Korea
• Samoa
• Tuvalu
• Vanuatu
5  World health statistics 2012. Geneva, WHO, 2012. Available at: http://www.who.
int/entity/healthinfo/EN_WHS2012_Full.pdf (accessed on 14 May 2013).
6  Causes of death 2008 summary tables. Geneva, Health Statistics and Informatics 
Department, World Health Organization, May 2011. Available at: http://www.
who.int/entity/gho/mortality_burden_disease/global_burden_disease_
DTH6_2008.xls (accessed on 14 May 2013).
7  Global status report on noncommunicable diseases 2010. Geneva, WHO, 2011. 
Available at: http://whqlibdoc.who.int/publications/2011/9789240686458_eng.
pdf (accessed on 14 May 2013).
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National coordination
Ten responding Member States (66.7%) reported the existence 
of a written national strategy or plan that focuses exclusively 
or primarily on the prevention and control of viral hepatitis 
(Figure 1). One of the ten Member States with a strategy or plan 
(Mongolia) reported that it focuses exclusively on viral hepatitis, 
and fi ve (Brunei Darussalam, Cambodia, Lao People’s Democratic 
Republic, Malaysia and Tonga) reported that it addresses other 
diseases as well. Two countries (China and Kiribati) reported 
that the strategy or plan addresses only hepatitis B, and two 
(Australia and Japan) reported that it addresses hepatitis B and 
hepatitis C.
Figure 1. Responses to the question, “Is there a written 
national strategy or plan that focuses exclusively or primarily 
on the prevention and control of viral hepatitis?”
Yes
No
No response
No data
The ten Member States that reported the existence of a 
strategy or plan were asked about its specifi c components. 
All ten reported the inclusion of components for raising 
awareness, vaccination and general prevention. Nine reported 
the inclusion of a component for prevention of transmission 
in health-care settings, eight reported the inclusion of a 
component for surveillance and seven reported the inclusion of 
a component for treatment and care. Five reported the inclusion 
of components for coinfection with HIV and the prevention of 
transmission via injecting drug use.
Five responding Member States (33.3%) reported that they 
have a governmental unit or department responsible solely for 
viral hepatitis-related activities. Member States that did so were 
asked to indicate the number of staff  members in the unit or 
department. Responses (N=5) ranged from 0.1 (New Zealand) 
to 80 (Cambodia) (median, 7).
Member States were asked to report the number of people 
working full-time on hepatitis-related activities in all government 
agencies or bodies. Among the six Member States that provided 
data for this question, the number ranged from 0 to 84 (median, 
0.5), with Mongolia reporting the largest number.
Thirteen responding Member States (86.7%) reported that 
they have a viral hepatitis prevention and control programme 
that includes activities targeting specifi c populations. The 
populations most commonly targeted are health-care workers, 
including health-care waste handlers (69.2% of responding 
Member States within this subset) and people who inject drugs 
(46.2% of responding Member States within this subset). Groups 
identifi ed less frequently included indigenous populations, low-
income populations, prisoners, migrants, people living with HIV, 
those who are uninsured and those who are homeless.
Awareness-raising and partnerships
Six responding Member States (40.0%) reported that they had 
held events for World Hepatitis Day 2012 (28 July). Since January 
2011, nine responding Member States (60.0%) had funded 
some type of viral hepatitis public awareness campaign other 
than World Hepatitis Day (Table 1).
Eight responding Member States (53.3%) reported that they 
collaborated with civil society groups within their countries 
to develop and implement the governmental viral hepatitis 
prevention and control programme. For example, China 
reported collaborating with the Wu Jieping Medical Foundation 
and Chinese Foundation for Hepatitis Prevention and Control, 
while Malaysia reported collaborating with the Malaysian Liver 
Foundation. (Further examples can be found in the summaries 
of country fi ndings later in this chapter.)
Evidence-based policy and data for action
Twelve responding Member States (80.0%) reported that they 
have routine surveillance for viral hepatitis; details appear in 
Table 2.
Twelve responding Member States (80.0%) indicated that their 
countries have standard case defi nitions for hepatitis infection 
and 12 (80.0%) indicated that their countries have a central 
registry for the reporting of deaths, including hepatitis deaths.
Seven Member States reported on the proportion of hepatitis 
cases and deaths registered as “undiff erentiated” or “unclassifi ed” 
hepatitis. The reported proportions ranged from 0% to 30.0% 
(median, 1.0%). Additional survey fi ndings about surveillance 
are presented in Table 3.
Member States were asked how often hepatitis disease reports 
are published. Of the responding Member States, 33.3% 
reported that they publish hepatitis disease reports annually; 
13.3%, monthly; and 13.3%, weekly. No hepatitis disease report 
is published by 33.3% of responding Member States.
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Table 2. Types of surveillance in Member States that reported 
the existence of routine surveillance for viral hepatitis (N=12)
There is a national 
surveillance system for acute 
hepatitis infection for the 
following forms of hepatitis:
hepatitis A
hepatitis B
hepatitis C
hepatitis D
hepatitis E
There is a national 
surveillance system for 
chronic hepatitis infection 
for the following forms of 
hepatitis:
hepatitis B
hepatitis C
hepatitis D
Yes (%)
75.0
91.7
75.0
25.0
50.0
58.3
41.7
25.0
No (%)
8.3
8.3
16.7
41.7
25.0
33.2
50.0
58.3
Do not 
know 
(%)
0
0
0
0
0
0
0
0
No 
response 
(%)
16.7
0
8.3
33.3
25.0
8.3
8.3
16.7
Table 1. Topics of public awareness campaigns on viral 
hepatitis held in Member States since January 2011 (N=9)
General 
information about 
hepatitis and its 
transmission
Vaccination for 
hepatitis A and 
hepatitis B
Importance of 
knowing one’s 
hepatitis B and 
hepatitis C status
Safe water and 
good sanitation
Safer sex practices
Harm reduction for 
people who inject 
drugs
Safe workplace 
practices
Other a
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a  Details can be found in the summaries of country fi ndings later in this chapter.
Table 3. Data registration and surveillance (N=15)
Liver cancer cases are registered 
nationally
Cases with HIV/hepatitis 
coinfection are registered 
nationally
Hepatitis outbreaks are reported
If YES – Hepatitis outbreaks are 
further investigated (N=115)
Yes (%)
73.3
26.7
93.3
100
No (%)
20.0
66.7
0
0
Do not 
know 
(%)
6.7
6.7
6.7
0
No 
response 
(%)
0
0
0
0
Five responding Member States (33.3%, Australia, Cambodia, 
China, Japan, Lao People’s Democratic Republic) reported the 
existence of a national public health research agenda for viral 
hepatitis.
Six responding Member States (40.0%) reported that viral 
hepatitis serosurveys are conducted regularly. Among this 
subset of responding Member States, two (Australia and Lao 
People’s Democratic Republic) indicated that serosurveys take 
place every fi ve years. Two Member States in the same subset 
(Lao People’s Democratic Republic and Singapore) reported 
that the most recent viral hepatitis serosurvey was carried out 
in 2012.
Prevention of transmission
Five responding Member States (33.3%) reported that they have 
a national policy on hepatitis A vaccination.
Nine responding Member States (60.0%) reported that they 
have established the goal of eliminating or reducing hepatitis 
B (Figure 2). Member States with this goal were asked to specify 
the timeframe in which they seek to eliminate or reduce hepatitis 
B. Of the six Member States that answered this question, three 
(Brunei Darussalam, China and Mongolia) said 2012 and three 
(Cambodia, Lao People’s Democratic Republic and Papua New 
Guinea) said 2017.
Member States were asked to report, for a given recent year, 
the percentage of newborn infants who had received the fi rst 
dose of hepatitis B vaccine within 24 hours of birth. Among the 
13 Member States that provided this information, responses 
ranged from 0% to 98.0% (median, 55.0%). Member States were 
also asked to report, for a given recent year, the percentage of 
one-year-olds (ages 12–23 months) who had received three 
doses of hepatitis B vaccine. Among the 15 Member States that 
provided this information, responses ranged from 0% to 98.8% 
(median, 93.0%).
Fifteen responding Member States (100%) reported the 
existence of a national policy that specifi cally targets mother-
to-child transmission of hepatitis B; details are presented in 
Table 4. One third of Member States with such a policy (33.3%) 
indicated that one component of the policy calls for screening 
of all pregnant women for hepatitis B.
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a  One Member State that answered ”yes” to this question (Australia) added a 
comment indicating that the goal relates to reducing rather than eliminating 
hepatitis B.
Figure 2. Responses to the question, “Has your government 
established the goal of eliminating hepatitis B?” (N=15)
No 
(33.3%)
Yes a 
(60.0%)
Do not know 
6.7%
Fourteen responding Member States (91.3%) reported the 
existence of a specifi c national strategy and/or policy/guidelines 
for preventing hepatitis B and hepatitis C infection in health-
care settings.
Eleven responding Member States (73.3%) reported that health-
care workers are vaccinated against hepatitis B prior to starting 
work that might put them at risk of exposure to blood.
Twelve responding Member States (80.0%) reported the 
existence of a national policy on injection safety in health-
care settings. These Member States were asked which types 
of syringes the policy recommends for therapeutic injections. 
Single-use syringes are recommended in 100% of policies, and 
auto-disable syringes in 16.7% (Figure 3).
Twelve responding Member States (80.0%) reported that single-
use or auto-disable syringes, needles and cannulas are always 
available in all health-care facilities.
Member States were asked for offi  cial estimates of the number 
and percentage of unnecessary injections administered 
annually in health-care settings (e.g. injections that are given 
when an equivalent oral medication is available). Twelve 
Member States reported that the fi gures are not known and one 
(Tonga) reported that no unnecessary injection is administered 
annually in health-care settings. Cambodia reported that 50.0% 
of the total injections that are administered annually in health-
care settings are unnecessary and Mongolia reported that 
68.0% are unnecessary.
Additional fi ndings relating to the prevention of hepatitis 
transmission are presented in Table 5.
Table 4. Activities called for in national policy targeting 
mother-to-child transmission of hepatitis B (N=15)
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Screening, care and treatment
Member States were asked how health professionals in their 
countries obtain the skills and competencies required to 
eff ectively care for people with viral hepatitis. Responding 
Member States most frequently indicated that these are 
obtained in schools for health professionals (pre-service 
education, 80.0%). Additionally, on-the-job training was 
identifi ed in 66.7% of responses, and postgraduate training in 
53.3%.
Nine responding Member States (60.0%) reported the existence 
of national clinical guidelines for the management of viral 
hepatitis (Figure 4). Two of these nine Member States indicated 
that the guidelines include recommendations for cases with 
HIV coinfection. Five of 11 responding Member States (45.5%) 
indicated that there are national clinical guidelines for the 
management of HIV, which include recommendations for 
coinfection with viral hepatitis.
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Figure 4. Responses to the question, “Are there national 
clinical guidelines for the management of viral hepatitis?” 
(N=15)
No 
(40.0%)
Yes 
(60.0%)
Figure 3. Proportion of responding Member States with 
national policies on injection safety in health-care settings 
which recommend single-use syringes and auto-disable 
syringes for therapeutic injections (N=12)
a  Respondents could select both “single-use syringes” and “auto-disable syringes”.
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Single-use syringesa Auto-disable syringesa
Table 5. Hepatitis prevention: policies, practices and 
guidelines (N=15)
There is a national infection 
control policy for blood banks
All donated blood units 
(including family donations) and 
blood products nationwide are 
screened for hepatitis B
All donated blood units 
(including family donations) and 
blood products nationwide are 
screened for hepatitis C
There is a national policy relating 
to the prevention of viral 
hepatitis among people who 
inject drugs
The government has guidelines 
that address how hepatitis A 
and hepatitis E can be prevented 
through food and water safety
Yes (%)
86.7
100
80.0
33.3
46.7
No (%)
6.7
0
13.3
53.3
40.0
Do not 
know (%)
6.7
0
6.7
13.3
13.3
Ten responding Member States (66.7%) indicated that they 
have a national policy relating to screening and referral to care 
for hepatitis B. Five (33.3%) reported having such a policy for 
hepatitis C.
Regarding hepatitis B testing, 13 responding Member States 
(86.7%) indicated that people register by name for testing. 
Twelve members of that subset (92.3%) indicated that the 
names are kept confi dential. Seven responding Member States 
(46.7%) reported that the hepatitis B test is free of charge for 
all individuals. Among the eight other Member States, three 
(37.5%) reported that the hepatitis B test is free of charge for 
members of specifi c groups. Groups identifi ed included blood 
donors and health-care workers. Seven responding Member 
States (46.7%) reported that the hepatitis B test is compulsory 
for members of specifi c groups. Groups identifi ed included 
blood donors, health-care workers, pregnant women and 
imprisoned people who inject drugs.
Regarding hepatitis C testing, 10 responding Member States 
(66.7%) indicated that people register by name for testing. 
All members of that subset (100%) indicated that the names 
are kept confi dential. Four responding Member States 
(26.7%) reported that the hepatitis C test is free of charge for 
all individuals. Among the eight other Member States that 
answered the question, three (37.5%) reported that the hepatitis 
C test is free of charge for members of specifi c groups. Groups 
identifi ed included blood donors and health-care workers. 
Seven responding Member States (46.7%) reported that the 
hepatitis C test is compulsory for members of specifi c groups. 
Groups identifi ed included blood donors, pregnant women and 
imprisoned people who inject drugs.
Eight responding Member States (53.3%) reported that publicly 
funded treatment is available for hepatitis B and seven (46.7%) 
that publicly funded treatment is available for hepatitis C. One 
responding Member State reported the amount spent on 
publicly funded treatment for hepatitis B and hepatitis C. Details 
can be found in the summaries of country fi ndings later in this 
chapter (see New Zealand).
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Eleven responding Member States (73.3%) reported that at least 
one available drug for treating hepatitis B is on the national 
essential medicines list or subsidized by the government 
(Table 6). The drugs most commonly reported were lamivudine 
and interferon alpha.
Eight responding governments (53.3%) reported that at least 
one available drug for treating hepatitis C is on the national 
essential medicines list or subsidized by the government. The 
drugs most commonly reported were ribavirin, interferon alpha 
and pegylated interferon.
World Health Organization assistance
Member States were asked to indicate areas in which they 
might want assistance from WHO for the prevention and control 
of viral hepatitis. Respondents most commonly selected the 
following: increasing access to treatment (46.7%), increasing 
access to diagnostics (46.7%), improving laboratory capacity 
(46.7%) and developing education/training programmes 
for health professionals (46.7%) (Table 7). Responses from 
individual Member States appear in Annex C.
Lamivudine 
Interferon alpha 
Tenofovir
Pegylated interferon
Entecavir
Adefovir dipivoxil
Telbivudine
Ribavirin
Pegylated interferon
Interferon alpha
Telaprevir
Boceprevir
60.0
53.3
40.0
40.0
40.0
33.3
20.0
46.7
40.0
40.0
6.7
0.0
% of Member States reporting its 
inclusion (N=12)
% of Member States reporting its 
inclusion (N=12)
Drugs for treating 
hepatitis B
Drugs for treating 
hepatitis C
Table 6. Proportion of Member States reporting drugs for 
treating hepatitis B and C on national essential medicines 
lists or subsidized by governments
Awareness-raising, partnerships and resource mobilization (fi rst WHO strategic axis)
Developing the national plan for viral hepatitis prevention and control
Integrating viral hepatitis programmes into other health services
Awareness-raising
Evidence-based policy and data for action (second WHO strategic axis)
Viral hepatitis surveillance
Estimating the national burden of viral hepatitis
Developing tools to assess the eff ectiveness of interventions
Assessing the economic impact of viral hepatitis
Prevention of transmission (third WHO strategic axis)
Increasing coverage of the birth dose of the hepatitis B vaccine
Screening, care and treatment (fourth WHO strategic axis)
Increasing access to treatment
Increasing access to diagnostics
Improving laboratory quality
Developing education/training programmes for health professionals
40.0%
40.0%
33.3%
33.3%
26.7%
13.3%
20.0%
40.0% 
46.7%
46.7%
46.7%
46.7%
Table 7. Viral hepatitis control and prevention: areas in which Member States indicated interest in receiving WHO assistance 
(N=15)
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The Government of Australia reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses exclusively on the prevention 
and control of hepatitis B and hepatitis C. It 
includes components for raising awareness, 
surveillance,  vaccination,  prevention in gen-
eral, prevention of transmission via inject-
ing drug use, prevention of transmission in 
health-care settings, treatment and care, and 
coinfection with HIV.
There is no designated governmental unit/
department responsible solely for coordinat-
ing and/or carrying out viral hepatitis-related 
activities. It is not known how many people 
work full-time on hepatitis-related activities 
in all government agencies/bodies.
The government has a viral hepatitis preven-
tion and control programme that includes 
activities targeting the following specifi c 
populations: health-care workers (including 
health-care waste handlers), people who in-
ject drugs, migrants, prisoners, the homeless, 
people living with HIV, indigenous people, 
pregnant women, men who have sex with 
men, sex workers, partners and other house-
hold and intimate contacts of people who 
have chronic hepatitis B infection, people 
travelling to and from high-prevalence coun-
tries,  people with mental health issues, and 
children born to mothers who have tested 
positive for hepatitis B infection.
Awareness-raising and partnerships
The government held events for World Hepa-
titis Day 2012 and has funded other viral 
hepatitis public awareness campaigns since 
January 2011 (Annex A).
The government collaborates with the fol-
lowing in-country civil society groups to de-
velop and implement its viral hepatitis pre-
vention and control programme: Ministerial 
Advisory Committee on Blood Borne Viruses 
and Sexually Transmissible Infections, Blood 
Borne Viruses and Sexually Transmissible In-
fections Standing Committee, Australian Na-
tional Council on Drugs, Hepatitis Australia, 
Australian Society for HIV Medicine, and Aus-
tralian Injecting and Illicit Drug Users League 
Incorporated.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepatitis. 
There is a national surveillance system for the 
following types of acute hepatitis: A, B, C, D 
and E, and for the following types of chronic 
hepatitis: B, C and D.
There are standard case defi nitions for hepa-
titis. Deaths, including from hepatitis, are re-
ported to a central registry. No hepatitis case 
is reported as “undiff erentiated” or “unclassi-
fi ed” hepatitis.
Liver cancer cases are registered nationally, 
but cases with HIV/hepatitis coinfection are 
not.
The government publishes hepatitis disease 
reports annually.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. It is not known whether there 
is adequate laboratory capacity nationally to 
support investigation of viral hepatitis out-
breaks and other surveillance activities.
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are conducted regularly; the target 
population is the general population. The last 
serosurvey was carried out in 2007–2008. 
Prevention of transmission
There is a national policy on hepatitis A vac-
cination. 
The government has established the goal of 
eliminating hepatitis B but the timeframe is 
not specifi ed.
It is not known what percentage of newborn 
infants nationally in a given recent year re-
ceived the fi rst dose of hepatitis B vaccine 
within 24 hours of birth. In a given recent year, 
92% of one-year-olds (ages 12–23 months) 
received three doses of hepatitis B vaccine.
There is a national policy that specifi cally tar-
gets mother-to-child transmission of hepati-
tis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis B 
and hepatitis C infection in health-care set-
tings. Health-care workers are vaccinated 
against hepatitis B prior to starting work that 
might put them at risk of exposure to blood.
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
22.6
High-income
$38 110
8.73%
$3441.04
$2339.68
82
0.929
37
1.9
There is no national policy on injection safety 
in health-care settings. Single-use or auto-
disable syringes, needles and cannulas are 
always available in all health-care facilities.
Offi  cial government estimates of the number 
and percentage of unnecessary injections 
administered annually in health-care settings 
are not known.
There is a national infection control policy for 
blood banks. All donated blood units (includ-
ing family donations) and blood products 
nationwide are screened for hepatitis B and 
hepatitis C. 
There is no national policy relating to the pre-
vention of viral hepatitis among people who 
inject drugs.
The government has guidelines that address 
how hepatitis A and hepatitis E can be pre-
vented through food and water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care for 
people with viral hepatitis through schools 
for health professionals (pre-service educa-
tion), on-the-job training and postgraduate 
training. 
There are no national clinical guidelines for 
the management of viral hepatitis or for 
the management of HIV, which include rec-
ommendations for coinfection with viral 
hepatitis.
The government has national policies relat-
ing to screening and referral to care for hepa-
titis B and hepatitis C. 
People testing for both hepatitis B and hepa-
titis C register by name; the names are kept 
confi dential within the system. Hepatitis B 
tests are not free of charge for all individuals, 
but they are free for high-risk groups. Hepa-
titis C tests are not free of charge. Hepatitis B 
and hepatitis C tests are not compulsory for 
members of any specifi c group.
Publicly funded treatment is available for 
hepatitis B and hepatitis C. The following 
people are eligible: medicare holders. Infor-
mation was not provided on the amount 
spent by the government on such treatment 
for hepatitis B and hepatitis C.
The following drugs for treating hepatitis B 
are on the national essential medicines list 
or subsidized by the government: interferon 
alpha, pegylated interferon, lamivudine, 
adefovir dipivoxil, entecavir, telbivudine and 
tenofovir. The following drugs for treating 
hepatitis C are on the national essential medi-
cines list or subsidized by the government: 
interferon alpha, pegylated interferon and 
ribavirin.
The Government of Australia did not indicate 
a need for assistance from WHO in relation to 
viral hepatitis prevention and control.
Australia
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Brunei Darussalam
The Government of Brunei Darussalam 
reports as follows.
National coordination
There is a written national strategy or plan 
that focuses primarily on the prevention 
and control of viral hepatitis, and also in-
tegrates other diseases. It includes com-
ponents for raising awareness, surveil-
lance,  vaccination, prevention in general, 
prevention of transmission via injecting 
drug use, prevention of transmission in 
health-care settings, treatment and care, 
and coinfection with HIV.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. It is not known how 
many people work full-time on hepatitis-
related activities in all government agen-
cies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs, migrants, prison-
ers, people living with HIV, pregnant wom-
en, blood donors and blood recipients.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012, but has fund-
ed other viral hepatitis public awareness 
campaigns since January 2011 (Annex A).
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, and for the following types of 
chronic hepatitis: B and C. 
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Informa-
tion was not provided on the percentage 
of hepatitis cases reported as “undiff eren-
tiated” or “unknown” hepatitis.
Liver cancer cases are registered nation-
ally, but cases with HIV/hepatitis coinfec-
tion are not.
The government does not publish hepati-
tis disease reports.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis A, hepatitis B and hepati-
tis C, but it is not known if this is the case 
for hepatitis E.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly. 
Prevention of transmission
There is a national policy on hepatitis A 
vaccination. 
The government has established the goal 
of eliminating hepatitis B by 2012. 
Nationally, 95% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 93% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is a national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
0.4
High-income
--
2.84%
$1448.74
$1229.77
77
0.838
29
2.0
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, but not 
for the management of HIV, which include 
recommendations for coinfection with vi-
ral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are not 
free of charge for all individuals, but they 
are free for citizens, permanent residents 
and all children under the age of 12 years. 
Hepatitis B and hepatitis C tests are not 
compulsory for members of any specifi c 
group.
Publicly funded treatment is available for 
hepatitis B and hepatitis C. The following 
groups are eligible: citizens, permanent 
residents and all children under the age 
of 12 years. The amount spent by the gov-
ernment on publicly funded treatment for 
hepatitis B and hepatitis C is not known.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: in-
terferon alpha, pegylated interferon and 
lamivudine. The following drugs for treat-
ing hepatitis C are on the national essen-
tial medicines list or subsidized by the 
government: interferon alpha, pegylated 
interferon and ribavirin.
The Government of Brunei Darussalam 
did not indicate a need for assistance from 
WHO in relation to viral hepatitis preven-
tion and control.
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The Government of Cambodia reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses primarily on the prevention 
and control of viral hepatitis, and also in-
tegrates other diseases. It includes com-
ponents for raising awareness, surveil-
lance,  vaccination, prevention in general, 
prevention of transmission via injecting 
drug use, prevention of transmission in 
health-care settings, treatment and care, 
and coinfection with HIV.
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities: the National Immuniza-
tion Programme. It has 80 staff  members. 
There is one full-time equivalent staff 
member who works on hepatitis-related 
activities in all government agencies/
bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c population: newborn children.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government collaborates with the fol-
lowing in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme: PATH 
and the Reproductive and Child Health Al-
liance.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis; it is based on syndromic reporting for 
jaundice.
There are no standard case defi nitions 
for hepatitis. Hepatitis deaths are not re-
ported to a central registry. The percent-
age of hepatitis cases reported as “undif-
ferentiated” or “unclassifi ed” hepatitis is 
not known.
Liver cancer cases are registered nation-
ally, but cases with HIV/hepatitis coinfec-
tion are not.
The government published hepatitis dis-
ease reports in 2006 and 2011.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target population is children under the 
age of 5 years. Information was not pro-
vided on when the last serosurvey was 
carried out.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has established the goal 
of eliminating hepatitis B by 2017.
Nationally, 68% of newborn infants in a 
given recent year received the fi rst dose 
of hepatitis B vaccine within 24 hours of 
birth and 94% of one-year-olds (ages 12–
23 months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are not vac-
cinated against hepatitis B prior to start-
ing work that might put them at risk of 
exposure to blood.
There is a national policy on injection 
safety in health-care settings, which rec-
ommends single-use and auto-disable 
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
14.3
Low-income
$2230
5.61%
$121.08
$45.08
61
0.523
23
2.6
syringes for therapeutic injections. Single-
use or auto-disable syringes, needles and 
cannulas are always available in all health-
care facilities.
Fifty percent of injections administered 
annually in health-care settings are un-
necessary, according to offi  cial govern-
ment estimates. 
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government does not have guide-
lines that address how hepatitis A and 
hepatitis E can be prevented through 
food and water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education) and on-the-job training. 
There are national clinical guidelines for 
the management of viral hepatitis, but 
they do not include recommendations for 
cases with HIV coinfection. There are na-
tional clinical guidelines for the manage-
ment of HIV, which include recommenda-
tions for coinfection with viral hepatitis. 
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals, and are compul-
sory for blood donors.
Publicly funded treatment is available for 
hepatitis B and hepatitis C. Low-income 
people are eligible. The amount spent by 
the government on such treatment is not 
known.
No drug for treating hepatitis B or hepati-
tis C is on the national essential medicines 
list or subsidized by the government. 
The Government of Cambodia welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
Cambodia
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China
The Government of China reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses exclusively on the preven-
tion and control of hepatitis B. It includes 
components for raising awareness, surveil-
lance, vaccination, prevention in general, 
prevention of transmission via injecting 
drug use, prevention of transmission in 
health-care settings, and treatment and 
care.
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities. The name of this offi  ce 
was not provided. It has seven staff  mem-
bers. There are seven full-time equivalent 
staff  members who work on hepatitis-
related activities in all government agen-
cies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers) 
and people who inject drugs.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 and has funded other 
viral hepatitis public awareness cam-
paigns since January 2011 (Annex A).
The government collaborates with the fol-
lowing in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme: the 
Wu Jieping Medical Foundation and the 
Chinese Foundation for Hepatitis Preven-
tion and Control.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B, C and E, and for the following types of 
chronic hepatitis: B and C.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Informa-
tion was not provided on the percentage 
of hepatitis cases reported as “undiff eren-
tiated” or “unknown” hepatitis.
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports monthly. 
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis A, hepatitis B and hepati-
tis C, but not for hepatitis E.
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target populations are children and the 
general population. The last serosurvey 
was carried out in 2006. 
Prevention of transmission
There is a national policy on hepatitis A 
vaccination. 
The government has established the goal 
of eliminating hepatitis B by 2012. 
Nationally, 91% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 94% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
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There is a national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepati-
tis E can be prevented through food and 
water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B, but not for hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are not 
free of charge for all individuals. They are 
free for certain groups, but information 
was not provided on which groups. Hepa-
titis B and hepatitis C tests are not compul-
sory for members of any specifi c group.
Publicly funded treatment is available for 
hepatitis B, but not for hepatitis C. Informa-
tion was not provided on who is eligible or 
the amount spent by the government on 
such treatment.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: in-
terferon alpha, pegylated interferon, lami-
vudine, adefovir dipivoxil, entecavir, telbi-
vudine and tenofovir. The following drug 
for treating hepatitis C is on the national 
essential medicines list or subsidized by 
the government: ribavirin.
The Government of China welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
The Government of Japan reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses exclusively on the prevention 
and control of hepatitis B and hepatitis C. 
It includes components for raising aware-
ness, vaccination, prevention in general, 
prevention of transmission in health-care 
settings, and treatment and care.
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities: the Offi  ce for Promotion 
of Hepatitis Measures within the Health 
Service Bureau of the Ministry of Health, 
Labour and Welfare. It has 12 staff  mem-
bers. There are two full-time equivalent 
staff  members who work on hepatitis-
related activities in all government agen-
cies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c population: health-care workers 
(including health-care waste handlers).
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 and has funded other 
viral hepatitis public awareness cam-
paigns since January 2011 (Annex A).
The government collaborates with the 
following in-country civil society groups 
to develop and implement its viral hepa-
titis prevention and control programme: 
the Japan Hepatitis Council and the Viral 
Hepatitis Research Foundation of Japan.
Evidence-based policy and data for 
action
There is routine surveillance for viral 
hepatitis. There is a national surveillance 
system for the following types of acute 
hepatitis: A, B, C, D and E, but not for any 
type of chronic hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepa-
titis, are reported to a central registry. Of 
hepatitis cases, 5.6% are reported as “un-
diff erentiated” or “unclassifi ed” hepatitis.
Liver cancer cases are registered nation-
ally, but cases with HIV/hepatitis coinfec-
tion are not.
The government publishes hepatitis dis-
ease reports weekly.
Hepatitis outbreaks are required to be 
reported to the government. There is ad-
equate laboratory capacity nationally to 
support investigation of viral hepatitis 
outbreaks and other surveillance activi-
ties.
There is a national public health research 
agenda for viral hepatitis. It is not known 
whether viral hepatitis serosurveys are 
conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, no newborn infant in a given 
recent year received the fi rst dose of hep-
atitis B vaccine within 24 hours of birth 
and no one-year-old (age 12–23 months) 
in a given recent year received three dos-
es of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
It is not known whether there is a national 
policy on injection safety in health-care 
settings, or whether single-use or auto-
disable syringes, needles and cannulas 
are always available in all health-care fa-
cilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
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There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government does not have guide-
lines that address how hepatitis A and 
hepatitis E can be prevented through 
food and water safety.
Screening, care and treatment
It is not known how health professionals 
obtain the skills and competencies re-
quired to eff ectively care for people with 
viral hepatitis. 
There are national clinical guidelines for 
the management of viral hepatitis, but 
they do not include recommendations for 
cases with HIV coinfection. There are na-
tional clinical guidelines for the manage-
ment of HIV, which include recommenda-
tions for coinfection with viral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C.
People testing for hepatitis B and hepati-
tis C do not register by name. Hepatitis B 
and hepatitis C tests are free of charge for 
all individuals and are not compulsory for 
members of any specifi c group.
Publicly funded treatment is available for 
hepatitis B and hepatitis C. The following 
group is eligible for such treatment for 
hepatitis B: patients receiving interferon 
therapy or nucleoside analogue therapy. 
The following group is eligible for publicly 
funded treatment for hepatitis C: patients 
receiving interferon therapy. Information 
was not provided on the amount spent 
by the government on such treatment for 
hepatitis B and hepatitis C.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: 
pegylated interferon, lamivudine, adefo-
vir dipivoxil and entecavir. The following 
drugs for treating hepatitis C are on the 
national essential medicines list or sub-
sidized by the government: interferon 
alpha, pegylated interferon, ribavirin and 
telaprevir.
The Government of Japan did not indicate 
a need for assistance from WHO in relation 
to viral hepatitis prevention and control.
Japan
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Kiribati
The Government of Kiribati reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses exclusively on the prevention 
and control of hepatitis B. It includes com-
ponents for raising awareness, vaccina-
tion, prevention in general, prevention of 
transmission in health-care settings, and 
treatment and care.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. It is not known how 
many people work full-time on hepatitis-
related activities in all government agen-
cies/bodies.
The government does not have a viral 
hepatitis prevention and control pro-
gramme that includes activities targeting 
specifi c populations.
Awareness-raising and partnerships
It is not known whether the government 
held events for World Hepatitis Day 2012. 
It has not funded other viral hepatitis pub-
lic awareness campaigns since January 
2011.
The government collaborates with the fol-
lowing in-country civil society group to 
develop and implement its viral hepatitis 
prevention and control programme: the 
Kiribati Family Health Association.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for acute hepatitis B, but not for any type 
of chronic hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Informa-
tion was not provided on the percentage 
of hepatitis cases reported as “undiff eren-
tiated” or “unknown” hepatitis.
Liver cancer cases are not registered na-
tionally, but cases with HIV/hepatitis coin-
fection are.
The government does not publish hepati-
tis disease reports.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is inadequate labora-
tory capacity nationally to support inves-
tigation of viral hepatitis outbreaks and 
other surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
It is not known whether the government 
has established the goal of eliminating 
hepatitis B.
Information was not provided on the per-
centage of newborn infants nationally in 
a given recent year who received the fi rst 
dose of hepatitis B vaccine within 24 hours 
of birth. In a given recent year, 77.9% of 
one-year-olds (ages 12–23 months) re-
ceived three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is no specifi c national strategy and/
or policy/guidelines for preventing hepa-
titis B and hepatitis C infection in health-
care settings. Health-care workers are not 
vaccinated against hepatitis B prior to 
starting work that might put them at risk 
of exposure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
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products nationwide are screened for 
hepatitis B and hepatitis C. 
It is not known whether there is a national 
policy relating to the prevention of viral 
hepatitis among people who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education) and postgraduate training. 
There are no national clinical guidelines 
for the management of viral hepatitis. In-
formation was not provided on whether 
there are national clinical guidelines for 
the management of HIV, which include 
recommendations for coinfection with vi-
ral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B, but not for hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals, and are compul-
sory for blood donors, pregnant women, 
sailors and overseas workers.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
No drug for treating hepatitis B or hepatitis 
C is on the national essential medicines list 
or subsidized by the government. 
The Government of Kiribati welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
The Government of Lao People’s Demo-
cratic Republic reports as follows.
National coordination
There is a written national strategy or plan 
that focuses primarily on the prevention 
and control of viral hepatitis, and also in-
tegrates other diseases. It includes com-
ponents for raising awareness, surveil-
lance, vaccination, prevention in general 
and prevention of transmission in health-
care settings.
There is no designated governmental 
unit/department responsible solely for 
coordinating and/or carrying out viral 
hepatitis-related activities. Information 
was not provided on how many people 
work full-time on hepatitis-related activi-
ties in all government agencies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
newborns and children.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012, but has funded 
other viral hepatitis public awareness 
campaigns since January 2011 (Annex A).
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral 
hepatitis. There is a national surveillance 
system for the following types of acute 
hepatitis: B, C and E. Information was not 
provided on whether there is a national 
surveillance system for any type of chron-
ic hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepati-
tis, are reported to a central registry. The 
percentage of hepatitis cases reported as 
“undiff erentiated” or “unclassifi ed” hepati-
tis is not known.
Liver cancer cases and cases with HIV/
hepatitis coinfection are not registered 
nationally. 
It is not known whether the government 
publishes hepatitis disease reports.
Hepatitis outbreaks are required to be 
reported to the government and are fur-
ther investigated. There is inadequate 
laboratory capacity nationally to support 
hepatitis B outbreak investigations and 
other surveillance activities. Information 
was not provided on whether there is 
adequate laboratory capacity nationally 
to support investigation of other types of 
viral hepatitis outbreaks and other surveil-
lance activities.
There is a national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target populations are children aged 5–9 
years and women aged 15–45 years. The 
last serosurvey was carried out in 2012.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has established the goal 
of eliminating hepatitis B by 2017.
Nationally, 20% of newborn infants in a 
given recent year received the fi rst dose 
of hepatitis B vaccine within 24 hours of 
birth and 79% of one-year-olds (ages 12–
23 months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is no specifi c national strategy 
and/or policy/guidelines for preventing 
hepatitis B and hepatitis C infection in 
health-care settings. Health-care workers 
are vaccinated against hepatitis B prior to 
starting work that might put them at risk 
of exposure to blood.
There is a national policy on injection 
safety in health-care settings, which rec-
ommends single-use and auto-disable 
syringes for therapeutic injections. Single-
use or auto-disable syringes, needles and 
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cannulas are always available in all health-
care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
It is not known whether there is a national 
policy relating to the prevention of viral 
hepatitis among people who inject drugs.
It is not known whether the government 
has guidelines that address how hepa-
titis A and hepatitis E can be prevented 
through food and water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education) and on-the-job training. 
There are national clinical guidelines for 
the management of viral hepatitis, but it 
is not known whether they include rec-
ommendations for cases with HIV coin-
fection.
It is not known whether the government 
has national policies relating to screening 
and referral to care for hepatitis B. Infor-
mation was not provided on whether the 
government has national policies relating 
to screening and referral to care for hepa-
titis C. 
People testing for hepatitis B register by 
name. Information was not provided on 
whether their names are kept confi den-
tial within the system. Hepatitis B tests are 
not free of charge. Information was not 
provided on whether people testing for 
hepatitis C register by name, or whether 
hepatitis C tests are free of charge for all 
individuals. Information was not provided 
on whether hepatitis B or hepatitis C tests 
are compulsory for members of any spe-
cifi c group.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
The following drug for treating hepatitis B 
is on the national essential medicines list 
or subsidized by the government: inter-
feron alpha. No drug for treating hepatitis 
C is on the national essential medicines 
list or subsidized by the government.
The Government of Lao People’s Demo-
cratic Republic welcomes assistance from 
WHO in one or more areas of viral hepati-
tis prevention and control (Annex C).
Lao People’s Democratic Republic
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Malaysia
The Government of Malaysia reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses primarily on the prevention 
and control of viral hepatitis, and also in-
tegrates other diseases. It includes com-
ponents for raising awareness, surveil-
lance, vaccination, prevention in general, 
prevention of transmission via injecting 
drug use, prevention of transmission in 
health-care settings, treatment and care, 
and coinfection with HIV.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. It is not known how 
many people work full-time on hepatitis-
related activities in all government agen-
cies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
people who inject drugs and blood do-
nors.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 and has funded other 
viral hepatitis public awareness cam-
paigns since January 2011 (Annex A).
The government collaborates with the fol-
lowing in-country civil society group to 
develop and implement its viral hepatitis 
prevention and control programme: the 
Malaysian Liver Foundation.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B and C, and for the following types of 
chronic hepatitis: B and C. 
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Of hepa-
titis cases, 2% are reported as “undiff eren-
tiated” or “unclassifi ed” hepatitis. 
Liver cancer cases and cases with HIV/hep-
atitis coinfection are registered nationally. 
The government publishes hepatitis dis-
ease reports annually. 
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis A, hepatitis B and hepati-
tis C, but not for hepatitis E.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 91.13% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 97.37% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is a national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
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The government has guidelines that ad-
dress how hepatitis A and hepatitis E can be 
prevented through food and water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are no national clinical guidelines 
for the management of viral hepatitis, 
but there are for the management of HIV, 
which include recommendations for coin-
fection with viral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B and hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are not 
free of charge for all individuals, but they 
are free for health-care workers following 
exposure. Hepatitis B tests are compulsory 
for health-care workers and blood donors. 
Hepatitis C tests are compulsory for blood 
donors.
Publicly funded treatment for hepatitis B 
and hepatitis C is available to Malaysian 
citizens who seek care at certain public hos-
pitals. Information was not provided on the 
amount spent by the government on such 
treatment for hepatitis B and hepatitis C.
The following drugs for treating hepatitis B 
are on the national essential medicines list 
or subsidized by the government: inter-
feron alpha, pegylated interferon, lamivu-
dine, adefovir dipivoxil, entecavir, telbivu-
dine and tenofovir. The following drugs for 
treating hepatitis C are on the national es-
sential medicines list or subsidized by the 
government: interferon alpha, pegylated 
interferon and ribavirin. 
The Government of Malaysia did not in-
dicate a need for assistance from WHO in 
relation to viral hepatitis prevention and 
control.
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
The Government of Mongolia reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses exclusively on the prevention 
and control of viral hepatitis. It includes 
components for raising awareness, sur-
veillance, vaccination, prevention in gen-
eral, prevention of transmission in health-
care settings and coinfection with HIV.
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities: Hepatitis Surveillance 
Unit, National Center for Communicable 
Diseases. It has fi ve staff  members. There 
are 84 full-time equivalent staff  members 
who work on hepatitis-related activities in 
all government agencies/bodies.
The government does not have a viral 
hepatitis prevention and control pro-
gramme that includes activities targeting 
specifi c populations.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 and has funded other 
viral hepatitis public awareness cam-
paigns since January 2011 (Annex A).
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral 
hepatitis. There is a national surveillance 
system for the following types of acute 
hepatitis: A, B and C, and for the following 
types of chronic hepatitis: B, C and D.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepa-
titis, are reported to a central registry. Of 
hepatitis cases, 1.1% is reported as “undif-
ferentiated” or “unclassifi ed” hepatitis. 
Liver cancer cases are registered nation-
ally, but cases with HIV/hepatitis coinfec-
tion are not. 
The government publishes hepatitis dis-
ease reports monthly. 
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak 
investigations and other surveillance 
activities for hepatitis A, hepatitis B and 
hepatitis C, but not for hepatitis E.
Information was not provided on whether 
there is a national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are not conducted regularly.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination. 
The government has established the goal 
of eliminating hepatitis B by 2012.
Nationally, 96.2% of newborn infants in a 
given recent year received the fi rst dose 
of hepatitis B vaccine within 24 hours of 
birth and 98.8% of one-year-olds (ages 
12–23 months) in a given recent year re-
ceived three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. However, health-care workers 
are not vaccinated against hepatitis B pri-
or to starting work that might put them at 
risk of exposure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
2.8
Lower–middle-income
$4290
5.44%
$217.53
$119.84
69
0.653
25
2.5
According to offi  cial government esti-
mates, 68% of injections administered 
annually in health-care settings are un-
necessary. 
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education). 
There are national clinical guidelines for 
the management of viral hepatitis, but 
they do not include recommendations for 
cases with HIV coinfection.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for hepatitis B and hepati-
tis C do not register by name. Hepatitis B 
and hepatitis C tests are not free of charge 
and are not compulsory for members of 
any specifi c group.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C, but hospitali-
zation for acute hepatitis is free of charge.
The following drug for treating hepatitis 
B is on the national essential medicines 
list or subsidized by the government: 
lamivudine. The following drug for treat-
ing hepatitis C is on the national essential 
medicines list or subsidized by the gov-
ernment: ribavirin. 
The Government of Mongolia welcomes 
assistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
New Zealand
The Government of New Zealand reports 
as follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is a designated governmental unit/
department responsible solely for coordi-
nating and/or carrying out viral hepatitis-
related activities: the Public Health, Sector 
Capability and Implementation Business 
Unit of the Ministry of Health. It has one 
tenth of one full-time staff  member. It is 
not known how many people work full-
time on hepatitis-related activities in all 
government agencies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c population: people who inject 
drugs.
Awareness-raising and partnerships
The government held events for World 
Hepatitis Day 2012 and has funded other 
viral hepatitis public awareness cam-
paigns since January 2011 (Annex A). 
The government collaborates with the 
following in-country civil society groups 
to develop and implement its viral hepa-
titis prevention and control programme: 
the Hepatitis Foundation of New Zealand, 
Needle Exchange New Zealand and the 
Hepatitis C Support Group.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B, C, D and E, and for chronic hepatitis D. 
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Of hepa-
titis cases, 6.4% are reported as “undiff er-
entiated” or “unclassifi ed” hepatitis. 
Liver cancer cases are registered nation-
ally, but cases with HIV/hepatitis coinfec-
tion are not. 
The government publishes hepatitis dis-
ease reports annually. 
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target population is people who inject 
drugs. The last serosurvey was carried out 
in 2009.
Prevention of transmission
There is a national policy on hepatitis A 
vaccination. 
The government has not established the 
goal of eliminating hepatitis B.
Nationally, no newborn infant in a given 
recent year received the fi rst dose of hepa-
titis B vaccine within 24 hours of birth. In 
a given recent year, 93% of one-year-olds 
(ages 12–23 months) received three doses 
of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
4.4
High-income
$28 930
10.10%
$3020.05
$2513.32
81
0.908
37
2.2
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training.
There are no national clinical guidelines 
for the management of viral hepatitis, 
but there are for the management of HIV, 
which include recommendations for coin-
fection with viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are free of 
charge for all individuals. Hepatitis B tests 
are compulsory for blood donors and im-
migrants, and hepatitis C tests for blood 
donors.
Publicly funded treatment for hepatitis B 
and hepatitis C is available to some seg-
ments of the population, but information 
was not provided on who is eligible. In fi s-
cal year 2011/2012, the government spent 
NZ$ 16 080 000 (US$ 13 026 971) on such 
treatment for hepatitis B and hepatitis C.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: lami-
vudine, adefovir dipivoxil, entecavir and 
tenofovir. The following drugs for treating 
hepatitis C are on the national essential 
medicines list or subsidized by the gov-
ernment: interferon alpha, pegylated in-
terferon and ribavirin.
The Government of New Zealand did not 
indicate a need for assistance from WHO 
in relation to viral hepatitis prevention and 
control.
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
The Government of Papua New Guinea 
reports as follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for 
coordinating and/or carrying out viral 
hepatitis-related activities. There are no 
people working full-time on hepatitis-re-
lated activities in any government agen-
cies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c population: health-care workers 
(including health-care waste handlers).
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is no routine surveillance for viral 
hepatitis.
There are no standard case defi nitions 
for hepatitis. Hepatitis deaths are not re-
ported to a central registry. Information 
was not provided on the percentage of 
hepatitis cases reported as “undiff erenti-
ated” or “unknown” hepatitis.
Liver cancer cases and cases with HIV/
hepatitis coinfection are not registered 
nationally. 
The government does not publish hepati-
tis disease reports.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is inadequate labora-
tory capacity nationally to support inves-
tigation of viral hepatitis outbreaks and 
other surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has established the goal 
of eliminating hepatitis B by 2017.
Nationally, 31% of newborn infants in a 
given recent year received the fi rst dose 
of hepatitis B vaccine within 24 hours of 
birth and 61% of one-year-olds (ages 12–
23 months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is no specifi c national strategy 
and/or policy/guidelines for preventing 
hepatitis B and hepatitis C infection in 
health-care settings. However, a hepatitis 
B vaccination programme for health-care 
workers was planned for February 2013.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are not al-
ways available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
7.0
Lower–middle-income
$2570
3.58%
$87.71
$62.76
63
0.466
20
4.0
sary injections administered annually in 
health-care settings are not known.
There is no national infection control 
policy for blood banks. All donated blood 
units (including family donations) and 
blood products nationwide are screened 
for hepatitis B, but not for hepatitis C. 
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
It is not known whether the government 
has guidelines that address how hepa-
titis A and hepatitis E can be prevented 
through food and water safety.
Screening, care and treatment
It is not known how health professionals 
obtain the skills and competencies re-
quired to eff ectively care for people with 
viral hepatitis. 
There are no national clinical guidelines 
for the management of viral hepatitis or 
for the management of HIV, which include 
recommendations for coinfection with vi-
ral hepatitis.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B, but not for hepatitis C. 
People testing for hepatitis B register by 
name; the names are kept confi dential 
within the system. Hepatitis B tests are 
free of charge for all individuals and not 
compulsory for members of any specifi c 
group. Information was not provided on 
whether people testing for hepatitis C reg-
ister by name, whether the tests are free 
of charge for all individuals or compulsory 
for members of any specifi c group.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
The following drugs for treating hepatitis 
B are on the national essential medicines 
list or subsidized by the government: 
lamivudine and tenofovir. No drug for 
treating hepatitis C is on the national es-
sential medicines list or subsidized by the 
government.
The Government of Papua New Guinea 
welcomes assistance from WHO in one or 
more areas of viral hepatitis prevention 
and control (Annex C).
Papua New Guinea
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Singapore
The Government of Singapore reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. There are no people 
working full-time on hepatitis-related ac-
tivities in any government agency/body.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers) 
and people who inject drugs.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: 
A, B, C and E, and for chronic hepatitis B. 
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. No hepa-
titis case is reported as “undiff erentiated” 
or “unclassifi ed” hepatitis. 
Liver cancer cases are registered nation-
ally, but cases with HIV/hepatitis coinfec-
tion are not.
The government publishes hepatitis dis-
ease reports weekly and annually. 
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are conducted regularly; the 
target populations are children under the 
age of 17 years and the general popula-
tion. The last serosurvey was carried out 
in 2012.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination. 
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 31% of newborn infants in a 
given recent year received the fi rst dose of 
hepatitis B vaccine within 24 hours of birth 
and 61% of one-year-olds (ages 12–23 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C. 
There is a national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government does not have guidelines 
that address how hepatitis A and hepati-
5.2
High-income
$59 380
3.96%
$2272.64
$824.98
82
0.866
38
1.3
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
tis E can be prevented through food and 
water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, which 
include recommendations for cases with 
HIV coinfection.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B, but not for hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are not 
free of charge. Hepatitis B tests are com-
pulsory for injecting drug users in prison 
settings, and hepatitis C tests for health-
care workers and injecting drug users in 
prison settings.
Publicly funded treatment for hepatitis B 
and hepatitis C is available to the entire 
population. The amount spent by the gov-
ernment on such treatment is not known.
The following drugs for treating hepatitis B 
are on the national essential medicines list 
or subsidized by the government: inter-
feron alpha, pegylated interferon, lamivu-
dine, adefovir dipivoxil and entecavir. The 
following drugs for treating hepatitis C are 
on the national essential medicines list or 
subsidized by the government: interferon 
alpha and pegylated interferon.
The Government of Singapore did not in-
dicate a need for assistance from WHO in 
relation to viral hepatitis prevention and 
control.
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
The Government of Solomon Islands re-
ports as follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis. 
There is no designated governmental 
unit/department responsible solely for 
coordinating and/or carrying out viral 
hepatitis-related activities. It is not known 
how many people work full-time on hep-
atitis-related activities in all government 
agencies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c population: all children under the 
age of 12 months.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012 and has not 
funded other viral hepatitis public aware-
ness campaigns since January 2011.
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is no routine surveillance for viral 
hepatitis.
It is not known whether there are stand-
ard case defi nitions for hepatitis. Hepatitis 
deaths are not reported to a central regis-
try. Information was not provided on the 
percentage of hepatitis cases reported as 
“undiff erentiated” or “unknown” hepatitis.
It is not known whether liver cancer cases 
and cases with HIV/hepatitis coinfection 
are registered nationally. 
The government does not publish hepati-
tis disease reports.
It is not known whether hepatitis out-
breaks are required to be reported to the 
government. There is adequate labora-
tory capacity nationally to support inves-
tigation of viral hepatitis outbreaks and 
other surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination. 
The government has not established the 
goal of eliminating hepatitis B.
Nationally, 24% of newborn infants in a 
given recent year received the fi rst dose 
of hepatitis B vaccine within 24 hours of 
birth and 77% of one-year-olds (ages 12–
23 months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is no specifi c national strategy and/
or policy/guidelines for preventing hepa-
titis B and hepatitis C infection in health-
care settings.
It is not known whether there is a national 
policy on injection safety in health-care 
settings. Single-use or auto-disable sy-
ringes, needles and cannulas are not al-
ways available in all health-care facilities.
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
7.0
Lower–middle-income
$2350
8.55%
$227.32
$212.30
71
0.510
20
4.2
It is not known whether there is a national 
infection control policy for blood banks. 
All donated blood units and blood prod-
ucts nationwide are screened for hepatitis 
B, but it is not known whether all donated 
blood units (including family donations) 
and blood products nationwide are 
screened for hepatitis C.
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government does not have guide-
lines that address how hepatitis A and 
hepatitis E can be prevented through 
food and water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through on-
the-job training. 
There are no national clinical guidelines 
for the management of viral hepatitis. In-
formation was not provided on whether 
there are national clinical guidelines for 
the management of HIV, which include 
recommendations for coinfection with 
viral hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for hepatitis B register by 
name; the names are kept confi dential 
within the system. Hepatitis B tests are 
free of charge for all individuals and are 
not compulsory for members of any spe-
cifi c group. Information was not provided 
on whether people testing for hepatitis C 
register by name, whether the tests are 
free of charge for all individuals or wheth-
er they are compulsory for members of 
any specifi c group.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
No drug for treating hepatitis B or hepati-
tis C is on the national essential medicines 
list or subsidized by the government.
The Government of Solomon Islands wel-
comes assistance from WHO in one or 
more areas of viral hepatitis prevention 
and control (Annex C).
Solomon Islands
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GLOBAL POLICY REPORT ON THE PREVENTION AND CONTROL OF VIRAL HEPATITIS
Tonga
The Government of Tonga reports as 
follows.
National coordination
There is a written national strategy or plan 
that focuses primarily on the prevention 
and control of viral hepatitis, and also in-
tegrates other diseases. It includes compo-
nents for raising awareness, surveillance, 
vaccination and prevention in general. 
There is no designated governmental 
unit/department responsible solely for co-
ordinating and/or carrying out viral hepa-
titis-related activities. There are no people 
working full-time on hepatitis-related ac-
tivities in any government agency/body.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c populations: health-care workers 
(including health-care waste handlers), 
newborns and infants.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012, but has fund-
ed other viral hepatitis public awareness 
campaigns since January 2011 (Annex A).
The government collaborates with the fol-
lowing in-country civil society group to 
develop and implement its viral hepatitis 
prevention and control programme: Ton-
ga Red Cross Society.
Evidence-based policy and data for 
action
There is routine surveillance for viral hepa-
titis. There is a national surveillance system 
for the following types of acute hepatitis: A 
and B, and for chronic hepatitis B. 
There are standard case defi nitions for 
hepatitis. Deaths, including from hepatitis, 
are reported to a central registry. Of hepa-
titis cases, 30% are reported as “undiff er-
entiated” or “unclassifi ed” hepatitis. 
Liver cancer cases are registered nation-
ally, but cases with HIV/hepatitis coinfec-
tion are not.
The government publishes hepatitis dis-
ease reports annually. 
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support outbreak in-
vestigations and other surveillance activi-
ties for hepatitis A and hepatitis B, but not 
for hepatitis C and hepatitis E.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis se-
rosurveys are not conducted regularly, but 
they are conducted when donor funding 
is available. The target population is chil-
dren aged 5–6 years. The last serosurvey 
was carried out in 2010.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination. 
The government has established the goal 
of eliminating hepatitis B but did not pro-
vide information about a specifi c time-
frame for this.
Nationally, 98% of newborn infants in a 
given recent year received the fi rst dose 
of hepatitis B vaccine within 24 hours of 
birth and 98% of one-year-olds (ages 12–3 
months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are vacci-
nated against hepatitis B prior to starting 
work that might put them at risk of expo-
sure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
No injection administered annually in 
health-care settings is unnecessary, ac-
cording to offi  cial government estimates.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B, but not for hepatitis C. 
0.1
Lower–middle-income
$5000
5.07%
$229.18
$186.78
71
0.704
21
3.9
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
There is no national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government has guidelines that ad-
dress how hepatitis A and hepatitis E can 
be prevented through food and water 
safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education), on-the-job training and 
postgraduate training. 
There are national clinical guidelines for 
the management of viral hepatitis, but 
they do not include recommendations for 
cases with HIV coinfection.
The government has national policies re-
lating to screening and referral to care for 
hepatitis B, but not for hepatitis C. 
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B tests are free of charge for all 
individuals. Information was not provided 
on whether hepatitis C tests are free of 
charge for all individuals. Hepatitis B and 
hepatitis C tests are compulsory for mi-
grants.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
The following drug for treating hepatitis B 
is on the national essential medicines list 
or subsidized by the government: inter-
feron alpha. No drug for treating hepatitis 
C is on the national essential medicines list 
or subsidized by the government.
The Government of Tonga welcomes as-
sistance from WHO in one or more areas 
of viral hepatitis prevention and control 
(Annex C).
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The Government of Viet Nam reports as 
follows.
National coordination
There is no written national strategy or 
plan that focuses exclusively or prima-
rily on the prevention and control of viral 
hepatitis.
There is no designated governmental 
unit/department responsible solely for 
coordinating and/or carrying out viral 
hepatitis-related activities. It is not known 
how many people work full-time on hep-
atitis-related activities in all government 
agencies/bodies.
The government has a viral hepatitis pre-
vention and control programme that in-
cludes activities targeting the following 
specifi c population: newborns.
Awareness-raising and partnerships
The government did not hold events for 
World Hepatitis Day 2012. It is not known 
whether the government has funded oth-
er viral hepatitis public awareness cam-
paigns since January 2011.
The government does not collaborate 
with in-country civil society groups to 
develop and implement its viral hepatitis 
prevention and control programme.
Evidence-based policy and data for 
action
There is no routine surveillance for viral 
hepatitis.
There are standard case defi nitions for 
hepatitis. Deaths, including from hepa-
titis, are reported to a central registry. 
Information was not provided on the 
percentage of hepatitis cases reported as 
“undiff erentiated” or “unknown” hepatitis.
Liver cancer cases and cases with HIV/
hepatitis coinfection are registered na-
tionally. 
The government does not publish hepati-
tis disease reports.
Hepatitis outbreaks are required to be re-
ported to the government and are further 
investigated. There is adequate laboratory 
capacity nationally to support investiga-
tion of viral hepatitis outbreaks and other 
surveillance activities.
There is no national public health research 
agenda for viral hepatitis. Viral hepatitis 
serosurveys are not conducted regularly.
Prevention of transmission
There is no national policy on hepatitis A 
vaccination.
The government has established the goal 
of eliminating hepatitis B but did not pro-
vide information about a specifi c time-
frame for this.
Nationally, 55% of newborn infants in a 
given recent year received the fi rst dose 
of hepatitis B vaccine within 24 hours of 
birth and 95% of one-year-olds (ages 12–
23 months) in a given recent year received 
three doses of hepatitis B vaccine.
There is a national policy that specifi cally 
targets mother-to-child transmission of 
hepatitis B (Annex B).
There is a specifi c national strategy and/or 
policy/guidelines for preventing hepatitis 
B and hepatitis C infection in health-care 
settings. Health-care workers are not vac-
cinated against hepatitis B prior to start-
ing work that might put them at risk of 
exposure to blood.
There is a national policy on injection safe-
ty in health-care settings, which recom-
mends single-use syringes for therapeutic 
injections. Single-use or auto-disable sy-
ringes, needles and cannulas are always 
available in all health-care facilities.
Population (in millions) (2011)
Country classifi cation (2012)
Gross national income per capita (PPP int $) (2011)
Total health expenditure as % of GDP (2010)
Per capita total health expenditure (PPP int $) (2010)
Per capita government health expenditure (PPP int $) (2010)
Life expectancy at birth (in years) (2009)
Human Development Index (2011)
Median age (in years) (2010)
Total fertility rate per woman (2010)
88.8
Lower–middle-income
$3250
6.84%
$215.34
$81.49
72
0.593
28
1.8
Offi  cial government estimates of the 
number and percentage of unneces-
sary injections administered annually in 
health-care settings are not known.
There is a national infection control policy 
for blood banks. All donated blood units 
(including family donations) and blood 
products nationwide are screened for 
hepatitis B and hepatitis C.
There is a national policy relating to the 
prevention of viral hepatitis among peo-
ple who inject drugs.
The government does not have guide-
lines that address how hepatitis A and 
hepatitis E can be prevented through 
food and water safety.
Screening, care and treatment
Health professionals obtain the skills and 
competencies required to eff ectively care 
for people with viral hepatitis through 
schools for health professionals (pre-serv-
ice education). 
There are national clinical guidelines for 
the management of viral hepatitis. In-
formation was not provided on whether 
these guidelines include recommenda-
tions for cases with HIV coinfection. There 
are national clinical guidelines for the 
management of HIV, which include rec-
ommendations for coinfection with viral 
hepatitis.
The government does not have national 
policies relating to screening and referral 
to care for hepatitis B or hepatitis C.
People testing for both hepatitis B and 
hepatitis C register by name; the names 
are kept confi dential within the system. 
Hepatitis B and hepatitis C tests are not 
free of charge, and are compulsory for 
blood donors.
Publicly funded treatment is not available 
for hepatitis B or hepatitis C.
No drug for treating hepatitis B or hepati-
tis C is on the national essential medicines 
list or subsidized by the government. 
The Government of Viet Nam welcomes 
assistance from WHO in one or more ar-
eas of viral hepatitis prevention and con-
trol (Annex C).
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ANNEX A: Primary topics or messages of public health 
awareness campaigns on viral hepatitis held since 
January 2011a
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a  The table lists all 126 Member States that responded to the survey, including Member States that did not provide responses to this survey question (i.e. Member States 
that did not report any primary topics or messages). Responses were provided by 36 Member States.
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El Salvador
Estonia
Finland
France
Georgia
Germany
Grenada
Guatemala
Guyana
Honduras
Hungary
India
Indonesia
Iran (Islamic Republic of)
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kiribati
Kuwait
Kyrgyzstan
Lao People’s Democratic 
Republic
Latvia
Lebanon
Lithuania
Luxembourg
Malaysia
Maldives
Mali
Malta
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Nepal
Netherlands
New Zealand
Nicaragua
Nigeria
Oman
Pakistan
Panama
Papua New Guinea
Paraguay
Peru
Poland
Qatar
Republic of Moldova
Russian Federation
Rwanda
Saint Kitts and Nevis
Saint Lucia
San Marino
Serbia
Sierra Leone
Singapore
Slovakia
Slovenia
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Somalia
South Africa
South Sudan
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ANNEX A: Primary topics or messages of public health awareness campaigns on 
viral hepatitis held since January 2011 (continued)
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Timor-Leste
Tonga
Turkey
Ukraine
United Kingdom of Great 
Britain and Northern Ireland
United Republic of Tanzania
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Uruguay
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Viet Nam
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ANNEX B: Components of national policies that target 
mother-to-child transmission of hepatitis Ba
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a  The table lists all 126 Member States that responded to the survey, including Member States that did not provide responses to this survey question (i.e. Member States 
that did not report having a policy with any of the specifi ed activities). Responses were provided by 96 Member States.
Afghanistan
Albania
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Antigua and Barbuda
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Australia
Austria
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El Salvador
Estonia
Finland
France
Georgia
Germany
Grenada
Guatemala
Guyana
Honduras
Hungary
India
Indonesia
Iran (Islamic Republic of)
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kiribati
Kuwait
Kyrgyzstan
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ANNEX B: Components of national policies that target mother-to-child 
transmission of hepatitis B (continued)
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Nepal
Netherlands
New Zealand
Nicaragua
Nigeria
Oman
Pakistan
Panama
Papua New Guinea
Paraguay
Peru
Poland
Qatar
Republic of Moldova
Russian Federation
Rwanda
Saint Kitts and Nevis
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San Marino
Serbia
Sierra Leone
Singapore
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South Sudan
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ANNEX C: Areas in which Member States indicated 
that they might want assistance from the World Health 
Organization for the prevention and control of viral 
hepatitisa
a  The table lists all 126 Member States responding to the survey, including Member States that did not provide responses to this survey question (i.e. Member States that 
did not indicate an interest in receiving specifi c forms of assistance). Responses were provided by 100 Member States.
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(continued)
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ANNEX D: Study methodology and limitations
This report is based on a survey of all Member States of the World 
Health Organization (WHO). The survey was written in English 
and piloted across 13 WHO Member States. After feedback was 
incorporated into a fi nal version, the survey was translated into 
French, Spanish, Portuguese and Russian. 
Responses to the survey were sought from the identifi ed focal 
point for viral hepatitis at the national department or ministry 
of health in each WHO Member State. These individuals 
were identifi ed both through direct communication with 
government agencies and through international, regional and 
country offi  ces of WHO. Data collection took place from July 
2012 to February 2013.
The global, regional and country summaries in this report 
were developed using the completed survey responses 
supplemented by any additional details received. Quantitative 
data presented in tables and fi gures may total slightly less or 
slightly more than 100% due to the rounding of decimals. For 
country summaries that report the amount spent on publicly 
funded treatment for hepatitis B and hepatitis C, the United 
States dollar amount was calculated by converting from the 
local currency using the average 2012 exchange rate (1 January 
2012–31 December 2012). The source for historical exchange 
rates was http://www.oanda.com/currency/average.
Country summaries are prefaced by additional country data 
intended to provide an overview of the context in which policy 
and programme development takes place. Sources for these 
data are provided in Table 1.
A number of study limitations may have infl uenced the fi ndings 
presented in this report. 
Of the 194 Member States, 126 responded to the survey (64.9%), 
while 68 did not provide responses. The research team’s inability 
to obtain responses from some countries may be attributable to 
the lack of any clear national focal point or department leading 
viral hepatitis prevention and control eff orts. Hence, countries 
with weak national viral hepatitis programmes may be 
underrepresented in the survey fi ndings and the full extent of 
any gap in the policy response to hepatitis may not be refl ected 
in the report.
Furthermore, the survey asked only about the existence of 
national policies, strategies and programmes; it did not seek to 
assess their quality or impact. Caution must be exercised in using 
survey fi ndings to draw conclusions about implementation, 
service uptake and health outcomes. 
Linguistic and defi nitional considerations should also be 
highlighted. As the survey was limited to the aforementioned 
fi ve languages, although mitigated by many WHO country 
offi  ces that provided assistance to respondents, this may have 
aff ected both response rates and respondents’ thorough and 
clear understanding of the questions. Furthermore, some terms 
used in the survey may be understood diff erently in diff erent 
regions and countries.
Table 1. Sources for country context data
Population (in millions)
Country classifi cation
Gross national income per 
capita (purchasing power 
parity in international 
dollars [PPP int $])
Total health expenditure as 
% of GDP
Per capita total health 
expenditure (PPP int $)
Per capita government 
health expenditure (PPP 
int $)
Life expectancy at birth
Human Development Index
Median age
Total fertility rate per 
woman
World population prospects: the 2010 
revision. New York, United Nations, 
Department of Economic and Social 
Aff airs, Population Division, 2011. 
The World Bank. Country and 
lending groups (web site). http://
data.worldbank.org/about/country-
classifi cations/country-and-lending-
groups (accessed 15 October 2012). 
The World Bank. GNI per capita, PPP 
(current international $)(web site). 
http://data.worldbank.org/indicator/
NY.GNP.PCAP.PP.CD/countries?displa
y=default3Fcid3DEXT_BoletinES_W_
EXT (accessed 15 October 2012). 
The WHO Global Health Observatory 
(web site). http://apps.who.int/
gho/data/node.main (accessed 15 
October 2012). 
The WHO Global Health Observatory 
(web site). http://apps.who.int/
gho/data/node.main (accessed 15 
October 2012). 
The WHO Global Health Observatory 
(web site). http://apps.who.int/gho/
data/node.main(accessed 15 October 
2012). 
The WHO Global Health Observatory 
(web site). http://apps.who.int/
gho/data/node.main (accessed 15 
October 2012). 
Human development Index tables. 
Human development report 
2011 – sustainability and equity: a 
better future for all. United Nations 
Development Programme, 2011.   
hdr.undp.org/en/media/HDR_2011_
Statistical_Tables.xls (accessed 15 
May 2013).
The WHO Global Health Observatory 
(web site). http://apps.who.int/
gho/data/node.main (accessed 15 
October 2012). 
The WHO Global Health Observatory 
(web site). http://apps.who.int/
gho/data/node.main (accessed 15 
October 2012).
Finally, the data included here are those reported by the 
identifi ed focal point from each Member State. It was not 
possible to verify the data submitted prior to publication of this 
report. 
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ANNEX E: Responding to viral hepatitis: the World Health 
Organization/World Hepatitis Alliance 2012 survey of 
national governments
Your cooperation is requested in gathering data that will enable 
the World Health Organization and the World Hepatitis Alliance 
to assess the response to viral hepatitis at the global, regional 
and national levels.
This information is vital for measuring progress, identifying gaps 
and guiding future eff orts. Please fully answer all questions 
in English. You may provide supporting information in any 
language. If you do not know the answer to a question, please 
make every eff ort to fi nd the information. Please submit the 
completed survey, along with all supporting information, to 
obaran@who.int with a cc to hepatitis@cphiv.dk.
1.  In your country, is there a written national strategy or plan 
that focuses exclusively or primarily on the prevention and 
control of viral hepatitis?a
(   ) yes                      (   ) no                 (   ) do not know
a  Please e-mail us the relevant supporting information, 
including if you have a strategy or plan for other diseases 
which includes viral hepatitis.
If yes –
Is the strategy or plan exclusive for viral hepatitis or does it 
also address other diseases (e.g. HIV, sexually transmitted 
infections)?
a. (   ) exclusive for viral hepatitis  
b. (   ) only for hepatitis B
c. (   ) only for hepatitis C
d. (   ) integrated with other diseases  
e. (   ) do not know
Please indicate whether the following are components of the 
strategy or plan:
2.  Is there a designated governmental unit/department 
responsible only for coordinating and/or carrying out viral 
hepatitis-related activities?
(   ) yes                      (   ) no                 (   ) do not know
a. If yes, how many staff  members does it have?
b. Name of unit/department 
(   ) yes     (   ) no     (   ) do not know
(   ) yes     (   ) no     (   ) do not know
(   ) yes     (   ) no     (   ) do not know
(   ) yes     (   ) no     (   ) do not know
(   ) yes     (   ) no     (   ) do not know
(   ) yes     (   ) no     (   ) do not know
(   ) yes     (   ) no     (   ) do not know
(   ) yes     (   ) no     (   ) do not know
1. Raising awareness
2. Surveillance
3. Vaccination
4. Prevention in general
5.  Prevention of 
transmission via 
injecting drug use
6.  Prevention of 
transmission in 
health-care settings
7. Treatment and care
8. Coinfection with HIV
Where appropriate, please give the names and contact 
details of colleagues who provided supporting information.
Contact information
First name 
Last name
Position
Organization
Street address
City
Postal code / zip code
Country
Phone number
E-mail address
Web site
3.  How many people work full-time (or how many full-
time equivalent staff ) on hepatitis-related activities in all 
government agencies/bodies? 
                             people                                (   ) do not know
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4.  Did your government hold events for World Hepatitis Day 
2012?a 
(   ) yes                      (   ) no                 (   ) do not know
a Please e-mail us the relevant supporting information.
8. Is there routine surveillance for viral hepatitis?
(   ) yes                      (   ) no                 (   ) do not know
If yes, please answer the following questions regarding viral 
hepatitis surveillance. If no, please proceed to Question 11.
5.  Has your government funded any public viral hepatitis 
awareness campaign since January 2011, other than World 
Hepatitis Day?a 
(   ) yes                      (   ) no                 (   ) do not know
a  Please e-mail us the relevant supporting information 
(including the names of the campaigns).
If yes, what were the primary topics or messages of the 
campaigns?
a. (   )  General information about hepatitis and its 
transmission
b. (   ) Vaccination for hepatitis A and hepatitis B
c. (   )  Importance of knowing one’s hepatitis B and 
hepatitis C status 
d. (   ) Safe water and good sanitation
e.  (   ) Safer sex practices
f.   (   ) Harm reduction for people who inject drugs
g.  (   ) Safe workplace practices
h.  (   ) Other – please specify:
 a. 
 b.
 c.
7.  Does your government collaborate with any civil society group 
within your country (such as patient groups or national or local 
nongovernmental organizations) to develop and implement 
its viral hepatitis prevention and control programme? If yes, 
please name major partners. 
(   ) yes        (   ) no         major partners
a.
b.
c.
6.  Does your government have a viral hepatitis prevention and 
control programme that includes activities targeting specifi c 
populations?
(   ) yes                      (   ) no                 (   ) do not know
If yes, please indicate which populations:
a. (   )  Health workers (including health-care waste handlers)
b. (   )  People who inject drugs
c.  (   )  Migrants
d. (   )  Prisoners
e. (   )  The homeless
f. (   )  People living with HIV
g. (   )  Low-income populations
h. (   )  The uninsured
i. (   )  Indigenous people
j. (   )  Other - (please specify):
9.  Is there a national surveillance system for the following types 
of acute viral hepatitis infection? Please check all that apply.
(   ) yes                      (   ) no                 (   ) do not know
10.  Is there a national surveillance system for chronic hepatitis 
infection? Please check all that apply.
(   ) yes                     (   ) no                      (   ) do not know
11.  Are there standard case defi nitions for hepatitis infections?
(   ) yes                     (   ) no                      (   ) do not know
12.  Are deaths, including from hepatitis, reported to a central 
registry?
(   ) yes                     (   ) no                      (   ) do not know
13.  What percentage of hepatitis cases are reported as 
“undiff erentiated” or “unclassifi ed” hepatitis?
(   ) yes                     (   ) no                      (   ) do not know
If yes, please e-mail us the defi nitions and/or source used.
(   ) yes     (   ) no     (   ) do not know
(   ) yes     (   ) no     (   ) do not know
(   ) yes     (   ) no     (   ) do not know
(   ) yes     (   ) no     (   ) do not know
(   ) yes     (   ) no     (   ) do not know
(   ) yes     (   ) no     (   ) do not know
(   ) yes     (   ) no     (   ) do not know
(   ) yes     (   ) no     (   ) do not know
a.  Hepatitis A
b.  Hepatitis B
c.  Hepatitis C
d.  Hepatitis D
e.  Hepatitis E
a.  Hepatitis B
b.  Hepatitis C
c.  Hepatitis D
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18.  Is there a national public health research agenda for viral 
hepatitis?a 
(   ) yes                      (   ) no                 (   ) do not know
a  Please e-mail us the relevant documentation, including 
information about the budget and networks involved.
19.  Are viral hepatitis serosurveys conducted regularly? 
(   ) yes                      (   ) no                 (   ) do not know
If yes –
a.  How often?
b.  When was the last one carried out?
c.  Please specify the target populations:
 1. (   ) Children (please specify age group): 
 2. (   ) General population
 3. (   ) People who inject drugs
 4. (   ) Men who have sex with men
 5. (   ) Other groups:
20.  Is there adequate laboratory capacity nationally to support 
investigation of viral hepatitis outbreaks and other 
surveillance activities?
(   ) yes                     (   ) no                      (   ) do not know
21.  Is there a national hepatitis A vaccination policy?
(   ) yes                     (   ) no                      (   ) do not know
If yes, does the policy address vaccination for the following 
groups? Please check all that apply.
a.  (   ) Travellers to highly endemic countries
b.  (   ) Military personnel
c.  (   )  Children, as part of the national routine vaccination 
programme
d.  (   ) Ecological and sanitary workers
e.  (   ) Other – please specify:
14.  Are liver cancer cases registered nationally?
(   ) yes                     (   ) no                      (   ) do not know
22.  Has your government established the goal of eliminating 
hepatitis B?
(   ) yes                     (   ) no                      (   ) do not know
a.  If yes, in what timeframe (e.g. an end date)?
23.  Nationally, what percentage of newborn infants in a given 
recent year received the fi rst dose of hepatitis B vaccine 
within 24 hours of birth? 
24.  Nationally, what percentage of one-year-olds (ages 12–23 
months) in a given recent year received three doses of 
hepatitis B vaccine? 
15.  Are cases with HIV/hepatitis coinfection registered 
nationally?
(   ) yes                     (   ) no                      (   ) do not know
17.  Are hepatitis outbreaks required to be reported to the 
government?
(   ) yes                     (   ) no                      (   ) do not know
a. If yes, are they further investigated?
(   ) yes                     (   ) no                      (   ) do not know
16.  How often are hepatitis disease reports published?
a.  (   ) weekly b.  (   ) monthly c.  (   ) annually
d.  (   ) no reports published           e.  (   ) other: 
(   ) yes     (   ) no     (   ) do not know
(   ) yes     (   ) no     (   ) do not know
(   ) yes     (   ) no     (   ) do not know
(   ) yes     (   ) no     (   ) do not know
a.  Hepatitis A
b.  Hepatitis B
c.  Hepatitis C
d.  Hepatitis E
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25.  Nationally, what percentage of one-year-olds (ages 12–23 
months) in a given recent year received three doses of 
hepatitis B vaccine?
Is there a national policy that specifi cally targets mother-to-
child transmission of hepatitis B? Please check the following 
if the policy calls for any of these activities:
a.  (   ) All pregnant women are screened for hepatitis B
b.  (   )  All pregnant women found to have hepatitis B are 
counselled
c.  (   )  Health-care providers follow up with all pregnant 
women found to have hepatitis B during pregnancy 
for the purpose of encouraging them to give birth at 
health-care facilities
d.  (   )  Upon delivery, all infants born to women with hepatitis 
B receive hepatitis B immunoglobulin
e.  (   )  All infants receive the fi rst dose of hepatitis B vaccine 
within 24 hours of birth
f.  (   )  All infants receive the second and third doses of 
hepatitis B vaccine within 12 months of birth
29.  What are your government’s offi  cial estimates of the number 
and percentage of unnecessary injections administered 
annually in health-care settings? (e.g. injections that are 
given when an equivalent oral medication is available)
a.  Number                                               (   ) do not know
 (   ) do not knowb.   Percentage                                
(as a proportion of total 
injections administered 
annually in health-care 
settings)
26.  Is there a specifi c national strategy and/or policy/guidelines 
for preventing hepatitis B and hepatitis C infection in health-
care settings?
(   ) yes                     (   ) no                      (   ) do not know
a.   If yes, are health workers vaccinated against hepatitis 
B prior to starting work that might put them at risk of 
exposure to blood?
(   ) yes                     (   ) no                      (   ) do not know
31.  Are all donated blood units (including family donations) and 
blood products nationwide screened for hepatitis B?
(   ) yes                     (   ) no                      (   ) do not know
32.  Are all donated blood units (including family donations) and 
blood products nationwide screened for hepatitis C?
(   ) yes                     (   ) no                      (   ) do not know
33.  Is there a national policy relating to the prevention of viral 
hepatitis among people who inject drugs?a
(   ) yes                     (   ) no                      (   ) do not know
a  Please e-mail us the relevant supporting information.
34.  Does your government have guidelines that address how 
hepatitis A and hepatitis E can be prevented through food 
and water safety?
(   ) yes                     (   ) no                      (   ) do not know
35.  How do health professionals in your country obtain the skills 
and competencies required to eff ectively care for people 
with viral hepatitis?
a.  (   ) schools for health professionals (pre-service education)
b.  (   ) on-the-job training
c.  (   ) postgraduate training
d.  (   ) other:
e.  (   ) do not know
28.  Are single-use or auto-disable syringes, needles and cannulas 
always available in all health-care facilities?
(   ) yes                     (   ) no                      (   ) do not know
27.  Is there a national policy on injection safety in health-care 
settings?
(   ) yes                     (   ) no                      (   ) do not know
a.   If yes, what type of syringes does the policy recommend 
for therapeutic injections?
1. (   ) single-use syringes
2. (   ) auto-disable syringes
3. (   ) do not know
30.  Is there a national infection control policy for blood banks?a 
(   ) yes                      (   ) no                 (   ) do not know
a  Please e-mail us the relevant supporting information, 
including the percentage of blood donations screened for 
hepatitis B virus, hepatitis C virus and HIV.
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36.  Does your government have a national policy relating to 
screening and referral to care for the following?a
(   ) yes                     (   ) no                      (   ) do not know
38.  Are there national clinical guidelines for the management of 
viral hepatitis?a
(   ) yes                     (   ) no                      (   ) do not know
a Please e-mail us the relevant supporting information.
a.   If yes, do they include recommendations for cases with 
HIV coinfection?
     (   ) yes                     (   ) no                      (   ) do not know
b.   If no, are there national clinical guidelines for the 
management of HIV,which include recommendations for 
coinfection with viral hepatitis?
     (   ) yes                     (   ) no                      (   ) do not know
39. Is publicly funded treatment available for hepatitis B?
(   ) yes                     (   ) no                      (   ) do not know
a.   If yes, who is eligible for publicly funded treatment for 
hepatitis B? Please specify: 
40. Is publicly funded treatment available for hepatitis C?
(   ) yes                     (   ) no                      (   ) do not know
a.   If yes, who is eligible for publicly funded treatment for 
hepatitis C? Please specify: 
41.  How much does the government spend on publicly funded 
treatment for hepatitis B and hepatitis C? (Please indicate 
currency. Please also indicate whether the amount is for one 
or both of the infections.) 
42.  Which of the following drugs for treating hepatitis B and 
hepatitis C are on the national essential medicines list or 
subsidized by the government? (Please check all that apply.)
a.  Available drugs for treating hepatitis B:
 1. (   ) Interferon alpha
 2. (   ) Pegylated interferon
 3. (   ) Lamivudine (Epivir-HBV, Zeffi  x or Heptodin)
 4. (   ) Adefovir dipivoxil (Hepsera)
 5. (   ) Entecavir (Baraclude)
 6. (   ) Telbivudine (Tyzeka, Sebivo)
 7. (   ) Tenofovir (Viread)
 8. (   ) Other:
b.  Available drugs for treating hepatitis C:
 1. (   ) Interferon alpha
 2. (   )  Pegylated interferon
 3. (   )  Ribavirin
 4. (   )  Boceprevir (Victrelis)
 5. (   )  Telaprevir (Incivo, Incivek)
 6. (   )  Other:
(   ) yes     (   ) no     (   ) do not know
(   ) yes     (   ) no     (   ) do not know
a.  Hepatitis B
b.  Hepatitis C
a Please e-mail us the relevant supporting information.
37.  Please answer the following questions about hepatitis B 
and hepatitis C testing in your country. Please check the 
appropriate boxes.
(   ) yes
(   ) no
(   ) yes
(   ) no
(   ) yes
(   ) no
(   ) yes
(   ) no
a.  Hepatitis B b.  Hepatitis C
(   ) yes (please
indicate):
(   ) no
(   ) yes (please
indicate):
(   ) no
(   ) yes (please
indicate):
(   ) no
(   ) yes (please
indicate):
(   ) no
(   ) confi dential
(   ) open access
(   ) confi dential
(   ) open access
1.   When testing, do 
people register 
by name?
2.   If people register 
by name, are 
their names kept 
confi dential 
within the 
system, or is 
there open 
access to the 
names?
3.   Is the test free 
of charge for all 
individuals?
4.   Is the test free 
of charge for 
members of any 
specifi c group?
5.   Is the test 
compulsory for 
members of any 
specifi c group?
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43.  Please indicate in which areas, if any, your government might 
want assistance from the World Health Organization for the 
prevention and control of viral hepatitis:
a. 
b.
c. 
d. 
e. 
f. 
g.
h.
i.
j. 
k.
l.
m.
(   )  Developing the national plan for viral hepatitis 
prevention and control 
(   )  Viral hepatitis surveillance
(   )   Increasing coverage of the birth dose of the hepatitis 
B vaccine
(   )  Estimating the national burden of viral hepatitis
(   )   Developing tools to assess the eff ectiveness of 
interventions
(   )  Increasing access to treatment
(   )  Increasing access to diagnostics
(   )  Improving laboratory quality
(   )  Awareness-raising
(   )  Developing education/training programmes for health 
professionals
(   ) Assessing the economic impact of viral hepatitis
(   )  Integrating viral hepatitis programmes into other 
health services
(   ) Other – please specify:
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www.who.int/topics/hepatitis
World Health Organization
20 Avenue Appia
1211 Geneva 27
Switzerland
hepatitis@who.int
